{"6313f1238925e040a1876f3af49d8a14cfb2acf9": [["AbstractWheather children are easily susceptible to SARS-CoV-2 infection is still a debated question and a currently a hot topic, particularly in view of important decisions on school opening.", [["SARS-CoV-2 infection", "DISEASE", 52, 72], ["children", "ORGANISM", 17, 25], ["SARS-CoV-2", "ORGANISM", 52, 62], ["children", "SPECIES", 17, 25], ["SARS-CoV-2", "SPECIES", 52, 62], ["SARS", "PROBLEM", 52, 56], ["2 infection", "PROBLEM", 61, 72], ["infection", "OBSERVATION", 63, 72]]], ["For this reason, we decide to describe preliminary data showing the prevalence of anti-SARS-CoV-2 IgG in children with known household exposure to SARS-CoV-2.AbstractOur report shows that household transmission of SARS-CoV-2 is high in both adults and children, with similar rates of SARS-CoV-2 IgG in all age groups, including the younger children.", [["SARS", "DISEASE", 147, 151], ["SARS", "DISEASE", 214, 218], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 82, 101], ["children", "ORGANISM", 105, 113], ["CoV-2", "ORGANISM", 152, 157], ["SARS-CoV-2", "ORGANISM", 214, 224], ["children", "ORGANISM", 252, 260], ["SARS-CoV-2", "ORGANISM", 284, 294], ["IgG", "ORGANISM", 295, 298], ["children", "ORGANISM", 340, 348], ["anti-SARS-CoV-2 IgG", "PROTEIN", 82, 101], ["IgG", "PROTEIN", 295, 298], ["children", "SPECIES", 105, 113], ["children", "SPECIES", 252, 260], ["children", "SPECIES", 340, 348], ["SARS-CoV", "SPECIES", 147, 155], ["SARS-CoV", "SPECIES", 214, 222], ["SARS-CoV", "SPECIES", 284, 292], ["preliminary data", "TEST", 39, 55]]], ["A total of 44 out of 80 household contacts (55%) of index patients had anti SARS-CoV-2 IgG.", [["patients", "ORGANISM", 58, 66], ["SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 76, 90], ["anti SARS-CoV-2 IgG", "PROTEIN", 71, 90], ["patients", "SPECIES", 58, 66], ["anti SARS", "TEST", 71, 80], ["CoV", "TEST", 81, 84]]], ["In particular, 16 (59,26%) adult partners had IgG antibodies compared with 28 (52,83%) of pediatric contacts (P > 0.05).", [["IgG antibodies", "PROTEIN", 46, 60], ["IgG antibodies", "TEST", 46, 60]]], ["Among the pediatric population, children \u2265 5 years of age had similar probability of having SARS-CoV-2 IgG (21/39, 53.8%) compared with those < 5 years (7/14, 50%) (P > 0.05).AbstractAdult partners and children also had a probability of having SARS-CoV-2 IgG.", [["SARS", "DISEASE", 92, 96], ["children", "ORGANISM", 32, 40], ["children", "ORGANISM", 202, 210], ["SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 244, 258], ["IgG", "PROTEIN", 103, 106], ["SARS-CoV-2 IgG", "PROTEIN", 244, 258], ["children", "SPECIES", 32, 40], ["children", "SPECIES", 202, 210], ["SARS", "PROBLEM", 92, 96], ["CoV", "TEST", 97, 100], ["IgG", "TEST", 103, 106], ["SARS", "PROBLEM", 244, 248], ["CoV", "TEST", 249, 252]]], ["Interestingly, 35.7% of children and 33.3% of adults with SARS-CoV-2 IgG were previously diagnosed as COVID-19 cases.AbstractSince this evidence of high rate of IgG in children exposed to SARS-CoV-2 has public health implication, with this comment we highlight the need of establishing appropriate guidelines for school opening and other social activities related to childhood.Abstract.", [["SARS", "DISEASE", 58, 62], ["SARS", "DISEASE", 188, 192], ["children", "ORGANISM", 24, 32], ["adults", "ORGANISM", 46, 52], ["SARS-CoV-2", "ORGANISM", 58, 68], ["IgG", "ORGANISM", 69, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 161, 164], ["children", "ORGANISM", 168, 176], ["SARS-CoV-2", "ORGANISM", 188, 198], ["IgG", "PROTEIN", 69, 72], ["IgG", "PROTEIN", 161, 164], ["children", "SPECIES", 24, 32], ["children", "SPECIES", 168, 176], ["SARS-CoV", "SPECIES", 188, 196], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["IgG", "TEST", 69, 72], ["COVID", "TEST", 102, 107], ["high rate of IgG", "PROBLEM", 148, 164], ["SARS", "PROBLEM", 188, 192], ["high", "OBSERVATION_MODIFIER", 148, 152]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)AbstractThe copyright holder for this preprint this version posted August 12, 2020. . https://doi.org/10.1101/2020.08.10.20169912 doi: medRxiv preprint Eight months after the first outbreak in China, the SARS-CoV-2 pandemic is continuing to put a strain on the health systems around the world.", [["CC", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 403, 407], ["CoV-2", "ORGANISM", 408, 413], ["The copyright holder", "TREATMENT", 207, 227], ["med", "ANATOMY", 102, 105]]], ["A much-debated aspect of the disease concerns its impact on children.AbstractThe study of the prevalence and contagiousness of the disease among children produced conflicting results: on the one hand, low infection rates among children (1) and a low number of serious diseases (2) have been described, on the other hand, a serious, albeit rare, inflammatory complication has been reported (3) .", [["low infection", "DISEASE", 201, 214], ["children", "ORGANISM", 60, 68], ["children", "ORGANISM", 145, 153], ["children", "ORGANISM", 227, 235], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 145, 153], ["children", "SPECIES", 227, 235], ["the disease", "PROBLEM", 25, 36], ["The study", "TEST", 77, 86], ["the disease", "PROBLEM", 127, 138], ["low infection rates", "PROBLEM", 201, 220], ["serious diseases", "PROBLEM", 260, 276], ["inflammatory complication", "PROBLEM", 345, 370], ["disease", "OBSERVATION", 29, 36], ["low", "OBSERVATION_MODIFIER", 201, 204], ["infection", "OBSERVATION", 205, 214], ["low number", "OBSERVATION_MODIFIER", 246, 256], ["serious", "OBSERVATION_MODIFIER", 260, 267], ["diseases", "OBSERVATION", 268, 276], ["inflammatory", "OBSERVATION", 345, 357]]], ["Similarly, on the one hand, low infectiousness rates in the school environment have been described (4), while a recent published data highlighted an easy spread of the disease among children in a summer camp (5) .", [["children", "ORGANISM", 182, 190], ["children", "SPECIES", 182, 190], ["low infectiousness rates", "PROBLEM", 28, 52], ["the disease", "PROBLEM", 164, 175], ["low", "OBSERVATION_MODIFIER", 28, 31], ["infectiousness", "OBSERVATION", 32, 46], ["easy", "OBSERVATION_MODIFIER", 149, 153], ["spread", "OBSERVATION_MODIFIER", 154, 160]]], ["This is of particular concern as the return to school is one of the most critical steps to be addressed in phase two of the pandemic.AbstractTo better characterize the possibility of children to be infected with the novel coronavirus, we studied the prevalence of anti-SARS-CoV-2 IgG in children with known household exposure to SARS-CoV-2, and to compare this data with adult partners exposed to the same index case (supplementary material for more methodological details) (6, 7) .", [["SARS", "DISEASE", 329, 333], ["children", "ORGANISM", 183, 191], ["coronavirus", "ORGANISM", 222, 233], ["anti-SARS-CoV-2 IgG", "ORGANISM", 264, 283], ["children", "ORGANISM", 287, 295], ["anti-SARS-CoV-2 IgG", "PROTEIN", 264, 283], ["children", "SPECIES", 183, 191], ["children", "SPECIES", 287, 295], ["SARS-CoV", "SPECIES", 329, 337], ["the novel coronavirus", "PROBLEM", 212, 233], ["infected", "OBSERVATION", 198, 206]]], ["The full study is still ongoing, aiming to evaluate the presence of neutralizing antibodies in adults and children exposed to SARS-CoV-2 and to prospectively follow-up these families in order to understand if a specific antibody pattern protects from further infection.AbstractOf 405 adults with COVID-19 evaluated in the outpatient post COVID unit, 33 were living with children younger than 18 years of age.", [["SARS", "DISEASE", 126, 130], ["infection", "DISEASE", 259, 268], ["children", "ORGANISM", 106, 114], ["SARS-CoV-2", "ORGANISM", 126, 136], ["children", "ORGANISM", 370, 378], ["neutralizing antibodies", "PROTEIN", 68, 91], ["children", "SPECIES", 106, 114], ["children", "SPECIES", 370, 378], ["SARS-CoV", "SPECIES", 126, 134], ["The full study", "TEST", 0, 14], ["neutralizing antibodies", "PROBLEM", 68, 91], ["a specific antibody pattern", "PROBLEM", 209, 236], ["further infection", "PROBLEM", 251, 268], ["COVID", "TEST", 296, 301], ["infection", "OBSERVATION", 259, 268]]], ["At the time of COVID-19 diagnosis of the index case, a total of 80 household contacts were living in the same household and were enrolled in the study of which 53 were children and 27 adult partners (figure 1).AbstractAnti SARS-CoV-2 IgG were present in 44 (55%) household contacts of which 16 (59,26%) were adult partners and 28 (52,83%) were pediatric contacts (P > 0.05).", [["children", "ORGANISM", 168, 176], ["CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 228, 237], ["IgG", "PROTEIN", 234, 237], ["children", "SPECIES", 168, 176], ["AbstractAnti SARS", "TEST", 210, 227], ["CoV", "TEST", 228, 231], ["IgG", "TEST", 234, 237]]], ["Similar relative frequencies of seropositivity where present in children \u2265 5 years of age (21/39, 53.8%) and those < 5 years (7/14, 50%) (P > 0.05).", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["seropositivity", "OBSERVATION", 32, 46]]], ["Adult partners and children also had a similar relative frequency of having SARS-CoV-2 IgG.", [["SARS", "DISEASE", 76, 80], ["children", "ORGANISM", 19, 27], ["SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 76, 90], ["SARS-CoV-2 IgG", "PROTEIN", 76, 90], ["children", "SPECIES", 19, 27], ["SARS-CoV", "SPECIES", 76, 84], ["SARS", "PROBLEM", 76, 80]]], ["Interestingly, ten children (35.7%) and five adults (33.3%) adults with SARS-CoV-2AbstractIgG reported a history of diagnosis of COVID-19.Abstract.", [["SARS", "DISEASE", 72, 76], ["children", "ORGANISM", 19, 27], ["adults", "ORGANISM", 60, 66], ["children", "SPECIES", 19, 27], ["SARS", "PROBLEM", 72, 76], ["COVID", "TEST", 129, 134]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 12, 2020. . https://doi.org/10.1101/2020.08.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["10.20169912 doi: medRxiv preprint Our report shows that household transmission of SARS-CoV-2 is high in both adults and children, with similar rates of SARS-CoV-2 IgG in all age groups, including the younger children.", [["SARS", "DISEASE", 82, 86], ["SARS-CoV-2", "ORGANISM", 82, 92], ["children", "ORGANISM", 120, 128], ["SARS-CoV-2", "ORGANISM", 152, 162], ["IgG", "ORGANISM", 163, 166], ["children", "ORGANISM", 208, 216], ["IgG", "PROTEIN", 163, 166], ["children", "SPECIES", 120, 128], ["children", "SPECIES", 208, 216], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 152, 160]]], ["SARS-CoV-2 infection rate was higher in our cohort compared with a large contact tracing study performed in South Korea (8) .", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["2 infection rate", "PROBLEM", 9, 25], ["a large contact tracing study", "TEST", 65, 94]]], ["This difference could be related to the study design involving serology.", [["the study", "TEST", 36, 45], ["serology", "TEST", 63, 71]]], ["Importantly, more of the 60% of the household contacts we evaluated, including children,(which was not certified by peer review)were not diagnosed SARS-CoV-2 infection before this study probably because most of them did not develop symptoms and were not tested with nasopharyngeal swabs.", [["nasopharyngeal swabs", "ANATOMY", 266, 286], ["SARS-CoV-2 infection", "DISEASE", 147, 167], ["children", "ORGANISM", 79, 87], ["CoV-2", "ORGANISM", 152, 157], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 266, 286], ["children", "SPECIES", 79, 87], ["SARS-CoV-2", "SPECIES", 147, 157], ["SARS", "PROBLEM", 147, 151], ["CoV-2 infection", "PROBLEM", 152, 167], ["this study", "TEST", 175, 185], ["symptoms", "PROBLEM", 232, 240], ["nasopharyngeal swabs", "TEST", 266, 286]]], ["This strongly suggests that the real burden of the SARS-CoV-2 pandemic, in particular the pediatric cases, is hugely underestimated (9, 10).(which was not certified by peer review)Our findings have public health implications, since highlight that children of all age groups have high probability of being infected with SARS-CoV-2 if closely exposed to an index case.(which was not certified by peer review)Considering that recent studies suggested that children can have similar (or even higher) viral loads than adults on nasopharyngeal swabs, even if asymptomatic (11), our study further supports the importance of the need of appropriate procedural guidelines of childhood activities, including schools, in the time of COVID-19.", [["nasopharyngeal swabs", "ANATOMY", 523, 543], ["SARS", "DISEASE", 51, 55], ["SARS", "DISEASE", 319, 323], ["SARS-CoV-2", "ORGANISM", 51, 61], ["children", "ORGANISM", 247, 255], ["SARS-CoV-2", "ORGANISM", 319, 329], ["children", "ORGANISM", 453, 461], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 523, 543], ["children", "SPECIES", 247, 255], ["children", "SPECIES", 453, 461], ["SARS-CoV", "SPECIES", 319, 327], ["the SARS", "TEST", 47, 55], ["pandemic", "PROBLEM", 62, 70], ["recent studies", "TEST", 423, 437], ["viral loads", "PROBLEM", 496, 507], ["nasopharyngeal swabs", "TEST", 523, 543], ["asymptomatic", "PROBLEM", 553, 565], ["our study", "TEST", 572, 581], ["COVID", "TEST", 722, 727], ["hugely", "OBSERVATION_MODIFIER", 110, 116], ["underestimated", "OBSERVATION_MODIFIER", 117, 131], ["infected", "OBSERVATION", 305, 313]]], ["Although access to school is a priority right of children with several benefits on all aspects of child development, the growing evidences that children can easily being infected with SARS-CoV-2 and contribute to virus spread should be used to implement public health recommendations, including hand and respiratory hygiene, physical distancing, masking and active surveillance to reduce and/or prevent of SARS-CoV-2 transmission within childhood environments.(which was not certified by peer review)Data availability All the data and material are available upon request to the corresponding author.", [["hand", "ANATOMY", 295, 299], ["respiratory", "ANATOMY", 304, 315], ["SARS", "DISEASE", 184, 188], ["SARS", "DISEASE", 406, 410], ["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 144, 152], ["SARS-CoV-2", "ORGANISM", 184, 194], ["hand", "ORGANISM_SUBDIVISION", 295, 299], ["SARS-CoV-2", "ORGANISM", 406, 416], ["children", "SPECIES", 49, 57], ["children", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 184, 192], ["SARS-CoV", "SPECIES", 406, 414], ["SARS", "PROBLEM", 184, 188], ["CoV", "TEST", 189, 192], ["virus spread", "PROBLEM", 213, 225], ["hand and respiratory hygiene", "TREATMENT", 295, 323], ["SARS", "PROBLEM", 406, 410]]]], "f72a13492d6572a289270bd443bbb62727cdd279": [["We describe the case of a 66-year-old male initially too afraid to leave his home due to the COVID-19 pandemic, and intentionally delaying his presentation to the emergency department with a 1-week history of persistent clinical deterioration, painful left inguinal lump and scrotal swelling.", [["left inguinal lump", "ANATOMY", 252, 270], ["scrotal", "ANATOMY", 275, 282], ["pandemic", "DISEASE", 102, 110], ["left inguinal lump", "DISEASE", 252, 270], ["scrotal swelling", "DISEASE", 275, 291], ["male", "ORGANISM", 38, 42], ["persistent clinical deterioration", "PROBLEM", 209, 242], ["painful left inguinal lump", "PROBLEM", 244, 270], ["scrotal swelling", "PROBLEM", 275, 291], ["persistent", "OBSERVATION_MODIFIER", 209, 219], ["painful", "OBSERVATION_MODIFIER", 244, 251], ["left", "ANATOMY_MODIFIER", 252, 256], ["inguinal", "ANATOMY", 257, 265], ["lump", "OBSERVATION", 266, 270], ["scrotal", "ANATOMY", 275, 282], ["swelling", "OBSERVATION", 283, 291]]], ["His associated symptoms included anuria, faecal urgency and passage of blood-stained mucous motions.", [["faecal", "ANATOMY", 41, 47], ["blood", "ANATOMY", 71, 76], ["mucous", "ANATOMY", 85, 91], ["anuria", "DISEASE", 33, 39], ["faecal urgency", "DISEASE", 41, 55], ["faecal", "ORGANISM_SUBSTANCE", 41, 47], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["mucous", "MULTI-TISSUE_STRUCTURE", 85, 91], ["His associated symptoms", "PROBLEM", 0, 23], ["anuria", "PROBLEM", 33, 39], ["faecal urgency", "PROBLEM", 41, 55], ["passage of blood-stained mucous motions", "PROBLEM", 60, 99], ["anuria", "OBSERVATION", 33, 39], ["faecal urgency", "OBSERVATION", 41, 55], ["mucous motions", "OBSERVATION", 85, 99]]], ["His relevant background included diabetes mellitus, renal impairment and chronic anaemia.", [["renal", "ANATOMY", 52, 57], ["diabetes mellitus", "DISEASE", 33, 50], ["renal impairment", "DISEASE", 52, 68], ["anaemia", "DISEASE", 81, 88], ["renal", "ORGAN", 52, 57], ["diabetes mellitus", "PROBLEM", 33, 50], ["renal impairment", "PROBLEM", 52, 68], ["chronic anaemia", "PROBLEM", 73, 88], ["diabetes mellitus", "OBSERVATION", 33, 50], ["renal", "ANATOMY", 52, 57], ["impairment", "OBSERVATION", 58, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["anaemia", "OBSERVATION", 81, 88]]], ["On examination, he looked pale and was confused, with normal observations apart from isolated hypotension (90/40 mmHg).", [["hypotension", "DISEASE", 94, 105], ["examination", "TEST", 3, 14], ["pale", "PROBLEM", 26, 30], ["confused", "PROBLEM", 39, 47], ["isolated hypotension", "PROBLEM", 85, 105], ["hypotension", "OBSERVATION", 94, 105]]], ["His abdomen was soft, non-distended with a painful left irreducible inguinal lump extending into the scrotum, suggestive of a complicated incarcerated inguinal hernia.", [["abdomen", "ANATOMY", 4, 11], ["inguinal lump", "ANATOMY", 68, 81], ["scrotum", "ANATOMY", 101, 108], ["inguinal hernia", "ANATOMY", 151, 166], ["inguinal hernia", "DISEASE", 151, 166], ["abdomen", "ORGAN", 4, 11], ["scrotum", "ORGAN", 101, 108], ["non-distended", "PROBLEM", 22, 35], ["a painful left irreducible inguinal lump", "PROBLEM", 41, 81], ["a complicated incarcerated inguinal hernia", "PROBLEM", 124, 166], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 16, 20], ["non-distended", "OBSERVATION", 22, 35], ["painful", "OBSERVATION_MODIFIER", 43, 50], ["left", "ANATOMY_MODIFIER", 51, 55], ["irreducible", "OBSERVATION_MODIFIER", 56, 67], ["inguinal", "ANATOMY", 68, 76], ["lump", "OBSERVATION", 77, 81], ["scrotum", "ANATOMY", 101, 108], ["suggestive of", "UNCERTAINTY", 110, 123], ["complicated", "OBSERVATION_MODIFIER", 126, 137], ["incarcerated", "OBSERVATION_MODIFIER", 138, 150], ["inguinal", "ANATOMY", 151, 159], ["hernia", "OBSERVATION", 160, 166]]], ["His scrotum was grossly enlarged, erythematous and tender with evidence of subcutaneous crepitus (Fig. 1) .", [["scrotum", "ANATOMY", 4, 11], ["erythematous", "ANATOMY", 34, 46], ["subcutaneous crepitus", "ANATOMY", 75, 96], ["subcutaneous crepitus", "DISEASE", 75, 96], ["scrotum", "ORGAN", 4, 11], ["grossly enlarged", "PROBLEM", 16, 32], ["erythematous", "PROBLEM", 34, 46], ["tender", "PROBLEM", 51, 57], ["subcutaneous crepitus (Fig", "PROBLEM", 75, 101], ["scrotum", "ANATOMY", 4, 11], ["grossly", "OBSERVATION_MODIFIER", 16, 23], ["enlarged", "OBSERVATION", 24, 32], ["erythematous", "OBSERVATION_MODIFIER", 34, 46], ["tender", "OBSERVATION", 51, 57], ["subcutaneous", "ANATOMY", 75, 87], ["crepitus", "OBSERVATION", 88, 96], ["Fig", "OBSERVATION_MODIFIER", 98, 101]]], ["A digital rectal examination revealed a firm irregular low rectal mass with per rectal bleeding.", [["rectal", "ANATOMY", 10, 16], ["rectal mass", "ANATOMY", 59, 70], ["rectal", "ANATOMY", 80, 86], ["low rectal mass", "DISEASE", 55, 70], ["rectal bleeding", "DISEASE", 80, 95], ["rectal", "ORGAN", 10, 16], ["rectal", "ORGAN", 59, 65], ["rectal", "ORGANISM_SUBDIVISION", 80, 86], ["A digital rectal examination", "TEST", 0, 28], ["a firm irregular low rectal mass", "PROBLEM", 38, 70], ["rectal bleeding", "PROBLEM", 80, 95], ["rectal", "ANATOMY", 10, 16], ["firm", "OBSERVATION_MODIFIER", 40, 44], ["irregular", "OBSERVATION_MODIFIER", 45, 54], ["low", "OBSERVATION_MODIFIER", 55, 58], ["rectal", "ANATOMY", 59, 65], ["mass", "OBSERVATION", 66, 70], ["rectal", "ANATOMY", 80, 86], ["bleeding", "OBSERVATION", 87, 95]]]], "d1106741a9079d7bd78b3532d8fcde2fcf174dba": [["The diffusion of the novel coronavirus SARS-CoV-2 has rapidly spread worldwide, with several cases requiring intensive care and hospitalization because of the severe respiratory symptoms requiring assisting devices.", [["respiratory", "ANATOMY", 166, 177], ["SARS", "DISEASE", 39, 43], ["coronavirus SARS-CoV-2", "ORGANISM", 27, 49], ["coronavirus SARS-CoV", "SPECIES", 27, 47], ["SARS-CoV", "SPECIES", 39, 47], ["intensive care", "TREATMENT", 109, 123], ["the severe respiratory symptoms", "PROBLEM", 155, 186], ["assisting devices", "TREATMENT", 197, 214], ["rapidly", "OBSERVATION_MODIFIER", 54, 61], ["spread", "OBSERVATION_MODIFIER", 62, 68], ["worldwide", "OBSERVATION_MODIFIER", 69, 78], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["respiratory", "ANATOMY", 166, 177], ["symptoms", "OBSERVATION", 178, 186]]], ["Miller Fisher syndrome (MFS), a variant of Guillain-Barr\u00e9 syndrome (GBS), is characterized by the clinical triad of ophthalmoplegia, ataxia, and areflexia.", [["Fisher syndrome", "DISEASE", 7, 22], ["MFS", "DISEASE", 24, 27], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 43, 66], ["GBS", "DISEASE", 68, 71], ["ophthalmoplegia", "DISEASE", 116, 131], ["ataxia", "DISEASE", 133, 139], ["areflexia", "DISEASE", 145, 154], ["Guillain-Barr\u00e9", "ORGANISM", 43, 57], ["Miller Fisher syndrome", "PROBLEM", 0, 22], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 43, 66], ["GBS", "PROBLEM", 68, 71], ["ophthalmoplegia", "PROBLEM", 116, 131], ["ataxia", "PROBLEM", 133, 139], ["areflexia", "PROBLEM", 145, 154], ["Fisher syndrome", "OBSERVATION", 7, 22], ["Barr\u00e9 syndrome", "OBSERVATION", 52, 66], ["ophthalmoplegia", "OBSERVATION", 116, 131], ["areflexia", "OBSERVATION", 145, 154]]], ["About 60% of the above mentioned autoimmune syndromes can be infection-related by humoral and cellular cross-reactivity (Pusch et al. 2018) , most frequently gastrointestinal (Campylobacter jejuni) or respiratory tract infections, including influenza (Sellers et al. 2017) .", [["cellular", "ANATOMY", 94, 102], ["gastrointestinal", "ANATOMY", 158, 174], ["respiratory tract", "ANATOMY", 201, 218], ["autoimmune syndromes", "DISEASE", 33, 53], ["infection", "DISEASE", 61, 70], ["gastrointestinal (Campylobacter jejuni", "DISEASE", 158, 196], ["respiratory tract infections", "DISEASE", 201, 229], ["influenza", "DISEASE", 241, 250], ["cellular", "CELL", 94, 102], ["gastrointestinal", "ORGANISM_SUBDIVISION", 158, 174], ["Campylobacter jejuni", "ORGANISM", 176, 196], ["Campylobacter jejuni", "SPECIES", 176, 196], ["Campylobacter jejuni", "SPECIES", 176, 196], ["autoimmune syndromes", "PROBLEM", 33, 53], ["infection", "PROBLEM", 61, 70], ["frequently gastrointestinal (Campylobacter jejuni)", "PROBLEM", 147, 197], ["respiratory tract infections", "PROBLEM", 201, 229], ["influenza", "PROBLEM", 241, 250], ["autoimmune syndromes", "OBSERVATION", 33, 53], ["infection", "OBSERVATION", 61, 70], ["cellular cross-reactivity", "OBSERVATION", 94, 119], ["gastrointestinal", "ANATOMY", 158, 174], ["Campylobacter jejuni", "ANATOMY", 176, 196], ["respiratory tract", "ANATOMY", 201, 218]]]], "PMC7392427": [["The StudyWe used publicly available 2017 Behavioral Risk Factor Surveillance System (BRFSS) data (4) from telephone surveys of 444,649 randomly selected adults >18 years of age in the 50 states and the District of Columbia (DC).", [["DC", "ANATOMY", 224, 226]]], ["We chose to use 2017 data to include hypertension, which was not addressed in 2018.", [["hypertension", "DISEASE", 37, 49], ["hypertension", "PROBLEM", 37, 49], ["hypertension", "OBSERVATION", 37, 49]]], ["Weights and stratum variables needed for analysis were included.The StudyWe did not age-adjust results in order to reflect the age distribution of each state rather than a standard population.", [["stratum", "ANATOMY", 12, 19], ["Weights", "TEST", 0, 7], ["stratum variables", "TEST", 12, 29], ["analysis", "TEST", 41, 49]]], ["The median response rate for cell phone and landline surveys combined was 47.2%, ranging from 33.9% in California to 61.1% in Utah (5).", [["cell", "ANATOMY", 29, 33], ["cell", "CELL", 29, 33], ["landline surveys", "TEST", 44, 60]]], ["Reliability and validity of the BRFSS have been found to be moderate to high for many survey measures, in particular those used here, which can be checked versus medical records (6).The StudyThe key variable was a composite measure including adults reporting that they were ever told they had CVD (heart attack, angina, coronary heart disease, or stroke), diabetes, asthma, chronic obstructive pulmonary disease, hypertension, or cancer other than skin.", [["heart", "ANATOMY", 298, 303], ["coronary", "ANATOMY", 320, 328], ["heart", "ANATOMY", 329, 334], ["pulmonary", "ANATOMY", 394, 403], ["cancer", "ANATOMY", 430, 436], ["skin", "ANATOMY", 448, 452], ["CVD", "DISEASE", 293, 296], ["heart attack", "DISEASE", 298, 310], ["angina", "DISEASE", 312, 318], ["coronary heart disease", "DISEASE", 320, 342], ["stroke", "DISEASE", 347, 353], ["diabetes", "DISEASE", 356, 364], ["asthma", "DISEASE", 366, 372], ["chronic obstructive pulmonary disease", "DISEASE", 374, 411], ["hypertension", "DISEASE", 413, 425], ["cancer", "DISEASE", 430, 436], ["heart", "ORGAN", 298, 303], ["heart", "ORGAN", 329, 334], ["pulmonary", "ORGAN", 394, 403], ["cancer", "CANCER", 430, 436], ["skin", "ORGAN", 448, 452], ["the BRFSS", "TEST", 28, 37], ["The Study", "TEST", 182, 191], ["CVD (heart attack", "PROBLEM", 293, 310], ["angina", "PROBLEM", 312, 318], ["coronary heart disease", "PROBLEM", 320, 342], ["stroke", "PROBLEM", 347, 353], ["diabetes", "PROBLEM", 356, 364], ["asthma", "PROBLEM", 366, 372], ["chronic obstructive pulmonary disease", "PROBLEM", 374, 411], ["hypertension", "PROBLEM", 413, 425], ["cancer", "PROBLEM", 430, 436], ["heart", "ANATOMY", 298, 303], ["coronary heart", "ANATOMY", 320, 334], ["disease", "OBSERVATION", 335, 342], ["stroke", "OBSERVATION", 347, 353], ["asthma", "OBSERVATION", 366, 372], ["chronic", "OBSERVATION_MODIFIER", 374, 381], ["obstructive", "OBSERVATION_MODIFIER", 382, 393], ["pulmonary", "ANATOMY", 394, 403], ["disease", "OBSERVATION", 404, 411], ["hypertension", "OBSERVATION", 413, 425], ["cancer", "OBSERVATION", 430, 436], ["skin", "ANATOMY", 448, 452]]], ["We counted the number of chronic conditions for each respondent and adults who reported >1 condition and were considered to be at heightened risk for complications from COVID-19.", [["chronic conditions", "PROBLEM", 25, 43], ["complications", "PROBLEM", 150, 163], ["COVID", "TEST", 169, 174], ["chronic", "OBSERVATION_MODIFIER", 25, 32]]], ["A secondary measure was receipt of a seasonal influenza vaccination in the past year as a rough estimate of potential demand for a COVID-19 vaccine when available.The StudyDemographic measures included age group (18\u201329, 30\u201339, 40\u201349, 50\u201359, 60\u201369, 70\u201379, and >80 years of age; we created these measures by combining 5-year age groups provided in the dataset); self-reported race/ethnicity (non-Hispanic White, Black or African American, Hispanic of any race, American Indian/Alaska native, Asian/Pacific Islander, and other); health insurance coverage (any kind of healthcare coverage, including health insurance, prepaid plans such as health maintenance organizations, or government plans such as Medicare, or Indian Health Service); employment status (employed or self-employed, out of work, homemaker, student, retired, or unable to work); and state of residence, which included DC.The StudyWe used Stata version 14.1 (StataCorp LP, https://www.stata.com) for analysis to account for the complex sample design of the BRFSS.", [["DC", "ANATOMY", 882, 884], ["DC", "CELL_TYPE", 882, 884], ["a seasonal influenza vaccination", "TREATMENT", 35, 67], ["a COVID-19 vaccine", "TREATMENT", 129, 147], ["Stata version", "TEST", 902, 915], ["StataCorp LP", "TEST", 922, 934], ["analysis", "TEST", 963, 971]]], ["Missing values were excluded from analysis.The StudyAmong 444,649 survey respondents, 48.7% were male, 13.9% were >70 years of age, 63.3% were white, 18.2% were retired, and 12.1% were uninsured.", [["Missing values", "TEST", 0, 14], ["analysis", "TEST", 34, 42], ["white", "TEST", 143, 148]]], ["We obtained similar results for the study sample when 11,508 records that had missing values were removed.", [["the study sample", "TEST", 32, 48]]], ["Overall, 45.4% (95% CI 45.1%\u201345.7%) of respondents fit the description of being at heightened risk for complications from COVID-19.The StudyAmong all adults, 26.7% (95% CI 26.5%\u201327.0%) reported 1 chronic condition, 12.0% (95% CI 11.8%\u201312.2%) reported 2 chronic conditions, 4.7% (95% CI 4.6%\u20134.8%) reported 3 chronic conditions, and 2.0% (95% CI 1.9%\u20132.1%) reported >4 chronic conditions.", [["Overall", "TEST", 0, 7], ["CI", "TEST", 20, 22], ["complications", "PROBLEM", 103, 116], ["COVID", "TEST", 122, 127], ["CI", "TEST", 169, 171], ["chronic condition", "TEST", 196, 213], ["CI", "TEST", 226, 228], ["\u2013", "TEST", 234, 235], ["2 chronic conditions", "PROBLEM", 251, 271], ["CI", "TEST", 283, 285], ["\u2013", "TEST", 290, 291], ["3 chronic conditions", "PROBLEM", 306, 326], ["CI", "TEST", 342, 344], ["4 chronic conditions", "PROBLEM", 366, 386], ["chronic", "OBSERVATION_MODIFIER", 196, 203], ["chronic", "OBSERVATION_MODIFIER", 368, 375]]], ["Prevalence rates of separate chronic conditions were 8.5% for CVD, 6.6% for chronic obstructive pulmonary disease, 9.1% for asthma (and still have it), 10.8% for diabetes, 32.4% for hypertension, and 6.8% for cancer.", [["pulmonary", "ANATOMY", 96, 105], ["cancer", "ANATOMY", 209, 215], ["CVD", "DISEASE", 62, 65], ["chronic obstructive pulmonary disease", "DISEASE", 76, 113], ["asthma", "DISEASE", 124, 130], ["diabetes", "DISEASE", 162, 170], ["hypertension", "DISEASE", 182, 194], ["cancer", "DISEASE", 209, 215], ["pulmonary", "ORGAN", 96, 105], ["cancer", "CANCER", 209, 215], ["separate chronic conditions", "TREATMENT", 20, 47], ["CVD", "TEST", 62, 65], ["chronic obstructive pulmonary disease", "PROBLEM", 76, 113], ["asthma", "PROBLEM", 124, 130], ["diabetes", "PROBLEM", 162, 170], ["hypertension", "PROBLEM", 182, 194], ["cancer", "PROBLEM", 209, 215], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["obstructive", "OBSERVATION_MODIFIER", 84, 95], ["pulmonary", "ANATOMY", 96, 105], ["disease", "OBSERVATION", 106, 113], ["cancer", "OBSERVATION", 209, 215]]], ["Although the percentage of adults with any of the chronic conditions increased with age (Table 1), more than half (53.4%) of the total were 18\u201359 years of age.", [["the chronic conditions", "PROBLEM", 46, 68], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["conditions", "OBSERVATION", 58, 68], ["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["Rates also varied by state, race/ethnicity, insurance status, and employment, but not by sex (Table 1).The StudyState results obtained directly from Stata (Table 2) list the number of adults in each state at increased risk for complications and the percentage that number represents among all states.", [["adults", "ORGANISM", 184, 190], ["The StudyState results", "TEST", 103, 125], ["complications", "PROBLEM", 227, 240]]], ["Results for reporting a seasonal influenza vaccination in the past year were 40.3% (95% CI 40.0%\u201340.6%) for all adults, including 33.7% (95% CI 33.3%\u201334.2%) for adults who had none of the chronic conditions and 48.0% (95% CI 47.5%\u201348.5%) for persons who had any of the 6 chronic conditions.ConclusionsWe estimated that 45.4% of US adults, with a wide range across age groups and states, might be at increased risks for complications from COVID-19 because of existing chronic conditions.", [["influenza", "DISEASE", 33, 42], ["persons", "ORGANISM", 242, 249], ["persons", "SPECIES", 242, 249], ["a seasonal influenza vaccination", "PROBLEM", 22, 54], ["CI", "TEST", 88, 90], ["CI", "TEST", 141, 143], ["the chronic conditions", "PROBLEM", 184, 206], ["CI", "TEST", 222, 224], ["the 6 chronic conditions", "PROBLEM", 265, 289], ["US adults", "TEST", 328, 337], ["complications", "PROBLEM", 419, 432], ["COVID", "TEST", 438, 443], ["existing chronic conditions", "PROBLEM", 458, 485], ["chronic", "OBSERVATION_MODIFIER", 188, 195], ["chronic", "OBSERVATION_MODIFIER", 467, 474], ["conditions", "OBSERVATION", 475, 485]]], ["The 18.7% who reported >2 chronic conditions might be at even greater risk on the basis of other studies (7).", [["2 chronic conditions", "PROBLEM", 24, 44], ["other studies", "TEST", 91, 104]]], ["Although complication rates increased with increasing age, 53% of those at greater risk for complications were <60 years of age.", [["complication rates", "PROBLEM", 9, 27], ["complications", "PROBLEM", 92, 105], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["increasing", "OBSERVATION_MODIFIER", 43, 53]]], ["Preliminary data suggest that some of these same chronic conditions increase risk for COVID-19 complications in the United States (8).", [["COVID", "DISEASE", 86, 91], ["Preliminary data", "TEST", 0, 16], ["these same chronic conditions", "PROBLEM", 38, 67], ["COVID-19 complications", "PROBLEM", 86, 108]]], ["Another BRFSS study that omitted hypertension and used a different definition of risk estimated that 37.6% of US adults were at risk for complications (9).ConclusionsThe list of chronic conditions used in our analysis is similar to groups at increased risk for seasonal influenza complications (10), except that the influenza group includes obese adults.", [["hypertension", "DISEASE", 33, 45], ["influenza complications", "DISEASE", 270, 293], ["influenza", "DISEASE", 316, 325], ["adults", "ORGANISM", 113, 119], ["adults", "ORGANISM", 347, 353], ["Another BRFSS study", "TEST", 0, 19], ["hypertension", "PROBLEM", 33, 45], ["complications", "PROBLEM", 137, 150], ["chronic conditions", "PROBLEM", 178, 196], ["our analysis", "TEST", 205, 217], ["seasonal influenza complications", "PROBLEM", 261, 293], ["the influenza group", "PROBLEM", 312, 331], ["obese adults", "PROBLEM", 341, 353], ["hypertension", "OBSERVATION", 33, 45], ["chronic", "OBSERVATION_MODIFIER", 178, 185]]], ["Obesity is much lower in China than in the United States (11), which might account for that difference.", [["Obesity", "DISEASE", 0, 7], ["Obesity", "PROBLEM", 0, 7], ["much", "OBSERVATION_MODIFIER", 11, 15], ["lower", "OBSERVATION_MODIFIER", 16, 21], ["might account for", "UNCERTAINTY", 69, 86]]], ["Both lists include persons with chronic diseases for which behavioral risk factors have been well identified (12,13).", [["chronic diseases", "DISEASE", 32, 48], ["persons", "ORGANISM", 19, 26], ["persons", "SPECIES", 19, 26], ["chronic diseases", "PROBLEM", 32, 48], ["behavioral risk factors", "PROBLEM", 59, 82], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["diseases", "OBSERVATION", 40, 48]]], ["In particular, the 7 risk factors of smoking, sedentary lifestyle, obesity, diabetes, hypertension, high cholesterol, and inadequate fruit and vegetable consumption together contributed to an average of 41.4% of the burden of 5 of the 6 chronic conditions used in our study (all except cancer); obesity and smoking contributed the most to the burden (12).", [["vegetable", "ANATOMY", 143, 152], ["cancer", "ANATOMY", 286, 292], ["smoking", "CHEMICAL", 37, 44], ["obesity", "DISEASE", 67, 74], ["diabetes", "DISEASE", 76, 84], ["hypertension", "DISEASE", 86, 98], ["cholesterol", "CHEMICAL", 105, 116], ["cancer", "DISEASE", 286, 292], ["obesity", "DISEASE", 295, 302], ["smoking", "CHEMICAL", 307, 314], ["cholesterol", "CHEMICAL", 105, 116], ["cholesterol", "SIMPLE_CHEMICAL", 105, 116], ["fruit", "ORGANISM_SUBDIVISION", 133, 138], ["vegetable", "ORGANISM_SUBDIVISION", 143, 152], ["cancer", "CANCER", 286, 292], ["obesity", "PROBLEM", 67, 74], ["diabetes", "PROBLEM", 76, 84], ["hypertension", "PROBLEM", 86, 98], ["high cholesterol", "PROBLEM", 100, 116], ["inadequate fruit", "PROBLEM", 122, 138], ["the 6 chronic conditions", "PROBLEM", 231, 255], ["our study", "TEST", 264, 273], ["cancer", "PROBLEM", 286, 292], ["obesity", "PROBLEM", 295, 302], ["obesity", "OBSERVATION", 67, 74], ["diabetes", "OBSERVATION", 76, 84], ["hypertension", "OBSERVATION", 86, 98], ["high cholesterol", "OBSERVATION", 100, 116], ["cancer", "OBSERVATION", 286, 292], ["obesity", "OBSERVATION", 295, 302]]], ["Results showing seasonal influenza vaccination rates <50% are concerning.", [["seasonal influenza vaccination rates", "PROBLEM", 16, 52], ["seasonal", "OBSERVATION_MODIFIER", 16, 24], ["influenza", "OBSERVATION", 25, 34]]], ["Although a vaccine specific for this coronavirus is currently unavailable, results for seasonal influenza vaccination suggest that it might not be widely used.ConclusionsOur study does not address possible differences in contracting the disease, only the risk for development of complications among persons who have COVID-19 on the basis of results for China (1\u20133).", [["influenza", "DISEASE", 96, 105], ["coronavirus", "ORGANISM", 37, 48], ["persons", "ORGANISM", 299, 306], ["coronavirus", "SPECIES", 37, 48], ["persons", "SPECIES", 299, 306], ["coronavirus", "SPECIES", 37, 48], ["a vaccine", "TREATMENT", 9, 18], ["this coronavirus", "PROBLEM", 32, 48], ["seasonal influenza vaccination", "TREATMENT", 87, 117], ["Our study", "TEST", 170, 179], ["the disease", "PROBLEM", 233, 244], ["COVID", "TEST", 316, 321], ["disease", "OBSERVATION", 237, 244]]], ["However, as long as a respondent was told they had a chronic condition, validity was high.", [["a chronic condition", "PROBLEM", 51, 70], ["chronic", "OBSERVATION_MODIFIER", 53, 60]]], ["Age groups used for analysis did not match those used for weighting data, but that limitation should have a minimal effect on results.", [["analysis", "TEST", 20, 28], ["weighting data", "TEST", 58, 72]]], ["Low response rates could introduce bias but, as noted, validity appears high for the measures used in this study.ConclusionsWe estimated that 45.4% of US adults are potentially at increased risk for complications from COVID-19 because of chronic conditions that are, in turn, associated with common modifiable risk factors.", [["adults", "ORGANISM", 154, 160], ["Low response rates", "PROBLEM", 0, 18], ["this study", "TEST", 102, 112], ["complications", "PROBLEM", 199, 212], ["COVID", "TEST", 218, 223], ["chronic conditions", "PROBLEM", 238, 256], ["common modifiable risk factors", "PROBLEM", 292, 322], ["chronic", "OBSERVATION_MODIFIER", 238, 245], ["conditions", "OBSERVATION", 246, 256]]], ["Such estimates will vary depending on exact criteria used and the prevalence of the risk factors associated with the chronic conditions, along with age, state of residence, and other demographic factors.", [["the risk factors", "PROBLEM", 80, 96], ["the chronic conditions", "PROBLEM", 113, 135], ["chronic", "OBSERVATION_MODIFIER", 117, 124]]]], "123aeb506a00c84bc0ba38d819b62c3b027edc16": [["IntroductionIsatin (1H-indole-2,3-dione) is a privileged natural product found in various plants including those of the genus Isatis (Guo and Chen, 1986) and has also been found in humans as a metabolic derivative of adrenaline (Ischia et al., 1988) .", [["IntroductionIsatin (1H-indole-2,3-dione", "CHEMICAL", 0, 39], ["adrenaline", "CHEMICAL", 217, 227], ["IntroductionIsatin", "CHEMICAL", 0, 18], ["1H-indole-2,3-dione", "CHEMICAL", 20, 39], ["adrenaline", "CHEMICAL", 217, 227], ["IntroductionIsatin", "SIMPLE_CHEMICAL", 0, 18], ["1H-indole-2,3-dione", "SIMPLE_CHEMICAL", 20, 39], ["humans", "ORGANISM", 181, 187], ["adrenaline", "SIMPLE_CHEMICAL", 217, 227], ["humans", "SPECIES", 181, 187], ["humans", "SPECIES", 181, 187], ["IntroductionIsatin", "TEST", 0, 18]]], ["The synthetic flexibility of isatin has led to the synthesis of an array of substituted derivatives displaying a broad spectrum of biological properties and the derivatives have been developed for therapeutic applications.", [["isatin", "CHEMICAL", 29, 35], ["isatin", "CHEMICAL", 29, 35], ["isatin", "SIMPLE_CHEMICAL", 29, 35], ["substituted derivatives", "TREATMENT", 76, 99], ["the derivatives", "TREATMENT", 157, 172], ["therapeutic applications", "TREATMENT", 197, 221]]], ["The various biological properties of isatin include, antibacterial/antifungal (Varma and Nobles 1975) , antiviral (Varma and Nobles 1967) , anticancer (Matesic et al., 2008) , anti-HIV/ antitubercular (Sriram et al., 2006) , antiprotozoal (Raj et al., 2012, Imam and , antihelminthic (El-Sawi et al., 1998) and other biological activities (Silva et al., 2001 , Pandeya et al., 2005 .IntroductionOn the other hand substituted isatin derivatives have been reported to possess DNA gyrase inhibitor (Oblack et al., 2005) , human rhinovirus 3C protease inhibitor (Webber et al., 1996) , SARS corona virus 3C-like protease inhibitor (Zhou et al., 2006) and caspase-3 inhibitor activities (Chu et al., 2005) .", [["anticancer", "ANATOMY", 140, 150], ["isatin", "CHEMICAL", 37, 43], ["isatin", "CHEMICAL", 425, 431], ["isatin", "CHEMICAL", 37, 43], ["isatin", "CHEMICAL", 425, 431], ["isatin", "SIMPLE_CHEMICAL", 37, 43], ["anticancer", "CANCER", 140, 150], ["isatin derivatives", "SIMPLE_CHEMICAL", 425, 443], ["DNA", "CELLULAR_COMPONENT", 474, 477], ["human", "ORGANISM", 519, 524], ["rhinovirus 3C", "ORGANISM", 525, 538], ["SARS corona virus 3C", "ORGANISM", 582, 602], ["caspase-3", "GENE_OR_GENE_PRODUCT", 651, 660], ["HIV", "SPECIES", 181, 184], ["human", "SPECIES", 519, 524], ["HIV", "SPECIES", 181, 184], ["human rhinovirus 3C", "SPECIES", 519, 538], ["SARS corona virus", "SPECIES", 582, 599], ["isatin", "TREATMENT", 37, 43], ["antibacterial/antifungal (Varma", "TREATMENT", 53, 84], ["antiviral (Varma", "TREATMENT", 104, 120], ["anti-HIV/ antitubercular (Sriram et", "TREATMENT", 176, 211], ["IntroductionOn the other hand substituted isatin derivatives", "TREATMENT", 383, 443], ["DNA gyrase inhibitor", "TREATMENT", 474, 494], ["human rhinovirus 3C protease inhibitor", "TREATMENT", 519, 557], ["SARS corona virus 3C", "TREATMENT", 582, 602], ["protease inhibitor", "TREATMENT", 608, 626], ["caspase", "TREATMENT", 651, 658]]], ["Investigation of the structureactivity relationships of isatin derivatives has revealed that 5-halogenated (Sriram et al., 2005) and N-alkylated isatin (Chen et al., 2005; Singh et al., 2011) derivatives are proved to be showing marked rise in biological activity.", [["isatin", "CHEMICAL", 56, 62], ["5-halogenated", "CHEMICAL", 93, 106], ["N-alkylated isatin", "CHEMICAL", 133, 151], ["isatin", "CHEMICAL", 56, 62], ["N-alkylated isatin", "CHEMICAL", 133, 151], ["isatin derivatives", "SIMPLE_CHEMICAL", 56, 74], ["5-halogenated", "SIMPLE_CHEMICAL", 93, 106], ["N-alkylated isatin", "SIMPLE_CHEMICAL", 133, 151], ["isatin derivatives", "TREATMENT", 56, 74], ["N-alkylated isatin", "TREATMENT", 133, 151], ["marked rise in biological activity", "PROBLEM", 229, 263], ["marked", "OBSERVATION_MODIFIER", 229, 235], ["rise", "OBSERVATION_MODIFIER", 236, 240], ["biological activity", "OBSERVATION", 244, 263]]], ["For example compound 5-fluoro-3-substituted-2-oxindole (SU11248) has been approved by FDA for the treatment of gastrointestinal stromal tumours and advanced renal cell carcinoma (Prenen et al., 2006; Motzer et al., 2006) .IntroductionInspired with the biological profile of isatins and their increasing importance in pharmaceutical and biological fields, and in connection with our research on the design and synthesis of biologically active and pharmacologically important new heterocycles (Narender et al., 2006; Ravinder et al., 2010 Ravinder et al., , 2012 , it was thought worthwhile to synthesize the title compounds with a view to obtain certain new chemical entities in order to prepare molecules having potentially enhanced biological activities and to have them evaluated for their bioactivity.", [["gastrointestinal stromal tumours", "ANATOMY", 111, 143], ["renal cell carcinoma", "ANATOMY", 157, 177], ["5-fluoro-3-substituted-2-oxindole", "CHEMICAL", 21, 54], ["SU11248", "CHEMICAL", 56, 63], ["gastrointestinal stromal tumours", "DISEASE", 111, 143], ["renal cell carcinoma", "DISEASE", 157, 177], ["isatins", "CHEMICAL", 274, 281], ["5-fluoro-3-substituted-2-oxindole", "CHEMICAL", 21, 54], ["SU11248", "CHEMICAL", 56, 63], ["isatins", "CHEMICAL", 274, 281], ["heterocycles", "CHEMICAL", 478, 490], ["5-fluoro-3-substituted-2-oxindole", "SIMPLE_CHEMICAL", 21, 54], ["SU11248", "SIMPLE_CHEMICAL", 56, 63], ["gastrointestinal stromal tumours", "CANCER", 111, 143], ["renal cell carcinoma", "CANCER", 157, 177], ["isatins", "SIMPLE_CHEMICAL", 274, 281], ["fluoro", "TEST", 23, 29], ["gastrointestinal stromal tumours", "PROBLEM", 111, 143], ["advanced renal cell carcinoma", "PROBLEM", 148, 177], ["gastrointestinal", "ANATOMY", 111, 127], ["stromal tumours", "OBSERVATION", 128, 143], ["advanced", "OBSERVATION_MODIFIER", 148, 156], ["renal", "ANATOMY", 157, 162], ["cell carcinoma", "OBSERVATION", 163, 177]]], ["Herein, we report the synthesis of Baylis-Hillman adduct-derived N-cinnamyl-substituted isatin derivatives and screening of their antitubercular and anticancer activity.ChemistryThe starting substrates, 5-halo-isatin derivatives (2a-d) were obtained commercially whereas Baylis-Hillman bromides (1a-c) were prepared by treating Baylis-Hillman adducts (Basavaiah et al., 2010; Sing and Batra 2008) with conc.", [["anticancer", "ANATOMY", 149, 159], ["N-cinnamyl-substituted isatin", "CHEMICAL", 65, 94], ["5-halo-isatin", "CHEMICAL", 203, 216], ["Baylis-Hillman bromides", "CHEMICAL", 271, 294], ["1a-c", "CHEMICAL", 296, 300], ["N-cinnamyl-substituted isatin", "CHEMICAL", 65, 94], ["5-halo-isatin", "CHEMICAL", 203, 216], ["Baylis-Hillman bromides", "CHEMICAL", 271, 294], ["Baylis-Hillman adduct-derived N-cinnamyl-substituted isatin derivatives", "SIMPLE_CHEMICAL", 35, 106], ["anticancer", "CANCER", 149, 159], ["5-halo-isatin derivatives", "SIMPLE_CHEMICAL", 203, 228], ["2a-d", "SIMPLE_CHEMICAL", 230, 234], ["Baylis-Hillman bromides", "SIMPLE_CHEMICAL", 271, 294], ["1a-c", "SIMPLE_CHEMICAL", 296, 300], ["Baylis-Hillman adducts", "SIMPLE_CHEMICAL", 328, 350], ["Baylis", "TEST", 35, 41], ["Hillman adduct", "TREATMENT", 42, 56], ["cinnamyl", "TREATMENT", 67, 75], ["substituted isatin derivatives", "TREATMENT", 76, 106], ["screening", "TREATMENT", 111, 120], ["their antitubercular and anticancer activity", "TREATMENT", 124, 168], ["Chemistry", "TEST", 169, 178], ["substrates", "TEST", 191, 201], ["halo-isatin derivatives", "TREATMENT", 205, 228], ["Hillman bromides", "TREATMENT", 278, 294], ["anticancer activity", "OBSERVATION", 149, 168]]], ["HBr at 0\u00b0C in DCM solvent (Buchholz and Hoffmann 1991) .", [["HBr", "CHEMICAL", 0, 3], ["HBr", "SIMPLE_CHEMICAL", 0, 3], ["HBr", "PROBLEM", 0, 3]]], ["During the optimization studies, we focused our efforts on searching suitable reaction conditions for the preparation of target compounds.", [["the optimization studies", "TEST", 7, 31], ["searching suitable reaction conditions", "TREATMENT", 59, 97]]], ["Initially, the reaction was carried out between Baylis-Hillman bromide (1a) and isatin (2a) using different bases such as NaH, KOH, K 2 CO 3 , NEt 3 , NaOMe and in various solvents such as DMF, acetonitrile and MeOH (Scheme 1).", [["Baylis-Hillman bromide", "CHEMICAL", 48, 70], ["isatin", "CHEMICAL", 80, 86], ["NaH", "CHEMICAL", 122, 125], ["KOH", "CHEMICAL", 127, 130], ["K", "CHEMICAL", 132, 133], ["NEt 3 , NaOMe", "CHEMICAL", 143, 156], ["DMF, acetonitrile and MeOH", "CHEMICAL", 189, 215], ["bromide", "CHEMICAL", 63, 70], ["isatin", "CHEMICAL", 80, 86], ["NaH", "CHEMICAL", 122, 125], ["KOH", "CHEMICAL", 127, 130], ["K 2 CO 3", "CHEMICAL", 132, 140], ["NEt 3", "CHEMICAL", 143, 148], ["NaOMe", "CHEMICAL", 151, 156], ["DMF", "CHEMICAL", 189, 192], ["acetonitrile", "CHEMICAL", 194, 206], ["MeOH", "CHEMICAL", 211, 215], ["Baylis-Hillman bromide", "SIMPLE_CHEMICAL", 48, 70], ["1a)", "SIMPLE_CHEMICAL", 72, 75], ["isatin (2a)", "SIMPLE_CHEMICAL", 80, 91], ["NaH", "SIMPLE_CHEMICAL", 122, 125], ["KOH", "SIMPLE_CHEMICAL", 127, 130], ["K 2 CO 3", "SIMPLE_CHEMICAL", 132, 140], ["NEt 3", "SIMPLE_CHEMICAL", 143, 148], ["NaOMe", "SIMPLE_CHEMICAL", 151, 156], ["DMF", "SIMPLE_CHEMICAL", 189, 192], ["acetonitrile", "SIMPLE_CHEMICAL", 194, 206], ["MeOH", "SIMPLE_CHEMICAL", 211, 215], ["the reaction", "PROBLEM", 11, 23], ["Baylis-Hillman bromide", "TREATMENT", 48, 70], ["isatin (2a)", "TREATMENT", 80, 91], ["KOH", "TEST", 127, 130], ["K", "TEST", 132, 133], ["NEt", "TEST", 143, 146], ["various solvents", "TREATMENT", 164, 180], ["DMF", "TREATMENT", 189, 192], ["acetonitrile", "TREATMENT", 194, 206], ["MeOH (Scheme", "TREATMENT", 211, 223], ["bases", "ANATOMY_MODIFIER", 108, 113]]], ["In our study, it was observed that K 2 CO 3 in acetonitrile was suitable to promote and complete the reaction in which the product (3a) was obtained in good yield (87 %).", [["K", "CHEMICAL", 35, 36], ["acetonitrile", "CHEMICAL", 47, 59], ["CO 3", "CHEMICAL", 39, 43], ["acetonitrile", "CHEMICAL", 47, 59], ["K 2 CO 3", "SIMPLE_CHEMICAL", 35, 43], ["acetonitrile", "SIMPLE_CHEMICAL", 47, 59], ["our study", "TEST", 3, 12], ["K 2 CO", "TEST", 35, 41], ["the reaction", "PROBLEM", 97, 109]]], ["From mechanistic view, the nucleophile can attack on allyl bromide of Baylis-Hillman adduct in two fashions (S N 2 and S N 2 0 ) leading to the formation of two products (I and II) as shown in Scheme 2, literature also revealed the formation of two types of products while treating the Baylis-Hillman bromides (Buchholz and Hoffmann 1991) with nucleophile; but in our study, in this reaction only S N 2-type product was obtained exclusively rather than S N 2 0 -type product.", [["allyl bromide", "CHEMICAL", 53, 66], ["Baylis-Hillman", "CHEMICAL", 70, 84], ["Baylis-Hillman bromides", "CHEMICAL", 286, 309], ["Buchholz", "CHEMICAL", 311, 319], ["S N 2-type", "CHEMICAL", 397, 407], ["allyl bromide", "CHEMICAL", 53, 66], ["Baylis-Hillman", "CHEMICAL", 70, 84], ["Baylis-Hillman bromides", "CHEMICAL", 286, 309], ["Buchholz", "CHEMICAL", 311, 319], ["S N", "CHEMICAL", 397, 400], ["allyl bromide", "SIMPLE_CHEMICAL", 53, 66], ["Baylis-Hillman adduct", "SIMPLE_CHEMICAL", 70, 91], ["S N 2 0", "SIMPLE_CHEMICAL", 119, 126], ["Baylis-Hillman bromides", "SIMPLE_CHEMICAL", 286, 309], ["Buchholz", "SIMPLE_CHEMICAL", 311, 319], ["S N 2-type", "SIMPLE_CHEMICAL", 397, 407], ["I and II", "PROTEIN", 171, 179], ["allyl bromide", "TREATMENT", 53, 66], ["Baylis", "TEST", 70, 76], ["products", "TREATMENT", 258, 266], ["the Baylis-Hillman bromides", "TREATMENT", 282, 309], ["nucleophile", "TREATMENT", 344, 355], ["our study", "TEST", 364, 373], ["this reaction", "PROBLEM", 378, 391]]], ["We reasoned that bulky isatin nucleophile fails to attack at bposition of the Baylis-Hillman bromide (S N 2 0 path) due to steric repulsion gained by aromatic group, hence it is attacking at steric-free allyl carbon having bromide group via S N 2 path and leads to the compound I exclusively which is confirmed by spectral analysis.", [["isatin", "CHEMICAL", 23, 29], ["Baylis-Hillman bromide", "CHEMICAL", 78, 100], ["S N", "CHEMICAL", 102, 105], ["allyl carbon", "CHEMICAL", 203, 215], ["bromide", "CHEMICAL", 223, 230], ["isatin", "CHEMICAL", 23, 29], ["bromide", "CHEMICAL", 93, 100], ["S N 2 0", "CHEMICAL", 102, 109], ["allyl carbon", "CHEMICAL", 203, 215], ["bromide", "CHEMICAL", 223, 230], ["S N", "CHEMICAL", 241, 244], ["isatin nucleophile", "SIMPLE_CHEMICAL", 23, 41], ["Baylis-Hillman bromide", "SIMPLE_CHEMICAL", 78, 100], ["allyl carbon", "SIMPLE_CHEMICAL", 203, 215], ["bromide", "SIMPLE_CHEMICAL", 223, 230], ["bulky isatin nucleophile", "TREATMENT", 17, 41], ["the Baylis-Hillman bromide", "TREATMENT", 74, 100], ["steric repulsion", "PROBLEM", 123, 139], ["steric-free allyl carbon", "TREATMENT", 191, 215], ["bromide group via S N 2 path", "TREATMENT", 223, 251], ["spectral analysis", "TEST", 314, 331], ["steric repulsion", "OBSERVATION", 123, 139]]], ["A series of compounds (3b-l) were synthesized with this optimized conditions in good yields (80-93 %).", [["3b-l", "SIMPLE_CHEMICAL", 23, 27], ["compounds (3b-l)", "TREATMENT", 12, 28]]], ["All the products synthesized were well characterized by spectroscopic techniques.", [["spectroscopic techniques", "TEST", 56, 80]]], ["Thus the synthesized products were screened for their anticancer activity against four different cell lines by MTT assay method and antituberculosis activity against Mycobacterium tuberculosis H 37 Rv strain ATCC 27294 by agar dilution method.Antitubercular studiesAll the synthesized compounds (3a-l) were screened for their in vitro antitubercular activity against MTB (M. tuberculosis H 37 Rv strain ATCC 27294) by agar dilution method for the determination of MIC in duplicate.", [["anticancer", "ANATOMY", 54, 64], ["cell lines", "ANATOMY", 97, 107], ["ATCC 27294", "ANATOMY", 403, 413], ["Mycobacterium tuberculosis", "DISEASE", 166, 192], ["ATCC 27294", "CHEMICAL", 208, 218], ["ATCC 27294", "CHEMICAL", 403, 413], ["MIC", "CHEMICAL", 464, 467], ["MTT", "CHEMICAL", 111, 114], ["anticancer", "CANCER", 54, 64], ["cell lines", "CELL", 97, 107], ["3a-l", "SIMPLE_CHEMICAL", 296, 300], ["M. tuberculosis H 37", "ORGANISM", 372, 392], ["cell lines", "CELL_LINE", 97, 107], ["Mycobacterium tuberculosis", "SPECIES", 166, 192], ["M. tuberculosis", "SPECIES", 372, 387], ["Mycobacterium tuberculosis H 37 Rv strain ATCC 27294", "SPECIES", 166, 218], ["M. tuberculosis H 37 Rv strain ATCC 27294", "SPECIES", 372, 413], ["the synthesized products", "TREATMENT", 5, 29], ["four different cell lines", "TREATMENT", 82, 107], ["MTT assay method", "TEST", 111, 127], ["antituberculosis activity", "TEST", 132, 157], ["Mycobacterium tuberculosis H", "PROBLEM", 166, 194], ["Rv strain ATCC", "TEST", 198, 212], ["agar dilution method", "TEST", 222, 242], ["Antitubercular studies", "TEST", 243, 265], ["MTB", "PROBLEM", 367, 370], ["Rv strain ATCC", "TEST", 393, 407], ["cell lines", "OBSERVATION", 97, 107]]], ["The minimum inhibitory concentration (MIC; lg/mL) was determined for each compound.", [["The minimum inhibitory concentration (MIC; lg/mL", "TREATMENT", 0, 48]]], ["The MIC is defined as the minimum concentration of compound required to completely inhibit the bacterial growth.", [["The MIC", "TREATMENT", 0, 7], ["the bacterial growth", "PROBLEM", 91, 111], ["bacterial", "OBSERVATION_MODIFIER", 95, 104], ["growth", "OBSERVATION_MODIFIER", 105, 111]]], ["Rifampicin, Isoniazid, Ethambutol and Pyrazinamide were used as reference drugs.", [["Rifampicin", "CHEMICAL", 0, 10], ["Isoniazid", "CHEMICAL", 12, 21], ["Ethambutol", "CHEMICAL", 23, 33], ["Pyrazinamide", "CHEMICAL", 38, 50], ["Rifampicin", "CHEMICAL", 0, 10], ["Isoniazid", "CHEMICAL", 12, 21], ["Ethambutol", "CHEMICAL", 23, 33], ["Pyrazinamide", "CHEMICAL", 38, 50], ["Rifampicin", "SIMPLE_CHEMICAL", 0, 10], ["Isoniazid", "SIMPLE_CHEMICAL", 12, 21], ["Ethambutol", "SIMPLE_CHEMICAL", 23, 33], ["Pyrazinamide", "SIMPLE_CHEMICAL", 38, 50], ["Rifampicin", "TREATMENT", 0, 10], ["Isoniazid", "TREATMENT", 12, 21], ["Ethambutol", "TREATMENT", 23, 33], ["Pyrazinamide", "TREATMENT", 38, 50]]], ["The results of in vitro antitubercular activities (MIC in lg/mL) along with the standard drugs for comparison are summarized in Table 1 .", [["vitro antitubercular activities (MIC in lg/mL)", "TREATMENT", 18, 64], ["the standard drugs", "TREATMENT", 76, 94]]], ["All the screened compounds have shown moderate to good in vitro activity against M. tuberculosis, with MIC in the range of 1.56-25 Scheme 1 Synthesis of N-cinnamyl-substituted isatin derivatives Med Chem Res (2014 Res ( ) 23:1934 Res ( -1940 Res ( 1935 lg/mL.", [["M. tuberculosis", "DISEASE", 81, 96], ["MIC", "CHEMICAL", 103, 106], ["N-cinnamyl-substituted isatin", "CHEMICAL", 153, 182], ["N-cinnamyl-substituted isatin", "CHEMICAL", 153, 182], ["Res", "CHEMICAL", 204, 207], ["Res", "CHEMICAL", 214, 217], ["M. tuberculosis", "ORGANISM", 81, 96], ["N-cinnamyl-substituted isatin", "SIMPLE_CHEMICAL", 153, 182], ["Med Chem Res", "SIMPLE_CHEMICAL", 195, 207], ["M. tuberculosis", "SPECIES", 81, 96], ["M. tuberculosis", "SPECIES", 81, 96], ["M. tuberculosis", "PROBLEM", 81, 96], ["MIC", "TEST", 103, 106], ["cinnamyl-substituted isatin derivatives", "TREATMENT", 155, 194], ["moderate", "OBSERVATION_MODIFIER", 38, 46], ["tuberculosis", "OBSERVATION", 84, 96]]], ["All the compounds are more potent than Pyrazinamide drug (50.77 lg/mL) and less potent than Rifampicin (0.1 lg/mL).", [["Pyrazinamide", "CHEMICAL", 39, 51], ["Rifampicin", "CHEMICAL", 92, 102], ["Pyrazinamide", "CHEMICAL", 39, 51], ["Rifampicin", "CHEMICAL", 92, 102], ["Pyrazinamide", "SIMPLE_CHEMICAL", 39, 51], ["Rifampicin", "SIMPLE_CHEMICAL", 92, 102], ["Pyrazinamide drug", "TREATMENT", 39, 56], ["Rifampicin", "TREATMENT", 92, 102]]], ["The compounds 3f, 3g and 3i are showing better activity than Ethambutol (7.64 lg/mL).", [["compounds 3f, 3g and 3i", "CHEMICAL", 4, 27], ["Ethambutol", "CHEMICAL", 61, 71], ["Ethambutol", "CHEMICAL", 61, 71], ["3g", "SIMPLE_CHEMICAL", 18, 20], ["3i", "SIMPLE_CHEMICAL", 25, 27], ["Ethambutol", "SIMPLE_CHEMICAL", 61, 71], ["Ethambutol", "TREATMENT", 61, 71], ["compounds 3f", "OBSERVATION", 4, 16]]], ["The results clearly indicate that the antitubercular activity of the synthesized compounds depend on the substituent's present on both moieties (isatin, cinnamyl).", [["isatin", "CHEMICAL", 145, 151], ["cinnamyl", "CHEMICAL", 153, 161], ["isatin", "CHEMICAL", 145, 151], ["cinnamyl", "CHEMICAL", 153, 161], ["isatin", "SIMPLE_CHEMICAL", 145, 151], ["cinnamyl", "SIMPLE_CHEMICAL", 153, 161], ["the antitubercular activity of the synthesized compounds", "PROBLEM", 34, 90], ["antitubercular activity", "OBSERVATION", 38, 61]]], ["The compound (3a) that does not have any substituent on both the moieties as well as the compounds that are having one halo substituent either on isatin (3b-d) or cinnamyl moiety (3e) are displaying poor activity except the compound 3i having nitro group on phenyl ring.", [["isatin", "CHEMICAL", 146, 152], ["cinnamyl", "CHEMICAL", 163, 171], ["nitro", "CHEMICAL", 243, 248], ["isatin", "CHEMICAL", 146, 152], ["cinnamyl", "CHEMICAL", 163, 171], ["nitro", "CHEMICAL", 243, 248], ["phenyl", "CHEMICAL", 258, 264], ["isatin (3b-d)", "SIMPLE_CHEMICAL", 146, 159], ["cinnamyl moiety (3e)", "SIMPLE_CHEMICAL", 163, 183], ["3i", "SIMPLE_CHEMICAL", 233, 235], ["nitro group", "SIMPLE_CHEMICAL", 243, 254], ["phenyl ring", "SIMPLE_CHEMICAL", 258, 269], ["one halo substituent", "PROBLEM", 115, 135], ["isatin", "TEST", 146, 152], ["nitro group on phenyl ring", "TREATMENT", 243, 269], ["poor activity", "OBSERVATION", 199, 212]]], ["The compounds that are having different halogen substituents on both the moieties (3f, 3g) are showing moderate antitubercular activity except the compound 3h, having bromine substituent on both the moieties.", [["3f, 3g", "CHEMICAL", 83, 89], ["bromine", "CHEMICAL", 167, 174], ["halogen", "CHEMICAL", 40, 47], ["bromine", "CHEMICAL", 167, 174], ["bromine substituent", "SIMPLE_CHEMICAL", 167, 186], ["different halogen substituents", "PROBLEM", 30, 60], ["moderate antitubercular activity", "PROBLEM", 103, 135], ["bromine substituent", "TREATMENT", 167, 186], ["halogen substituents", "OBSERVATION", 40, 60], ["moderate", "OBSERVATION_MODIFIER", 103, 111], ["antitubercular activity", "OBSERVATION", 112, 135], ["bromine substituent", "OBSERVATION", 167, 186], ["moieties", "ANATOMY_MODIFIER", 199, 207]]], ["Replacement of the halogen groups on phenyl ring of cinnamyl moiety of compounds (3f-h) with nitro group (3j-l) enhanced the antitubercular activity (1.56 lg/mL), which is close to that of the standard Isoniazid drug (0.36 lg/mL).Cytotoxic evaluationThe in vitro results of antitubercular activity encouraged us to evaluate their anticancer effects against a panel of four cell lines.", [["anticancer", "ANATOMY", 330, 340], ["cell lines", "ANATOMY", 373, 383], ["phenyl ring", "CHEMICAL", 37, 48], ["cinnamyl", "CHEMICAL", 52, 60], ["nitro", "CHEMICAL", 93, 98], ["3j-l", "CHEMICAL", 106, 110], ["Isoniazid", "CHEMICAL", 202, 211], ["halogen", "CHEMICAL", 19, 26], ["phenyl", "CHEMICAL", 37, 43], ["cinnamyl", "CHEMICAL", 52, 60], ["nitro", "CHEMICAL", 93, 98], ["Isoniazid", "CHEMICAL", 202, 211], ["phenyl ring", "SIMPLE_CHEMICAL", 37, 48], ["cinnamyl moiety", "SIMPLE_CHEMICAL", 52, 67], ["nitro", "SIMPLE_CHEMICAL", 93, 98], ["3j-l", "SIMPLE_CHEMICAL", 106, 110], ["Isoniazid", "SIMPLE_CHEMICAL", 202, 211], ["anticancer", "CANCER", 330, 340], ["cell lines", "CELL", 373, 383], ["cell lines", "CELL_LINE", 373, 383], ["Replacement of the halogen groups", "TREATMENT", 0, 33], ["phenyl ring of cinnamyl moiety of compounds", "TREATMENT", 37, 80], ["nitro group (3j-l)", "TREATMENT", 93, 111], ["the antitubercular activity", "TEST", 121, 148], ["the standard Isoniazid drug", "TREATMENT", 189, 216], ["Cytotoxic evaluation", "TEST", 230, 250], ["four cell lines", "TREATMENT", 368, 383], ["antitubercular activity", "OBSERVATION", 274, 297], ["four cell lines", "OBSERVATION", 368, 383]]], ["The preliminary cytotoxicity for a set of compounds (3a-l) was screened in four cell lines comprising non-cancerous Chinese hamster ovary cells (CHO) and cancerous Colo 205 (human colon cancer), Sup-T1 (human lymphoma) and C6 glioma (rat glioma) cell lines were determined by MTT assay method.", [["cell lines", "ANATOMY", 80, 90], ["non-cancerous Chinese hamster ovary cells", "ANATOMY", 102, 143], ["CHO", "ANATOMY", 145, 148], ["cancerous Colo 205", "ANATOMY", 154, 172], ["colon cancer", "ANATOMY", 180, 192], ["Sup-T1", "ANATOMY", 195, 201], ["lymphoma", "ANATOMY", 209, 217], ["C6 glioma", "ANATOMY", 223, 232], ["glioma) cell lines", "ANATOMY", 238, 256], ["colon cancer", "DISEASE", 180, 192], ["human lymphoma", "DISEASE", 203, 217], ["glioma", "DISEASE", 226, 232], ["MTT", "CHEMICAL", 276, 279], ["3a-l", "SIMPLE_CHEMICAL", 53, 57], ["cell lines", "CELL", 80, 90], ["non-cancerous Chinese hamster ovary cells", "CELL", 102, 143], ["CHO", "CELL", 145, 148], ["cancerous Colo 205", "CELL", 154, 172], ["human", "ORGANISM", 174, 179], ["colon cancer", "CANCER", 180, 192], ["Sup-T1", "CELL", 195, 201], ["human", "ORGANISM", 203, 208], ["lymphoma", "CELL", 209, 217], ["C6 glioma", "CELL", 223, 232], ["rat", "ORGANISM", 234, 237], ["glioma) cell lines", "CELL", 238, 256], ["cell lines", "CELL_LINE", 80, 90], ["non-cancerous Chinese hamster ovary cells", "CELL_LINE", 102, 143], ["CHO", "CELL_LINE", 145, 148], ["cancerous Colo 205", "CELL_LINE", 154, 172], ["Sup-T1", "CELL_LINE", 195, 201], ["C6 glioma (rat glioma) cell lines", "CELL_LINE", 223, 256], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 203, 208], ["rat", "SPECIES", 234, 237], ["Chinese hamster", "SPECIES", 116, 131], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 203, 208], ["The preliminary cytotoxicity", "TEST", 0, 28], ["four cell lines", "TREATMENT", 75, 90], ["non-cancerous Chinese hamster ovary cells", "PROBLEM", 102, 143], ["cancerous Colo", "PROBLEM", 154, 168], ["human colon cancer", "PROBLEM", 174, 192], ["Sup-T1 (human lymphoma)", "PROBLEM", 195, 218], ["C6 glioma (rat glioma)", "PROBLEM", 223, 245], ["cell lines", "TREATMENT", 246, 256], ["MTT assay method", "TEST", 276, 292], ["cell lines", "OBSERVATION", 80, 90], ["hamster ovary cells", "OBSERVATION", 124, 143], ["colon", "ANATOMY", 180, 185], ["cancer", "OBSERVATION", 186, 192], ["lymphoma", "OBSERVATION", 209, 217], ["C6 glioma", "ANATOMY", 223, 232], ["glioma", "ANATOMY", 238, 244], ["cell lines", "OBSERVATION", 246, 256]]], ["The resulting data show specific cytotoxicity of compound 3l on cancerous cell lines.", [["cancerous cell lines", "ANATOMY", 64, 84], ["compound 3l", "CHEMICAL", 49, 60], ["3l", "SIMPLE_CHEMICAL", 58, 60], ["cancerous cell lines", "CELL", 64, 84], ["cancerous cell lines", "CELL_LINE", 64, 84], ["The resulting data", "TEST", 0, 18], ["specific cytotoxicity of compound", "PROBLEM", 24, 57], ["cancerous cell lines", "TREATMENT", 64, 84], ["compound", "OBSERVATION_MODIFIER", 49, 57], ["3l", "OBSERVATION_MODIFIER", 58, 60], ["cancerous cell lines", "OBSERVATION", 64, 84]]], ["Further, compound 3l is found to be more toxic (0 % cell viability, Fig. 1b , c) towards C6 glioma and Sup-T1 cells.", [["cell", "ANATOMY", 52, 56], ["C6 glioma", "ANATOMY", 89, 98], ["Sup-T1 cells", "ANATOMY", 103, 115], ["compound 3l", "CHEMICAL", 9, 20], ["cell", "CELL", 52, 56], ["C6 glioma", "CELL", 89, 98], ["Sup-T1 cells", "CELL", 103, 115], ["C6 glioma", "CELL_LINE", 89, 98], ["Sup-T1 cells", "CELL_LINE", 103, 115], ["more toxic", "PROBLEM", 36, 46], ["cell viability", "TEST", 52, 66], ["Fig.", "TEST", 68, 72], ["C6 glioma", "PROBLEM", 89, 98], ["more", "OBSERVATION_MODIFIER", 36, 40], ["toxic", "OBSERVATION_MODIFIER", 41, 46], ["C6 glioma", "ANATOMY", 89, 98]]], ["However, compounds 3a-k are found to be equally toxic to both cancerous and non-cancerous cells.", [["cancerous", "ANATOMY", 62, 71], ["non-cancerous cells", "ANATOMY", 76, 95], ["cancerous", "CELL", 62, 71], ["non-cancerous cells", "CELL", 76, 95], ["cancerous and non-cancerous cells", "CELL_TYPE", 62, 95], ["equally toxic to both cancerous and non-cancerous cells", "PROBLEM", 40, 95], ["toxic", "OBSERVATION_MODIFIER", 48, 53], ["cancerous", "OBSERVATION", 62, 71], ["non-cancerous cells", "OBSERVATION", 76, 95]]], ["Interestingly, compounds 3d-f showed higher cytotoxicity in colon cells when compared to C6 glioma and Sup-T1cells ( Fig. 1b-d) .Cytotoxic evaluationThe results suggest that compound 3l in the series of compounds 3a-l is active on cancer cells, C6 glioma in particular.", [["colon cells", "ANATOMY", 60, 71], ["C6 glioma", "ANATOMY", 89, 98], ["Sup-T1cells", "ANATOMY", 103, 114], ["cancer cells", "ANATOMY", 231, 243], ["C6 glioma", "ANATOMY", 245, 254], ["compound 3l", "CHEMICAL", 174, 185], ["compounds 3a-l", "CHEMICAL", 203, 217], ["cancer", "DISEASE", 231, 237], ["glioma", "DISEASE", 248, 254], ["3d-f", "SIMPLE_CHEMICAL", 25, 29], ["colon cells", "CELL", 60, 71], ["C6 glioma", "CANCER", 89, 98], ["Sup-T1cells", "CELL", 103, 114], ["3l", "SIMPLE_CHEMICAL", 183, 185], ["3a-l", "SIMPLE_CHEMICAL", 213, 217], ["cancer cells", "CELL", 231, 243], ["C6 glioma", "CANCER", 245, 254], ["colon cells", "CELL_TYPE", 60, 71], ["Sup-T1cells", "CELL_LINE", 103, 114], ["cancer cells", "CELL_TYPE", 231, 243], ["higher cytotoxicity in colon cells", "PROBLEM", 37, 71], ["C6 glioma", "TEST", 89, 98], ["Sup-T1cells", "TEST", 103, 114], ["Cytotoxic evaluation", "TEST", 129, 149], ["compound 3l", "PROBLEM", 174, 185], ["active on cancer cells", "PROBLEM", 221, 243], ["C6 glioma", "PROBLEM", 245, 254], ["colon", "ANATOMY", 60, 65], ["C6 glioma", "ANATOMY", 89, 98], ["compound 3l", "OBSERVATION", 174, 185], ["active", "OBSERVATION_MODIFIER", 221, 227], ["cancer cells", "OBSERVATION", 231, 243], ["C6 glioma", "OBSERVATION", 245, 254]]], ["More comprehensive activity studies need to be carried out to establish the anticancer activity of the compound 3l.ExperimentalAll chemicals were of research grade and were used asobtained commercially from Aldrich.", [["anticancer", "ANATOMY", 76, 86], ["anticancer", "CANCER", 76, 86], ["comprehensive activity studies", "TEST", 5, 35], ["research grade", "TEST", 149, 163]]], ["The reactions were carried out in a round-bottomed flask of 25 mL capacity at room temperature in an efficient fume hood.", [["The reactions", "PROBLEM", 0, 13]]], ["The progress of all the reactions was monitored by TLC, using TLC aluminium sheets precoated with silica gel 60 F 254 to a thickness of 0.25 mm (Merck).", [["TLC aluminium", "CHEMICAL", 62, 75], ["silica gel", "CHEMICAL", 98, 108], ["aluminium", "CHEMICAL", 66, 75], ["silica", "CHEMICAL", 98, 104], ["TLC", "TEST", 51, 54], ["TLC aluminium sheets", "TREATMENT", 62, 82], ["silica gel", "TREATMENT", 98, 108]]], ["Flash column chromatography was done using silica gel (Merck, 60-120 mesh).", [["silica gel", "CHEMICAL", 43, 53], ["silica gel", "CHEMICAL", 43, 53], ["silica", "SIMPLE_CHEMICAL", 43, 49], ["Flash column chromatography", "TEST", 0, 27], ["silica gel", "TREATMENT", 43, 53], ["Merck", "TEST", 55, 60]]], ["Melting points were determined on a MEL-TEMP II melting point apparatus and were uncorrected.", [["Melting points", "PROBLEM", 0, 14], ["a MEL", "TEST", 34, 39]]], ["IR spectra were recorded on a Perkin-Elmer FT-IR spectrophotometer.", [["IR spectra", "TEST", 0, 10]]], ["1 H and 13 C NMR spectra were recorded on a Varian Gemini 200 MHz, Bruker Avance 300 MHz spectrometer; TMS was used as an internal standard in CDCl 3 /DMSO-d 6 .", [["1 H", "CHEMICAL", 0, 3], ["C", "CHEMICAL", 11, 12], ["CDCl 3", "CHEMICAL", 143, 149], ["DMSO", "CHEMICAL", 151, 155], ["NMR spectra", "TEST", 13, 24], ["a Varian Gemini", "TREATMENT", 42, 57], ["TMS", "TEST", 103, 106]]], ["Mass spectra were recorded on VG Micro mass 7070 H (EI), QSTAR XL High resolution mass spectrometer (HRMS) and Thermofinnigan ESI ion trap Mass Spectrometer.ExperimentalGeneral experimental procedure for the preparation of N-cinnamyl-substituted isatin derivative (3a-l)ExperimentalTo a solution of isatin 2a (147 mg, 1.0 mmol) in acetonitrile (10 mL), K 2 CO 3 (166 mg, 1.2 mmol) was added followed by Baylis-Hillman bromide 1a (305 mg, 1.2 mmol) at room temperature and the reaction mixture was stirred for 10-12 h.", [["N-cinnamyl-substituted isatin", "CHEMICAL", 223, 252], ["isatin 2a", "CHEMICAL", 299, 308], ["acetonitrile", "CHEMICAL", 331, 343], ["K 2 CO 3", "CHEMICAL", 353, 361], ["Baylis-Hillman bromide", "CHEMICAL", 403, 425], ["N-cinnamyl-substituted isatin", "CHEMICAL", 223, 252], ["isatin", "CHEMICAL", 299, 305], ["acetonitrile", "CHEMICAL", 331, 343], ["CO 3", "CHEMICAL", 357, 361], ["bromide", "CHEMICAL", 418, 425], ["N-cinnamyl-substituted isatin derivative", "SIMPLE_CHEMICAL", 223, 263], ["3a-l)ExperimentalTo", "SIMPLE_CHEMICAL", 265, 284], ["isatin 2a", "SIMPLE_CHEMICAL", 299, 308], ["acetonitrile", "SIMPLE_CHEMICAL", 331, 343], ["K 2 CO 3", "SIMPLE_CHEMICAL", 353, 361], ["Baylis-Hillman bromide 1a", "SIMPLE_CHEMICAL", 403, 428], ["Mass spectra", "PROBLEM", 0, 12], ["VG Micro mass", "TEST", 30, 43], ["QSTAR", "TEST", 57, 62], ["High resolution mass spectrometer", "PROBLEM", 66, 99], ["HRMS", "TEST", 101, 105], ["Thermofinnigan ESI ion trap Mass Spectrometer", "TREATMENT", 111, 156], ["ExperimentalGeneral experimental procedure", "TREATMENT", 157, 199], ["N-cinnamyl", "TREATMENT", 223, 233], ["substituted isatin derivative", "TREATMENT", 234, 263], ["a solution of isatin 2a", "TREATMENT", 285, 308], ["acetonitrile", "TREATMENT", 331, 343], ["K 2 CO", "TREATMENT", 353, 359], ["Baylis-Hillman bromide 1a", "TREATMENT", 403, 428], ["the reaction mixture", "TREATMENT", 472, 492]]], ["Upon completion of the reaction, the mixture was filtered and the filtrate was diluted with water (50 mL) andExperimentalScheme 2 Nucleophilic substitution on Baylis-Hillman bromide extracted with EtOAc (50 mL 9 3).", [["Baylis-Hillman bromide", "CHEMICAL", 159, 181], ["bromide", "CHEMICAL", 174, 181], ["EtOAc", "CHEMICAL", 197, 202], ["Baylis-Hillman bromide", "SIMPLE_CHEMICAL", 159, 181], ["EtOAc", "SIMPLE_CHEMICAL", 197, 202], ["the reaction", "PROBLEM", 19, 31], ["the filtrate", "TREATMENT", 62, 74], ["water", "TREATMENT", 92, 97], ["ExperimentalScheme 2 Nucleophilic substitution", "TREATMENT", 109, 155], ["Baylis", "TREATMENT", 159, 165], ["Hillman bromide", "TREATMENT", 166, 181], ["EtOAc", "TREATMENT", 197, 202]]], ["The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure and the obtained crude product was purified by silica gel column chromatography (60-120 mesh, eluent: EtOAc/hexane, 3:7) to afford pure cinnamylsubstituted isatin derivative 3a as solid compound.", [["Na 2 SO 4", "CHEMICAL", 44, 53], ["silica gel", "CHEMICAL", 152, 162], ["EtOAc/hexane", "CHEMICAL", 207, 219], ["cinnamylsubstituted isatin", "CHEMICAL", 241, 267], ["Na 2 SO 4", "CHEMICAL", 44, 53], ["silica gel", "CHEMICAL", 152, 162], ["EtOAc", "CHEMICAL", 207, 212], ["hexane", "CHEMICAL", 213, 219], ["cinnamylsubstituted isatin", "CHEMICAL", 241, 267], ["silica", "SIMPLE_CHEMICAL", 152, 158], ["hexane", "SIMPLE_CHEMICAL", 213, 219], ["cinnamylsubstituted isatin derivative 3a", "SIMPLE_CHEMICAL", 241, 281], ["solid compound", "SIMPLE_CHEMICAL", 285, 299], ["The combined organic layers", "TREATMENT", 0, 27], ["the obtained crude product", "TREATMENT", 109, 135], ["silica gel column chromatography", "TEST", 152, 184], ["EtOAc/hexane", "TREATMENT", 207, 219], ["pure cinnamylsubstituted isatin derivative", "TREATMENT", 236, 278], ["organic", "OBSERVATION_MODIFIER", 13, 20], ["layers", "OBSERVATION_MODIFIER", 21, 27]]], ["8, 144.3, 146.5, 157.3, 157.6, 160.6, 166.6, 182 Methyl ( 9, 52.7, 112.2, 112.4, 118.1, 123.3, 123.7, 124.3, 124.6, 128.3, 129.6, 140.5, 141.5, 146.5, 147.7, 157.", [["Methyl", "CHEMICAL", 49, 55], ["Methyl", "CHEMICAL", 49, 55], ["Methyl", "TEST", 49, 55]]], ["9, 160.7, 166.0, 181.8; MS (m/ 8, 52.7, 112.8, 116.6, 123.3, 123.7, 127.8, 129.1, 129.6, 136.6, 140.5, 141.7, 147.7, 149.2, 157.4, 166.", [["MS", "TEST", 24, 26]]], ["Cytotoxicity assay procedureMethyl(E)-2-[(2,3-dioxo-2,3-dihydro-1H-1-indolyl)methyl]-The potential effects on cell viability were investigated by using the MTT assay (Sigma, USA) [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] as an indicator of metabolically active cells (Van de Loosdrecht et al., 1994; Alley et al., 1988) .", [["cell", "ANATOMY", 110, 114], ["cells", "ANATOMY", 282, 287], ["procedureMethyl(E)-2-[(2,3-dioxo-2,3-dihydro-1H-1-indolyl)methyl", "CHEMICAL", 19, 83], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 180, 240], ["procedureMethyl(E)-2-[(2,3-dioxo-2,3-dihydro-1H-1-indolyl)methyl", "CHEMICAL", 19, 83], ["MTT", "CHEMICAL", 156, 159], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 180, 240], ["procedureMethyl(E)-2-[(2,3-dioxo-2,3-dihydro-1H-1-indolyl)methyl", "SIMPLE_CHEMICAL", 19, 83], ["cell", "CELL", 110, 114], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 180, 240], ["cells", "CELL", 282, 287], ["metabolically active cells", "CELL_TYPE", 261, 287], ["Cytotoxicity", "TEST", 0, 12], ["dioxo", "TREATMENT", 46, 51], ["dihydro", "TREATMENT", 56, 63], ["indolyl)methyl", "TREATMENT", 69, 83], ["cell viability", "TREATMENT", 110, 124], ["the MTT assay", "TEST", 152, 165], ["dimethylthiazol", "TREATMENT", 187, 202], ["diphenyltetrazolium bromide", "TREATMENT", 213, 240]]], ["The four different cell lines used are CHO, Colo 205, Sup-T1 and C6 glioma were seeded into 96-well plates in a volume of 200 mL of culture medium and incubated overnight at 37\u00b0C in a CO 2 incubator before addition of test compound.", [["cell lines", "ANATOMY", 19, 29], ["CHO", "ANATOMY", 39, 42], ["Colo 205", "ANATOMY", 44, 52], ["Sup-T1", "ANATOMY", 54, 60], ["C6 glioma", "ANATOMY", 65, 74], ["CO 2", "CHEMICAL", 184, 188], ["cell lines", "CELL", 19, 29], ["CHO", "CELL", 39, 42], ["Colo 205", "CELL", 44, 52], ["Sup-T1", "CELL", 54, 60], ["C6 glioma", "CELL", 65, 74], ["cell lines", "CELL_LINE", 19, 29], ["CHO", "CELL_LINE", 39, 42], ["Colo 205", "CELL_LINE", 44, 52], ["Sup-T1", "CELL_LINE", 54, 60], ["C6 glioma", "CELL_LINE", 65, 74], ["CHO", "TEST", 39, 42], ["Colo", "TEST", 44, 48], ["Sup-T1 and C6 glioma", "TREATMENT", 54, 74], ["culture medium", "TEST", 132, 146], ["a CO 2 incubator", "TREATMENT", 182, 198], ["test compound", "TEST", 218, 231], ["four", "OBSERVATION_MODIFIER", 4, 8], ["different", "OBSERVATION_MODIFIER", 9, 18], ["cell lines", "OBSERVATION", 19, 29], ["C6 glioma", "ANATOMY", 65, 74]]], ["Cells were then exposed to known concentrations of the compound to be tested (1 mM, 100 lM, 100 nM and 100 pM expressed as final concentration) for 16 h at 37\u00b0C in a CO 2 incubator with 5 % CO 2 .", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 166, 170], ["CO 2", "CHEMICAL", 190, 194], ["Cells", "CELL", 0, 5], ["a CO 2 incubator", "TREATMENT", 164, 180]]], ["After drug exposure, the culture medium was removed and 20 lL of MTT reagent (diluted in culture medium, 1 mg/mL) was added.", [["MTT reagent", "CHEMICAL", 65, 76], ["MTT", "CHEMICAL", 65, 68], ["MTT", "SIMPLE_CHEMICAL", 65, 68], ["the culture medium", "TEST", 21, 39], ["MTT reagent", "TREATMENT", 65, 76], ["culture medium", "TREATMENT", 89, 103]]], ["After incubating for 5 h in a humidified atmosphere, the MTT/medium was removed and DMSO (200 lL) was added to dissolve the formazan crystals.", [["MTT", "CHEMICAL", 57, 60], ["DMSO", "CHEMICAL", 84, 88], ["formazan", "CHEMICAL", 124, 132], ["MTT", "CHEMICAL", 57, 60], ["DMSO", "CHEMICAL", 84, 88], ["formazan", "CHEMICAL", 124, 132], ["MTT", "SIMPLE_CHEMICAL", 57, 60], ["DMSO", "SIMPLE_CHEMICAL", 84, 88], ["formazan crystals", "SIMPLE_CHEMICAL", 124, 141], ["a humidified atmosphere", "TREATMENT", 28, 51], ["the MTT/medium", "TREATMENT", 53, 67], ["DMSO", "TREATMENT", 84, 88], ["the formazan crystals", "TREATMENT", 120, 141], ["formazan crystals", "OBSERVATION", 124, 141]]], ["Absorbance of the coloured solution was measured by an ELISA using a NJ-2300 microplate spectrophotometer with a test wavelength of 570 nm.", [["the coloured solution", "TREATMENT", 14, 35], ["a NJ-2300 microplate spectrophotometer", "TREATMENT", 67, 105], ["a test wavelength", "TEST", 111, 128]]], ["Results were evaluated by comparing the absorbance of the wells containing compound-treated cells with the absorbance of wells containing 0.1 % DMSO alone (solvent control).", [["cells", "ANATOMY", 92, 97], ["DMSO", "CHEMICAL", 144, 148], ["DMSO", "CHEMICAL", 144, 148], ["cells", "CELL", 92, 97], ["DMSO", "SIMPLE_CHEMICAL", 144, 148], ["compound-treated cells", "CELL_LINE", 75, 97], ["compound-treated cells", "TREATMENT", 75, 97], ["the absorbance of wells", "TREATMENT", 103, 126], ["0.1 % DMSO", "TREATMENT", 138, 148]]], ["Conventionally, cell viability was estimated to be 100 % in the solvent control.", [["cell", "ANATOMY", 16, 20], ["cell", "CELL", 16, 20], ["cell viability", "TEST", 16, 30], ["the solvent control", "TREATMENT", 60, 79], ["cell viability", "OBSERVATION", 16, 30]]], ["All assays were performed in triplicate and mean standard deviation values were used to estimate cell viability.ConclusionIn conclusion, a series of new Baylis-Hillman adduct-derived N-cinnamyl-substituted isatin derivatives was synthesized in a simple and efficient manner.", [["cell", "ANATOMY", 97, 101], ["adduct", "CHEMICAL", 168, 174], ["N-cinnamyl-substituted isatin", "CHEMICAL", 183, 212], ["N-cinnamyl-substituted isatin", "CHEMICAL", 183, 212], ["cell", "CELL", 97, 101], ["Baylis-Hillman adduct-derived N-cinnamyl-substituted isatin derivatives", "SIMPLE_CHEMICAL", 153, 224], ["All assays", "TEST", 0, 10], ["mean standard deviation values", "TEST", 44, 74], ["new Baylis", "TEST", 149, 159], ["Hillman adduct", "TREATMENT", 160, 174], ["cinnamyl-substituted isatin derivatives", "TREATMENT", 185, 224], ["cell viability", "OBSERVATION", 97, 111]]], ["All the synthesized compounds were evaluated for their antitubercular and anticancer activities.", [["anticancer", "ANATOMY", 74, 84], ["anticancer", "CANCER", 74, 84], ["their antitubercular and anticancer activities", "TREATMENT", 49, 95]]], ["These compounds have inhibited Mycobacterium strains, especially compounds 3j-l have shown overall good activity on M. tuberculosis H 37 Rv strain ATCC 27294.", [["ATCC 27294", "CHEMICAL", 147, 157], ["Mycobacterium strains", "ORGANISM", 31, 52], ["M. tuberculosis H 37", "ORGANISM", 116, 136], ["M. tuberculosis", "SPECIES", 116, 131], ["M. tuberculosis", "SPECIES", 116, 131], ["ATCC 27294", "SPECIES", 147, 157], ["Mycobacterium strains", "PROBLEM", 31, 52], ["Rv strain ATCC", "TEST", 137, 151], ["Mycobacterium strains", "OBSERVATION", 31, 52], ["overall", "OBSERVATION_MODIFIER", 91, 98], ["good", "OBSERVATION_MODIFIER", 99, 103], ["activity", "OBSERVATION_MODIFIER", 104, 112]]], ["The compound 3l showed a specific cytotoxicity on cancerous cell lines Colo 205, Sup-T1 and C6-glioma, whereas it is non-cytotoxic to non-cancerous cell line (CHO).", [["cancerous cell lines Colo 205", "ANATOMY", 50, 79], ["Sup-T1", "ANATOMY", 81, 87], ["C6-glioma", "ANATOMY", 92, 101], ["non-cancerous cell line", "ANATOMY", 134, 157], ["CHO", "ANATOMY", 159, 162], ["compound 3l", "CHEMICAL", 4, 15], ["glioma", "DISEASE", 95, 101], ["3l", "SIMPLE_CHEMICAL", 13, 15], ["cancerous cell lines Colo 205", "CELL", 50, 79], ["Sup-T1", "CELL", 81, 87], ["C6-glioma", "CANCER", 92, 101], ["non-cancerous cell line", "CELL", 134, 157], ["CHO", "CELL", 159, 162], ["cancerous cell lines", "CELL_LINE", 50, 70], ["Colo 205", "CELL_LINE", 71, 79], ["Sup", "CELL_LINE", 81, 84], ["T1", "CELL_LINE", 85, 87], ["C6", "CELL_LINE", 92, 94], ["non-cancerous cell line", "CELL_LINE", 134, 157], ["CHO", "CELL_LINE", 159, 162], ["a specific cytotoxicity on cancerous cell lines Colo", "PROBLEM", 23, 75], ["C6-glioma", "PROBLEM", 92, 101], ["cytotoxicity", "OBSERVATION_MODIFIER", 34, 46], ["cancerous cell lines", "OBSERVATION", 50, 70], ["C6", "ANATOMY", 92, 94], ["glioma", "ANATOMY", 95, 101], ["non-cytotoxic", "OBSERVATION_MODIFIER", 117, 130], ["non-cancerous cell line", "OBSERVATION", 134, 157]]]], "PMC7119136": [["IntroductionPr\u00e8s de 35 ann\u00e9es apr\u00e8s leur premi\u00e8re description par Hamre et Procknow et Tyrrel et Bynoe [1], [2], les coronavirus humains connaissent un regain d'int\u00e9r\u00eat depuis 2003 et la mise en \u00e9vidence d'un nouveau coronavirus responsable du syndrome respiratoire aigu s\u00e9v\u00e8re ou SRAS [3].IntroductionDepuis lors plusieurs coronavirus humains ont \u00e9t\u00e9 identifi\u00e9s tel que le coronavirus humain (HCoV) NL63 (\u00e9galement connu sous le nom de new-heaven) el HCoV HKU1 [4], [5], [6].IntroductionDeux autres HCoV, connus depuis 35 ans, (HCoV 229-E et OC43) sont responsables de pr\u00e8s d'un tiers des rhumes chez l'enfant et l'adulte.", [["coronavirus humain", "DISEASE", 374, 392], ["coronavirus", "SPECIES", 324, 335], ["coronavirus", "SPECIES", 374, 385], ["\u00e9t\u00e9 identifi\u00e9s tel que le coronavirus humain (HCoV) NL63 (\u00e9galement connu sous le nom de new-heaven) el HCoV HKU1", "SPECIES", 348, 461], ["les coronavirus humains", "TEST", 113, 136], ["coronavirus", "PROBLEM", 217, 228], ["du syndrome", "PROBLEM", 241, 252], ["IntroductionDepuis", "TEST", 290, 308], ["coronavirus", "TEST", 324, 335], ["humains", "TEST", 336, 343], ["HCoV", "TEST", 394, 398], ["IntroductionDeux", "TEST", 476, 492], ["HCoV", "TEST", 529, 533], ["du syndrome", "OBSERVATION", 241, 252]]], ["Les HCoV pourraient \u00eatre impliqu\u00e9s dans d'autres pathologies infectieuses : bronchiolites et bronchopneumopathies, p\u00e9ricardites, m\u00e9ningites, maladie de Kawasaki, scl\u00e9rose en plaques et malaise grave du nourrisson [7], [8], [9], [10], [11], [12].IntroductionLa transmission des HCoV, comme celle de nombreux autres virus \u00e0 tropisme respiratoire (rhinovirus, VRS, m\u00e9tapneumovirus), est interhumaine par les s\u00e9cr\u00e9tions rhinopharyng\u00e9es [13].", [["[9]", "SIMPLE_CHEMICAL", 223, 226], ["[10]", "SIMPLE_CHEMICAL", 228, 232], ["'autres pathologies infectieuses", "PROBLEM", 41, 73], ["bronchiolites", "PROBLEM", 76, 89], ["et bronchopneumopathies", "PROBLEM", 90, 113], ["p\u00e9ricardites", "PROBLEM", 115, 127], ["scl\u00e9rose en plaques et malaise", "PROBLEM", 162, 192], ["grave du nourrisson", "TEST", 193, 212], ["rhinovirus", "PROBLEM", 345, 355], ["VRS", "TEST", 357, 360], ["m\u00e9tapneumovirus", "TEST", 362, 377]]], ["Nous avons r\u00e9cemment mis en \u00e9vidence le r\u00f4le des HCoV dans la survenue d'infections nosocomiales chez les nouveau-n\u00e9s [14], [15], [16], [17], [18], [19], [20].", [["infections", "DISEASE", 73, 83], ["[15], [16], [17], [18], [19], [20]", "SIMPLE_CHEMICAL", 124, 158], ["'infections", "TEST", 72, 83], ["chez les nouveau", "TEST", 97, 113], ["n\u00e9s", "TEST", 114, 117]]], ["Ces virus pourraient \u00eatre introduits \u00e0 l'h\u00f4pital par le personnel, les visiteurs ou les enfants hospitalis\u00e9s.", [["Ces virus", "ORGANISM", 0, 9], ["Ces", "TEST", 0, 3]]], ["Une origine maternof\u0153tale doit, cependant, \u00eatre explor\u00e9e en raison de la fr\u00e9quence de ce mode de contamination dans les mod\u00e8les animaux [21] et de la constatation de l'existence d'infections n\u00e9onatales chez le nouveau-n\u00e9.IntroductionL'objectif principal de ce travail est d'\u00e9tudier la transmission maternof\u0153tale des coronavirus humains pouvant expliquer les cas d'infections n\u00e9onatales observ\u00e9s dans les \u00e9tudes pr\u00e9c\u00e9dentes.", [["infections", "DISEASE", 180, 190], ["infections", "DISEASE", 364, 374], ["'infections", "PROBLEM", 179, 190], ["IntroductionL'objectif principal de ce travail est d'\u00e9tudier la transmission maternof\u0153tale des", "TREATMENT", 221, 315], ["'infections", "PROBLEM", 363, 374]]], ["Les objectifs secondaires r\u00e9sident en l'\u00e9tude de la symptomatologie maternelle et n\u00e9onatale des infections \u00e0 HCoV, et en la mise en \u00e9vidence du portage g\u00e9nital du HCoV.Type de\u00a0l'\u00e9tude ::: Patients et\u00a0m\u00e9thodesIl s'agit d'une \u00e9tude pilote, prospective, \u00e9pid\u00e9miologique et monocentrique.Patients ::: Patients et\u00a0m\u00e9thodesInclusions des couples m\u00e8res\u2013enfants se pr\u00e9sentant en travail, en salle de naissance au CHU de Brest sur deux p\u00e9riodes \u00e9pid\u00e9miologiques, de juillet 2003 \u00e0 juin 2004 puis de mars 2005 \u00e0 ao\u00fbt 2005.Patients ::: Patients et\u00a0m\u00e9thodesCrit\u00e8res d'inclusion : toute femme enceinte se pr\u00e9sentant en travail dans le service de gyn\u00e9cologie\u2013obst\u00e9trique du CHU de Brest.Patients ::: Patients et\u00a0m\u00e9thodesCrit\u00e8res d'exclusion : urgence vitale, maternelle ou f\u0153tale.Patients ::: Patients et\u00a0m\u00e9thodesEntretien et explication de la lettre d'information aux parents, recueil des formulaires de consentement \u00e9clair\u00e9.Patients ::: Patients et\u00a0m\u00e9thodesRecueil des donn\u00e9es anamnestiques de fa\u00e7on extemporan\u00e9e et prospective.Recueil, transport et\u00a0conservation des\u00a0pr\u00e9l\u00e8vements ::: Patients et\u00a0m\u00e9thodesPr\u00e9l\u00e8vement vaginal r\u00e9alis\u00e9 lors du d\u00e9but du travail, plac\u00e9 dans un milieu de culture virale achemin\u00e9 directement au laboratoire pour stockage \u00e0 \u201370 \u00b0C.Recueil, transport et\u00a0conservation des\u00a0pr\u00e9l\u00e8vements ::: Patients et\u00a0m\u00e9thodesRecueil des s\u00e9cr\u00e9tions nasales maternelles par aspirateur de mucosit\u00e9s et des s\u00e9cr\u00e9tions rhinopharyng\u00e9es, et gastriques du nouveau-n\u00e9 lors de l'aspiration syst\u00e9matique \u00e0 la naissance.Recueil, transport et\u00a0conservation des\u00a0pr\u00e9l\u00e8vements ::: Patients et\u00a0m\u00e9thodesRecueil des \u00e9chantillons et transport imm\u00e9diat au laboratoire pour r\u00e9alisation d'aliquotes et cong\u00e9lation \u00e0 \u201370 \u00b0C.Diagnostic virologique ::: Patients et\u00a0m\u00e9thodesAnalyse virologique des souches HCoV 229-E et OC43 par technique de reverse transcription-polymerase chain reaction (RT-PCR) en temps r\u00e9el d\u00e9j\u00e0 d\u00e9crite [22].Diagnostic virologique ::: Patients et\u00a0m\u00e9thodesDescription de la RT-PCR en temps r\u00e9el :\u25cfextraction de l'ARN viral \u00e0 l'aide de la trousse QIAGEN \u00ab QIAamp MinElute Virus Spin Kit \u00bb ;\u25cfreverse transcription (ou transcription inverse) utilisant la SuperScript II (Invitrogen) et des amorces al\u00e9atoires hexanucl\u00e9otidiques ;\u25cfPCR en temps r\u00e9el (LightCycler 2.0, Roche Applied Science).", [["infections", "DISEASE", 96, 106], ["Patients", "ORGANISM", 188, 196], ["Patients", "ORGANISM", 284, 292], ["Patients", "ORGANISM", 297, 305], ["Patients", "ORGANISM", 512, 520], ["Patients", "ORGANISM", 525, 533], ["Patients", "ORGANISM", 673, 681], ["Patients", "ORGANISM", 686, 694], ["Patients", "ORGANISM", 766, 774], ["Patients", "ORGANISM", 779, 787], ["Patients", "ORGANISM", 912, 920], ["Patients", "ORGANISM", 925, 933], ["Patients", "ORGANISM", 1072, 1080], ["Patients", "ORGANISM", 1300, 1308], ["Patients", "ORGANISM", 1559, 1567], ["Patients", "ORGANISM", 1721, 1729], ["Patients", "ORGANISM", 1925, 1933], ["Patients", "SPECIES", 188, 196], ["Patients", "SPECIES", 284, 292], ["Patients", "SPECIES", 297, 305], ["Patients", "SPECIES", 512, 520], ["Patients", "SPECIES", 525, 533], ["Patients", "SPECIES", 673, 681], ["Patients", "SPECIES", 686, 694], ["Patients", "SPECIES", 766, 774], ["Patients", "SPECIES", 779, 787], ["Patients", "SPECIES", 912, 920], ["Patients", "SPECIES", 925, 933], ["Patients", "SPECIES", 1072, 1080], ["Patients", "SPECIES", 1300, 1308], ["Patients", "SPECIES", 1559, 1567], ["Patients", "SPECIES", 1721, 1729], ["Patients", "SPECIES", 1925, 1933], ["en l'\u00e9tude", "TREATMENT", 35, 45], ["et n\u00e9onatale des infections", "PROBLEM", 79, 106], ["\u00e9pid\u00e9miologique et monocentrique", "TREATMENT", 251, 283], ["Pr\u00e9l\u00e8vement", "TEST", 1092, 1103], ["HCoV", "TEST", 1773, 1777], ["E et OC43 par technique", "TREATMENT", 1782, 1805], ["polymerase chain reaction", "PROBLEM", 1831, 1856], ["PCR", "TEST", 1861, 1864], ["PCR", "TEST", 1966, 1969], ["\u25cfreverse transcription", "TREATMENT", 2078, 2100], ["ou transcription inverse", "TREATMENT", 2102, 2126], ["utilisant la SuperScript II (Invitrogen) et des", "TREATMENT", 2128, 2175], ["hexanucl\u00e9otidiques", "TEST", 2195, 2213], ["PCR", "TEST", 2216, 2219], ["LightCycler", "TEST", 2235, 2246]]], ["Les sondes fluorescentes utilis\u00e9es sont des sondes TaqMan marqu\u00e9es \u00e0 chaque extr\u00e9mit\u00e9 par un fluorophore FAM (6-carboxy-fluoresc\u00e9ine) en 5\u2032 et TAMRA (6-carboxy-t\u00e9tram\u00e9thylrhodamine) en 3\u2032 respectivement en tant que rapporteur et bloqueur.", [["6-carboxy-t\u00e9tram\u00e9thylrhodamine", "CHEMICAL", 150, 180], ["extr\u00e9mit\u00e9 par un fluorophore FAM", "TREATMENT", 76, 108], ["carboxy-fluoresc\u00e9ine)", "TREATMENT", 112, 133], ["et TAMRA (6-carboxy-t\u00e9tram\u00e9thylrhodamine)", "TREATMENT", 140, 181]]], ["Les amorces et les sondes Taqman ont pour cible une r\u00e9gion du g\u00e8ne N codant pour le nucl\u00e9ocapside des HCoV.", [["Taqman", "TEST", 26, 32], ["ont pour cible", "TEST", 33, 47]]]], "3f435fdb73c41bc0799d3c505e86e40593b9ca28": [["The novel coronavirus infection COVID-19 pandemic has spread all over the world, as declared by World Health Organization on March 11th 2020 [1, 2] .", [["coronavirus infection", "DISEASE", 10, 31], ["coronavirus", "ORGANISM", 10, 21], ["COVID-19", "ORGANISM", 32, 40], ["coronavirus", "SPECIES", 10, 21], ["The novel coronavirus infection COVID", "PROBLEM", 0, 37], ["pandemic", "PROBLEM", 41, 49], ["coronavirus", "OBSERVATION_MODIFIER", 10, 21], ["infection", "OBSERVATION", 22, 31]]]], "PMC4634243": [["BackgroundAvian influenza virus (AIV) is a negative\u2010sense, segmented, single\u2010stranded RNA virus that belongs to the Orthomyxoviridae family.1,2,3Globally, AIVs occasionally cause infection in humans and their livestock, such as poultry, pigs, and other wild animals with harmful outcomes.", [["infection", "DISEASE", 179, 188], ["BackgroundAvian influenza virus", "ORGANISM", 0, 31], ["AIV", "ORGANISM", 33, 36], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 116, 132], ["AIVs", "SIMPLE_CHEMICAL", 155, 159], ["humans", "ORGANISM", 192, 198], ["pigs", "ORGANISM", 237, 241], ["Orthomyxoviridae family", "PROTEIN", 116, 139], ["BackgroundAvian influenza virus", "SPECIES", 0, 31], ["humans", "SPECIES", 192, 198], ["pigs", "SPECIES", 237, 241], ["BackgroundAvian influenza virus", "SPECIES", 0, 31], ["AIV", "SPECIES", 33, 36], ["humans", "SPECIES", 192, 198], ["poultry", "SPECIES", 228, 235], ["pigs", "SPECIES", 237, 241], ["BackgroundAvian influenza virus", "PROBLEM", 0, 31], ["a negative\u2010sense, segmented, single\u2010stranded RNA virus", "PROBLEM", 41, 95], ["infection", "PROBLEM", 179, 188], ["influenza virus", "OBSERVATION", 16, 31], ["infection", "OBSERVATION", 179, 188]]], ["Some of the highly pathogenic AIV (HPAIV) strains, in particular H5N1, have occasionally infected humans with high mortality rates exceeding 60%.4,5,6As a consequence of high rates of antigenic drift and shift, reassortant strains and novel mutants have emerged, and some have acquired the ability to cross\u2010species barriers and become pathogenic in their new hosts.7", [["AIV", "ORGANISM", 30, 33], ["HPAIV", "ORGANISM", 35, 40], ["H5N1", "ORGANISM", 65, 69], ["humans", "ORGANISM", 98, 104], ["H5N1", "SPECIES", 65, 69], ["humans", "SPECIES", 98, 104], ["AIV", "SPECIES", 30, 33], ["HPAIV", "SPECIES", 35, 40], ["humans", "SPECIES", 98, 104], ["the highly pathogenic AIV (HPAIV) strains", "PROBLEM", 8, 49], ["H5N1", "PROBLEM", 65, 69], ["occasionally infected humans", "PROBLEM", 76, 104], ["high mortality rates", "PROBLEM", 110, 130], ["antigenic drift", "PROBLEM", 184, 199], ["reassortant strains", "PROBLEM", 211, 230], ["novel mutants", "PROBLEM", 235, 248], ["pathogenic", "PROBLEM", 335, 345], ["highly", "OBSERVATION_MODIFIER", 12, 18], ["pathogenic", "OBSERVATION_MODIFIER", 19, 29], ["AIV", "OBSERVATION", 30, 33], ["occasionally", "OBSERVATION_MODIFIER", 76, 88], ["infected", "OBSERVATION", 89, 97], ["high", "OBSERVATION_MODIFIER", 110, 114], ["antigenic drift", "OBSERVATION", 184, 199], ["pathogenic", "OBSERVATION", 335, 345]]]], "2b4144b17be18dbf20753f2011d72865430a0a7d": [["Aan de hand van een leverbiopt stelden wij de diagnose 'uitgebreid kleincellig longcarcinoom' ('extensivedisease'-SCLC).", [["extensivedisease'-SCLC", "ANATOMY", 96, 118], ["SCLC", "DISEASE", 114, 118], ["'extensivedisease'-SCLC", "CANCER", 95, 118]]], ["Gezien haar pre-existente verminderde nierfunctie (bloedonderzoeken van enkele jaren geleden toonden vergelijkbare waarden) en verminderde linkerventrikelfunctie kozen wij voor behandeling met carboplatine.", [["carboplatine", "CHEMICAL", 193, 205], ["carboplatine", "CHEMICAL", 193, 205], ["carboplatine", "SIMPLE_CHEMICAL", 193, 205]]], ["Hieraan werd een halve dosis etoposide toegevoegd, aangepast aan de leverenzymwaarden.", [["etoposide", "CHEMICAL", 29, 38], ["aangepast aan de leverenzymwaarden", "CHEMICAL", 51, 85], ["etoposide", "CHEMICAL", 29, 38], ["Hieraan", "TREATMENT", 0, 7], ["een halve dosis etoposide", "TREATMENT", 13, 38]]], ["Wij overwogen ook tumorlysisprofylaxe, maar zagen daarvan af na raadpleging van nationale en internationale richtlijnen.", [["na", "CHEMICAL", 61, 63], ["Wij overwogen ook tumorlysisprofylaxe, maar zagen daarvan af na raadpleging van nationale en internationale richtlijnen", "SPECIES", 0, 119], ["tumorlysisprofylaxe", "TREATMENT", 18, 37]]], ["1-3 De chemotherapie begon met carboplatine op dag 1 en etoposide op dag 1-3.", [["carboplatine", "CHEMICAL", 31, 43], ["etoposide", "CHEMICAL", 56, 65], ["carboplatine", "CHEMICAL", 31, 43], ["etoposide", "CHEMICAL", 56, 65], ["carboplatine op dag", "TREATMENT", 31, 50], ["en etoposide op dag", "TREATMENT", 53, 72]]], ["Enkele uren na de tweede gift etoposide meldde pati\u00ebnte dat zij haar benen 'ineens' niet meer kon bewegen.", [["na", "CHEMICAL", 12, 14], ["etoposide", "CHEMICAL", 30, 39]]], ["Bij lichamelijk onderzoek was er nu een parti\u00eble dwarslaesie met areflexie en afwezige vibratie-en positiezin.", [["positiezin", "CHEMICAL", 99, 109], ["Bij lichamelijk onderzoek", "TREATMENT", 0, 25], ["areflexie en afwezige vibratie", "TREATMENT", 65, 95], ["en positiezin", "TREATMENT", 96, 109]]], ["Een MRI-scan toonde een complete destructie van de 6e thoracale wervel, met myelumcompressie.", [["Een MRI", "TEST", 0, 7], ["scan", "TEST", 8, 12]]], ["Pati\u00ebnte werd dezelfde dag nog bestraald; ze kreeg al dexamethason als anti-emeticum bij de chemotherapie en als pijnbestrijding bij de leverkapselrek.", [["ze kreeg al dexamethason als anti-emeticum bij de chemotherapie", "TREATMENT", 42, 105]]], ["Op de CT-scan die 4 dagen eerder was gemaakt, was slechts een afwijking te zien die wees op een al dan niet pathologische inzakkingsfractuur (figuur 2).", [["Op de CT-scan", "TEST", 0, 13]]], ["Zij ontwikkelde oligurie bij een acute verslechtering van de nierinsuffici\u00ebntie.", [["acute", "OBSERVATION_MODIFIER", 33, 38]]], ["Daarop begonnen wij behandeling met allopurinol en rasburicase en pasten agressieve hydratie toe.", [["allopurinol", "CHEMICAL", 36, 47], ["allopurinol", "CHEMICAL", 36, 47], ["allopurinol", "SIMPLE_CHEMICAL", 36, 47], ["Daarop", "TREATMENT", 0, 6], ["allopurinol en rasburicase", "TREATMENT", 36, 62], ["toe", "ANATOMY", 93, 96]]], ["Pati\u00ebnte kreeg de 3e gift etoposide niet meer.", [["etoposide", "CHEMICAL", 26, 35]]], ["Op verzoek van pati\u00ebnte en", [["Op verzoek van pati\u00ebnte en", "SPECIES", 0, 26]]]], "3cb4e0df9f98eb23f6c2f0189f23bbf37006addc": [["IntroductionThe isolation and cultivation of rotaviruses were problematic until the recognition that treatment with pancreatic proteolytic enzymes enhances viral replication in vitro (reviewed in 10).", [["pancreatic", "ANATOMY", 116, 126], ["rotaviruses", "ORGANISM", 45, 56], ["pancreatic", "ORGAN", 116, 126], ["pancreatic proteolytic enzymes", "PROTEIN", 116, 146], ["The isolation", "TREATMENT", 12, 25], ["cultivation", "TREATMENT", 30, 41], ["rotaviruses", "PROBLEM", 45, 56], ["pancreatic proteolytic enzymes", "TREATMENT", 116, 146], ["viral replication", "TREATMENT", 156, 173], ["pancreatic", "ANATOMY", 116, 126]]], ["Primary epithelial cells or epithelial cell lines are most often used for in vitro cultivation of mammalian rotaviruses (reviewed in 10) .", [["Primary epithelial cells", "ANATOMY", 0, 24], ["epithelial cell lines", "ANATOMY", 28, 49], ["Primary epithelial cells", "CELL", 0, 24], ["epithelial cell lines", "CELL", 28, 49], ["mammalian rotaviruses", "ORGANISM", 98, 119], ["Primary epithelial cells", "CELL_TYPE", 0, 24], ["epithelial cell lines", "CELL_LINE", 28, 49], ["Primary epithelial cells", "PROBLEM", 0, 24], ["epithelial cell lines", "PROBLEM", 28, 49], ["mammalian rotaviruses", "PROBLEM", 98, 119], ["epithelial cells", "OBSERVATION", 8, 24], ["epithelial cell lines", "OBSERVATION", 28, 49], ["mammalian rotaviruses", "OBSERVATION", 98, 119]]], ["Similarly, avian rotaviruses are grown in either primary avian kidney- (20) or embryo liver cell (12) cultures or in the epitheliM cell line MA 104 (19) .IntroductionIn vivo studies on the pathogenesis of infection with rotavirus in mammals and birds confirmed that viral replication occurs mostly in the mature epithelial cells of the intestinal villi.", [["kidney", "ANATOMY", 63, 69], ["embryo liver cell (12) cultures", "ANATOMY", 79, 110], ["epitheliM cell line", "ANATOMY", 121, 140], ["epithelial cells", "ANATOMY", 312, 328], ["intestinal villi", "ANATOMY", 336, 352], ["infection", "DISEASE", 205, 214], ["avian rotaviruses", "ORGANISM", 11, 28], ["avian", "ORGANISM", 57, 62], ["kidney", "ORGAN", 63, 69], ["embryo liver cell", "CELL", 79, 96], ["epitheliM cell line MA 104", "CELL", 121, 147], ["rotavirus", "ORGANISM", 220, 229], ["epithelial cells", "CELL", 312, 328], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 336, 352], ["embryo liver cell (12) cultures", "CELL_LINE", 79, 110], ["epitheliM cell line", "CELL_LINE", 121, 140], ["MA 104", "CELL_LINE", 141, 147], ["mature epithelial cells", "CELL_TYPE", 305, 328], ["rotaviruses", "SPECIES", 17, 28], ["rotavirus", "SPECIES", 220, 229], ["avian rotaviruses", "PROBLEM", 11, 28], ["embryo liver cell", "PROBLEM", 79, 96], ["cultures", "TEST", 102, 110], ["the epitheliM cell line MA", "TEST", 117, 143], ["infection", "PROBLEM", 205, 214], ["rotavirus in mammals", "PROBLEM", 220, 240], ["viral replication", "PROBLEM", 266, 283], ["rotaviruses", "OBSERVATION", 17, 28], ["grown", "OBSERVATION_MODIFIER", 33, 38], ["kidney", "ANATOMY", 63, 69], ["liver", "ANATOMY", 86, 91], ["infection", "OBSERVATION", 205, 214], ["viral replication", "OBSERVATION", 266, 283], ["mature epithelial cells", "OBSERVATION", 305, 328], ["intestinal villi", "ANATOMY", 336, 352]]], ["Occasionally, macrophages with rotavirus particles have been observed in the lamina propria of rotavirusinfected calves (17) and virus antigens have been demonstrated in scattered lymphocytes in the mesentric lymph nodes of infected piglets (18).", [["macrophages", "ANATOMY", 14, 25], ["lamina propria", "ANATOMY", 77, 91], ["lymphocytes", "ANATOMY", 180, 191], ["mesentric lymph nodes", "ANATOMY", 199, 220], ["macrophages", "CELL", 14, 25], ["rotavirus", "ORGANISM", 31, 40], ["lamina propria", "TISSUE", 77, 91], ["calves", "ORGANISM", 113, 119], ["lymphocytes", "CELL", 180, 191], ["mesentric lymph nodes", "MULTI-TISSUE_STRUCTURE", 199, 220], ["piglets", "ORGANISM", 233, 240], ["macrophages", "CELL_TYPE", 14, 25], ["scattered lymphocytes", "CELL_TYPE", 170, 191], ["calves", "SPECIES", 113, 119], ["piglets", "SPECIES", 233, 240], ["rotavirus", "SPECIES", 31, 40], ["rotavirus particles", "PROBLEM", 31, 50], ["virus antigens", "PROBLEM", 129, 143], ["scattered lymphocytes", "PROBLEM", 170, 191], ["macrophages", "OBSERVATION", 14, 25], ["rotavirus particles", "OBSERVATION", 31, 50], ["lamina", "ANATOMY_MODIFIER", 77, 83], ["propria", "ANATOMY_MODIFIER", 84, 91], ["rotavirusinfected calves", "ANATOMY", 95, 119], ["scattered", "OBSERVATION_MODIFIER", 170, 179], ["lymphocytes", "OBSERVATION", 180, 191], ["mesentric", "ANATOMY", 199, 208], ["lymph nodes", "OBSERVATION", 209, 220], ["infected", "OBSERVATION_MODIFIER", 224, 232], ["piglets", "OBSERVATION_MODIFIER", 233, 240]]], ["Recently, YAso~ and SC~AT (21) described the presence of cells positive for rotavirus antigen in the lymphocytic areas of the cecal tonsils of experimentally infected chickens and turkeys.", [["cells", "ANATOMY", 57, 62], ["lymphocytic areas", "ANATOMY", 101, 118], ["cecal tonsils", "ANATOMY", 126, 139], ["YAso", "GENE_OR_GENE_PRODUCT", 10, 14], ["cells", "CELL", 57, 62], ["rotavirus antigen", "GENE_OR_GENE_PRODUCT", 76, 93], ["cecal tonsils", "MULTI-TISSUE_STRUCTURE", 126, 139], ["chickens", "ORGANISM", 167, 175], ["turkeys", "ORGANISM", 180, 187], ["rotavirus antigen", "PROTEIN", 76, 93], ["chickens", "SPECIES", 167, 175], ["turkeys", "SPECIES", 180, 187], ["rotavirus", "SPECIES", 76, 85], ["chickens", "SPECIES", 167, 175], ["turkeys", "SPECIES", 180, 187], ["cells positive", "PROBLEM", 57, 71], ["rotavirus antigen", "PROBLEM", 76, 93], ["rotavirus", "OBSERVATION", 76, 85], ["lymphocytic", "OBSERVATION", 101, 112], ["cecal tonsils", "ANATOMY", 126, 139], ["experimentally", "OBSERVATION_MODIFIER", 143, 157], ["infected chickens", "OBSERVATION", 158, 175]]], ["It was not clear if there was active virus replication or whether these cells were macrophages, antigen-presenting cells or lymphoc)~es.There is a paucity of information on replication of rotaviruses in lymphocytes.", [["cells", "ANATOMY", 72, 77], ["macrophages", "ANATOMY", 83, 94], ["cells", "ANATOMY", 115, 120], ["lymphocytes", "ANATOMY", 203, 214], ["cells", "CELL", 72, 77], ["macrophages", "CELL", 83, 94], ["antigen", "GENE_OR_GENE_PRODUCT", 96, 103], ["cells", "CELL", 115, 120], ["lymphoc", "CELL", 124, 131], ["rotaviruses", "ORGANISM", 188, 199], ["lymphocytes", "CELL", 203, 214], ["macrophages", "CELL_TYPE", 83, 94], ["antigen-presenting cells", "CELL_TYPE", 96, 120], ["lymphoc", "CELL_TYPE", 124, 131], ["lymphocytes", "CELL_TYPE", 203, 214], ["active virus replication", "PROBLEM", 30, 54], ["these cells", "PROBLEM", 66, 77], ["macrophages", "PROBLEM", 83, 94], ["antigen", "TEST", 96, 103], ["rotaviruses in lymphocytes", "PROBLEM", 188, 214], ["paucity", "OBSERVATION_MODIFIER", 147, 154], ["rotaviruses", "OBSERVATION", 188, 199], ["lymphocytes", "ANATOMY", 203, 214]]], ["Only NOZAWA and FONSECA (13) have reported that human rotavirus can replicate in mitogen-stimulated peripheral blood lymphocytes.", [["peripheral blood lymphocytes", "ANATOMY", 100, 128], ["human", "ORGANISM", 48, 53], ["rotavirus", "ORGANISM", 54, 63], ["peripheral blood lymphocytes", "CELL", 100, 128], ["mitogen-stimulated peripheral blood lymphocytes", "CELL_TYPE", 81, 128], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["human rotavirus", "PROBLEM", 48, 63], ["blood lymphocytes", "ANATOMY", 111, 128]]], ["In this paper we report that several avian rotaviruses can infect both nonstimulated avian splenic lymphocytes and lymphoblastoid cell lines transformed by avian tumor viruses.Virus StrainsThe following avian rotaviruses were used: chicken isolates Ch-1 and Ch-2, turkey isolates Tu-1 and Tu-2 and the pheasant isolate Ph-I (20) .", [["splenic lymphocytes", "ANATOMY", 91, 110], ["lymphoblastoid cell lines", "ANATOMY", 115, 140], ["tumor", "ANATOMY", 162, 167], ["avian tumor", "DISEASE", 156, 167], ["avian", "ORGANISM", 37, 42], ["rotaviruses", "ORGANISM", 43, 54], ["avian", "ORGANISM", 85, 90], ["splenic lymphocytes", "CELL", 91, 110], ["lymphoblastoid cell lines", "CELL", 115, 140], ["avian tumor viruses", "ORGANISM", 156, 175], ["Virus", "ORGANISM", 176, 181], ["avian", "ORGANISM", 203, 208], ["rotaviruses", "ORGANISM", 209, 220], ["chicken", "ORGANISM", 232, 239], ["Ch-1", "CELL", 249, 253], ["Ch-2", "CELL", 258, 262], ["turkey", "ORGANISM", 264, 270], ["Tu-1", "CELL", 280, 284], ["Tu-2", "CELL", 289, 293], ["nonstimulated avian splenic lymphocytes", "CELL_TYPE", 71, 110], ["lymphoblastoid cell lines", "CELL_LINE", 115, 140], ["chicken", "SPECIES", 232, 239], ["turkey", "SPECIES", 264, 270], ["pheasant", "SPECIES", 302, 310], ["chicken", "SPECIES", 232, 239], ["Ch-1", "SPECIES", 249, 253], ["Tu-1", "SPECIES", 280, 284], ["several avian rotaviruses", "PROBLEM", 29, 54], ["lymphoblastoid cell lines", "TREATMENT", 115, 140], ["avian tumor viruses", "PROBLEM", 156, 175], ["Virus Strains", "PROBLEM", 176, 189], ["avian rotaviruses", "TREATMENT", 203, 220], ["chicken isolates Ch", "TEST", 232, 251], ["Ch", "TEST", 258, 260], ["turkey isolates", "TEST", 264, 279], ["Tu", "TEST", 280, 282], ["Tu", "TEST", 289, 291], ["the pheasant isolate Ph", "TEST", 298, 321], ["splenic", "ANATOMY", 91, 98], ["lymphocytes", "OBSERVATION", 99, 110], ["lymphoblastoid cell lines", "OBSERVATION", 115, 140], ["tumor viruses", "OBSERVATION", 162, 175]]], ["Virus stocks were prepared from infected chick kidney cell cultures (CKC) between passage levels 5 and 10 and stored at -80 \u00b0 C.Cell CulturesThe use of CKC cultures for rotavirus propagation has been described elsewhere (20) .", [["kidney cell cultures", "ANATOMY", 47, 67], ["CKC", "ANATOMY", 69, 72], ["CKC cultures", "ANATOMY", 152, 164], ["rotavirus propagation", "DISEASE", 169, 190], ["Virus", "ORGANISM", 0, 5], ["chick", "ORGANISM", 41, 46], ["kidney cell cultures", "CELL", 47, 67], ["CKC", "CELL", 69, 72], ["CKC cultures", "CELL", 152, 164], ["rotavirus", "ORGANISM", 169, 178], ["infected chick kidney cell cultures", "CELL_LINE", 32, 67], ["CKC", "CELL_LINE", 69, 72], ["CKC cultures", "CELL_LINE", 152, 164], ["chick", "SPECIES", 41, 46], ["chick", "SPECIES", 41, 46], ["rotavirus", "SPECIES", 169, 178], ["Virus stocks", "TREATMENT", 0, 12], ["infected chick kidney cell cultures", "TEST", 32, 67], ["CKC", "TEST", 69, 72], ["passage levels", "TEST", 82, 96], ["C.Cell Cultures", "TEST", 126, 141], ["CKC cultures", "TEST", 152, 164], ["rotavirus propagation", "PROBLEM", 169, 190], ["kidney", "ANATOMY", 47, 53], ["cell", "OBSERVATION", 54, 58]]], ["Short-term spleen cell cultures were prepared from spleens obtained[ from 5-to 8-week-old, specific-pathogen-free chickens as described by CAL~EK et al. (4) .", [["spleen cell cultures", "ANATOMY", 11, 31], ["spleens", "ANATOMY", 51, 58], ["spleen cell cultures", "CELL", 11, 31], ["spleens", "ORGAN", 51, 58], ["chickens", "ORGANISM", 114, 122], ["Short-term spleen cell cultures", "CELL_LINE", 0, 31], ["chickens", "SPECIES", 114, 122], ["chickens", "SPECIES", 114, 122], ["Short-term spleen cell cultures", "TEST", 0, 31], ["spleen", "ANATOMY", 11, 17], ["cell cultures", "OBSERVATION", 18, 31], ["spleens", "ANATOMY", 51, 58]]], ["Briefly: spleens were collected aseptically and gently forced through a 60 ~m autoclavable screen (Tetco, Inc., Elmsford, NY).", [["spleens", "ANATOMY", 9, 16], ["spleens", "ORGAN", 9, 16], ["spleens", "ANATOMY", 9, 16]]], ["Cells were centrifuged over Ficoll-Paque (Pharmaeia, Inc, Piscataway, NJ).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["The splenic lymphocytes collected from the interface, were washed twice in PBS and counted.", [["splenic lymphocytes", "ANATOMY", 4, 23], ["splenic lymphocytes", "CELL", 4, 23], ["splenic lymphocytes", "CELL_TYPE", 4, 23], ["splenic", "ANATOMY", 4, 11], ["lymphocytes", "OBSERVATION", 12, 23], ["interface", "OBSERVATION_MODIFIER", 43, 52]]], ["These cells consist mainly of T and B cells, macrophages and natural killer cells.", [["cells", "ANATOMY", 6, 11], ["T", "ANATOMY", 30, 31], ["B cells", "ANATOMY", 36, 43], ["macrophages", "ANATOMY", 45, 56], ["natural killer cells", "ANATOMY", 61, 81], ["cells", "CELL", 6, 11], ["T", "CELL", 30, 31], ["B cells", "CELL", 36, 43], ["macrophages", "CELL", 45, 56], ["natural killer cells", "CELL", 61, 81], ["T and B cells", "CELL_TYPE", 30, 43], ["macrophages", "CELL_TYPE", 45, 56], ["natural killer cells", "CELL_TYPE", 61, 81], ["These cells", "TEST", 0, 11], ["macrophages", "ANATOMY", 45, 56], ["natural killer cells", "OBSERVATION", 61, 81]]], ["Five \u00d7 106 spleen cells were cultured in 1 ml of LM-Hahn (LMH) n~mdium (3) in plastic tubes (=~ 2057, Falcon Plastics, Oxnard, CA) with caps loose at 41 \u00b0 C in a humidified atmosphere of 5 percent CO: in air.", [["spleen cells", "ANATOMY", 11, 23], ["n~mdium", "CHEMICAL", 63, 70], ["CO", "CHEMICAL", 197, 199], ["spleen cells", "CELL", 11, 23], ["CO", "SIMPLE_CHEMICAL", 197, 199], ["\u00d7 106 spleen cells", "CELL_LINE", 5, 23], ["spleen cells", "TEST", 11, 23], ["n~mdium", "TEST", 63, 70], ["a humidified atmosphere", "TREATMENT", 160, 183], ["spleen", "ANATOMY", 11, 17], ["LM", "ANATOMY", 49, 51], ["plastic tubes", "OBSERVATION", 78, 91], ["air", "ANATOMY", 204, 207]]], ["LMH-medium consists of equM parts of Leibovitz and McCoy medium (both from Gibco, Grand Island, NY) supplemented with 10 percent heatinactivated chicken serum and 8 percent fetal bovine serum (FBS), 5 percent tryptose phosphate broth, 0.0] mM 2-mercaptoethanol, 2 mM glutamine, t m~ sodium pyruvate and antibiotics.", [["serum", "ANATOMY", 153, 158], ["fetal bovine serum", "ANATOMY", 173, 191], ["FBS", "ANATOMY", 193, 196], ["tryptose phosphate", "CHEMICAL", 209, 227], ["2-mercaptoethanol", "CHEMICAL", 243, 260], ["glutamine", "CHEMICAL", 267, 276], ["sodium pyruvate", "CHEMICAL", 283, 298], ["tryptose phosphate", "CHEMICAL", 209, 227], ["2-mercaptoethanol", "CHEMICAL", 243, 260], ["glutamine", "CHEMICAL", 267, 276], ["sodium pyruvate", "CHEMICAL", 283, 298], ["Leibovitz", "SIMPLE_CHEMICAL", 37, 46], ["chicken", "ORGANISM", 145, 152], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["bovine", "ORGANISM", 179, 185], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["FBS", "ORGANISM_SUBSTANCE", 193, 196], ["tryptose", "SIMPLE_CHEMICAL", 209, 217], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 243, 260], ["glutamine", "AMINO_ACID", 267, 276], ["t m~ sodium pyruvate", "SIMPLE_CHEMICAL", 278, 298], ["chicken", "SPECIES", 145, 152], ["bovine", "SPECIES", 179, 185], ["chicken", "SPECIES", 145, 152], ["bovine", "SPECIES", 179, 185], ["10 percent heatinactivated chicken", "TREATMENT", 118, 152], ["serum", "TEST", 153, 158], ["fetal bovine serum", "TEST", 173, 191], ["FBS", "TEST", 193, 196], ["tryptose phosphate broth", "TEST", 209, 233], ["mercaptoethanol", "TREATMENT", 245, 260], ["2 mM glutamine", "TREATMENT", 262, 276], ["t m~ sodium pyruvate", "TREATMENT", 278, 298], ["antibiotics", "TREATMENT", 303, 314], ["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["The use of chicken serum and FBS is essential for the cultivation of avian lymphoblastoid cells and tbr the short term (48 to 72 hours) cultivation of avian splenic lymphocytes.", [["serum", "ANATOMY", 19, 24], ["FBS", "ANATOMY", 29, 32], ["lymphoblastoid cells", "ANATOMY", 75, 95], ["splenic lymphocytes", "ANATOMY", 157, 176], ["chicken", "ORGANISM", 11, 18], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["FBS", "ORGANISM_SUBSTANCE", 29, 32], ["avian", "ORGANISM", 69, 74], ["lymphoblastoid cells", "CELL", 75, 95], ["avian", "ORGANISM", 151, 156], ["splenic lymphocytes", "CELL", 157, 176], ["avian lymphoblastoid cells", "CELL_TYPE", 69, 95], ["avian splenic lymphocytes", "CELL_TYPE", 151, 176], ["chicken", "SPECIES", 11, 18], ["chicken", "SPECIES", 11, 18], ["chicken serum and FBS", "TEST", 11, 32], ["avian lymphoblastoid cells", "TREATMENT", 69, 95], ["avian lymphoblastoid cells", "OBSERVATION", 69, 95], ["splenic", "ANATOMY", 157, 164], ["lymphocytes", "OBSERVATION", 165, 176]]], ["The following lymphoblastoid cell lines were used: i) Two Marek's disease virus-transformed cell lines: MDCC-CU 2 and CU 36 (2, 3), which are beth I a-expressing T cells (15) . ii) Two avian leukosis virus-transformed cell lines: LSCC-CU l0 (2) and RP-9 (14) , which are B cells, iii) One cell line transformed by reticuloendotheliosis virus: RECC-CU 60, which is a pre-T, pre~B cell line (D. WEI~STOCK, personal communication).Inoculation ProceduresPrior to infection of CKC, spleen cells or lymphoblastoid cell lines, the rotaviruses were treated with 5 ~g/ml trypsin for 1 hour at 37 \u00b0 C (19) .", [["lymphoblastoid cell lines", "ANATOMY", 14, 39], ["cell lines", "ANATOMY", 92, 102], ["beth I a-expressing T cells", "ANATOMY", 142, 169], ["cell lines", "ANATOMY", 218, 228], ["LSCC", "ANATOMY", 230, 234], ["RP-9", "ANATOMY", 249, 253], ["B cells", "ANATOMY", 271, 278], ["cell line", "ANATOMY", 289, 298], ["pre-T", "ANATOMY", 366, 371], ["pre~B cell line", "ANATOMY", 373, 388], ["CKC", "ANATOMY", 472, 475], ["spleen cells", "ANATOMY", 477, 489], ["lymphoblastoid cell lines", "ANATOMY", 493, 518], ["Marek's disease", "DISEASE", 58, 73], ["leukosis", "DISEASE", 191, 199], ["infection", "DISEASE", 459, 468], ["lymphoblastoid cell lines", "CELL", 14, 39], ["Marek's disease virus", "ORGANISM", 58, 79], ["cell lines", "CELL", 92, 102], ["MDCC-CU 2", "CELL", 104, 113], ["CU 36", "CELL", 118, 123], ["T cells", "CELL", 162, 169], ["avian leukosis virus", "ORGANISM", 185, 205], ["cell lines", "CELL", 218, 228], ["LSCC-CU l0 (2", "CELL", 230, 243], ["RP-9", "CELL", 249, 253], ["B cells", "CELL", 271, 278], ["cell line", "CELL", 289, 298], ["reticuloendotheliosis virus", "ORGANISM", 314, 341], ["RECC-CU 60", "CELL", 343, 353], ["pre-T", "CELL", 366, 371], ["pre~B cell line", "CELL", 373, 388], ["CKC", "CELL", 472, 475], ["spleen cells", "CELL", 477, 489], ["lymphoblastoid cell lines", "CELL", 493, 518], ["rotaviruses", "ORGANISM", 524, 535], ["trypsin", "GENE_OR_GENE_PRODUCT", 562, 569], ["lymphoblastoid cell lines", "CELL_LINE", 14, 39], ["transformed cell lines", "CELL_LINE", 80, 102], ["MDCC", "CELL_LINE", 104, 108], ["CU 2", "CELL_LINE", 109, 113], ["CU 36", "CELL_LINE", 118, 123], ["beth I a-expressing T cells", "CELL_LINE", 142, 169], ["transformed cell lines", "CELL_LINE", 206, 228], ["B cells", "CELL_TYPE", 271, 278], ["cell line", "CELL_LINE", 289, 298], ["pre-T, pre~B cell line", "CELL_LINE", 366, 388], ["CKC, spleen cells", "CELL_LINE", 472, 489], ["lymphoblastoid cell lines", "CELL_LINE", 493, 518], ["trypsin", "PROTEIN", 562, 569], ["avian leukosis virus", "SPECIES", 185, 205], ["Marek's disease virus", "SPECIES", 58, 79], ["The following lymphoblastoid cell lines", "TREATMENT", 0, 39], ["Two Marek's disease virus", "PROBLEM", 54, 79], ["MDCC", "TEST", 104, 108], ["Two avian leukosis virus", "PROBLEM", 181, 205], ["LSCC", "TEST", 230, 234], ["RP", "TEST", 249, 251], ["One cell line", "TREATMENT", 285, 298], ["infection", "PROBLEM", 459, 468], ["CKC", "PROBLEM", 472, 475], ["spleen cells", "PROBLEM", 477, 489], ["lymphoblastoid cell lines", "TREATMENT", 493, 518], ["the rotaviruses", "PROBLEM", 520, 535], ["lymphoblastoid cell lines", "OBSERVATION", 14, 39], ["cell lines", "OBSERVATION", 92, 102], ["avian leukosis virus", "OBSERVATION", 185, 205], ["cell lines", "OBSERVATION", 218, 228], ["LSCC", "ANATOMY", 230, 234], ["cell line", "OBSERVATION", 289, 298], ["reticuloendotheliosis virus", "OBSERVATION", 314, 341], ["cell line", "OBSERVATION", 379, 388], ["infection", "OBSERVATION", 459, 468], ["spleen", "ANATOMY", 477, 483], ["lymphoblastoid cell lines", "OBSERVATION", 493, 518]]], ["Lymphoblastoid cell lines were washed twice in PBS, and 1 \u00d7 106 cells/ml were resuspended in 0.4 ml PBS containing different concentrations of trypsin-treated rot~virus and incubated ~br 1 hour at 37 \u00b0 C. The cells were washed 1 to 6 times, placed in 1 ml of LMH and incubated at 38 \u00b0 or 41 \u00b0 C. Spleen cell cultures were infected tbllowing the same method, except that 5 x 106 cells per culture were used.", [["Lymphoblastoid cell lines", "ANATOMY", 0, 25], ["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 209, 214], ["Spleen cell cultures", "ANATOMY", 296, 316], ["cells", "ANATOMY", 378, 383], ["Lymphoblastoid cell lines", "CELL", 0, 25], ["cells", "CELL", 64, 69], ["trypsin", "SIMPLE_CHEMICAL", 143, 150], ["cells", "CELL", 209, 214], ["Spleen cell cultures", "CELL", 296, 316], ["cells", "CELL", 378, 383], ["Lymphoblastoid cell lines", "CELL_LINE", 0, 25], ["trypsin", "PROTEIN", 143, 150], ["Lymphoblastoid cell lines", "TREATMENT", 0, 25], ["trypsin", "TREATMENT", 143, 150], ["rot~virus", "TREATMENT", 159, 168], ["Spleen cell cultures", "TEST", 296, 316], ["culture", "TEST", 388, 395], ["cell lines", "OBSERVATION", 15, 25], ["Spleen", "ANATOMY", 296, 302], ["cell", "OBSERVATION", 303, 307]]], ["CKC cultures, cultivated on glass coverslips were infected as described elsewhere (20) .Antisera, Monoclonal Antibodies and Fluorescent Antibody Conjugat~Convalescent antisera against rotavirus were obtained from SPF-chickens infected with the Ch-2 strain of rotavirus.", [["CKC cultures", "ANATOMY", 0, 12], ["rotavirus", "DISEASE", 259, 268], ["CKC cultures", "CELL", 0, 12], ["Antisera", "ORGANISM_SUBSTANCE", 88, 96], ["rotavirus", "ORGANISM", 184, 193], ["chickens", "ORGANISM", 217, 225], ["Ch-2", "ORGANISM", 244, 248], ["rotavirus", "ORGANISM", 259, 268], ["CKC cultures", "CELL_LINE", 0, 12], ["Monoclonal Antibodies", "PROTEIN", 98, 119], ["chickens", "SPECIES", 217, 225], ["rotavirus", "SPECIES", 184, 193], ["chickens", "SPECIES", 217, 225], ["Ch-2 strain", "SPECIES", 244, 255], ["rotavirus", "SPECIES", 259, 268], ["CKC cultures", "TEST", 0, 12], ["glass coverslips", "TREATMENT", 28, 44], ["Antisera", "TEST", 88, 96], ["Monoclonal Antibodies", "TEST", 98, 119], ["Fluorescent Antibody", "TEST", 124, 144], ["Convalescent antisera", "TREATMENT", 154, 175], ["rotavirus", "PROBLEM", 184, 193], ["rotavirus", "PROBLEM", 259, 268], ["rotavirus", "OBSERVATION", 259, 268]]], ["These sera were conjugated with fluorescein isothiocyanate (20) for immunofluorescence tests and also used in a virus-neutralization assay.Antisera, Monoclonal Antibodies and Fluorescent Antibody Conjugat~Mouse monoclonal IgG anti-chicken IgM (~ chain) (MACIgm) (7), mouse monoclonal anti-chicken I a (MAIa) (11) , mouse monoclonal anti-chicken panlymphocy~ antigen (~LACLA), which detects immature B ceils prior to hatching, some macrophages and circulating T cells (C.-L. CHEN, personal communication) and a mouse monoclonal antibody against circulating T cells (MATs) (A. BENEDICT, personal communication) were used as previously described (16) .Antisera, Monoclonal Antibodies and Fluorescent Antibody Conjugatabbit IgG antimouse Ig (heavy and light chain, Miles-Yeda Ltd, Rehovot, Israel) (l~AM) and goat IgG antirabbit Ig/s conjugated with rhodamine (GARG-TRITC) (Cappel Laboratories, West Chester, PA) were used for indirect fluorescent antibody tests in conjunction with monoclonal antibodies.Tests for Infected Cells in CultureThe numbers of infected cells in the lymphoblastoid and spleen cell cultures were determined as described by CALNEK et al. (4) for MDV-infected lymphocytes.", [["sera", "ANATOMY", 6, 10], ["B ceils", "ANATOMY", 399, 406], ["macrophages", "ANATOMY", 431, 442], ["T cells", "ANATOMY", 459, 466], ["T cells", "ANATOMY", 556, 563], ["Cells", "ANATOMY", 1020, 1025], ["Culture", "ANATOMY", 1029, 1036], ["cells", "ANATOMY", 1060, 1065], ["lymphoblastoid", "ANATOMY", 1073, 1087], ["spleen cell cultures", "ANATOMY", 1092, 1112], ["lymphocytes", "ANATOMY", 1180, 1191], ["fluorescein isothiocyanate", "CHEMICAL", 32, 58], ["rhodamine", "CHEMICAL", 846, 855], ["GARG-TRITC", "CHEMICAL", 857, 867], ["fluorescein isothiocyanate", "CHEMICAL", 32, 58], ["rhodamine", "CHEMICAL", 846, 855], ["TRITC", "CHEMICAL", 862, 867], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 32, 58], ["Antisera", "ORGANISM_SUBSTANCE", 139, 147], ["mouse", "ORGANISM", 267, 272], ["MAIa", "ORGANISM", 302, 306], ["mouse", "ORGANISM", 315, 320], ["panlymphocy~ antigen", "GENE_OR_GENE_PRODUCT", 345, 365], ["LACLA", "GENE_OR_GENE_PRODUCT", 368, 373], ["B ceils", "CELL", 399, 406], ["macrophages", "CELL", 431, 442], ["circulating T cells", "CELL", 447, 466], ["C.-L. CHEN", "CELL", 468, 478], ["mouse", "ORGANISM", 510, 515], ["T cells", "CELL", 556, 563], ["MATs", "CELL", 565, 569], ["Antisera", "ORGANISM_SUBSTANCE", 649, 657], ["Rehovot", "SIMPLE_CHEMICAL", 777, 784], ["goat", "ORGANISM", 805, 809], ["rhodamine", "SIMPLE_CHEMICAL", 846, 855], ["GARG-TRITC", "SIMPLE_CHEMICAL", 857, 867], ["Cells", "CELL", 1020, 1025], ["cells", "CELL", 1060, 1065], ["lymphoblastoid", "CELL", 1073, 1087], ["spleen cell cultures", "CELL", 1092, 1112], ["MDV", "ORGANISM", 1167, 1170], ["lymphocytes", "CELL", 1180, 1191], ["Monoclonal Antibodies", "PROTEIN", 149, 170], ["Fluorescent Antibody Conjugat~Mouse monoclonal IgG anti-chicken IgM (~ chain", "PROTEIN", 175, 251], ["MACIgm", "PROTEIN", 254, 260], ["mouse monoclonal anti-chicken I", "PROTEIN", 267, 298], ["MAIa", "PROTEIN", 302, 306], ["mouse monoclonal anti-chicken panlymphocy~ antigen", "PROTEIN", 315, 365], ["LACLA", "PROTEIN", 368, 373], ["macrophages", "CELL_TYPE", 431, 442], ["circulating T cells", "CELL_TYPE", 447, 466], ["mouse monoclonal antibody", "PROTEIN", 510, 535], ["circulating T cells", "CELL_TYPE", 544, 563], ["Monoclonal Antibodies", "PROTEIN", 659, 680], ["Fluorescent Antibody Conjugatabbit IgG antimouse Ig", "PROTEIN", 685, 736], ["heavy and light chain", "PROTEIN", 738, 759], ["goat IgG", "PROTEIN", 805, 813], ["antirabbit Ig", "PROTEIN", 814, 827], ["monoclonal antibodies", "PROTEIN", 979, 1000], ["infected cells", "CELL_TYPE", 1051, 1065], ["lymphoblastoid and spleen cell cultures", "CELL_LINE", 1073, 1112], ["MDV-infected lymphocytes", "CELL_TYPE", 1167, 1191], ["Mouse", "SPECIES", 205, 210], ["mouse", "SPECIES", 267, 272], ["mouse", "SPECIES", 315, 320], ["mouse", "SPECIES", 510, 515], ["antimouse", "SPECIES", 724, 733], ["goat", "SPECIES", 805, 809], ["Mouse", "SPECIES", 205, 210], ["mouse", "SPECIES", 267, 272], ["mouse", "SPECIES", 315, 320], ["C.-L. CHEN", "SPECIES", 468, 478], ["mouse", "SPECIES", 510, 515], ["goat", "SPECIES", 805, 809], ["MDV", "SPECIES", 1167, 1170], ["These sera", "TEST", 0, 10], ["fluorescein isothiocyanate", "TREATMENT", 32, 58], ["immunofluorescence tests", "TEST", 68, 92], ["Antisera", "TEST", 139, 147], ["Monoclonal Antibodies", "TEST", 149, 170], ["Fluorescent Antibody", "TEST", 175, 195], ["Conjugat", "TEST", 196, 204], ["Mouse monoclonal IgG anti-chicken IgM", "TEST", 205, 242], ["mouse monoclonal anti-chicken panlymphocy~ antigen", "PROBLEM", 315, 365], ["immature B ceils", "PROBLEM", 390, 406], ["some macrophages", "PROBLEM", 426, 442], ["circulating T cells", "PROBLEM", 447, 466], ["a mouse monoclonal antibody", "TEST", 508, 535], ["Antisera", "TEST", 649, 657], ["Monoclonal Antibodies", "TEST", 659, 680], ["Fluorescent Antibody", "TEST", 685, 705], ["Conjugatabbit", "TEST", 706, 719], ["IgG", "TEST", 720, 723], ["Ig", "TEST", 734, 736], ["light chain", "TEST", 748, 759], ["goat IgG antirabbit Ig", "TEST", 805, 827], ["rhodamine", "TREATMENT", 846, 855], ["indirect fluorescent antibody tests", "TEST", 923, 958], ["monoclonal antibodies", "TEST", 979, 1000], ["Tests", "TEST", 1001, 1006], ["Infected Cells", "PROBLEM", 1011, 1025], ["Culture", "TEST", 1029, 1036], ["infected cells", "PROBLEM", 1051, 1065], ["spleen cell cultures", "TEST", 1092, 1112], ["MDV", "PROBLEM", 1167, 1170], ["infected lymphocytes", "PROBLEM", 1171, 1191], ["Infected Cells", "OBSERVATION", 1011, 1025], ["infected cells", "OBSERVATION", 1051, 1065], ["lymphoblastoid", "ANATOMY", 1073, 1087], ["spleen", "ANATOMY", 1092, 1098], ["cell cultures", "OBSERVATION", 1099, 1112], ["infected lymphocytes", "OBSERVATION", 1171, 1191]]], ["Briefly: The number of live cells in each culture was estimated by counting cells in a hematoc~e counter using trypan blue dye exclusion.", [["cells", "ANATOMY", 28, 33], ["cells", "ANATOMY", 76, 81], ["trypan blue", "CHEMICAL", 111, 122], ["trypan blue", "CHEMICAL", 111, 122], ["cells", "CELL", 28, 33], ["cells", "CELL", 76, 81], ["trypan blue dye", "SIMPLE_CHEMICAL", 111, 126], ["live cells", "CELL_TYPE", 23, 33], ["live cells", "PROBLEM", 23, 33], ["each culture", "TEST", 37, 49], ["a hematoc~e counter", "TREATMENT", 85, 104], ["trypan blue dye exclusion", "TREATMENT", 111, 136]]], ["Cells were washed once in PBS, resuspended in 0.1 ml of PBS and 10 txl drop smears were air-dried on glass slides and acetone-fixed.", [["Cells", "ANATOMY", 0, 5], ["acetone", "CHEMICAL", 118, 125], ["acetone", "CHEMICAL", 118, 125], ["Cells", "CELL", 0, 5], ["acetone", "SIMPLE_CHEMICAL", 118, 125], ["PBS", "TREATMENT", 56, 59], ["txl drop smears", "TEST", 67, 82], ["acetone", "TREATMENT", 118, 125]]], ["Smears were then stained with FITC-conjugated rotavirus antibodies or with the goat antiserum against human rotavirus followed by FITC-conjugated swine anti-sheep IgG.", [["Smears", "ANATOMY", 0, 6], ["FITC", "CHEMICAL", 30, 34], ["FITC", "CHEMICAL", 130, 134], ["Smears", "ORGANISM_SUBSTANCE", 0, 6], ["FITC", "SIMPLE_CHEMICAL", 30, 34], ["rotavirus", "ORGANISM", 46, 55], ["goat", "ORGANISM", 79, 83], ["antiserum", "ORGANISM_SUBSTANCE", 84, 93], ["human", "ORGANISM", 102, 107], ["rotavirus", "ORGANISM", 108, 117], ["FITC", "SIMPLE_CHEMICAL", 130, 134], ["swine", "ORGANISM", 146, 151], ["FITC", "PROTEIN", 30, 34], ["rotavirus antibodies", "PROTEIN", 46, 66], ["FITC-conjugated swine anti-sheep IgG", "PROTEIN", 130, 166], ["goat", "SPECIES", 79, 83], ["human", "SPECIES", 102, 107], ["swine", "SPECIES", 146, 151], ["rotavirus", "SPECIES", 46, 55], ["goat", "SPECIES", 79, 83], ["human rotavirus", "SPECIES", 102, 117], ["swine", "SPECIES", 146, 151], ["Smears", "TEST", 0, 6], ["FITC", "TEST", 30, 34], ["conjugated rotavirus antibodies", "PROBLEM", 35, 66], ["the goat antiserum", "TREATMENT", 75, 93], ["human rotavirus", "TREATMENT", 102, 117], ["FITC-conjugated swine anti-sheep IgG", "TREATMENT", 130, 166]]], ["The number of positive cells was enumerated using a Leitz fluorescence microscope with epiillumination.", [["cells", "ANATOMY", 23, 28], ["cells", "CELL", 23, 28], ["positive cells", "CELL_TYPE", 14, 28], ["positive cells", "PROBLEM", 14, 28], ["a Leitz fluorescence microscope", "TEST", 50, 81], ["epiillumination", "PROBLEM", 87, 102], ["positive cells", "OBSERVATION", 14, 28]]], ["Supernatant fluids were harvested from lymphoblastoid cell line cultures, frozen at -70\u00b0C and assayed on CKC cultures for virus titers.Dual Fluorescence TestsLymphocyte surface markers on rotavirus-infectcd spleen cells were detected following the technique described by CALNEK et al. (5) for MDV-infected lymphocytes.", [["Supernatant fluids", "ANATOMY", 0, 18], ["lymphoblastoid cell line cultures", "ANATOMY", 39, 72], ["surface", "ANATOMY", 169, 176], ["spleen cells", "ANATOMY", 207, 219], ["lymphocytes", "ANATOMY", 306, 317], ["Supernatant fluids", "ORGANISM_SUBSTANCE", 0, 18], ["lymphoblastoid cell line cultures", "CELL", 39, 72], ["C", "GENE_OR_GENE_PRODUCT", 88, 89], ["CKC cultures", "CELL", 105, 117], ["rotavirus", "ORGANISM", 188, 197], ["spleen cells", "CELL", 207, 219], ["MDV", "ORGANISM", 293, 296], ["lymphocytes", "CELL", 306, 317], ["lymphoblastoid cell line cultures", "CELL_LINE", 39, 72], ["CKC cultures", "CELL_LINE", 105, 117], ["Dual Fluorescence TestsLymphocyte surface markers", "PROTEIN", 135, 184], ["rotavirus-infectcd spleen cells", "CELL_TYPE", 188, 219], ["MDV-infected lymphocytes", "CELL_TYPE", 293, 317], ["MDV", "SPECIES", 293, 296], ["Supernatant fluids", "TREATMENT", 0, 18], ["lymphoblastoid cell line cultures", "TEST", 39, 72], ["frozen", "TEST", 74, 80], ["CKC cultures", "TEST", 105, 117], ["virus titers", "PROBLEM", 122, 134], ["Dual Fluorescence TestsLymphocyte surface markers", "TEST", 135, 184], ["rotavirus", "TEST", 188, 197], ["infectcd spleen cells", "PROBLEM", 198, 219], ["the technique", "TEST", 244, 257], ["MDV", "PROBLEM", 293, 296], ["infected lymphocytes", "PROBLEM", 297, 317], ["fluids", "OBSERVATION", 12, 18], ["lymphoblastoid cell line", "OBSERVATION", 39, 63], ["spleen", "ANATOMY", 207, 213], ["infected lymphocytes", "OBSERVATION", 297, 317]]], ["Briefly, spleen cells were washed in modified PBS (MPBS), containing 1 percent bovine serum albumin and 0.1 percent sodium azide, and then sequentially treated with the desired monoclonal antibody, RAM, and GARG-TRITC.", [["spleen cells", "ANATOMY", 9, 21], ["serum", "ANATOMY", 86, 91], ["sodium azide", "CHEMICAL", 116, 128], ["sodium azide", "CHEMICAL", 116, 128], ["spleen cells", "CELL", 9, 21], ["MPBS", "SIMPLE_CHEMICAL", 51, 55], ["bovine", "ORGANISM", 79, 85], ["serum", "ORGANISM_SUBSTANCE", 86, 91], ["albumin", "SIMPLE_CHEMICAL", 92, 99], ["sodium azide", "SIMPLE_CHEMICAL", 116, 128], ["GARG-TRITC", "GENE_OR_GENE_PRODUCT", 207, 217], ["spleen cells", "CELL_TYPE", 9, 21], ["monoclonal antibody", "PROTEIN", 177, 196], ["RAM", "PROTEIN", 198, 201], ["GARG", "PROTEIN", 207, 211], ["bovine", "SPECIES", 79, 85], ["bovine", "SPECIES", 79, 85], ["MPBS", "TEST", 51, 55], ["1 percent bovine serum albumin", "TREATMENT", 69, 99], ["percent sodium azide", "TEST", 108, 128], ["spleen", "ANATOMY", 9, 15]]], ["Ten ~l drop smears were air-dried, fixed in acetone and stained with the FITC-conjugated chicken antirotaserum.", [["antirotaserum", "CHEMICAL", 97, 110], ["acetone", "CHEMICAL", 44, 51], ["FITC", "CHEMICAL", 73, 77], ["acetone", "SIMPLE_CHEMICAL", 44, 51], ["FITC", "SIMPLE_CHEMICAL", 73, 77], ["chicken", "ORGANISM", 89, 96], ["antirotaserum", "SIMPLE_CHEMICAL", 97, 110], ["chicken", "SPECIES", 89, 96], ["chicken antirotaserum", "SPECIES", 89, 110], ["Ten ~l drop smears", "TEST", 0, 18], ["the FITC-conjugated chicken antirotaserum", "TREATMENT", 69, 110], ["air-dried", "OBSERVATION", 24, 33]]], ["The Leitz microscope was equipped with filters suitable for exciting either conjugate, and by switching from one to the other it was possible to determine whether or not a given virus antigenpositive cell had a given surface marker.Virus-neutralization AssaysVirus-neutralization assays were conducted using the Ch-2 rotavirus strain and heatinactivated sera from rotavirus-infected birds, while sera from SPF birds were used as a negative control.", [["antigenpositive cell", "ANATOMY", 184, 204], ["surface", "ANATOMY", 217, 224], ["sera", "ANATOMY", 354, 358], ["sera", "ANATOMY", 396, 400], ["rotavirus-infected", "DISEASE", 364, 382], ["cell", "CELL", 200, 204], ["Virus", "ORGANISM", 232, 237], ["AssaysVirus", "SIMPLE_CHEMICAL", 253, 264], ["Ch-2 rotavirus", "ORGANISM", 312, 326], ["sera", "ORGANISM_SUBSTANCE", 354, 358], ["rotavirus", "ORGANISM", 364, 373], ["birds", "ORGANISM", 383, 388], ["sera", "ORGANISM_SUBSTANCE", 396, 400], ["SPF birds", "ORGANISM", 406, 415], ["virus antigenpositive cell", "CELL_TYPE", 178, 204], ["Ch-2 rotavirus", "SPECIES", 312, 326], ["SPF", "SPECIES", 406, 409], ["The Leitz microscope", "TREATMENT", 0, 20], ["filters", "TREATMENT", 39, 46], ["a given virus antigenpositive cell", "PROBLEM", 170, 204], ["Virus", "TEST", 232, 237], ["neutralization AssaysVirus", "TREATMENT", 238, 264], ["neutralization assays", "TEST", 265, 286], ["the Ch", "TEST", 308, 314], ["rotavirus strain", "PROBLEM", 317, 333], ["heatinactivated sera", "PROBLEM", 338, 358], ["rotavirus", "PROBLEM", 364, 373], ["SPF birds", "TREATMENT", 406, 415]]], ["Aliquots of l04 TCIDs0 in 0.25 ml of trypsin-treated virus were mixed with 0.2 ml of appropriate se~-dm dilutions and incubated for 1 hour at 37 \u00b0 C. The virus-serum mixture was added to 106 washed and drained MDCC-CU 36 cells, incubated for an additional hour at 37 \u00b0 C, washed again and resuspended in LMH medium.", [["Aliquots", "ANATOMY", 0, 8], ["serum", "ANATOMY", 160, 165], ["MDCC-CU 36 cells", "ANATOMY", 210, 226], ["TCIDs0", "CHEMICAL", 16, 22], ["trypsin", "CHEMICAL", 37, 44], ["trypsin", "GENE_OR_GENE_PRODUCT", 37, 44], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["MDCC-CU 36 cells", "CELL", 210, 226], ["trypsin", "PROTEIN", 37, 44], ["MDCC-CU 36 cells", "CELL_LINE", 210, 226], ["l04 TCIDs0", "TREATMENT", 12, 22], ["trypsin-treated virus", "TREATMENT", 37, 58], ["appropriate se~-dm dilutions", "TREATMENT", 85, 113], ["The virus-serum mixture", "TEST", 150, 173]]], ["Cells were examined by immunofluorescence test for virus replication at 24 hours of incubation.Infection of Lymphoblastoid Cell Lines and Chidcen Spleen Cell8In vitro exposure of different cell lines to the trypsin-treated Ch-2 strain of rotavirus resulted in the establishment of infection in a dose-dependent fashion (Table 1) .", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 123, 127], ["cell lines", "ANATOMY", 189, 199], ["Ch-2", "CHEMICAL", 223, 227], ["rotavirus", "DISEASE", 238, 247], ["infection", "DISEASE", 281, 290], ["Cells", "CELL", 0, 5], ["Lymphoblastoid Cell Lines", "CELL", 108, 133], ["Chidcen Spleen Cell8In", "CELL", 138, 160], ["cell lines", "CELL", 189, 199], ["trypsin", "GENE_OR_GENE_PRODUCT", 207, 214], ["Ch-2 strain", "ORGANISM", 223, 234], ["rotavirus", "ORGANISM", 238, 247], ["cell lines", "CELL_LINE", 189, 199], ["trypsin", "PROTEIN", 207, 214], ["rotavirus", "SPECIES", 238, 247], ["immunofluorescence test", "TEST", 23, 46], ["virus replication", "TREATMENT", 51, 68], ["Infection", "PROBLEM", 95, 104], ["Lymphoblastoid Cell Lines", "TREATMENT", 108, 133], ["Chidcen Spleen Cell8In vitro exposure", "TREATMENT", 138, 175], ["different cell lines", "TREATMENT", 179, 199], ["the trypsin", "TEST", 203, 214], ["rotavirus", "PROBLEM", 238, 247], ["infection", "PROBLEM", 281, 290], ["Lymphoblastoid Cell Lines", "OBSERVATION", 108, 133], ["Spleen", "ANATOMY", 146, 152], ["different cell lines", "OBSERVATION", 179, 199], ["infection", "OBSERVATION", 281, 290]]], ["Other avian rotavirus isolates were also able to infect lymphobIastoid celt lines (Table 2) .", [["lymphobIastoid celt lines", "ANATOMY", 56, 81], ["avian", "ORGANISM", 6, 11], ["rotavirus", "ORGANISM", 12, 21], ["lymphobIastoid celt lines", "CELL", 56, 81], ["lymphobIastoid celt lines", "CELL_LINE", 56, 81], ["avian rotavirus", "SPECIES", 6, 21], ["Other avian rotavirus isolates", "PROBLEM", 0, 30]]], ["Cells with fluorescent cytoplasmic staining were present in infected but not in control, mock-infected cultures after staining with the rotavirus-speeific conjugate.", [["Cells", "ANATOMY", 0, 5], ["cytoplasmic", "ANATOMY", 23, 34], ["cultures", "ANATOMY", 103, 111], ["Cells", "CELL", 0, 5], ["cytoplasmic", "ORGANISM_SUBSTANCE", 23, 34], ["cultures", "CELL", 103, 111], ["rotavirus", "ORGANISM", 136, 145], ["speeific conjugate", "SIMPLE_CHEMICAL", 146, 164], ["mock-infected cultures", "CELL_LINE", 89, 111], ["rotavirus-speeific conjugate", "PROTEIN", 136, 164], ["fluorescent cytoplasmic staining", "PROBLEM", 11, 43], ["infected cultures", "TEST", 94, 111], ["staining", "TEST", 118, 126], ["the rotavirus", "TEST", 132, 145], ["cytoplasmic staining", "OBSERVATION", 23, 43]]], ["Likewise, the use of the goat antirotavirus serum in an indirect FA assay showed positive cells in the infected, but not in the control cultures.", [["serum", "ANATOMY", 44, 49], ["cells", "ANATOMY", 90, 95], ["goat", "ORGANISM", 25, 29], ["antirotavirus", "ORGANISM", 30, 43], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["FA", "SIMPLE_CHEMICAL", 65, 67], ["cells", "CELL", 90, 95], ["positive cells", "CELL_TYPE", 81, 95], ["goat", "SPECIES", 25, 29], ["goat", "SPECIES", 25, 29], ["the goat antirotavirus serum", "TEST", 21, 49], ["an indirect FA assay", "TEST", 53, 73], ["positive cells", "PROBLEM", 81, 95], ["the infected", "PROBLEM", 99, 111], ["the control cultures", "TEST", 124, 144], ["positive cells", "OBSERVATION", 81, 95], ["infected", "OBSERVATION", 103, 111]]], ["Specific staining was absent when a normal goat serum, free of antibodies to rotavirus, was used.", [["serum", "ANATOMY", 48, 53], ["goat", "ORGANISM", 43, 47], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["rotavirus", "ORGANISM", 77, 86], ["antibodies", "PROTEIN", 63, 73], ["goat", "SPECIES", 43, 47], ["goat", "SPECIES", 43, 47], ["rotavirus", "SPECIES", 77, 86], ["Specific staining", "TEST", 0, 17], ["antibodies", "TREATMENT", 63, 73], ["rotavirus", "PROBLEM", 77, 86]]], ["Splenic lymphocytes exposed to the trypsin-treated Ch-2 strain showed similar specific cytoplasmic staining as the infected lymphoblastoid cell 1 \u00d7 I06 lymphoblastoid cells were infected with 4 \u00d7 t06 TCIDs0 as determined by centt~fugation on CKC-eulture b Each culture was centrifuged, rcsuspended in I00 txI and 2 smears were made using 10 pl/smear Table 3 . lines.", [["Splenic lymphocytes", "ANATOMY", 0, 19], ["cytoplasmic", "ANATOMY", 87, 98], ["lymphoblastoid cell 1 \u00d7 I06 lymphoblastoid cells", "ANATOMY", 124, 172], ["Splenic lymphocytes", "CELL", 0, 19], ["trypsin", "GENE_OR_GENE_PRODUCT", 35, 42], ["Ch-2", "CELL", 51, 55], ["cytoplasmic", "ORGANISM_SUBSTANCE", 87, 98], ["lymphoblastoid cell 1 \u00d7 I06 lymphoblastoid cells", "CELL", 124, 172], ["Splenic lymphocytes", "CELL_TYPE", 0, 19], ["trypsin", "PROTEIN", 35, 42], ["infected lymphoblastoid cell 1 \u00d7 I06 lymphoblastoid cells", "CELL_LINE", 115, 172], ["CKC", "DNA", 242, 245], ["Splenic lymphocytes", "PROBLEM", 0, 19], ["the trypsin", "TEST", 31, 42], ["2 strain", "PROBLEM", 54, 62], ["similar specific cytoplasmic staining", "PROBLEM", 70, 107], ["the infected lymphoblastoid cell", "PROBLEM", 111, 143], ["I06 lymphoblastoid cells", "PROBLEM", 148, 172], ["CKC", "TEST", 242, 245], ["Each culture", "TEST", 256, 268], ["lymphocytes", "OBSERVATION", 8, 19], ["cytoplasmic staining", "OBSERVATION", 87, 107], ["infected", "OBSERVATION_MODIFIER", 115, 123], ["lymphoblastoid cell", "OBSERVATION", 124, 143]]], ["The number of infected cells was considerably lower in splenic tymphocymes than in the lymphoblastoid cell lines (Table 1 ).Relationship between titer of the inoculum, number of virus-positive lymphoblastoid cells and cell numbers after infection of LSCC-CU IO ~ with Ch-2 at 24 and 48 hours inAn increase in the number of positive cells was noticed at 48 hours compared to 24 hours of incubation at 41 \u00b0 C. However, there was no increase when the number of positive cells was expressed as a percent of the total number of cells (Table 3) .", [["cells", "ANATOMY", 23, 28], ["splenic tymphocymes", "ANATOMY", 55, 74], ["lymphoblastoid cell lines", "ANATOMY", 87, 112], ["lymphoblastoid cells", "ANATOMY", 193, 213], ["cell", "ANATOMY", 218, 222], ["LSCC", "ANATOMY", 250, 254], ["cells", "ANATOMY", 332, 337], ["cells", "ANATOMY", 467, 472], ["cells", "ANATOMY", 523, 528], ["infection", "DISEASE", 237, 246], ["cells", "CELL", 23, 28], ["splenic tymphocymes", "CELL", 55, 74], ["lymphoblastoid cell lines", "CELL", 87, 112], ["Table 1", "CELL", 114, 121], ["lymphoblastoid cells", "CELL", 193, 213], ["cell", "CELL", 218, 222], ["LSCC-CU IO", "CELL", 250, 260], ["Ch-2", "CELL", 268, 272], ["cells", "CELL", 332, 337], ["cells", "CELL", 467, 472], ["cells", "CELL", 523, 528], ["infected cells", "CELL_TYPE", 14, 28], ["splenic tymphocymes", "CELL_TYPE", 55, 74], ["lymphoblastoid cell lines", "CELL_LINE", 87, 112], ["virus-positive lymphoblastoid cells", "CELL_TYPE", 178, 213], ["positive cells", "CELL_TYPE", 323, 337], ["positive cells", "CELL_TYPE", 458, 472], ["infected cells", "PROBLEM", 14, 28], ["the lymphoblastoid cell lines", "TREATMENT", 83, 112], ["virus", "TEST", 178, 183], ["positive lymphoblastoid cells", "PROBLEM", 184, 213], ["cell numbers", "TEST", 218, 230], ["infection of LSCC", "PROBLEM", 237, 254], ["positive cells", "PROBLEM", 323, 337], ["positive cells", "PROBLEM", 458, 472], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infected cells", "OBSERVATION", 14, 28], ["considerably", "OBSERVATION_MODIFIER", 33, 45], ["lower", "OBSERVATION_MODIFIER", 46, 51], ["splenic", "ANATOMY", 55, 62], ["tymphocymes", "ANATOMY_MODIFIER", 63, 74], ["lymphoblastoid cell lines", "OBSERVATION", 87, 112], ["positive lymphoblastoid cells", "OBSERVATION", 184, 213], ["increase", "OBSERVATION_MODIFIER", 297, 305], ["positive cells", "OBSERVATION", 323, 337], ["no", "UNCERTAINTY", 427, 429], ["increase", "OBSERVATION_MODIFIER", 430, 438], ["positive cells", "OBSERVATION", 458, 472]]], ["Cell lines remained positive for virus during a 10day-culture period, but the percent of virus positive cells decreased markedly aider 4 days (Table 4 ).", [["Cell lines", "ANATOMY", 0, 10], ["cells", "ANATOMY", 104, 109], ["Cell lines", "CELL", 0, 10], ["cells", "CELL", 104, 109], ["virus positive cells", "CELL_TYPE", 89, 109], ["Cell lines", "TEST", 0, 10], ["virus", "PROBLEM", 33, 38], ["virus positive cells", "PROBLEM", 89, 109]]], ["Supernatant fluids collected from the infected lymphoblastoid cell lines at 8 and 10 days in culture were positive for cell-free virus.", [["Supernatant fluids", "ANATOMY", 0, 18], ["lymphoblastoid cell lines", "ANATOMY", 47, 72], ["cell", "ANATOMY", 119, 123], ["Supernatant fluids", "ORGANISM_SUBSTANCE", 0, 18], ["lymphoblastoid cell lines", "CELL", 47, 72], ["cell", "CELL", 119, 123], ["-free virus", "ORGANISM", 123, 134], ["infected lymphoblastoid cell lines", "CELL_LINE", 38, 72], ["Supernatant fluids", "TREATMENT", 0, 18], ["the infected lymphoblastoid cell lines", "TREATMENT", 34, 72], ["culture", "TEST", 93, 100], ["cell-free virus", "PROBLEM", 119, 134], ["fluids", "OBSERVATION", 12, 18], ["infected lymphoblastoid cell lines", "OBSERVATION", 38, 72], ["free virus", "OBSERVATION", 124, 134]]], ["Titers were between 103 and 104 TCIDs0 for each cell line.", [["cell line", "ANATOMY", 48, 57], ["cell line", "CELL", 48, 57], ["Titers", "TEST", 0, 6], ["each cell line", "TREATMENT", 43, 57], ["cell line", "OBSERVATION", 48, 57]]], ["Spleen cell cultures seemed to be less susceptible to infection than the lymphoblastoid cell lines.", [["Spleen cell cultures", "ANATOMY", 0, 20], ["lymphoblastoid cell lines", "ANATOMY", 73, 98], ["infection", "DISEASE", 54, 63], ["Spleen cell cultures", "CELL", 0, 20], ["lymphoblastoid cell lines", "CELL", 73, 98], ["Spleen cell cultures", "CELL_LINE", 0, 20], ["lymphoblastoid cell lines", "CELL_LINE", 73, 98], ["Spleen cell cultures", "TEST", 0, 20], ["infection", "PROBLEM", 54, 63], ["the lymphoblastoid cell lines", "TREATMENT", 69, 98], ["cell cultures", "OBSERVATION", 7, 20], ["infection", "OBSERVATION", 54, 63], ["lymphoblastoid cell lines", "OBSERVATION", 73, 98]]], ["Spleen cells do not survive very well under these conditions and the percentage of viable cells was only 44, 12 and 12 at 48 hours for the 3 spleen cell preparations in Table 1 .", [["Spleen cells", "ANATOMY", 0, 12], ["cells", "ANATOMY", 90, 95], ["spleen cell", "ANATOMY", 141, 152], ["Spleen cells", "CELL", 0, 12], ["cells", "CELL", 90, 95], ["spleen cell", "CELL", 141, 152], ["Spleen cells", "CELL_TYPE", 0, 12], ["the 3 spleen cell preparations", "TREATMENT", 135, 165], ["spleen", "ANATOMY", 141, 147], ["cell", "OBSERVATION", 148, 152]]], ["In contrast, the lymphoblastoid cell lines were either stable or increasing in cell numbers at 48 hours (data not shown).Culture ConditiowsThe importance of trypsin treatment prior t~) infection and temperature of incubation were examined.", [["lymphoblastoid cell lines", "ANATOMY", 17, 42], ["cell", "ANATOMY", 79, 83], ["infection", "DISEASE", 185, 194], ["lymphoblastoid cell lines", "CELL", 17, 42], ["cell", "CELL", 79, 83], ["trypsin", "GENE_OR_GENE_PRODUCT", 157, 164], ["lymphoblastoid cell lines", "CELL_LINE", 17, 42], ["trypsin", "PROTEIN", 157, 164], ["the lymphoblastoid cell lines", "TREATMENT", 13, 42], ["Culture", "TEST", 121, 128], ["trypsin treatment", "TREATMENT", 157, 174], ["infection", "PROBLEM", 185, 194], ["temperature of incubation", "TEST", 199, 224], ["lymphoblastoid cell lines", "OBSERVATION", 17, 42], ["stable", "OBSERVATION_MODIFIER", 55, 61], ["increasing", "OBSERVATION_MODIFIER", 65, 75], ["infection", "OBSERVATION", 185, 194]]], ["Absence of treatment of rotavirus with tr3q~sin decreased the infection rate tenfold but infection could be established in lymphoblast~id cell lines with non-t~psin-treated ~drus.", [["lymphoblast~id cell lines", "ANATOMY", 123, 148], ["tr3q~sin", "CHEMICAL", 39, 47], ["infection", "DISEASE", 62, 71], ["infection", "DISEASE", 89, 98], ["non-t~psin", "CHEMICAL", 154, 164], ["rotavirus", "ORGANISM", 24, 33], ["tr3q~sin", "GENE_OR_GENE_PRODUCT", 39, 47], ["lymphoblast~id cell lines", "CELL", 123, 148], ["non-t~psin", "SIMPLE_CHEMICAL", 154, 164], ["tr3q~sin", "PROTEIN", 39, 47], ["lymphoblast~id cell lines", "CELL_LINE", 123, 148], ["rotavirus", "SPECIES", 24, 33], ["treatment", "TREATMENT", 11, 20], ["rotavirus", "PROBLEM", 24, 33], ["tr3q~sin", "TREATMENT", 39, 47], ["the infection rate tenfold", "PROBLEM", 58, 84], ["infection", "PROBLEM", 89, 98], ["lymphoblast~id cell lines", "TREATMENT", 123, 148], ["non-t~psin", "TREATMENT", 154, 164], ["infection", "OBSERVATION", 62, 71], ["infection", "OBSERVATION", 89, 98], ["cell lines", "OBSERVATION", 138, 148]]], ["Due to the low level of infection, attempts were not made to infect splenic lymphocytes with nontrypsin-treated virus.", [["splenic lymphocytes", "ANATOMY", 68, 87], ["infection", "DISEASE", 24, 33], ["nontrypsin", "CHEMICAL", 93, 103], ["nontrypsin", "CHEMICAL", 93, 103], ["splenic lymphocytes", "CELL", 68, 87], ["nontrypsin", "SIMPLE_CHEMICAL", 93, 103], ["splenic lymphocytes", "CELL_TYPE", 68, 87], ["the low level of infection", "PROBLEM", 7, 33], ["nontrypsin-treated virus", "TREATMENT", 93, 117], ["low level", "OBSERVATION_MODIFIER", 11, 20], ["infection", "OBSERVATION", 24, 33], ["splenic", "ANATOMY", 68, 75], ["lymphocytes", "OBSERVATION", 76, 87]]], ["Cultures were incubated at 38 and 41 \u00b0 C after infection with Ch-2 and smears were made at 24 and 48 hours.", [["infection", "DISEASE", 47, 56], ["Ch-2", "CELL", 62, 66], ["Cultures", "TEST", 0, 8], ["infection", "PROBLEM", 47, 56], ["Ch", "TEST", 62, 64], ["smears", "TEST", 71, 77], ["infection", "OBSERVATION", 47, 56]]], ["There were no differences detectable in infection rates between the two temperatures (data not shown).Identification of Infected Spleen Cells by Surface MarkersSpleen cells infected with the Ch-2 strain of rotavirus were examined at 48 hours postinfection for the presence of rotavirus antigen and specific surface markers.", [["Spleen Cells", "ANATOMY", 129, 141], ["MarkersSpleen cells", "ANATOMY", 153, 172], ["surface", "ANATOMY", 307, 314], ["infection", "DISEASE", 40, 49], ["Spleen Cells", "CELL", 129, 141], ["Surface MarkersSpleen cells", "CELL", 145, 172], ["Ch-2 strain", "ORGANISM", 191, 202], ["rotavirus", "ORGANISM", 206, 215], ["rotavirus antigen", "GENE_OR_GENE_PRODUCT", 276, 293], ["Infected Spleen Cells", "CELL_TYPE", 120, 141], ["Surface MarkersSpleen cells", "CELL_LINE", 145, 172], ["rotavirus antigen", "PROTEIN", 276, 293], ["specific surface markers", "PROTEIN", 298, 322], ["Ch-2 strain", "SPECIES", 191, 202], ["rotavirus", "SPECIES", 206, 215], ["rotavirus", "SPECIES", 276, 285], ["infection rates", "PROBLEM", 40, 55], ["Infected Spleen Cells", "PROBLEM", 120, 141], ["Surface MarkersSpleen cells", "TEST", 145, 172], ["the Ch", "TEST", 187, 193], ["rotavirus", "PROBLEM", 206, 215], ["rotavirus antigen", "PROBLEM", 276, 293], ["no", "UNCERTAINTY", 11, 13], ["infection", "OBSERVATION", 40, 49], ["Infected Spleen Cells", "OBSERVATION", 120, 141], ["Surface", "OBSERVATION_MODIFIER", 145, 152], ["MarkersSpleen cells", "OBSERVATION", 153, 172], ["rotavirus", "OBSERVATION", 206, 215]]], ["The following surface antigens were present on some but not all of the rotavirus-infected spleen cells: I a, ~ and CLA.", [["surface", "ANATOMY", 14, 21], ["spleen cells", "ANATOMY", 90, 102], ["rotavirus", "ORGANISM", 71, 80], ["spleen cells", "CELL", 90, 102], ["CLA", "SIMPLE_CHEMICAL", 115, 118], ["rotavirus-infected spleen cells", "CELL_TYPE", 71, 102], ["infected spleen cells", "OBSERVATION", 81, 102]]], ["The actual numbers of cells positive for both rotavirus and surface markers were quite low.", [["cells", "ANATOMY", 22, 27], ["surface", "ANATOMY", 60, 67], ["cells", "CELL", 22, 27], ["rotavirus", "ORGANISM", 46, 55], ["rotavirus and surface markers", "PROTEIN", 46, 75], ["rotavirus", "SPECIES", 46, 55], ["both rotavirus", "PROBLEM", 41, 55], ["surface markers", "TEST", 60, 75], ["rotavirus", "OBSERVATION", 46, 55]]], ["Lymphocytes positive for rotavirus and T 3 were not detected.", [["Lymphocytes", "ANATOMY", 0, 11], ["Lymphocytes", "CELL", 0, 11], ["rotavirus", "ORGANISM", 25, 34], ["T 3", "GENE_OR_GENE_PRODUCT", 39, 42], ["Lymphocytes", "CELL_TYPE", 0, 11], ["Lymphocytes", "TEST", 0, 11], ["rotavirus", "PROBLEM", 25, 34], ["rotavirus", "OBSERVATION", 25, 34]]], ["Uninfected spleen cells confirmed the presence of the surface markers.Vi~nts Neutralization AssaysThe incubation of trypsin-treated rotavirus with dilutions of SPF serum, free of antibodies against rotavirus, resulted in considerable inhibition of infection of MDCC-CU 36 (Table 5) .", [["spleen cells", "ANATOMY", 11, 23], ["surface", "ANATOMY", 54, 61], ["serum", "ANATOMY", 164, 169], ["infection", "DISEASE", 248, 257], ["spleen cells", "CELL", 11, 23], ["trypsin", "GENE_OR_GENE_PRODUCT", 116, 123], ["rotavirus", "ORGANISM", 132, 141], ["SPF", "ORGANISM", 160, 163], ["serum", "ORGANISM_SUBSTANCE", 164, 169], ["rotavirus", "ORGANISM", 198, 207], ["surface markers", "PROTEIN", 54, 69], ["trypsin", "PROTEIN", 116, 123], ["antibodies", "PROTEIN", 179, 189], ["rotavirus", "SPECIES", 132, 141], ["SPF", "SPECIES", 160, 163], ["rotavirus", "SPECIES", 198, 207], ["Uninfected spleen cells", "PROBLEM", 0, 23], ["Vi~nts Neutralization", "TREATMENT", 70, 91], ["The incubation of trypsin", "TREATMENT", 98, 123], ["rotavirus", "PROBLEM", 132, 141], ["SPF serum", "TEST", 160, 169], ["antibodies", "TREATMENT", 179, 189], ["rotavirus", "PROBLEM", 198, 207], ["infection", "PROBLEM", 248, 257], ["spleen cells", "OBSERVATION", 11, 23], ["surface", "OBSERVATION_MODIFIER", 54, 61], ["markers", "OBSERVATION", 62, 69], ["infection", "OBSERVATION", 248, 257]]], ["A dilution of 1:80 resulted in a reduc-DiscussionThus far, only NOZAWA and FONSECA (13) have reported that rotaviruses can replicate in lymphocytes albeit after activation with mitogens.", [["lymphocytes", "ANATOMY", 136, 147], ["rotaviruses", "ORGANISM", 107, 118], ["lymphocytes", "CELL", 136, 147], ["lymphocytes", "CELL_TYPE", 136, 147], ["mitogens", "PROTEIN", 177, 185], ["A dilution", "TEST", 0, 10], ["rotaviruses", "PROBLEM", 107, 118], ["activation with mitogens", "TREATMENT", 161, 185], ["rotaviruses", "OBSERVATION", 107, 118]]], ["This paper extends their results and describes that avian rotaviruses can certainly infect and perhaps replicate in splenic lymphoeytes in the absence of mitogens, but, it can not be excluded that the low percentage of positive cells were activated cells.", [["splenic lymphoeytes", "ANATOMY", 116, 135], ["cells", "ANATOMY", 228, 233], ["cells", "ANATOMY", 249, 254], ["avian rotaviruses", "DISEASE", 52, 69], ["splenic lymphoeytes", "DISEASE", 116, 135], ["avian rotaviruses", "ORGANISM", 52, 69], ["splenic lymphoeytes", "CANCER", 116, 135], ["cells", "CELL", 228, 233], ["cells", "CELL", 249, 254], ["splenic lymphoeytes", "CELL_TYPE", 116, 135], ["mitogens", "PROTEIN", 154, 162], ["positive cells", "CELL_TYPE", 219, 233], ["activated cells", "CELL_TYPE", 239, 254], ["avian rotaviruses", "PROBLEM", 52, 69], ["positive cells", "PROBLEM", 219, 233], ["splenic", "ANATOMY", 116, 123], ["lymphoeytes", "OBSERVATION", 124, 135], ["mitogens", "OBSERVATION", 154, 162], ["low percentage", "OBSERVATION_MODIFIER", 201, 215], ["positive cells", "OBSERVATION", 219, 233]]], ["The surface markers present on virus-positive spleen cells are compatible with B and T cells (I a, ~x and CLA).", [["surface", "ANATOMY", 4, 11], ["spleen cells", "ANATOMY", 46, 58], ["B", "ANATOMY", 79, 80], ["T cells", "ANATOMY", 85, 92], ["spleen cells", "CELL", 46, 58], ["B", "CELL", 79, 80], ["T cells", "CELL", 85, 92], ["CLA", "SIMPLE_CHEMICAL", 106, 109], ["virus-positive spleen cells", "CELL_TYPE", 31, 58], ["B and T cells", "CELL_TYPE", 79, 92], ["CLA", "PROTEIN", 106, 109], ["The surface markers", "TEST", 0, 19], ["virus", "TEST", 31, 36], ["positive spleen cells", "PROBLEM", 37, 58], ["B and T cells", "PROBLEM", 79, 92], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["spleen", "ANATOMY", 46, 52], ["cells", "OBSERVATION", 53, 58], ["compatible with", "UNCERTAINTY", 63, 78]]], ["The finding that three different types of lymphoblastoid cell lines are susceptible to infection supports the concept that rot~viruses can infect both B and T lymphocytes.", [["lymphoblastoid cell lines", "ANATOMY", 42, 67], ["B", "ANATOMY", 151, 152], ["T lymphocytes", "ANATOMY", 157, 170], ["infection", "DISEASE", 87, 96], ["lymphoblastoid cell lines", "CELL", 42, 67], ["rot~viruses", "ORGANISM", 123, 134], ["B", "CELL", 151, 152], ["T lymphocytes", "CELL", 157, 170], ["lymphoblastoid cell lines", "CELL_LINE", 42, 67], ["B and T lymphocytes", "CELL_TYPE", 151, 170], ["lymphoblastoid cell lines", "TREATMENT", 42, 67], ["infection", "PROBLEM", 87, 96], ["lymphoblastoid cell lines", "OBSERVATION", 42, 67], ["infection", "OBSERVATION", 87, 96], ["lymphocytes", "ANATOMY", 159, 170]]], ["The question if cell-free infectious virus is indeed produced in lymphoblastoid cell lines is difficult to answer.", [["cell", "ANATOMY", 16, 20], ["lymphoblastoid cell lines", "ANATOMY", 65, 90], ["cell", "CELL", 16, 20], ["lymphoblastoid cell lines", "CELL", 65, 90], ["lymphoblastoid cell lines", "CELL_LINE", 65, 90], ["cell-free infectious virus", "PROBLEM", 16, 42], ["lymphoblastoid cell lines", "TREATMENT", 65, 90], ["free", "OBSERVATION_MODIFIER", 21, 25], ["infectious", "OBSERVATION", 26, 36], ["lymphoblastoid cell lines", "OBSERVATION", 65, 90]]], ["The recovery of low levels of infectious virus at 8 and l0 days in culture (Table 4) suggest that it is possible.", [["low levels of infectious virus", "PROBLEM", 16, 46], ["culture", "TEST", 67, 74], ["low levels", "OBSERVATION_MODIFIER", 16, 26], ["infectious", "OBSERVATION", 30, 40]]], ["On the other hand it can not be excluded that some of the original inoeulum survived outside the cells.DiscussionIt is still unresolved how rotavirus enters a cell.", [["inoeulum", "ANATOMY", 67, 75], ["cells", "ANATOMY", 97, 102], ["cell", "ANATOMY", 159, 163], ["cells", "CELL", 97, 102], ["rotavirus", "ORGANISM", 140, 149], ["cell", "CELL", 159, 163], ["rotavirus", "SPECIES", 140, 149], ["can not be excluded", "UNCERTAINTY", 21, 40], ["cells", "ANATOMY", 97, 102]]], ["Although the presence of receptors has been postulated, there is no conclusive proof for their existence (1).", [["no conclusive", "UNCERTAINTY", 65, 78]]], ["Infection of both CKC (10, 12) and lymphocytes requires activation of the virus by trypsin.", [["lymphocytes", "ANATOMY", 35, 46], ["CKC", "GENE_OR_GENE_PRODUCT", 18, 21], ["lymphocytes", "CELL", 35, 46], ["trypsin", "GENE_OR_GENE_PRODUCT", 83, 90], ["lymphocytes", "CELL_TYPE", 35, 46], ["trypsin", "PROTEIN", 83, 90], ["Infection of both CKC", "PROBLEM", 0, 21], ["lymphocytes", "PROBLEM", 35, 46], ["the virus", "PROBLEM", 70, 79], ["both", "ANATOMY_MODIFIER", 13, 17], ["CKC", "ANATOMY", 18, 21], ["lymphocytes", "ANATOMY", 35, 46]]], ["However, the establishment of infection in lymphocytes is much less efficient than the infection of CKC: 4 \u00d7 10 ~ TCIDs0 in CKC infected between 200 and 1400 lymphoblasteid cells depending on the cell line.", [["lymphocytes", "ANATOMY", 43, 54], ["CKC", "ANATOMY", 124, 127], ["lymphoblasteid cells", "ANATOMY", 158, 178], ["cell line", "ANATOMY", 196, 205], ["infection", "DISEASE", 30, 39], ["infection", "DISEASE", 87, 96], ["lymphocytes", "CELL", 43, 54], ["CKC", "CANCER", 100, 103], ["TCIDs0", "GENE_OR_GENE_PRODUCT", 114, 120], ["CKC", "CELL", 124, 127], ["lymphoblasteid cells", "CELL", 158, 178], ["cell line", "CELL", 196, 205], ["lymphocytes", "CELL_TYPE", 43, 54], ["cell line", "CELL_LINE", 196, 205], ["infection in lymphocytes", "PROBLEM", 30, 54], ["CKC", "TEST", 100, 103], ["TCIDs0", "TEST", 114, 120], ["CKC", "TEST", 124, 127], ["1400 lymphoblasteid cells", "PROBLEM", 153, 178], ["the cell line", "TREATMENT", 192, 205], ["infection", "OBSERVATION", 30, 39], ["lymphocytes", "OBSERVATION", 43, 54], ["much less efficient", "OBSERVATION_MODIFIER", 58, 77], ["infection", "OBSERVATION", 87, 96], ["cell line", "OBSERVATION", 196, 205]]], ["It is not clear if these differences are due to quantitative differences in expression of the putative receptors or that the lymphoblastoid cells lack certain enzymes important for viral replication.", [["lymphoblastoid cells", "ANATOMY", 125, 145], ["lymphoblastoid cells", "CELL", 125, 145], ["putative receptors", "PROTEIN", 94, 112], ["lymphoblastoid cells", "CELL_TYPE", 125, 145], ["enzymes", "PROTEIN", 159, 166], ["the putative receptors", "PROBLEM", 90, 112], ["the lymphoblastoid cells", "TREATMENT", 121, 145], ["viral replication", "TREATMENT", 181, 198], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["lymphoblastoid cells", "OBSERVATION", 125, 145]]], ["Clearly, the finding that lymphocytes and lymphoblastoid cells are susceptible to infection will be an important aspect in the search for a rotavirus receptor.DiscussionThe neutralization of rotavirus by normal SPF serum was not expected.", [["lymphocytes", "ANATOMY", 26, 37], ["lymphoblastoid cells", "ANATOMY", 42, 62], ["serum", "ANATOMY", 215, 220], ["infection", "DISEASE", 82, 91], ["lymphocytes", "CELL", 26, 37], ["lymphoblastoid cells", "CELL", 42, 62], ["rotavirus", "ORGANISM", 191, 200], ["SPF", "ORGANISM", 211, 214], ["serum", "ORGANISM_SUBSTANCE", 215, 220], ["lymphocytes", "CELL_TYPE", 26, 37], ["lymphoblastoid cells", "CELL_TYPE", 42, 62], ["rotavirus receptor", "PROTEIN", 140, 158], ["rotavirus", "SPECIES", 140, 149], ["rotavirus", "SPECIES", 191, 200], ["SPF", "SPECIES", 211, 214], ["lymphocytes", "PROBLEM", 26, 37], ["lymphoblastoid cells", "PROBLEM", 42, 62], ["infection", "PROBLEM", 82, 91], ["a rotavirus receptor", "TREATMENT", 138, 158], ["rotavirus", "PROBLEM", 191, 200], ["lymphocytes", "ANATOMY", 26, 37], ["lymphoblastoid cells", "OBSERVATION", 42, 62], ["infection", "OBSERVATION", 82, 91]]], ["The negative serum was obtained from our SPF flock of chickens free of antibodies to rotavirus as determined by indirect immunofluorescence.", [["serum", "ANATOMY", 13, 18], ["rotavirus", "DISEASE", 85, 94], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["chickens", "ORGANISM", 54, 62], ["rotavirus", "ORGANISM", 85, 94], ["antibodies", "PROTEIN", 71, 81], ["chickens", "SPECIES", 54, 62], ["chickens", "SPECIES", 54, 62], ["rotavirus", "SPECIES", 85, 94], ["antibodies", "TREATMENT", 71, 81], ["rotavirus", "TREATMENT", 85, 94], ["indirect immunofluorescence", "TEST", 112, 139], ["negative", "OBSERVATION", 4, 12]]], ["Sera from the departmental SPF flocks were also tested elsewhere and found to be free of antibodies to rotavirus (Dr. Stewart McNulty, Veterinary Research Laboratories, Belfast, personal communication).", [["rotavirus", "DISEASE", 103, 112], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["rotavirus", "ORGANISM", 103, 112], ["antibodies", "PROTEIN", 89, 99], ["rotavirus", "SPECIES", 103, 112], ["the departmental SPF flocks", "TEST", 10, 37]]], ["Virus neutralizing substances {VNS) have been described in the albumin fraction of FBS interfering with the replication of duck hepatitis virus (6) .", [["FBS", "ANATOMY", 83, 86], ["duck hepatitis virus", "DISEASE", 123, 143], ["Virus", "ORGANISM", 0, 5], ["albumin", "GENE_OR_GENE_PRODUCT", 63, 70], ["FBS", "ORGANISM_SUBSTANCE", 83, 86], ["duck hepatitis virus", "ORGANISM", 123, 143], ["duck hepatitis virus", "SPECIES", 123, 143], ["duck hepatitis virus", "SPECIES", 123, 143], ["Virus neutralizing substances", "TREATMENT", 0, 29], ["VNS", "PROBLEM", 31, 34], ["the albumin fraction", "TEST", 59, 79], ["FBS", "PROBLEM", 83, 86], ["duck hepatitis virus", "PROBLEM", 123, 143]]], ["LMH medium contains both chicken serum and FBS, buth the lymphoblastoid cells are washed prior to exposure with rotavirus.", [["serum", "ANATOMY", 33, 38], ["FBS", "ANATOMY", 43, 46], ["lymphoblastoid cells", "ANATOMY", 57, 77], ["chicken", "ORGANISM", 25, 32], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["FBS", "ORGANISM_SUBSTANCE", 43, 46], ["lymphoblastoid cells", "CELL", 57, 77], ["rotavirus", "ORGANISM", 112, 121], ["lymphoblastoid cells", "CELL_TYPE", 57, 77], ["chicken", "SPECIES", 25, 32], ["chicken", "SPECIES", 25, 32], ["rotavirus", "SPECIES", 112, 121], ["LMH medium", "PROBLEM", 0, 10], ["both chicken serum and FBS", "PROBLEM", 20, 46], ["the lymphoblastoid cells", "PROBLEM", 53, 77], ["rotavirus", "PROBLEM", 112, 121], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["both", "OBSERVATION_MODIFIER", 20, 24], ["lymphoblastoid cells", "OBSERVATION", 57, 77], ["rotavirus", "OBSERVATION", 112, 121]]], ["Apparently, the 1-hour incubation period with the chicken serum allows the VNS to interact with the trypsintreated virus.", [["serum", "ANATOMY", 58, 63], ["chicken", "ORGANISM", 50, 57], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["trypsintreated virus", "ORGANISM", 100, 120], ["chicken", "SPECIES", 50, 57], ["chicken", "SPECIES", 50, 57], ["the chicken serum", "PROBLEM", 46, 63], ["the VNS", "TREATMENT", 71, 78], ["the trypsintreated virus", "PROBLEM", 96, 120]]], ["It will be of interest to determine if the albumin fraction is responsible for the neutralization of the virus.", [["albumin", "GENE_OR_GENE_PRODUCT", 43, 50], ["the albumin fraction", "TEST", 39, 59], ["the neutralization of the virus", "PROBLEM", 79, 110]]]], "PMC7416852": [["IntroductionIn December 2019, cases presented with atypical pneumonia, which did not respond to antibiotherapy, fevfer, cough, acute respiratory failure, and a typical radiological pulmonary infiltration, began to appear in Wuhan, China.[1] Subsequently, it was understood that a previously noninfectious strain of the Coronaviridae family was responsible for these cases, the virus was isolated, and the genome structure was identified and was named as 2019 novel coronavirus which is also known as COVID-19 and SARS-CoV-2.[2] The World Health Organization has declared a pandemic on December 3, 2020, for COVID-19 that spread to the world quite rapidly.[3]IntroductionAlthough many treatment options for COVID-19 have been theoretically defined and clinical trials are still ongoing, there are not any fully effective drugs defined in the treatment of this disease yet.[4] However, due to its potential benefits, some medications that are previously used in the treatment of various diseases in humans are being used in the treatment of these patients worldwide despite the possible side effects and predicted to be effective against COVID-19.", [["respiratory", "ANATOMY", 133, 144], ["pulmonary", "ANATOMY", 181, 190], ["pneumonia", "DISEASE", 60, 69], ["cough", "DISEASE", 120, 125], ["acute respiratory failure", "DISEASE", 127, 152], ["COVID-19", "CHEMICAL", 706, 714], ["pulmonary", "ORGAN", 181, 190], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 319, 332], ["coronavirus", "ORGANISM", 465, 476], ["COVID-19", "SIMPLE_CHEMICAL", 706, 714], ["humans", "ORGANISM", 997, 1003], ["patients", "ORGANISM", 1045, 1053], ["Coronaviridae family", "PROTEIN", 319, 339], ["humans", "SPECIES", 997, 1003], ["patients", "SPECIES", 1045, 1053], ["SARS-CoV", "SPECIES", 513, 521], ["humans", "SPECIES", 997, 1003], ["atypical pneumonia", "PROBLEM", 51, 69], ["antibiotherapy", "TREATMENT", 96, 110], ["fevfer", "PROBLEM", 112, 118], ["cough", "PROBLEM", 120, 125], ["acute respiratory failure", "PROBLEM", 127, 152], ["a typical radiological pulmonary infiltration", "PROBLEM", 158, 203], ["a previously noninfectious strain", "PROBLEM", 278, 311], ["the virus", "PROBLEM", 373, 382], ["novel coronavirus", "PROBLEM", 459, 476], ["COVID", "TEST", 500, 505], ["SARS", "TEST", 513, 517], ["CoV", "TEST", 518, 521], ["COVID", "TEST", 607, 612], ["COVID", "TEST", 706, 711], ["drugs", "TREATMENT", 820, 825], ["this disease", "PROBLEM", 854, 866], ["some medications", "TREATMENT", 915, 931], ["various diseases in humans", "PROBLEM", 977, 1003], ["side effects", "PROBLEM", 1085, 1097], ["COVID", "TEST", 1136, 1141], ["atypical", "OBSERVATION_MODIFIER", 51, 59], ["pneumonia", "OBSERVATION", 60, 69], ["cough", "OBSERVATION", 120, 125], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["respiratory failure", "OBSERVATION", 133, 152], ["typical", "OBSERVATION_MODIFIER", 160, 167], ["radiological", "OBSERVATION_MODIFIER", 168, 180], ["pulmonary", "ANATOMY", 181, 190], ["infiltration", "OBSERVATION", 191, 203], ["noninfectious", "OBSERVATION", 291, 304], ["various", "OBSERVATION_MODIFIER", 977, 984], ["diseases", "OBSERVATION", 985, 993]]], ["Hydroxychloroquine is one of the most commonly used drugs in COVID-19 treatment.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["COVID-19", "CHEMICAL", 61, 69], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["COVID-19", "CHEMICAL", 61, 69], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["drugs in COVID", "TREATMENT", 52, 66]]], ["In this case report, it aimed to present a young patient who was diagnosed with COVID-19 and was sent home for isolation by giving hydroxychloroquine treatment whose QT interval was prolonged due to overdose after accidentally receiving 1,600 mg of hydroxychloroquine.", [["hydroxychloroquine", "CHEMICAL", 131, 149], ["overdose", "DISEASE", 199, 207], ["hydroxychloroquine", "CHEMICAL", 249, 267], ["hydroxychloroquine", "CHEMICAL", 131, 149], ["hydroxychloroquine", "CHEMICAL", 249, 267], ["patient", "ORGANISM", 49, 56], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 131, 149], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 249, 267], ["patient", "SPECIES", 49, 56], ["COVID", "TEST", 80, 85], ["isolation", "TREATMENT", 111, 120], ["hydroxychloroquine treatment", "TREATMENT", 131, 159], ["overdose", "PROBLEM", 199, 207], ["hydroxychloroquine", "TREATMENT", 249, 267]]], ["Although this case is not the first in the literature for hydroxychloroquine intoxication, it is the first case with prolonged QT interval due to COVID-19-related hydroxychloroquine overdose.", [["hydroxychloroquine", "CHEMICAL", 58, 76], ["COVID-19", "CHEMICAL", 146, 154], ["hydroxychloroquine", "CHEMICAL", 163, 181], ["overdose", "DISEASE", 182, 190], ["hydroxychloroquine", "CHEMICAL", 58, 76], ["COVID-19", "CHEMICAL", 146, 154], ["hydroxychloroquine", "CHEMICAL", 163, 181], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 58, 76], ["COVID-19", "SIMPLE_CHEMICAL", 146, 154], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 163, 181], ["hydroxychloroquine intoxication", "PROBLEM", 58, 89], ["prolonged QT interval", "PROBLEM", 117, 138], ["COVID", "TEST", 146, 151], ["hydroxychloroquine overdose", "PROBLEM", 163, 190]]], ["In addition, while the previously reported intoxication cases were due to a much higher dose of hydroxychloroquine intake, a relatively low dose of intoxication in this case is noteworthy.Case ReportA 28-year-old male patient was admitted to the emergency department with the complaints of nausea, diarrhea, and weakness that started 12 h ago.", [["hydroxychloroquine", "CHEMICAL", 96, 114], ["nausea", "DISEASE", 290, 296], ["diarrhea", "DISEASE", 298, 306], ["weakness", "DISEASE", 312, 320], ["hydroxychloroquine", "CHEMICAL", 96, 114], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 96, 114], ["male", "ORGANISM", 213, 217], ["patient", "ORGANISM", 218, 225], ["patient", "SPECIES", 218, 225], ["intoxication cases", "PROBLEM", 43, 61], ["hydroxychloroquine intake", "TREATMENT", 96, 121], ["intoxication", "PROBLEM", 148, 160], ["nausea", "PROBLEM", 290, 296], ["diarrhea", "PROBLEM", 298, 306], ["weakness", "PROBLEM", 312, 320], ["nausea", "OBSERVATION", 290, 296], ["diarrhea", "OBSERVATION", 298, 306], ["weakness", "OBSERVATION", 312, 320]]], ["The patient, who had no known chronic disease, was diagnosed with COVID-19 a day prior.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["known chronic disease", "PROBLEM", 24, 45], ["COVID", "TEST", 66, 71], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["disease", "OBSERVATION", 38, 45]]], ["Home isolation was recommended by giving hydroxychloroquine 2 \u00d7 200 mg P. O. and oseltamivir 2 \u00d7 75 mg P. O. for 5 days.", [["hydroxychloroquine", "CHEMICAL", 41, 59], ["oseltamivir", "CHEMICAL", 81, 92], ["hydroxychloroquine", "CHEMICAL", 41, 59], ["oseltamivir", "CHEMICAL", 81, 92], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 41, 59], ["Home isolation", "TREATMENT", 0, 14], ["hydroxychloroquine", "TREATMENT", 41, 59], ["oseltamivir", "TREATMENT", 81, 92]]], ["When the patient's detailed history was taken, it was learned that the patient's complaints started 6 h after accidentally taking 1.600 mg of hydroxychloroquine at the same time as a result of misunderstanding about how to use the medication.", [["hydroxychloroquine", "CHEMICAL", 142, 160], ["hydroxychloroquine", "CHEMICAL", 142, 160], ["patient", "ORGANISM", 9, 16], ["patient", "ORGANISM", 71, 78], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 142, 160], ["patient", "SPECIES", 9, 16], ["patient", "SPECIES", 71, 78], ["the patient's complaints", "PROBLEM", 67, 91], ["hydroxychloroquine", "TREATMENT", 142, 160], ["the medication", "TREATMENT", 227, 241]]], ["The Glasgow Coma Scale was 15, and neurological, respiratory, and abdominal examinations were normal.", [["neurological", "ANATOMY", 35, 47], ["abdominal", "ANATOMY", 66, 75], ["Coma", "DISEASE", 12, 16], ["abdominal", "ORGANISM_SUBDIVISION", 66, 75], ["The Glasgow Coma Scale", "TEST", 0, 22], ["abdominal examinations", "TEST", 66, 88], ["respiratory", "ANATOMY", 49, 60], ["abdominal", "ANATOMY", 66, 75], ["normal", "OBSERVATION", 94, 100]]], ["His pulse was 54 beats/min, oxygen saturation was 99%, arterial blood pressure was 122/82 mmHg, fever was 36.5\u00b0C, electrocardiography (ECG) showed sinus bradycardia, and corrected QT interval was calculated as 510 ms [Figure 1].", [["arterial", "ANATOMY", 55, 63], ["blood", "ANATOMY", 64, 69], ["sinus", "ANATOMY", 147, 152], ["oxygen", "CHEMICAL", 28, 34], ["fever", "DISEASE", 96, 101], ["sinus bradycardia", "DISEASE", 147, 164], ["oxygen", "CHEMICAL", 28, 34], ["oxygen", "SIMPLE_CHEMICAL", 28, 34], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 55, 69], ["sinus", "MULTI-TISSUE_STRUCTURE", 147, 152], ["His pulse", "TEST", 0, 9], ["oxygen saturation", "TEST", 28, 45], ["arterial blood pressure", "TEST", 55, 78], ["fever", "PROBLEM", 96, 101], ["electrocardiography", "TEST", 114, 133], ["ECG", "TEST", 135, 138], ["sinus bradycardia", "PROBLEM", 147, 164], ["corrected QT interval", "PROBLEM", 170, 191], ["sinus bradycardia", "ANATOMY", 147, 164]]], ["Although complete blood count, liver and kidney function tests, C-reactive protein, and blood electrolytes were normal in blood samples, 20 mEq potassium chloride was given intravenously with 500cc 0.9% isotonic sodium chloride as a liquid electrolyte supplement to the patient with prolonged QT interval in 2 h because blood potassium level was 3.2 mEq/L. The QT interval prolongation and bradycardia persisted, and the patient was hospitalized for follow-up and treatment due to the risk of sudden cardiac death and malign arrhythmias.", [["blood", "ANATOMY", 18, 23], ["liver", "ANATOMY", 31, 36], ["kidney", "ANATOMY", 41, 47], ["blood", "ANATOMY", 88, 93], ["blood samples", "ANATOMY", 122, 135], ["intravenously", "ANATOMY", 173, 186], ["blood", "ANATOMY", 320, 325], ["cardiac", "ANATOMY", 500, 507], ["potassium chloride", "CHEMICAL", 144, 162], ["sodium chloride", "CHEMICAL", 212, 227], ["potassium", "CHEMICAL", 326, 335], ["bradycardia", "DISEASE", 390, 401], ["sudden cardiac death", "DISEASE", 493, 513], ["arrhythmias", "DISEASE", 525, 536], ["potassium chloride", "CHEMICAL", 144, 162], ["sodium chloride", "CHEMICAL", 212, 227], ["potassium", "CHEMICAL", 326, 335], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["liver", "ORGAN", 31, 36], ["kidney", "ORGAN", 41, 47], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 64, 82], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["electrolytes", "ORGANISM_SUBSTANCE", 94, 106], ["blood samples", "ORGANISM_SUBSTANCE", 122, 135], ["mEq potassium chloride", "SIMPLE_CHEMICAL", 140, 162], ["sodium chloride", "SIMPLE_CHEMICAL", 212, 227], ["patient", "ORGANISM", 270, 277], ["blood", "ORGANISM_SUBSTANCE", 320, 325], ["potassium", "SIMPLE_CHEMICAL", 326, 335], ["patient", "ORGANISM", 421, 428], ["cardiac", "ORGAN", 500, 507], ["C-reactive protein", "PROTEIN", 64, 82], ["patient", "SPECIES", 270, 277], ["patient", "SPECIES", 421, 428], ["complete blood count", "TEST", 9, 29], ["kidney function tests", "TEST", 41, 62], ["C", "TEST", 64, 65], ["reactive protein", "TEST", 66, 82], ["blood electrolytes", "TEST", 88, 106], ["blood samples", "TEST", 122, 135], ["20 mEq potassium chloride", "TREATMENT", 137, 162], ["isotonic sodium chloride", "TREATMENT", 203, 227], ["a liquid electrolyte supplement", "TREATMENT", 231, 262], ["blood potassium level", "TEST", 320, 341], ["The QT interval prolongation", "PROBLEM", 357, 385], ["bradycardia", "PROBLEM", 390, 401], ["treatment", "TREATMENT", 464, 473], ["sudden cardiac death", "PROBLEM", 493, 513], ["malign arrhythmias", "PROBLEM", 518, 536], ["liver", "ANATOMY", 31, 36], ["kidney", "ANATOMY", 41, 47], ["reactive protein", "OBSERVATION", 66, 82], ["prolongation", "OBSERVATION_MODIFIER", 373, 385], ["cardiac", "ANATOMY", 500, 507], ["death", "OBSERVATION", 508, 513], ["malign arrhythmias", "OBSERVATION", 518, 536]]], ["Hydroxychloroquine was discontinued and treatment with oseltamivir 2 \u00d7 75 mg P. O. was continued to be given.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["oseltamivir", "CHEMICAL", 55, 66], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["oseltamivir", "CHEMICAL", 55, 66], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["treatment", "TREATMENT", 40, 49], ["oseltamivir", "TREATMENT", 55, 66]]], ["The patient was discharged on the 3rd day of his hospitalization after the corrected QT interval was detected to be 420 ms [Figure 2] and his bradycardia improved.", [["bradycardia", "DISEASE", 142, 153], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["his bradycardia", "PROBLEM", 138, 153]]], ["The patient gave written consent to publish his case and clinical images.DiscussionChloroquine and its derivative, hydroxychloroquine, have previously been shown to have antiviral activity in animal models for avian flu (H5N1) and in human studies for HIV.[56] It has also been shown to successfully inhibit COVID-19 inin vitro experiments.[7] However, current clinical trials of hydroxychloroquine indicate that this medication does not cause a significant difference compared to standard treatment for mortality, oxygen support requirement, frequency of acute respiratory distress, and negative conversion of SARS-CoV-2.", [["respiratory", "ANATOMY", 562, 573], ["Chloroquine", "CHEMICAL", 83, 94], ["hydroxychloroquine", "CHEMICAL", 115, 133], ["avian flu", "DISEASE", 210, 219], ["H5N1", "DISEASE", 221, 225], ["hydroxychloroquine", "CHEMICAL", 380, 398], ["oxygen", "CHEMICAL", 515, 521], ["respiratory distress", "DISEASE", 562, 582], ["SARS", "DISEASE", 611, 615], ["Chloroquine", "CHEMICAL", 83, 94], ["hydroxychloroquine", "CHEMICAL", 115, 133], ["hydroxychloroquine", "CHEMICAL", 380, 398], ["oxygen", "CHEMICAL", 515, 521], ["patient", "ORGANISM", 4, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 83, 94], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 115, 133], ["avian flu (H5N1", "ORGANISM", 210, 225], ["human", "ORGANISM", 234, 239], ["HIV", "ORGANISM", 252, 255], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 380, 398], ["oxygen", "SIMPLE_CHEMICAL", 515, 521], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 611, 621], ["patient", "SPECIES", 4, 11], ["avian flu", "SPECIES", 210, 219], ["human", "SPECIES", 234, 239], ["HIV", "SPECIES", 252, 255], ["H5N1", "SPECIES", 221, 225], ["human", "SPECIES", 234, 239], ["HIV", "SPECIES", 252, 255], ["SARS-CoV", "SPECIES", 611, 619], ["clinical images", "TEST", 57, 72], ["Chloroquine", "TREATMENT", 83, 94], ["its derivative", "TREATMENT", 99, 113], ["hydroxychloroquine", "TREATMENT", 115, 133], ["antiviral activity", "TREATMENT", 170, 188], ["avian flu (H5N1", "PROBLEM", 210, 225], ["HIV", "PROBLEM", 252, 255], ["COVID", "TEST", 308, 313], ["hydroxychloroquine", "TREATMENT", 380, 398], ["this medication", "TREATMENT", 413, 428], ["a significant difference", "PROBLEM", 444, 468], ["standard treatment", "TREATMENT", 481, 499], ["mortality", "PROBLEM", 504, 513], ["oxygen support requirement", "TREATMENT", 515, 541], ["acute respiratory distress", "PROBLEM", 556, 582], ["CoV", "TEST", 616, 619], ["acute", "OBSERVATION_MODIFIER", 556, 561], ["respiratory distress", "OBSERVATION", 562, 582]]], ["However, patients treated with hydroxychloroquine were reported to have significantly more frequent side effects, including cardiac arrest.[8910]DiscussionAs the Centers for Disease Control and Prevention (CDC) similarly suggested, Turkish Ministry of Health recommended hydroxychloroquine treatment (200 mg twice daily) in its national COVID-19 guideline as it was promising in the early stages of the pandemic, and this proposal is still up-to-date despite the publications against hydroxychloroquine.", [["cardiac", "ANATOMY", 124, 131], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["cardiac arrest", "DISEASE", 124, 138], ["hydroxychloroquine", "CHEMICAL", 271, 289], ["hydroxychloroquine", "CHEMICAL", 484, 502], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["hydroxychloroquine", "CHEMICAL", 271, 289], ["hydroxychloroquine", "CHEMICAL", 484, 502], ["patients", "ORGANISM", 9, 17], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 31, 49], ["cardiac", "ORGAN", 124, 131], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 271, 289], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 484, 502], ["patients", "SPECIES", 9, 17], ["hydroxychloroquine", "TREATMENT", 31, 49], ["cardiac arrest", "PROBLEM", 124, 138], ["Disease Control", "TREATMENT", 174, 189], ["hydroxychloroquine treatment", "TREATMENT", 271, 299], ["the pandemic", "PROBLEM", 399, 411], ["hydroxychloroquine", "TREATMENT", 484, 502], ["cardiac", "ANATOMY", 124, 131], ["arrest", "OBSERVATION", 132, 138], ["early stages", "OBSERVATION_MODIFIER", 383, 395]]], ["As studies against hydroxychloroquine came out, CDC updated their current recommendations, especially against high-dose use (600 mg twice daily).[1112] We already know that hydroxychloroquine has a wide profile of side effects.", [["hydroxychloroquine", "CHEMICAL", 19, 37], ["hydroxychloroquine", "CHEMICAL", 173, 191], ["hydroxychloroquine", "CHEMICAL", 19, 37], ["hydroxychloroquine", "CHEMICAL", 173, 191], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 19, 37], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 173, 191], ["hydroxychloroquine", "TREATMENT", 19, 37], ["hydroxychloroquine", "TREATMENT", 173, 191], ["side effects", "PROBLEM", 214, 226]]], ["Cardiac side effects associated with hydroxychloroquine are QRS interval prolongation, torsades de pointes, and QT interval prolongation which has generally been reported in acute intoxications or chronic overdoses.[131415] To our knowledge, there is not a reported case of prolonged QT interval because of hydroxychloroquine use or overdose due to COVID-19 treatment.DiscussionThe therapeutic, toxic, and lethal dose reported for chloroquine in the literature is 10 mg/kg, 20 mg/kg, and 30 mg/kg, respectively; however, no clear fatal dose threshold has been reported for hydroxychloroquine yet.", [["Cardiac", "ANATOMY", 0, 7], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["torsades de pointes", "DISEASE", 87, 106], ["QT interval prolongation", "DISEASE", 112, 136], ["hydroxychloroquine", "CHEMICAL", 307, 325], ["overdose", "DISEASE", 333, 341], ["COVID-19", "CHEMICAL", 349, 357], ["chloroquine", "CHEMICAL", 431, 442], ["hydroxychloroquine", "CHEMICAL", 573, 591], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["hydroxychloroquine", "CHEMICAL", 307, 325], ["COVID-19", "CHEMICAL", 349, 357], ["chloroquine", "CHEMICAL", 431, 442], ["hydroxychloroquine", "CHEMICAL", 573, 591], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 37, 55], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 307, 325], ["COVID-19", "SIMPLE_CHEMICAL", 349, 357], ["chloroquine", "SIMPLE_CHEMICAL", 431, 442], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 573, 591], ["Cardiac side effects", "PROBLEM", 0, 20], ["hydroxychloroquine", "TREATMENT", 37, 55], ["QRS interval prolongation", "PROBLEM", 60, 85], ["torsades de pointes", "PROBLEM", 87, 106], ["QT interval prolongation", "PROBLEM", 112, 136], ["acute intoxications", "PROBLEM", 174, 193], ["chronic overdoses", "PROBLEM", 197, 214], ["hydroxychloroquine use", "TREATMENT", 307, 329], ["overdose", "PROBLEM", 333, 341], ["COVID-19 treatment", "TREATMENT", 349, 367], ["chloroquine", "TREATMENT", 431, 442], ["hydroxychloroquine", "TREATMENT", 573, 591], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["intoxications", "OBSERVATION", 180, 193], ["chronic", "OBSERVATION_MODIFIER", 197, 204]]], ["In the case series, cardiac arrhythmias were reported between 4000 mg and 20,000 mg and death at 12,000 mg intake.[16] Although the total dose taken was 1,600 mg in our case and this dose is well below the reported doses, prolonged QT interval and bradycardia were observed.", [["cardiac", "ANATOMY", 20, 27], ["cardiac arrhythmias", "DISEASE", 20, 39], ["death", "DISEASE", 88, 93], ["bradycardia", "DISEASE", 248, 259], ["cardiac", "ORGAN", 20, 27], ["cardiac arrhythmias", "PROBLEM", 20, 39], ["death", "PROBLEM", 88, 93], ["prolonged QT interval", "PROBLEM", 222, 243], ["bradycardia", "PROBLEM", 248, 259], ["cardiac", "ANATOMY", 20, 27], ["arrhythmias", "OBSERVATION", 28, 39]]], ["This is also the first reported case of QT interval prolongation at a low dose of 1.600 mg in the literature.ConclusionHealth-care providers and patients should be alert for possible side effects of hydroxychloroquine, which is now used quite frequently in COVID-19 pandemic.", [["QT interval prolongation", "DISEASE", 40, 64], ["hydroxychloroquine", "CHEMICAL", 199, 217], ["hydroxychloroquine", "CHEMICAL", 199, 217], ["patients", "ORGANISM", 145, 153], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 199, 217], ["COVID-19", "ORGANISM", 257, 265], ["patients", "SPECIES", 145, 153], ["QT interval prolongation", "PROBLEM", 40, 64], ["hydroxychloroquine", "TREATMENT", 199, 217]]], ["Patients recommended for treatment in home isolation should be educated about the use, dosage, and possible side effects of this medicine.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["treatment", "TREATMENT", 25, 34], ["home isolation", "TREATMENT", 38, 52], ["this medicine", "TREATMENT", 124, 137]]], ["Serial ECG monitoring should be performed in patients who are admitted to the hospital due to drug-related QT interval prolongation and other cardiac side effects.", [["cardiac", "ANATOMY", 142, 149], ["QT interval prolongation", "DISEASE", 107, 131], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["Serial ECG monitoring", "TEST", 0, 21], ["drug-related QT interval prolongation", "PROBLEM", 94, 131], ["other cardiac side effects", "PROBLEM", 136, 162]]]], "278cb7a308b335493c0b307887a17a0626af8f91": [], "f8b28dc077a4d62178940c43350079dd6b0b91bd": [["BackgroundThe recently established virus family Mesoniviridae (order Nidovirales) comprises a group of positive-sense, singlestranded RNA ([+]ssRNA) insect viruses [1] .", [["virus family Mesoniviridae", "TREATMENT", 35, 61], ["singlestranded RNA", "PROBLEM", 119, 137], ["insect viruses", "PROBLEM", 149, 163]]], ["To date, the six described mesoniviruses, Cavally (CavV), DakNong (DKNG), Hana (HanaV), Meno (MenoV), Nam Dinh (NDiV) and Nse (NseV) have all been isolated from naturally infected mosquitoes collected in just two countries: C\u00f4te d'Ivoire (West Africa) and Vietnam (Southeast Asia) [2] [3] [4] [5] .", [["mesoniviruses", "GENE_OR_GENE_PRODUCT", 27, 40], ["CavV", "GENE_OR_GENE_PRODUCT", 51, 55], ["DakNong", "GENE_OR_GENE_PRODUCT", 58, 65], ["DKNG", "GENE_OR_GENE_PRODUCT", 67, 71], ["Hana (HanaV), Meno (MenoV)", "GENE_OR_GENE_PRODUCT", 74, 100], ["Nam Dinh (NDiV)", "GENE_OR_GENE_PRODUCT", 102, 117], ["Nse", "GENE_OR_GENE_PRODUCT", 122, 125], ["NseV", "GENE_OR_GENE_PRODUCT", 127, 131], ["[2] [3] [4", "SIMPLE_CHEMICAL", 281, 291], ["NDiV", "PROTEIN", 112, 116], ["Nam Dinh (NDiV)", "SPECIES", 102, 117], ["Cavally (CavV)", "TREATMENT", 42, 56], ["Meno (MenoV)", "TREATMENT", 88, 100], ["Vietnam (Southeast Asia)", "TREATMENT", 256, 280]]], ["Although these mosquito-associated viruses do not appear to infect vertebrates or to cause illness in humans or livestock, they are nonetheless of interest because of the structural and genetic similarities to other members of the order Nidovirales, namely viruses in the families Coronaviridae, Arteriviridae, and Roniviridae.", [["illness", "DISEASE", 91, 98], ["humans", "ORGANISM", 102, 108], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 237, 248], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 281, 294], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 296, 309], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 315, 326], ["humans", "SPECIES", 102, 108], ["humans", "SPECIES", 102, 108], ["these mosquito-associated viruses", "PROBLEM", 9, 42], ["illness", "PROBLEM", 91, 98], ["Nidovirales", "TREATMENT", 237, 248], ["the families Coronaviridae", "TREATMENT", 268, 294], ["Arteriviridae", "TREATMENT", 296, 309], ["Roniviridae", "TREATMENT", 315, 326], ["viruses", "OBSERVATION", 35, 42]]], ["Furthermore, the basal phylogenetic position of the mesoniviruses in relation to the Coronaviridae has led some authors to suggest that the coronaviruses, and possibly other viruses in the order Nidovirales, may have evolved in arthropods [3] [4] [5] .", [["coronaviruses", "ORGANISM", 140, 153], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 195, 206], ["the coronaviruses", "PROBLEM", 136, 153], ["other viruses", "PROBLEM", 168, 181], ["basal", "ANATOMY_MODIFIER", 17, 22], ["phylogenetic position", "OBSERVATION", 23, 44], ["coronaviruses", "OBSERVATION", 140, 153]]], ["Indeed, members of the Roniviridae naturally infect marine shrimp and can cause severe pathology in these economically important arthropods [6] .BackgroundIn this communication, we report the isolation and characterization of 13 additional mesoniviruses from mosquitoes collected in Thailand, Indonesia and the United States of America (USA).", [["Roniviridae", "GENE_OR_GENE_PRODUCT", 23, 34], ["the Roniviridae", "TREATMENT", 19, 34], ["severe pathology", "PROBLEM", 80, 96], ["the isolation", "TEST", 188, 201], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["pathology", "OBSERVATION", 87, 96]]], ["These 13 viruses appear to represent four distinct species in the family Mesoniviridae, three of which are novel.", [["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 73, 86], ["These 13 viruses", "PROBLEM", 0, 16], ["the family Mesoniviridae", "TREATMENT", 62, 86], ["appear to represent", "UNCERTAINTY", 17, 36], ["four", "OBSERVATION_MODIFIER", 37, 41], ["distinct", "OBSERVATION_MODIFIER", 42, 50], ["species", "OBSERVATION", 51, 58]]], ["Based on their wide geographic distribution, the limited sampling that has been done to date for these mosquito-specific viruses, and their broad species host range in mosquitoes, it seems likely that mesoniviruses are common in mosquito populations worldwide.", [["mesoniviruses", "DISEASE", 201, 214], ["mesoniviruses", "GENE_OR_GENE_PRODUCT", 201, 214], ["these mosquito-specific viruses", "PROBLEM", 97, 128], ["mesoniviruses", "PROBLEM", 201, 214], ["wide", "OBSERVATION_MODIFIER", 15, 19], ["geographic", "OBSERVATION_MODIFIER", 20, 30], ["distribution", "OBSERVATION_MODIFIER", 31, 43], ["viruses", "OBSERVATION", 121, 128], ["seems likely", "UNCERTAINTY", 183, 195]]], ["The potential biological significance and effect of mesoniviruses on mosquito vector competence is also discussed.Virus morphologyAll isolates had similar ultrastructure.", [["mesoniviruses", "SIMPLE_CHEMICAL", 52, 65], ["Virus", "ORGANISM", 114, 119], ["mesoniviruses", "TREATMENT", 52, 65], ["Virus morphology", "TEST", 114, 130], ["similar ultrastructure", "OBSERVATION", 147, 169]]], ["Mature virions 50 nm in diameter were located at the surface of infected C6/36 cells, either as individual particles or in groups ( Figure 1B,D) , similar to what has been reported recently [7] .", [["virions", "ANATOMY", 7, 14], ["surface", "ANATOMY", 53, 60], ["C6/36 cells", "ANATOMY", 73, 84], ["surface", "CELLULAR_COMPONENT", 53, 60], ["C6/36 cells", "CELL", 73, 84], ["infected C6/36 cells", "CELL_LINE", 64, 84], ["Mature virions", "PROBLEM", 0, 14], ["infected C6/36 cells", "PROBLEM", 64, 84], ["virions", "OBSERVATION_MODIFIER", 7, 14], ["50 nm", "OBSERVATION_MODIFIER", 15, 20], ["diameter", "OBSERVATION_MODIFIER", 24, 32], ["surface", "OBSERVATION_MODIFIER", 53, 60], ["infected", "OBSERVATION", 64, 72], ["C6", "ANATOMY_MODIFIER", 73, 75], ["36 cells", "OBSERVATION", 76, 84]]], ["They displayed a dense nucleocapsid core~40 nm in diameter and surrounding envelope ( Figure 1A ,B).", [["a dense nucleocapsid core", "PROBLEM", 15, 40], ["dense", "OBSERVATION_MODIFIER", 17, 22], ["nucleocapsid", "OBSERVATION", 23, 35], ["core", "OBSERVATION_MODIFIER", 36, 40], ["~", "OBSERVATION_MODIFIER", 40, 41], ["40 nm", "OBSERVATION_MODIFIER", 41, 46], ["diameter", "OBSERVATION_MODIFIER", 50, 58]]], ["Mature virions of the same size could also be found inside intracytoplasmic vacuoles ( Figure 1A ,B,D,E,F,H).", [["virions", "ANATOMY", 7, 14], ["intracytoplasmic vacuoles", "ANATOMY", 59, 84], ["intracytoplasmic vacuoles", "CELLULAR_COMPONENT", 59, 84], ["B", "PROTEIN", 98, 99], ["intracytoplasmic vacuoles", "TEST", 59, 84], ["virions", "OBSERVATION", 7, 14], ["size", "OBSERVATION_MODIFIER", 27, 31], ["intracytoplasmic vacuoles", "OBSERVATION", 59, 84]]], ["Some infected cells had paracrystalline arrays consisting of empty and full virus particles but with less electron-density than mature virions ( Figure 1C ).", [["cells", "ANATOMY", 14, 19], ["virions", "ANATOMY", 135, 142], ["cells", "CELL", 14, 19], ["infected cells", "CELL_TYPE", 5, 19], ["Some infected cells", "PROBLEM", 0, 19], ["paracrystalline arrays", "PROBLEM", 24, 46], ["empty and full virus particles", "PROBLEM", 61, 91], ["infected cells", "OBSERVATION", 5, 19], ["paracrystalline arrays", "OBSERVATION", 24, 46], ["empty", "OBSERVATION", 61, 66], ["full virus particles", "OBSERVATION", 71, 91], ["density", "OBSERVATION", 115, 122]]], ["At the periphery of these arrays, mature virions could be observed either free in the cytosol or inside vacuoles ( Figure 1C ).", [["virions", "ANATOMY", 41, 48], ["cytosol", "ANATOMY", 86, 93], ["vacuoles", "ANATOMY", 104, 112], ["cytosol", "CELLULAR_COMPONENT", 86, 93], ["vacuoles", "CELLULAR_COMPONENT", 104, 112], ["mature virions", "PROBLEM", 34, 48], ["periphery", "ANATOMY_MODIFIER", 7, 16], ["virions", "OBSERVATION", 41, 48]]], ["Moreover a recent report [8] , suggests that the mesonivirus virion diameter of~40-50 nm observed by us and others [7] may be significantly lower than its actual size, a discrepancy attributed to the method of preparation for alternative imaging technologies.", [["mesonivirus virion", "ORGANISM", 49, 67], ["the mesonivirus virion diameter", "TEST", 45, 76], ["alternative imaging technologies", "TEST", 226, 258], ["diameter", "OBSERVATION_MODIFIER", 68, 76], ["size", "OBSERVATION_MODIFIER", 162, 166]]], ["Employing cryoelectron tomography, Warrilow et al. [8] demonstrated on the surface of some virions the presence of spikelike projections displaying a globular head attached to the virion surface through a low density stalk, similar to what has been observed in other members of the order Nidovirales [9] .Genome sequence and organizationThe complete nucleotide sequences of all 13 isolates were determined by high-throughput Illumina sequencing with end-finishing by 5'-and 3'-RACE.", [["surface", "ANATOMY", 75, 82], ["head", "ANATOMY", 159, 163], ["surface", "ANATOMY", 187, 194], ["surface", "CELLULAR_COMPONENT", 75, 82], ["head", "ORGANISM_SUBDIVISION", 159, 163], ["virion surface", "CELLULAR_COMPONENT", 180, 194], ["globular head", "PROTEIN", 150, 163], ["5'-and 3'-RACE", "DNA", 467, 481], ["Employing cryoelectron tomography", "TEST", 0, 33], ["spikelike projections", "PROBLEM", 115, 136], ["a globular head", "PROBLEM", 148, 163], ["a low density stalk", "PROBLEM", 203, 222], ["Genome sequence", "TEST", 305, 320], ["The complete nucleotide sequences", "TEST", 337, 370], ["globular", "OBSERVATION", 150, 158], ["virion", "OBSERVATION_MODIFIER", 180, 186], ["surface", "OBSERVATION_MODIFIER", 187, 194], ["low density", "OBSERVATION_MODIFIER", 205, 216]]], ["Excluding the 3'-poly [A] tail, the (+) ssRNA genomes ranged in size from 20,127 nt (V3872) to 20,777 nt (JKT-10701).", [["JKT-10701", "CHEMICAL", 106, 115], ["JKT-10701", "CHEMICAL", 106, 115], ["3'-poly [A] tail", "DNA", 14, 30], ["ssRNA genomes", "DNA", 40, 53], ["ssRNA genomes", "TEST", 40, 53], ["size", "TEST", 64, 68], ["JKT", "TEST", 106, 109], ["tail", "ANATOMY", 26, 30], ["size", "OBSERVATION_MODIFIER", 64, 68]]], ["The organization of each genome was similar to that described previously for the mesoniviruses (NDiV, CavV, HanaV, NseV and MenoV), featuring a long 5'-untranslated region (5'-UTR) of 359 to 370 nt, six major long open reading frames (ORFs), and a long terminal region of 1780 to 1804 nt preceding the poly[A] tail ( Figure 2 ).", [["mesoniviruses", "GENE_OR_GENE_PRODUCT", 81, 94], ["NDiV", "GENE_OR_GENE_PRODUCT", 96, 100], ["CavV", "GENE_OR_GENE_PRODUCT", 102, 106], ["HanaV", "GENE_OR_GENE_PRODUCT", 108, 113], ["NseV", "GENE_OR_GENE_PRODUCT", 115, 119], ["MenoV", "GENE_OR_GENE_PRODUCT", 124, 129], ["mesoniviruses", "PROTEIN", 81, 94], ["NDiV", "DNA", 96, 100], ["CavV", "DNA", 102, 106], ["HanaV", "DNA", 108, 113], ["NseV", "DNA", 115, 119], ["MenoV", "DNA", 124, 129], ["long 5'-untranslated region", "DNA", 144, 171], ["5'-UTR", "DNA", 173, 179], ["long open reading frames", "DNA", 209, 233], ["ORFs", "DNA", 235, 239], ["long terminal region", "DNA", 248, 268], ["1780 to 1804 nt", "DNA", 272, 287], ["poly[A] tail", "DNA", 302, 314], ["the mesoniviruses", "TEST", 77, 94], ["CavV", "TEST", 102, 106], ["a long 5'-untranslated region", "PROBLEM", 142, 171], ["a long terminal region", "PROBLEM", 246, 268]]], ["An alignment that also included the five previously described mesoniviruses revealed block insertions in three groups of isolates: i) KP84-0156, KP84-0192 and KP84-0344 had a 180 nt insertion, ii) JKT-9853, JKT-9876, JKT-9891 and JKT-7774 had a 573 nt insertion, and iii) JKT-10701 had a 588 nt insertion.", [["KP84-0192", "CHEMICAL", 145, 154], ["KP84-0344", "CHEMICAL", 159, 168], ["JKT-9853", "CHEMICAL", 197, 205], ["JKT-9876", "CHEMICAL", 207, 215], ["JKT-9891", "CHEMICAL", 217, 225], ["JKT-7774", "CHEMICAL", 230, 238], ["JKT-10701", "CHEMICAL", 272, 281], ["KP84-0344", "CHEMICAL", 159, 168], ["JKT-9853", "CHEMICAL", 197, 205], ["JKT-9876", "CHEMICAL", 207, 215], ["JKT-9891", "CHEMICAL", 217, 225], ["JKT-7774", "CHEMICAL", 230, 238], ["mesoniviruses", "CANCER", 62, 75], ["KP84-0192", "CELL", 145, 154], ["KP84-0344", "CELL", 159, 168], ["mesoniviruses", "DNA", 62, 75], ["180 nt insertion", "DNA", 175, 191], ["JKT-7774", "DNA", 230, 238], ["573 nt insertion", "DNA", 245, 261], ["JKT-10701", "DNA", 272, 281], ["588 nt insertion", "DNA", 288, 304], ["block insertions", "PROBLEM", 85, 101], ["KP84", "TEST", 145, 149], ["KP84", "TEST", 159, 163], ["a 180 nt insertion", "TREATMENT", 173, 191], ["JKT", "TEST", 197, 200], ["JKT", "TEST", 207, 210], ["JKT", "TEST", 217, 220], ["JKT", "TEST", 230, 233], ["a 573 nt insertion", "TREATMENT", 243, 261], ["JKT", "TEST", 272, 275], ["a 588 nt insertion", "TREATMENT", 286, 304]]], ["These insertions accounted for most of the observed difference in genome size in the mesoniviruses ( Figure 2 ).", [["size", "OBSERVATION_MODIFIER", 73, 77]]], ["Excluding this region, which commenced~1300 nt from the 5'terminus, the mesoniviruses shared global nucleotide sequence identity of~43.7%.", [["nucleotide", "CHEMICAL", 100, 110], ["mesoniviruses", "GENE_OR_GENE_PRODUCT", 72, 85], ["5'terminus", "DNA", 56, 66], ["mesoniviruses", "DNA", 72, 85], ["global nucleotide sequence identity", "TEST", 93, 128]]], ["Maximum pairwise divergence was between MenoV and all other viruses (65.5% -67.6% identity).Phylogenetic analysis and species determinationTo determine the phylogenetic relationships of the newly identified insect viruses, maximum likelihood (ML) phylogenetic trees were constructed based on the amino acid alignments of ORF2a (unprocessed S protein) and a concatenated region of the highly conserved domains within ORF1ab (3CL pro , RdRp and ZnHel1).", [["amino acid", "CHEMICAL", 296, 306], ["amino acid", "CHEMICAL", 296, 306], ["amino acid", "AMINO_ACID", 296, 306], ["ORF2a", "GENE_OR_GENE_PRODUCT", 321, 326], ["unprocessed S protein", "GENE_OR_GENE_PRODUCT", 328, 349], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 416, 422], ["3CL pro", "GENE_OR_GENE_PRODUCT", 424, 431], ["RdRp", "GENE_OR_GENE_PRODUCT", 434, 438], ["ZnHel1", "GENE_OR_GENE_PRODUCT", 443, 449], ["ORF2a", "PROTEIN", 321, 326], ["unprocessed S protein", "PROTEIN", 328, 349], ["highly conserved domains", "PROTEIN", 384, 408], ["ORF1ab", "PROTEIN", 416, 422], ["3CL pro", "PROTEIN", 424, 431], ["RdRp", "PROTEIN", 434, 438], ["ZnHel1", "PROTEIN", 443, 449], ["Maximum pairwise divergence", "PROBLEM", 0, 27], ["Phylogenetic analysis", "TEST", 92, 113], ["species determination", "TEST", 118, 139], ["the newly identified insect viruses", "PROBLEM", 186, 221], ["the amino acid alignments", "TEST", 292, 317], ["RdRp and ZnHel1", "TREATMENT", 434, 449], ["insect viruses", "OBSERVATION", 207, 221]]], ["The phylogenies exhibited highly similar topologies and strongly indicated that the viruses identified in this study cluster within the previously identified insect-specific nidoviruses in the genus Mesonivirus (NDiV, CavV, HanaV, NseV and MenoV) ( Figure 3) .Phylogenetic analysis and species determinationA multiple sequence alignment of the 13 new genomes indicated high identity between multiple isolates, which was also confirmed by our phylogenetic analysis.", [["nidoviruses", "GENE_OR_GENE_PRODUCT", 174, 185], ["Mesonivirus", "GENE_OR_GENE_PRODUCT", 199, 210], ["NDiV", "GENE_OR_GENE_PRODUCT", 212, 216], ["CavV", "GENE_OR_GENE_PRODUCT", 218, 222], ["HanaV", "GENE_OR_GENE_PRODUCT", 224, 229], ["insect-specific nidoviruses", "PROTEIN", 158, 185], ["NDiV", "PROTEIN", 212, 216], ["CavV", "PROTEIN", 218, 222], ["HanaV", "PROTEIN", 224, 229], ["NseV", "PROTEIN", 231, 235], ["MenoV", "PROTEIN", 240, 245], ["The phylogenies", "TEST", 0, 15], ["the viruses", "PROBLEM", 80, 91], ["this study", "TEST", 106, 116], ["CavV", "TEST", 218, 222], ["Phylogenetic analysis", "TEST", 260, 281], ["species", "TEST", 286, 293], ["multiple sequence alignment", "TEST", 309, 336], ["high identity between multiple isolates", "PROBLEM", 369, 408], ["our phylogenetic analysis", "TEST", 438, 463], ["similar topologies", "OBSERVATION", 33, 51], ["viruses", "OBSERVATION", 84, 91], ["genus Mesonivirus", "ANATOMY", 193, 210], ["high identity", "OBSERVATION", 369, 382]]], ["Isolates KP84-0156, KP84-0192 and KP84-0344 differed only by ten nucleotide substitutions and a single 6-nt indel and formed a well-supported monophyletic clade in both phylogenies ( Figure 3 ).", [["KP84-0156, KP84-0192 and KP84-0344", "CHEMICAL", 9, 43], ["nucleotide", "CHEMICAL", 65, 75], ["nucleotide", "CHEMICAL", 65, 75], ["KP84-0156", "CELL", 9, 18], ["KP84-0192", "CELL", 20, 29], ["KP84-0344", "CELL", 34, 43], ["6-nt indel", "DNA", 103, 113], ["Isolates KP84-0156", "SPECIES", 0, 18], ["KP84-0344", "SPECIES", 34, 43], ["Isolates", "TEST", 0, 8], ["KP84", "TEST", 20, 24], ["KP84", "TEST", 34, 38], ["nucleotide substitutions", "TREATMENT", 65, 89], ["a single 6-nt indel", "TREATMENT", 94, 113], ["monophyletic clade", "TREATMENT", 142, 160]]], ["These should be considered isolates of the same virus (designated Kamphang Figure 2 Genome organisation of the mesoniviruses.", [["mesoniviruses", "CANCER", 111, 124], ["the same virus", "PROBLEM", 39, 53], ["the mesoniviruses", "TREATMENT", 107, 124]]], ["In ORF1a and ORF1b the putative ribosomal frame-shift (RFS) element and the locations of conserved functional domains, including the 3C-like serine protease (3CLP), RNA-dependent RNA polymerase (RdRp), zinc-binding (Z), helicase (Hel), exoribonuclease (ExoN), N7-methyltransferase (NMT) and 2'-O-methyltransferase (OMT) domains, are shown.", [["ribosomal", "ANATOMY", 32, 41], ["zinc", "CHEMICAL", 202, 206], ["serine", "CHEMICAL", 141, 147], ["zinc", "CHEMICAL", 202, 206], ["N7", "CHEMICAL", 260, 262], ["ORF1a", "GENE_OR_GENE_PRODUCT", 3, 8], ["ORF1b", "GENE_OR_GENE_PRODUCT", 13, 18], ["ribosomal", "CELLULAR_COMPONENT", 32, 41], ["3C-like serine protease", "GENE_OR_GENE_PRODUCT", 133, 156], ["3CLP", "GENE_OR_GENE_PRODUCT", 158, 162], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 165, 193], ["zinc-binding (Z)", "GENE_OR_GENE_PRODUCT", 202, 218], ["Hel", "GENE_OR_GENE_PRODUCT", 230, 233], ["exoribonuclease", "GENE_OR_GENE_PRODUCT", 236, 251], ["ExoN", "GENE_OR_GENE_PRODUCT", 253, 257], ["N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 260, 280], ["NMT", "GENE_OR_GENE_PRODUCT", 282, 285], ["2'-O-methyltransferase", "GENE_OR_GENE_PRODUCT", 291, 313], ["ORF1a", "DNA", 3, 8], ["ORF1b", "DNA", 13, 18], ["putative ribosomal frame-shift (RFS) element", "DNA", 23, 67], ["3C-like serine protease", "PROTEIN", 133, 156], ["3CLP", "PROTEIN", 158, 162], ["RNA-dependent RNA polymerase", "PROTEIN", 165, 193], ["RdRp", "PROTEIN", 195, 199], ["zinc-binding (Z), helicase", "PROTEIN", 202, 228], ["Hel", "PROTEIN", 230, 233], ["exoribonuclease", "PROTEIN", 236, 251], ["ExoN", "PROTEIN", 253, 257], ["N7-methyltransferase", "PROTEIN", 260, 280], ["NMT", "PROTEIN", 282, 285], ["2'-O-methyltransferase (OMT) domains", "PROTEIN", 291, 327], ["the 3C", "TEST", 129, 135], ["serine protease", "TREATMENT", 141, 156], ["RNA-dependent RNA polymerase", "PROBLEM", 165, 193], ["helicase (Hel)", "TREATMENT", 220, 234], ["exoribonuclease (ExoN)", "TREATMENT", 236, 258], ["N7-methyltransferase (NMT)", "TREATMENT", 260, 286], ["2'-O-methyltransferase (OMT) domains", "TREATMENT", 291, 327]]], ["Sequence insertions in ORF1a are shown as black blocks.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 23, 28], ["ORF1a", "DNA", 23, 28], ["Sequence insertions in ORF1a", "TREATMENT", 0, 28], ["black blocks", "PROBLEM", 42, 54]]], ["In ORF2a encoding the S glycoprotein the sites of proteolytic cleavage to generate S1, S2 and the uncharacterised N-terminal fragment are shown as black inverted triangles.", [["N", "CHEMICAL", 114, 115], ["ORF2a", "GENE_OR_GENE_PRODUCT", 3, 8], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 22, 36], ["S1", "GENE_OR_GENE_PRODUCT", 83, 85], ["S2", "GENE_OR_GENE_PRODUCT", 87, 89], ["ORF2a", "PROTEIN", 3, 8], ["S glycoprotein", "PROTEIN", 22, 36], ["S1", "PROTEIN", 83, 85], ["S2", "PROTEIN", 87, 89], ["N-terminal fragment", "PROTEIN", 114, 133], ["the S glycoprotein", "TREATMENT", 18, 36], ["proteolytic cleavage", "PROBLEM", 50, 70], ["the uncharacterised N-terminal fragment", "PROBLEM", 94, 133], ["black inverted triangles", "PROBLEM", 147, 171], ["proteolytic cleavage", "OBSERVATION", 50, 70], ["S1", "ANATOMY", 83, 85], ["S2", "ANATOMY", 87, 89], ["uncharacterised", "OBSERVATION_MODIFIER", 98, 113], ["terminal fragment", "OBSERVATION", 116, 133], ["black", "OBSERVATION_MODIFIER", 147, 152], ["inverted triangles", "OBSERVATION", 153, 171]]], ["Putative ORF4 that is relatively conserved in the 3'terminal region of the genome is shown as black rectangles and other small ORFs >180 nt that occur variously in the 3'-terminal domains and elsewhere in the genome are shown as grey rectangles.Phylogenetic analysis and species determinationPhet virus -KPhV).", [["3'terminal region", "ANATOMY", 50, 67], ["ORF4", "GENE_OR_GENE_PRODUCT", 9, 13], ["3'terminal region", "CELLULAR_COMPONENT", 50, 67], ["genome", "CELLULAR_COMPONENT", 75, 81], ["genome", "CELLULAR_COMPONENT", 209, 215], ["Phet virus -KPhV", "ORGANISM", 292, 308], ["ORF4", "DNA", 9, 13], ["3'terminal region", "DNA", 50, 67], ["black rectangles", "DNA", 94, 110], ["small ORFs", "DNA", 121, 131], ["3'-terminal domains", "DNA", 168, 187], ["Putative ORF4", "PROBLEM", 0, 13], ["black rectangles", "PROBLEM", 94, 110], ["other small ORFs", "PROBLEM", 115, 131], ["Phylogenetic analysis", "TEST", 245, 266], ["species determination", "TEST", 271, 292], ["relatively", "OBSERVATION_MODIFIER", 22, 32], ["conserved", "OBSERVATION_MODIFIER", 33, 42], ["terminal", "ANATOMY_MODIFIER", 52, 60], ["region", "ANATOMY_MODIFIER", 61, 67], ["genome", "ANATOMY", 75, 81], ["black rectangles", "OBSERVATION", 94, 110], ["small", "OBSERVATION_MODIFIER", 121, 126], ["ORFs", "OBSERVATION", 127, 131], ["genome", "ANATOMY", 209, 215], ["grey rectangles", "OBSERVATION", 229, 244]]], ["Likewise, JKT-9853, JKT-9876 and JKT-9891 differed by only single nucleotide substitutions and JKT-7774 differed by 68 nucleotide substitutions and two indels of 3 and 6 nucleotides, and these four viruses formed a strongly supported monophyletic clade in the ML trees, suggesting that they can be considered isolates of the same virus (designated Botang Baru virus -BBaV).", [["JKT-9853", "CHEMICAL", 10, 18], ["JKT-9876", "CHEMICAL", 20, 28], ["JKT-9891", "CHEMICAL", 33, 41], ["nucleotide", "CHEMICAL", 66, 76], ["JKT-7774", "CHEMICAL", 95, 103], ["nucleotide", "CHEMICAL", 119, 129], ["JKT-9853", "CHEMICAL", 10, 18], ["JKT-9876", "CHEMICAL", 20, 28], ["nucleotide", "CHEMICAL", 66, 76], ["JKT-7774", "CHEMICAL", 95, 103], ["nucleotide", "CHEMICAL", 119, 129], ["JKT-9853", "GENE_OR_GENE_PRODUCT", 10, 18], ["JKT-9876", "GENE_OR_GENE_PRODUCT", 20, 28], ["JKT-9891", "GENE_OR_GENE_PRODUCT", 33, 41], ["JKT-7774", "GENE_OR_GENE_PRODUCT", 95, 103], ["Botang Baru virus -BBaV", "ORGANISM", 348, 371], ["JKT-7774", "DNA", 95, 103], ["Baru virus", "SPECIES", 355, 365], ["JKT-9853", "SPECIES", 10, 18], ["Botang Baru virus -BBaV", "SPECIES", 348, 371], ["JKT", "TEST", 10, 13], ["JKT", "TEST", 20, 23], ["JKT", "TEST", 33, 36], ["single nucleotide substitutions", "TEST", 59, 90], ["JKT", "TEST", 95, 98], ["nucleotide substitutions", "TEST", 119, 143], ["two indels", "TEST", 148, 158], ["nucleotides", "TREATMENT", 170, 181], ["these four viruses", "PROBLEM", 187, 205], ["the same virus", "PROBLEM", 321, 335], ["monophyletic clade", "OBSERVATION", 234, 252]]], ["Isolates 16740, 16757, V3872 and V3982 were also closely related, differing by only 18-57 nucleotide substitutions (~0.1-0.3%) across the entire genome.", [["nucleotide", "CHEMICAL", 90, 100], ["nucleotide", "CHEMICAL", 90, 100], ["Isolates", "TEST", 0, 8], ["nucleotide substitutions", "TEST", 90, 114]]], ["The clade formed by these isolates in each ML tree clustered within a closely related monophyletic group that also included NDiV and isolate JKT-9982 ( Figure 3 ).", [["JKT-9982", "CHEMICAL", 141, 149], ["JKT-9982", "CELL", 141, 149], ["JKT-9982", "SPECIES", 141, 149], ["NDiV", "TEST", 124, 128], ["isolate JKT", "TEST", 133, 144]]], ["These can all be considered strains of NDiV.", [["NDiV", "GENE_OR_GENE_PRODUCT", 39, 43], ["NDiV", "SPECIES", 39, 43], ["NDiV", "TREATMENT", 39, 43]]], ["Finally, isolate JKT-10701 was clearly distinct from all other mesoniviruses in our phylogenetic analysis, and was considered a unique virus, Karang Sari (KSaV).Phylogenetic analysis and species determinationIt has recently been suggested that pairwise evolutionary distances (PED) can be used as a species demarcation criterion in the genus Mesonivirus [6] .", [["JKT-10701", "CHEMICAL", 17, 26], ["JKT-10701", "CELL", 17, 26], ["mesoniviruses", "CANCER", 63, 76], ["JKT-10701", "SPECIES", 17, 26], ["isolate JKT", "TEST", 9, 20], ["our phylogenetic analysis", "TEST", 80, 105], ["a unique virus", "PROBLEM", 126, 140], ["Phylogenetic analysis", "TEST", 161, 182], ["species determination", "TEST", 187, 208]]], ["We calculated the PED between the 13 new isolates described in this study and those of five previously described mesoniviruses (CavV, HanaV, NDiV, NseV and MenoV) using the conserved protein domains of ORF1ab (3CL pro ,RdRp and ZnHel1).", [["mesoniviruses", "GENE_OR_GENE_PRODUCT", 113, 126], ["CavV", "GENE_OR_GENE_PRODUCT", 128, 132], ["HanaV", "GENE_OR_GENE_PRODUCT", 134, 139], ["NDiV", "GENE_OR_GENE_PRODUCT", 141, 145], ["NseV", "GENE_OR_GENE_PRODUCT", 147, 151], ["MenoV", "GENE_OR_GENE_PRODUCT", 156, 161], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 202, 208], ["3CL pro", "GENE_OR_GENE_PRODUCT", 210, 217], ["RdRp", "GENE_OR_GENE_PRODUCT", 219, 223], ["ZnHel1", "GENE_OR_GENE_PRODUCT", 228, 234], ["mesoniviruses", "PROTEIN", 113, 126], ["CavV", "PROTEIN", 128, 132], ["HanaV", "PROTEIN", 134, 139], ["NDiV", "PROTEIN", 141, 145], ["NseV", "PROTEIN", 147, 151], ["MenoV", "PROTEIN", 156, 161], ["conserved protein domains", "PROTEIN", 173, 198], ["ORF1ab", "PROTEIN", 202, 208], ["3CL pro", "PROTEIN", 210, 217], ["RdRp", "PROTEIN", 219, 223], ["ZnHel1", "PROTEIN", 228, 234], ["this study", "TEST", 63, 73], ["CavV", "TREATMENT", 128, 132], ["NDiV", "TREATMENT", 141, 145], ["ORF1ab (3CL pro", "TREATMENT", 202, 217], ["RdRp", "TREATMENT", 219, 223]]], ["Based on this analysis, NDiV (including the Ngewontan and Houston strains) and CavV can be considered a single species, which has previously been designated at Alphamesonivirus-1.", [["NDiV", "CHEMICAL", 24, 28], ["NDiV", "GENE_OR_GENE_PRODUCT", 24, 28], ["CavV", "GENE_OR_GENE_PRODUCT", 79, 83], ["Alphamesonivirus-1", "ORGANISM", 160, 178], ["CavV", "PROTEIN", 79, 83], ["Alphamesonivirus-1", "SPECIES", 160, 178], ["this analysis", "TEST", 9, 22], ["CavV", "TREATMENT", 79, 83], ["a single species", "PROBLEM", 102, 118]]], ["The PED between each of these strains was substantially less than the suggested cutoff of 0.032 for species demarcation [6] .", [["these strains", "PROBLEM", 24, 37], ["species demarcation", "PROBLEM", 100, 119]]], ["By this method, each of the other previously described mesoniviruses -HanaV MenoV, and NseVwould also be considered unique species, as the PED between these viruses and all other mesoniviruses were considerably greater than 0.032.", [["mesoniviruses", "GENE_OR_GENE_PRODUCT", 55, 68], ["HanaV", "GENE_OR_GENE_PRODUCT", 70, 75], ["MenoV", "GENE_OR_GENE_PRODUCT", 76, 81], ["NseVwould", "GENE_OR_GENE_PRODUCT", 87, 96], ["unique species", "PROBLEM", 116, 130], ["these viruses", "PROBLEM", 151, 164], ["all other mesoniviruses", "TEST", 169, 192], ["viruses", "OBSERVATION", 157, 164]]], ["These viruses could be assigned to the species Alphamesonivirus-2, Alphamesonivirus-3 and Alphamesonivirus-4, respectively.", [["Alphamesonivirus-2", "ORGANISM", 47, 65], ["Alphamesonivirus-3", "ORGANISM", 67, 85], ["Alphamesonivirus-4", "CELL", 90, 108], ["These viruses", "PROBLEM", 0, 13], ["the species", "TEST", 35, 46], ["Alphamesonivirus", "TEST", 47, 63], ["Alphamesonivirus", "TEST", 67, 83], ["Alphamesonivirus", "TEST", 90, 106], ["viruses", "OBSERVATION", 6, 13]]], ["Similarly, novel viruses BBaV, KSaV and KPhV would each also be assigned to separate mesonovirus species: Alphamesonivirus-5, Alphamesonivirus-6 and Alphamesonivirus-7, respectively.", [["BBaV", "GENE_OR_GENE_PRODUCT", 25, 29], ["KSaV", "GENE_OR_GENE_PRODUCT", 31, 35], ["KPhV", "GENE_OR_GENE_PRODUCT", 40, 44], ["Alphamesonivirus-5", "ORGANISM", 106, 124], ["Alphamesonivirus-6", "ORGANISM", 126, 144], ["Alphamesonivirus-7", "ORGANISM", 149, 167], ["BBaV", "PROTEIN", 25, 29], ["KSaV", "PROTEIN", 31, 35], ["KPhV", "PROTEIN", 40, 44], ["KSaV", "SPECIES", 31, 35], ["KPhV", "SPECIES", 40, 44], ["Alphamesonivirus-5", "SPECIES", 106, 124], ["novel viruses BBaV", "PROBLEM", 11, 29], ["Alphamesonivirus", "TEST", 106, 122], ["Alphamesonivirus", "TEST", 126, 142], ["Alphamesonivirus", "TEST", 149, 165], ["viruses", "OBSERVATION", 17, 24]]], ["Strikingly, the vast majority of the genetic diversity that was measured within the genus Mesonivirus was present at the inter-species level (Additional file 1: Figure S1 ).", [["Mesonivirus", "GENE_OR_GENE_PRODUCT", 90, 101], ["vast", "OBSERVATION_MODIFIER", 16, 20], ["majority", "OBSERVATION_MODIFIER", 21, 29], ["genetic diversity", "OBSERVATION", 37, 54], ["genus Mesonivirus", "OBSERVATION", 84, 101]]], ["This pattern strongly supports the assignment of the current diversity of mesoniviruses into seven distinct species.Open reading framesIn mesoniviruses, ORF1a features a 3C-like protease (3CLpro) domain and flanking transmembrane domains, which are highly conserved amongst nidoviruses; these domains were identified in each of the new viruses.", [["mesoniviruses", "CANCER", 74, 87], ["ORF1a", "GENE_OR_GENE_PRODUCT", 153, 158], ["nidoviruses", "CANCER", 274, 285], ["Open reading frames", "DNA", 116, 135], ["ORF1a", "PROTEIN", 153, 158], ["3C-like protease (3CLpro) domain", "PROTEIN", 170, 202], ["flanking transmembrane domains", "PROTEIN", 207, 237], ["mesoniviruses into seven distinct species", "PROBLEM", 74, 115], ["a 3C-like protease (3CLpro) domain", "TREATMENT", 168, 202], ["flanking transmembrane domains", "PROBLEM", 207, 237], ["distinct", "OBSERVATION_MODIFIER", 99, 107], ["species", "OBSERVATION", 108, 115], ["new", "OBSERVATION_MODIFIER", 332, 335], ["viruses", "OBSERVATION", 336, 343]]], ["However, the block nucleotide sequence insertions resulted in a highly variable region near the N-terminus of ORF1a with insertions of various lengths ranging from 13 aa (MenV) to 196 aa (KSaV) (Additional file 2: Figure S2 ).", [["nucleotide", "CHEMICAL", 19, 29], ["nucleotide", "CHEMICAL", 19, 29], ["ORF1a", "GENE_OR_GENE_PRODUCT", 110, 115], ["ORF1a", "DNA", 110, 115], ["the block nucleotide sequence insertions", "TREATMENT", 9, 49], ["a highly variable region", "PROBLEM", 62, 86], ["various lengths", "TEST", 135, 150], ["highly", "OBSERVATION_MODIFIER", 64, 70], ["variable", "OBSERVATION_MODIFIER", 71, 79], ["N-terminus", "ANATOMY_MODIFIER", 96, 106], ["various", "OBSERVATION_MODIFIER", 135, 142], ["lengths", "OBSERVATION_MODIFIER", 143, 150]]], ["The inserted sequences (which apparently are unique to the mesoniviruses) featured variations on a common sequence (SKRKGK) at the terminal points.", [["mesoniviruses", "DNA", 59, 72], ["SKRKGK", "DNA", 116, 122], ["The inserted sequences", "TEST", 0, 22], ["a common sequence", "TEST", 97, 114], ["terminal", "ANATOMY_MODIFIER", 131, 139]]], ["There were also various short stretches of this sequence and other imperfectly repeated sequences within each insertion region suggesting possible origins through recombination or sequence duplication events.", [["insertion region", "DNA", 110, 126], ["this sequence", "TEST", 43, 56], ["other imperfectly repeated sequences", "TEST", 61, 97], ["sequence duplication events", "PROBLEM", 180, 207], ["suggesting possible", "UNCERTAINTY", 127, 146]]], ["As has been reported previously for other mesoniviruses, ORF1a is overlapped by ORF1b which contains highly conserved regions associated with the replicase complex including RNA-dependent RNA polymerase (RdRp), multinucleate zinc-binding module and associated helicase (ZnHel1), exoribonuclease (ExoN), N 7 -methyltransferase (NMT) and 2'-O-methyltransferase (OMT) domains.", [["zinc", "CHEMICAL", 225, 229], ["N", "CHEMICAL", 303, 304], ["ORF1a", "GENE_OR_GENE_PRODUCT", 57, 62], ["ORF1b", "GENE_OR_GENE_PRODUCT", 80, 85], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 174, 202], ["RdRp", "GENE_OR_GENE_PRODUCT", 204, 208], ["ZnHel1", "GENE_OR_GENE_PRODUCT", 270, 276], ["exoribonuclease", "GENE_OR_GENE_PRODUCT", 279, 294], ["N 7 -methyltransferase", "GENE_OR_GENE_PRODUCT", 303, 325], ["NMT", "GENE_OR_GENE_PRODUCT", 327, 330], ["2'-O-methyltransferase", "GENE_OR_GENE_PRODUCT", 336, 358], ["mesoniviruses", "PROTEIN", 42, 55], ["ORF1a", "PROTEIN", 57, 62], ["ORF1b", "PROTEIN", 80, 85], ["replicase complex", "PROTEIN", 146, 163], ["RNA-dependent RNA polymerase", "PROTEIN", 174, 202], ["RdRp", "PROTEIN", 204, 208], ["multinucleate zinc-binding module", "PROTEIN", 211, 244], ["associated helicase", "PROTEIN", 249, 268], ["ZnHel1", "PROTEIN", 270, 276], ["exoribonuclease", "PROTEIN", 279, 294], ["ExoN", "PROTEIN", 296, 300], ["N 7 -methyltransferase (NMT) and 2'-O-methyltransferase (OMT) domains", "PROTEIN", 303, 372], ["the replicase complex", "PROBLEM", 142, 163], ["RNA-dependent RNA polymerase", "PROBLEM", 174, 202], ["multinucleate zinc-binding module", "PROBLEM", 211, 244], ["helicase (ZnHel1)", "TREATMENT", 260, 277], ["exoribonuclease (ExoN), N 7 -methyltransferase (NMT)", "TREATMENT", 279, 331], ["methyltransferase (OMT) domains", "TREATMENT", 341, 372], ["binding module", "OBSERVATION", 230, 244]]], ["The ORF1a/ORF1b overlap includes a putative 'slippery' sequence (GGAUUUU), allowing ORF1b expression as a pp1ab polyprotein through a \u22121 ribosomal frame shift.Open reading framesORF2a encodes the S glycoprotein.", [["ribosomal", "ANATOMY", 137, 146], ["ORF1a", "GENE_OR_GENE_PRODUCT", 4, 9], ["ORF1b", "GENE_OR_GENE_PRODUCT", 10, 15], ["ORF1b", "GENE_OR_GENE_PRODUCT", 84, 89], ["pp1ab", "GENE_OR_GENE_PRODUCT", 106, 111], ["framesORF2a", "GENE_OR_GENE_PRODUCT", 172, 183], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 196, 210], ["ORF1a", "DNA", 4, 9], ["ORF1b", "DNA", 10, 15], ["putative 'slippery' sequence", "DNA", 35, 63], ["GGAUUUU", "DNA", 65, 72], ["ORF1b", "DNA", 84, 89], ["pp1ab polyprotein", "DNA", 106, 123], ["\u22121 ribosomal frame", "DNA", 134, 152], ["framesORF2a", "DNA", 172, 183], ["S glycoprotein", "PROTEIN", 196, 210], ["a putative 'slippery' sequence", "TREATMENT", 33, 63], ["a pp1ab polyprotein", "TREATMENT", 104, 123]]], ["In CavV, the S protein (p77) has been shown to be generated from the fulllength ORF2a polyprotein by internal signalase cleavage at the site 220 NAHC|STRID and is further processed to generate cleavage products S1 (p23) and S2 (p57), each of which is a structural component of virions [5] .", [["CavV", "GENE_OR_GENE_PRODUCT", 3, 7], ["p77", "GENE_OR_GENE_PRODUCT", 24, 27], ["ORF2a", "GENE_OR_GENE_PRODUCT", 80, 85], ["signalase", "GENE_OR_GENE_PRODUCT", 110, 119], ["STRID", "GENE_OR_GENE_PRODUCT", 150, 155], ["S1", "GENE_OR_GENE_PRODUCT", 211, 213], ["p23", "GENE_OR_GENE_PRODUCT", 215, 218], ["S2", "GENE_OR_GENE_PRODUCT", 224, 226], ["p57", "GENE_OR_GENE_PRODUCT", 228, 231], ["CavV", "PROTEIN", 3, 7], ["S protein", "PROTEIN", 13, 22], ["p77", "PROTEIN", 24, 27], ["fulllength ORF2a polyprotein", "PROTEIN", 69, 97], ["STRID", "PROTEIN", 150, 155], ["cleavage products", "PROTEIN", 193, 210], ["S1", "PROTEIN", 211, 213], ["p23", "PROTEIN", 215, 218], ["S2", "PROTEIN", 224, 226], ["p57", "PROTEIN", 228, 231], ["the S protein", "TEST", 9, 22], ["the fulllength ORF2a polyprotein", "TREATMENT", 65, 97], ["internal signalase cleavage", "TREATMENT", 101, 128], ["S2", "ANATOMY", 224, 226], ["virions", "OBSERVATION", 277, 284]]], ["A MUSCLE alignment of all available mesonivirus ORF2a polyprotein sequences (Additional file 3: Figure S3 ) indicated that the signalase cleavage site is relatively variable conforming only to the sequence motif [C/S]|[L/A/S] TRIDL and that the S1-S2 cleavage site (R|WDSSYV) is highly conserved.", [["ORF2a", "GENE_OR_GENE_PRODUCT", 48, 53], ["signalase", "GENE_OR_GENE_PRODUCT", 127, 136], ["S1-S2", "GENE_OR_GENE_PRODUCT", 245, 250], ["R|WDSSYV", "GENE_OR_GENE_PRODUCT", 266, 274], ["mesonivirus ORF2a polyprotein sequences", "DNA", 36, 75], ["signalase cleavage site", "DNA", 127, 150], ["S1-S2 cleavage site", "DNA", 245, 264], ["WDSSYV", "DNA", 268, 274], ["the signalase cleavage site", "PROBLEM", 123, 150], ["the sequence motif [C/S", "TEST", 193, 216], ["A/S", "TEST", 221, 224], ["TRIDL", "TEST", 226, 231], ["MUSCLE", "ANATOMY", 2, 8], ["S1", "ANATOMY", 245, 247], ["S2", "ANATOMY", 248, 250]]], ["The S protein, a class I transmembrane glycoprotein with a C-terminal transmembrane domain, features a set of 12 conserved cysteine residues which are likely to form 6 disulphide bridges, and 7 to 11 potential N-glycosylation sites, only 4 of which are conserved across all mesoniviruses.", [["C", "CHEMICAL", 59, 60], ["cysteine", "CHEMICAL", 123, 131], ["disulphide", "CHEMICAL", 168, 178], ["N", "CHEMICAL", 210, 211], ["cysteine", "AMINO_ACID", 123, 131], ["S protein", "PROTEIN", 4, 13], ["class I transmembrane glycoprotein", "PROTEIN", 17, 51], ["C-terminal transmembrane domain", "PROTEIN", 59, 90], ["N-glycosylation sites", "PROTEIN", 210, 231], ["a C-terminal transmembrane domain", "PROBLEM", 57, 90], ["conserved cysteine residues", "TREATMENT", 113, 140], ["glycosylation sites", "PROBLEM", 212, 231], ["cysteine residues", "OBSERVATION", 123, 140]]], ["Surprisingly, an Nterminal signal peptide is strongly predicted for the MenoV S protein (between amino acids A 20 and S 21 ) but not for those of any of the other mesoniviruses (http:// www.cbs.dtu.dk/services/SignalP).", [["amino acids", "CHEMICAL", 97, 108], ["amino acids", "CHEMICAL", 97, 108], ["MenoV S", "GENE_OR_GENE_PRODUCT", 72, 79], ["amino acids", "AMINO_ACID", 97, 108], ["MenoV S protein", "PROTEIN", 72, 87], ["S 21", "PROTEIN", 118, 122], ["www.cbs.dtu.dk/services/SignalP", "PROTEIN", 186, 217], ["an Nterminal signal peptide", "TEST", 14, 41], ["the MenoV S protein", "TEST", 68, 87], ["amino acids", "TEST", 97, 108]]], ["There is a relatively high level of amino acid sequence conservation in the S1 and S2 proteins (47.2% and 51.7% global identify, respectively).", [["amino acid", "CHEMICAL", 36, 46], ["amino acid", "CHEMICAL", 36, 46], ["amino acid", "AMINO_ACID", 36, 46], ["S1 and S2 proteins", "PROTEIN", 76, 94], ["amino acid sequence conservation", "TREATMENT", 36, 68], ["the S1 and S2 proteins", "TEST", 72, 94], ["relatively", "OBSERVATION_MODIFIER", 11, 21], ["high", "OBSERVATION_MODIFIER", 22, 26], ["S1", "ANATOMY", 76, 78], ["S2", "ANATOMY", 83, 85]]], ["However, the N-terminal product of signalase cleavage of the ORF2a polyprotein displays very low sequence conservation amongst the mesoniviruses (7.4% global identity).", [["N", "CHEMICAL", 13, 14], ["signalase", "GENE_OR_GENE_PRODUCT", 35, 44], ["ORF2a", "GENE_OR_GENE_PRODUCT", 61, 66], ["N-terminal product", "PROTEIN", 13, 31], ["signalase", "PROTEIN", 35, 44], ["ORF2a polyprotein", "PROTEIN", 61, 78], ["the ORF2a polyprotein", "TEST", 57, 78]]], ["This product, which is predicted to be positioned on the inside of the ER membrane (TMHMM server; www.cbs.dtu.dk/services/TMHMM-2.0) has not yet been identified in virions or infected cells.Open reading framesIn each of the mesoniviruses, the precise region of the genome encoding the highly variable N-terminal signalase cleavage product of the ORF2a polyprotein also contains an alternative open reading frame (ORF2b) which has been shown in CavV to encode the putative nucleoprotein p25 [5] .", [["ER membrane", "ANATOMY", 71, 82], ["virions", "ANATOMY", 164, 171], ["cells", "ANATOMY", 184, 189], ["N", "CHEMICAL", 301, 302], ["ER", "GENE_OR_GENE_PRODUCT", 71, 73], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["virions", "CELL", 164, 171], ["cells", "CELL", 184, 189], ["genome", "CELLULAR_COMPONENT", 265, 271], ["ORF2a", "GENE_OR_GENE_PRODUCT", 346, 351], ["ORF2b", "GENE_OR_GENE_PRODUCT", 413, 418], ["CavV", "GENE_OR_GENE_PRODUCT", 444, 448], ["p25", "GENE_OR_GENE_PRODUCT", 486, 489], ["ER", "PROTEIN", 71, 73], ["www.cbs.dtu.dk/services/TMHMM-2.0", "PROTEIN", 98, 131], ["infected cells", "CELL_TYPE", 175, 189], ["Open reading frames", "DNA", 190, 209], ["N-terminal signalase cleavage product", "PROTEIN", 301, 338], ["ORF2a polyprotein", "PROTEIN", 346, 363], ["open reading frame", "DNA", 393, 411], ["ORF2b", "DNA", 413, 418], ["CavV", "PROTEIN", 444, 448], ["putative nucleoprotein p25 [5]", "PROTEIN", 463, 493], ["infected cells", "PROBLEM", 175, 189], ["terminal signalase cleavage product", "TREATMENT", 303, 338], ["the ORF2a polyprotein", "TREATMENT", 342, 363], ["infected cells", "OBSERVATION", 175, 189]]], ["Our analysis indicated that the predicted molecular weights of the unmodified mesonivirus N proteins range from 23.69 kDa (NgeV) to 25.38 kDa (KSaV) and all are highly basic (pI >10).", [["mesonivirus N", "GENE_OR_GENE_PRODUCT", 78, 91], ["mesonivirus N proteins", "PROTEIN", 78, 100], ["23.69 kDa", "PROTEIN", 112, 121], ["NgeV", "PROTEIN", 123, 127], ["KSaV", "PROTEIN", 143, 147], ["Our analysis", "TEST", 0, 12], ["kDa", "TEST", 118, 121], ["kDa", "TEST", 138, 141], ["KSaV", "TEST", 143, 147], ["pI", "TEST", 175, 177]]], ["They display a moderate level of overall sequence conservation (34.1% global identity) due primarily to two highly conserved domains corresponding in KSaV to G 95 to A 176 (64.3% global sequence identity) and L 195 to F 210 (75.0% global sequence identity).Open reading framesThe third coding region, commencing immediately downstream of ORF2a, contains two overlapping long open reading frames (ORF3a and ORF3b) each encoding small hydrophobic proteins (Figure 4) .", [["ORF2a", "GENE_OR_GENE_PRODUCT", 338, 343], ["ORF3a", "GENE_OR_GENE_PRODUCT", 396, 401], ["ORF3b", "GENE_OR_GENE_PRODUCT", 406, 411], ["small hydrophobic proteins", "GENE_OR_GENE_PRODUCT", 427, 453], ["KSaV", "PROTEIN", 150, 154], ["F 210", "DNA", 218, 223], ["Open reading frames", "DNA", 257, 276], ["third coding region", "DNA", 280, 299], ["ORF2a", "DNA", 338, 343], ["long open reading frames", "DNA", 370, 394], ["ORF3a", "DNA", 396, 401], ["ORF3b", "DNA", 406, 411], ["small hydrophobic proteins", "PROTEIN", 427, 453], ["Figure 4", "PROTEIN", 455, 463], ["global sequence identity", "TEST", 179, 203], ["moderate", "OBSERVATION_MODIFIER", 15, 23], ["two", "OBSERVATION_MODIFIER", 354, 357], ["overlapping", "OBSERVATION_MODIFIER", 358, 369], ["long", "OBSERVATION_MODIFIER", 370, 374], ["small", "OBSERVATION_MODIFIER", 427, 432], ["hydrophobic proteins", "OBSERVATION", 433, 453]]], ["A Clustal X alignment of the mesonivirus ORF3a proteins and individual structural analyses using SignalP and TMHMM and NetNGlyc (www.expasy.org) indicated that each is a class I transmembrane glycoprotein with a predicted N-termimal signal peptide, an ectodomain containing a conserved set of 6 cysteine residues and a single conserved N-glycosylation site, a transmembrane domain and a C-terminal cytoplasmic domain ( Figure 4A, 4D) .", [["transmembrane", "ANATOMY", 360, 373], ["cytoplasmic", "ANATOMY", 398, 409], ["cysteine", "CHEMICAL", 295, 303], ["N", "CHEMICAL", 336, 337], ["C", "CHEMICAL", 387, 388], ["ORF3a", "GENE_OR_GENE_PRODUCT", 41, 46], ["cytoplasmic", "ORGANISM_SUBSTANCE", 398, 409], ["mesonivirus ORF3a proteins", "PROTEIN", 29, 55], ["SignalP", "PROTEIN", 97, 104], ["TMHMM", "PROTEIN", 109, 114], ["NetNGlyc", "PROTEIN", 119, 127], ["www.expasy.org", "PROTEIN", 129, 143], ["class I transmembrane glycoprotein", "PROTEIN", 170, 204], ["ectodomain", "PROTEIN", 252, 262], ["N-glycosylation site", "PROTEIN", 336, 356], ["transmembrane domain", "PROTEIN", 360, 380], ["C-terminal cytoplasmic domain", "PROTEIN", 387, 416], ["Figure 4A", "PROTEIN", 419, 428], ["4D", "PROTEIN", 430, 432], ["SignalP", "TEST", 97, 104], ["TMHMM", "TEST", 109, 114], ["an ectodomain", "PROBLEM", 249, 262], ["6 cysteine residues", "TREATMENT", 293, 312], ["a single conserved N-glycosylation site", "PROBLEM", 317, 356], ["a transmembrane domain", "PROBLEM", 358, 380], ["a C-terminal cytoplasmic domain", "TREATMENT", 385, 416], ["Clustal X alignment", "OBSERVATION_MODIFIER", 2, 21]]], ["The cysteine-rich region of the ectodomain displays moderately high sequence conservation including a stretch of 13 totally conserved amino acids adjacent to the transmembrane domain that is unusually rich in large aromatic residues (Y, W, F).", [["transmembrane", "ANATOMY", 162, 175], ["cysteine", "CHEMICAL", 4, 12], ["amino acids", "CHEMICAL", 134, 145], ["cysteine", "CHEMICAL", 4, 12], ["amino acids", "CHEMICAL", 134, 145], ["cysteine", "AMINO_ACID", 4, 12], ["amino acids", "AMINO_ACID", 134, 145], ["transmembrane", "CELLULAR_COMPONENT", 162, 175], ["cysteine-rich region", "PROTEIN", 4, 24], ["ectodomain", "PROTEIN", 32, 42], ["transmembrane domain", "PROTEIN", 162, 182], ["moderately high sequence conservation", "PROBLEM", 52, 89], ["amino acids", "TREATMENT", 134, 145], ["the transmembrane domain", "PROBLEM", 158, 182], ["large aromatic residues", "PROBLEM", 209, 232], ["cysteine", "OBSERVATION", 4, 12], ["rich", "ANATOMY_MODIFIER", 13, 17], ["region", "ANATOMY_MODIFIER", 18, 24], ["moderately", "OBSERVATION_MODIFIER", 52, 62], ["high", "OBSERVATION", 63, 67], ["unusually", "OBSERVATION_MODIFIER", 191, 200], ["rich", "OBSERVATION_MODIFIER", 201, 205], ["large", "OBSERVATION_MODIFIER", 209, 214], ["aromatic residues", "OBSERVATION", 215, 232]]], ["The cytoplasmic domain is highly variable in sequence, except for the completely conserved motif (H/S)YIPLLPR.", [["cytoplasmic", "ANATOMY", 4, 15], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["cytoplasmic domain", "PROTEIN", 4, 22], ["H/S)YIPLLPR", "PROTEIN", 98, 109], ["The cytoplasmic domain", "TEST", 0, 22], ["cytoplasmic domain", "OBSERVATION", 4, 22], ["highly", "OBSERVATION_MODIFIER", 26, 32], ["variable", "OBSERVATION_MODIFIER", 33, 41]]], ["No similar motif has been detected in a search of available eukaryote sequences.", [["eukaryote sequences", "DNA", 60, 79]]], ["The ORF3b proteins are each predicted to be class II transmembrane proteins with an N-terminal cytoplasmic domain, a transmembrane domain and a short Cterminal ectodomain ( Figure 4B, 4D) .", [["cytoplasmic", "ANATOMY", 95, 106], ["transmembrane", "ANATOMY", 117, 130], ["N", "CHEMICAL", 84, 85], ["ORF3b", "GENE_OR_GENE_PRODUCT", 4, 9], ["cytoplasmic", "ORGANISM_SUBSTANCE", 95, 106], ["ORF3b proteins", "PROTEIN", 4, 18], ["class II transmembrane proteins", "PROTEIN", 44, 75], ["N-terminal cytoplasmic domain", "PROTEIN", 84, 113], ["transmembrane domain", "PROTEIN", 117, 137], ["Cterminal ectodomain", "PROTEIN", 150, 170], ["Figure 4B", "PROTEIN", 173, 182], ["4D", "PROTEIN", 184, 186], ["The ORF3b proteins", "TEST", 0, 18], ["class II transmembrane proteins", "PROBLEM", 44, 75], ["an N-terminal cytoplasmic domain", "PROBLEM", 81, 113], ["a transmembrane domain", "PROBLEM", 115, 137], ["a short Cterminal ectodomain", "PROBLEM", 142, 170], ["cytoplasmic domain", "OBSERVATION", 95, 113]]], ["A single Nglycosylation site was predicted in the ectodomain of all the mesoniviruses, except NseV.", [["NseV", "GENE_OR_GENE_PRODUCT", 94, 98], ["Nglycosylation site", "DNA", 9, 28], ["ectodomain", "PROTEIN", 50, 60], ["mesoniviruses", "PROTEIN", 72, 85], ["NseV", "PROTEIN", 94, 98], ["A single Nglycosylation site", "PROBLEM", 0, 28]]], ["The ORF3b proteins display poor overall sequence conservation and have few features that suggest a biological function.Open reading framesThe long 3'-terminal region of all mesoniviruses, except MenoV, contained a small open reading frame, which was previously designated as ORF4.", [["ORF3b", "GENE_OR_GENE_PRODUCT", 4, 9], ["long 3'-terminal region", "CELLULAR_COMPONENT", 142, 165], ["MenoV", "GENE_OR_GENE_PRODUCT", 195, 200], ["ORF4", "GENE_OR_GENE_PRODUCT", 275, 279], ["ORF3b proteins", "PROTEIN", 4, 18], ["Open reading frames", "DNA", 119, 138], ["long 3'-terminal region", "DNA", 142, 165], ["mesoniviruses", "PROTEIN", 173, 186], ["MenoV", "PROTEIN", 195, 200], ["open reading frame", "DNA", 220, 238], ["ORF4", "DNA", 275, 279], ["The ORF3b proteins", "TEST", 0, 18], ["a small open reading frame", "PROBLEM", 212, 238], ["biological function", "OBSERVATION", 99, 118], ["long 3'-", "OBSERVATION_MODIFIER", 142, 150], ["terminal region", "ANATOMY_MODIFIER", 150, 165], ["all mesoniviruses", "ANATOMY", 169, 186], ["small", "OBSERVATION_MODIFIER", 214, 219], ["open", "OBSERVATION", 220, 224]]], ["A Clustal \u00d7 multiple sequence alignment of the putative proteins indicated that, although they varied in size (45 aa to 61 aa), there was a remarkable level of sequence identity, particularly in the N-terminal portion of the protein (Additional file 4: Figure S4 ).", [["N", "CHEMICAL", 199, 200], ["N-terminal portion", "PROTEIN", 199, 217], ["the putative proteins", "TEST", 43, 64], ["size", "OBSERVATION_MODIFIER", 105, 109]]], ["However, there are no obvious structuralcharacteristics that suggest a function and it is not known if these proteins are expressed in infected cells.Various other short ORFs (<150 nt) were detected in the 3'-terminal regions of each mesonivirus but none was obviously conserved.", [["cells", "ANATOMY", 144, 149], ["cells", "CELL", 144, 149], ["infected cells", "CELL_TYPE", 135, 149], ["short ORFs", "DNA", 164, 174], ["3'-terminal regions", "DNA", 206, 225], ["mesonivirus", "DNA", 234, 245], ["obvious structuralcharacteristics", "PROBLEM", 22, 55], ["these proteins", "PROBLEM", 103, 117], ["infected cells", "PROBLEM", 135, 149], ["Various other short ORFs", "PROBLEM", 150, 174], ["no", "UNCERTAINTY", 19, 21], ["obvious", "OBSERVATION_MODIFIER", 22, 29], ["structuralcharacteristics", "OBSERVATION", 30, 55], ["infected cells", "OBSERVATION", 135, 149], ["short", "OBSERVATION_MODIFIER", 164, 169], ["terminal", "ANATOMY_MODIFIER", 209, 217]]], ["Alternative ORFs of >180 nt (i.e., 60 amino acids) were also detected within other ORFs, including in ORF2a in the original strain of NDiV (72 aa) and the Ngewontan (72 aa) and Houston (61 aa) strains, in which the 5' region is missing (Figure 2) .", [["amino acids", "CHEMICAL", 38, 49], ["NDiV", "CHEMICAL", 134, 138], ["amino acids", "CHEMICAL", 38, 49], ["amino acids", "AMINO_ACID", 38, 49], ["ORF2a", "GENE_OR_GENE_PRODUCT", 102, 107], ["ORFs", "DNA", 12, 16], ["ORFs", "DNA", 83, 87], ["ORF2a", "DNA", 102, 107], ["5' region", "DNA", 215, 224], ["Alternative ORFs", "TEST", 0, 16], ["amino acids", "TEST", 38, 49], ["Houston (61 aa) strains", "TREATMENT", 177, 200]]], ["These ORFs share a relatively high degree of nucleotide sequence conservation (92%) but a lower level of amino acid sequence conservation (79%) and no obvious structural characteristics indicate the possible function of the encoded proteins.", [["nucleotide", "CHEMICAL", 45, 55], ["amino acid", "CHEMICAL", 105, 115], ["nucleotide", "CHEMICAL", 45, 55], ["amino acid", "CHEMICAL", 105, 115], ["amino acid", "AMINO_ACID", 105, 115], ["ORFs", "DNA", 6, 10], ["encoded proteins", "PROTEIN", 224, 240], ["These ORFs", "TEST", 0, 10], ["nucleotide sequence conservation", "TREATMENT", 45, 77], ["amino acid sequence conservation", "TEST", 105, 137], ["obvious structural characteristics", "PROBLEM", 151, 185], ["the encoded proteins", "PROBLEM", 220, 240], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["high degree", "OBSERVATION_MODIFIER", 30, 41]]], ["Another short ORF that displayed some degree of sequence conservation was found in the 3' region of ORF1a for all viruses except MenoV and KPhV (Figure 2 ).Transcription regulatory sequencesMesoniviruses have been shown previously to express a 3'-nested set of polyadenylated sub-genomic mRNAs produced by copy-choice mediated leader-body fusion at sites located immediately upstream of alternative transcription regulatory sequence (TRS) elements which occur in the 5'-UTR and in the regions preceding ORF2a/ ORF2b and ORF3a/ORF3b [5] .", [["body", "ANATOMY", 334, 338], ["3' region", "CELLULAR_COMPONENT", 87, 96], ["ORF1a", "GENE_OR_GENE_PRODUCT", 100, 105], ["Mesoniviruses", "GENE_OR_GENE_PRODUCT", 190, 203], ["ORF2a", "GENE_OR_GENE_PRODUCT", 503, 508], ["ORF2b", "GENE_OR_GENE_PRODUCT", 510, 515], ["ORF3a", "GENE_OR_GENE_PRODUCT", 520, 525], ["ORF3b", "GENE_OR_GENE_PRODUCT", 526, 531], ["ORF", "DNA", 14, 17], ["3' region", "DNA", 87, 96], ["ORF1a", "DNA", 100, 105], ["Transcription regulatory sequences", "DNA", 156, 190], ["polyadenylated sub-genomic mRNAs", "RNA", 261, 293], ["alternative transcription regulatory sequence (TRS) elements", "DNA", 387, 447], ["5'-UTR", "DNA", 467, 473], ["ORF2a", "DNA", 503, 508], ["ORF2b", "DNA", 510, 515], ["ORF3a", "DNA", 520, 525], ["ORF3b", "DNA", 526, 531], ["Another short ORF", "PROBLEM", 0, 17], ["ORF1a", "TREATMENT", 100, 105], ["all viruses", "PROBLEM", 110, 121], ["MenoV and KPhV (Figure", "TREATMENT", 129, 151], ["Transcription regulatory sequences", "TEST", 156, 190], ["polyadenylated sub-genomic mRNAs", "PROBLEM", 261, 293], ["body fusion", "TREATMENT", 334, 345], ["viruses", "OBSERVATION", 114, 121]]], ["Each of the previously identified leader-body fusion sites and TRS elements [AUxxUACUACUACUA and AGAx(x)ACUCUCCCA] were completely conserved across all new mesoniviruses examined in this study.Ribosomal frame-shift sitesIn nidoviruses, translation of ORF1b characteristically occurs through a ribosomal frame-shift at a 'slippery' sequence in the ORF1a/ORF1b overlap region to allow read-through synthesis of a polyprotein (pp1ab).", [["ribosomal", "ANATOMY", 293, 302], ["AGAx(x)ACUCUCCCA", "GENE_OR_GENE_PRODUCT", 97, 113], ["mesoniviruses", "CANCER", 156, 169], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 223, 234], ["ORF1b", "GENE_OR_GENE_PRODUCT", 251, 256], ["ribosomal", "CELLULAR_COMPONENT", 293, 302], ["ORF1a", "GENE_OR_GENE_PRODUCT", 347, 352], ["ORF1b", "GENE_OR_GENE_PRODUCT", 353, 358], ["pp1ab", "GENE_OR_GENE_PRODUCT", 424, 429], ["leader-body fusion sites", "DNA", 34, 58], ["TRS elements", "DNA", 63, 75], ["AUxxUACUACUACUA", "DNA", 77, 92], ["AGAx", "DNA", 97, 101], ["mesoniviruses", "DNA", 156, 169], ["Ribosomal frame-shift sites", "DNA", 193, 220], ["ORF1b", "PROTEIN", 251, 256], ["ribosomal frame", "DNA", 293, 308], ["slippery' sequence", "DNA", 321, 339], ["ORF1a/ORF1b overlap region", "DNA", 347, 373], ["pp1ab", "PROTEIN", 424, 429], ["leader-body fusion sites", "TREATMENT", 34, 58], ["AUxxUACUACUACUA and AGAx(x)ACUCUCCCA]", "PROBLEM", 77, 114], ["this study", "TEST", 182, 192], ["Ribosomal frame", "TREATMENT", 193, 208], ["shift sites", "PROBLEM", 209, 220], ["a 'slippery' sequence", "TREATMENT", 318, 339], ["a polyprotein (pp1ab)", "TREATMENT", 409, 430], ["body", "ANATOMY_MODIFIER", 41, 45], ["fusion sites", "OBSERVATION", 46, 58], ["shift sites", "OBSERVATION_MODIFIER", 209, 220]]], ["This is usually facilitated by an RNA pseudoknot in the sequence immediately downstream of the frame-shift site.", [["RNA pseudoknot", "RNA", 34, 48], ["frame-shift site", "DNA", 95, 111], ["an RNA pseudoknot in the sequence", "PROBLEM", 31, 64], ["RNA pseudoknot", "OBSERVATION", 34, 48]]], ["However, a previous analysis of the NDiV sequence failed to identify a predicted pseudoknot structure, suggesting that a stem-loop structure (predicted using pknotsRG; http://bibiserv.techfak.uni-bielefeld.de/pknotsrg/) in the same region of the genome may facilitate the frame-shift [3] .", [["NDiV sequence", "DNA", 36, 49], ["pseudoknot structure", "PROTEIN", 81, 101], ["stem-loop structure", "PROTEIN", 121, 140], ["a previous analysis", "TEST", 9, 28], ["the NDiV sequence", "TEST", 32, 49], ["a predicted pseudoknot structure", "PROBLEM", 69, 101], ["a stem-loop structure", "PROBLEM", 119, 140], ["loop structure", "OBSERVATION", 126, 140]]], ["However, our analysis using pknotsRG of the 13 new mesonivirus sequences and those of CavV, HanaV, NDiV, NseV and MenoV indicated that, although the slippery sequence (GGAUUUU) is completely conserved, the stem-loop structure predicted for NDiV is not predicted as the minimum free energy structure for any of the other viruses.", [["CavV", "GENE_OR_GENE_PRODUCT", 86, 90], ["HanaV", "GENE_OR_GENE_PRODUCT", 92, 97], ["NDiV", "GENE_OR_GENE_PRODUCT", 99, 103], ["NseV", "GENE_OR_GENE_PRODUCT", 105, 109], ["MenoV", "GENE_OR_GENE_PRODUCT", 114, 119], ["NDiV", "GENE_OR_GENE_PRODUCT", 240, 244], ["13 new mesonivirus sequences", "DNA", 44, 72], ["CavV", "PROTEIN", 86, 90], ["HanaV", "PROTEIN", 92, 97], ["NDiV", "PROTEIN", 99, 103], ["NseV", "PROTEIN", 105, 109], ["MenoV", "PROTEIN", 114, 119], ["slippery sequence", "DNA", 149, 166], ["NDiV", "PROTEIN", 240, 244], ["our analysis", "TEST", 9, 21], ["the slippery sequence", "TEST", 145, 166], ["the other viruses", "PROBLEM", 310, 327], ["stem", "ANATOMY", 206, 210], ["viruses", "OBSERVATION", 320, 327]]], ["Indeed, an alignment of the corresponding region of the genome of all mesoniviruses (Additional file 5: Figure S5 ) indicated that there was poor conservation of this sequence and few compensatory mutations that would preserve the stem-loop structure ( Figure 5a ).", [["stem-loop", "ANATOMY", 231, 240], ["this sequence", "TEST", 162, 175], ["few compensatory mutations", "PROBLEM", 180, 206], ["alignment", "OBSERVATION_MODIFIER", 11, 20], ["compensatory mutations", "OBSERVATION", 184, 206], ["stem", "OBSERVATION_MODIFIER", 231, 235]]], ["As functional pseudoknot structures are usually conserved, an alignment of all mesonivirus sequences extending 150 nt from the start of the 'slippery sequence' was analyzed using the IPknot server (http:// rna.naist.jp/ipknot) which predicts the consensus secondary structure from a multiple sequence alignment (by using integer programming to select the maximum expected accuracy (MEA) structure) [10] .", [["mesonivirus sequences", "DNA", 79, 100], ["150 nt", "DNA", 111, 117], ["IPknot server", "DNA", 183, 196], ["rna.naist.jp", "DNA", 206, 218], ["ipknot", "DNA", 219, 225], ["an alignment of all mesonivirus sequences", "TEST", 59, 100], ["the 'slippery sequence'", "TREATMENT", 136, 159], ["the IPknot server", "TEST", 179, 196], ["http:// rna.naist.jp/ipknot)", "TREATMENT", 198, 226], ["a multiple sequence alignment", "TEST", 281, 310], ["secondary structure", "OBSERVATION", 256, 275]]], ["As shown in Figure 5b , the IPknot algorithm predicted a conserved pseudoknot structure, which conformed to all nucleotide substitutions in the available mesoniviruses.Ribosomal frame-shift sitesAnalysis of the region of the ORF3a/ORF3b overlap indicated that it has a similar format to that of the ORF1a/ORF1b overlap region, featuring a long overlap region and potential slippery sequence (CACUUUU) that could result in read-through by a \u22121 ribosomal frameshift.", [["ribosomal", "ANATOMY", 443, 452], ["nucleotide", "CHEMICAL", 112, 122], ["nucleotide", "CHEMICAL", 112, 122], ["ORF3a", "GENE_OR_GENE_PRODUCT", 225, 230], ["ORF3b", "GENE_OR_GENE_PRODUCT", 231, 236], ["ORF1a", "GENE_OR_GENE_PRODUCT", 299, 304], ["ORF1b", "GENE_OR_GENE_PRODUCT", 305, 310], ["IPk", "DNA", 28, 31], ["mesoniviruses", "PROTEIN", 154, 167], ["Ribosomal frame-shift sites", "DNA", 168, 195], ["ORF3a", "DNA", 225, 230], ["ORF3b", "DNA", 231, 236], ["ORF1a/ORF1b overlap region", "DNA", 299, 325], ["long overlap region", "DNA", 339, 358], ["potential slippery sequence", "DNA", 363, 390], ["CACUUUU", "DNA", 392, 399], ["\u22121 ribosomal frameshift", "DNA", 440, 463], ["all nucleotide substitutions", "PROBLEM", 108, 136], ["Ribosomal frame", "TREATMENT", 168, 183], ["shift sites", "PROBLEM", 184, 195], ["the ORF3a/ORF3b overlap", "TEST", 221, 244], ["a long overlap region", "PROBLEM", 337, 358], ["a \u22121 ribosomal frameshift", "PROBLEM", 438, 463], ["shift sites", "OBSERVATION_MODIFIER", 184, 195], ["ribosomal frameshift", "OBSERVATION", 443, 463]]], ["Structural analyses using SignalP and TMHMM and NetNGlyc (www.expasy.org) indicated that a frame-shift at this site would result in a double-membrane-spanning glycoprotein (p3ab) of approximately 30-33 kDa (depending on whether one or two N-glysosylation sites are occupied) with both the N-terminal and C-terminal domains located in the extracellular lumen (Figure 4c, d) .Ribosomal frame-shift sitesA previous analysis of CavV proteins by mass spectrometry identified peptide sequences from proteins migrating in gels at 17, 18 19 and 20 kDa that corresponded to the 3a protein (designated the M protein) and these were considered to be variously glycosylated forms; no protein corresponding to the ORF3b gene product was detected [5] .", [["membrane", "ANATOMY", 141, 149], ["extracellular lumen", "ANATOMY", 338, 357], ["N", "CHEMICAL", 239, 240], ["C", "CHEMICAL", 304, 305], ["p3ab", "GENE_OR_GENE_PRODUCT", 173, 177], ["extracellular lumen", "CELLULAR_COMPONENT", 338, 357], ["CavV", "GENE_OR_GENE_PRODUCT", 424, 428], ["ORF3b", "GENE_OR_GENE_PRODUCT", 701, 706], ["SignalP", "PROTEIN", 26, 33], ["NetNGlyc", "PROTEIN", 48, 56], ["www.expasy.org", "PROTEIN", 58, 72], ["double-membrane-spanning glycoprotein", "PROTEIN", 134, 171], ["p3ab", "PROTEIN", 173, 177], ["N-glysosylation sites", "PROTEIN", 239, 260], ["N-terminal and C-terminal domains", "PROTEIN", 289, 322], ["Ribosomal frame-shift sites", "DNA", 374, 401], ["CavV proteins", "PROTEIN", 424, 437], ["3a protein", "PROTEIN", 569, 579], ["M protein", "PROTEIN", 596, 605], ["ORF3b gene product", "PROTEIN", 701, 719], ["Structural analyses", "TEST", 0, 19], ["SignalP", "TEST", 26, 33], ["TMHMM", "TEST", 38, 43], ["two N-glysosylation sites", "TREATMENT", 235, 260], ["the N-terminal and C-terminal domains", "TREATMENT", 285, 322], ["Ribosomal frame-shift sites", "PROBLEM", 374, 401], ["A previous analysis", "TEST", 401, 420], ["CavV proteins", "PROBLEM", 424, 437], ["mass spectrometry", "TEST", 441, 458], ["peptide sequences", "TEST", 470, 487], ["the 3a protein", "TEST", 565, 579], ["the M protein", "TEST", 592, 605], ["protein", "PROBLEM", 672, 679], ["extracellular", "ANATOMY_MODIFIER", 338, 351], ["lumen", "ANATOMY_MODIFIER", 352, 357]]], ["As for the ORF1a/ORF1b region, analysis of the genome region downstream of the putative ribosomal frame-shift element (RFS) element using pknotsRG identified various potential stem-loops but no commonly predicted minimum free energy structure.", [["ribosomal", "ANATOMY", 88, 97], ["ORF1a", "GENE_OR_GENE_PRODUCT", 11, 16], ["ORF1b", "GENE_OR_GENE_PRODUCT", 17, 22], ["ribosomal", "CELLULAR_COMPONENT", 88, 97], ["ORF1a/ORF1b region", "DNA", 11, 29], ["genome region", "DNA", 47, 60], ["putative ribosomal frame-shift element (RFS) element", "DNA", 79, 131], ["pknotsRG", "DNA", 138, 146], ["the ORF1a/ORF1b region", "TREATMENT", 7, 29], ["analysis", "TEST", 31, 39], ["ribosomal frame", "OBSERVATION", 88, 103], ["potential stem", "OBSERVATION", 166, 180], ["loops", "ANATOMY", 181, 186], ["no", "UNCERTAINTY", 191, 193], ["free", "OBSERVATION_MODIFIER", 221, 225], ["energy structure", "OBSERVATION", 226, 242]]], ["Analysis of a multiple sequence alignment of the region using the IPknot server also failed to predict a convincing pseudoknot structure.Discussion and conclusionsIn this study we have identified 13 mesonivirus isolates and characterized their genome organization and phylogenetic relationships.", [["IPknot server", "DNA", 66, 79], ["a multiple sequence alignment", "TEST", 12, 41], ["this study", "TEST", 166, 176], ["13 mesonivirus isolates", "PROBLEM", 196, 219], ["pseudoknot structure", "OBSERVATION", 116, 136], ["genome organization", "OBSERVATION", 244, 263]]], ["Based on species demarcation criteria employed previously for mesoniviruses [1] , five of these new isolates would be assigned to the same species as NDiV and CavV (Alphamesonivirus-1), other previously described mesoniviruses -HanaV MenoV, and NseV -would be assigned to three new species (Alphamesonivirus-2, Alphamesonivirus-3 and Alphamesonivirus-4, respectively), and eight of the new isolates would represent three new species (Alphamesonivirus-5, Alpha mesonivirus-6 and Alphamesonivirus-7) [6] .", [["NDiV", "GENE_OR_GENE_PRODUCT", 150, 154], ["CavV", "GENE_OR_GENE_PRODUCT", 159, 163], ["Alphamesonivirus-1", "ORGANISM", 165, 183], ["mesoniviruses", "GENE_OR_GENE_PRODUCT", 213, 226], ["MenoV", "GENE_OR_GENE_PRODUCT", 234, 239], ["NseV", "GENE_OR_GENE_PRODUCT", 245, 249], ["Alphamesonivirus-2", "ORGANISM", 291, 309], ["Alphamesonivirus-3", "ORGANISM", 311, 329], ["Alphamesonivirus-4", "ORGANISM", 334, 352], ["Alphamesonivirus-5", "ORGANISM", 434, 452], ["Alpha mesonivirus-6", "ORGANISM", 454, 473], ["Alphamesonivirus-7", "ORGANISM", 478, 496], ["NseV", "PROTEIN", 245, 249], ["NDiV", "SPECIES", 150, 154], ["Alphamesonivirus-1", "SPECIES", 165, 183], ["these new isolates", "TREATMENT", 90, 108], ["CavV (Alphamesonivirus", "TREATMENT", 159, 181], ["NseV", "TREATMENT", 245, 249], ["Alphamesonivirus", "TEST", 291, 307], ["Alphamesonivirus", "TEST", 311, 327], ["Alphamesonivirus", "TEST", 334, 350], ["three new species", "PROBLEM", 415, 432], ["Alphamesonivirus", "TEST", 434, 450], ["Alpha mesonivirus", "TREATMENT", 454, 471], ["Alphamesonivirus", "TEST", 478, 494]]], ["However, we consider this basis for species demarcation, which employs only a genetic standard of pairwise sequence divergence to assign viruses to a species, should be re-evaluated following further assessment of the ecology of these viruses and their potential for genetic recombination which may provide a more informed analysis of suitable species demarcation criteria.Discussion and conclusionsThe isolates of viruses assigned to the species Alphamesonivirus-1 illustrate the wide geographic distribution and mosquito host range of some mesoniviruses.", [["Alphamesonivirus-1", "ORGANISM", 447, 465], ["mesoniviruses", "CANCER", 542, 555], ["Alphamesonivirus-1", "SPECIES", 447, 465], ["species demarcation", "PROBLEM", 36, 55], ["pairwise sequence divergence", "PROBLEM", 98, 126], ["further assessment", "TEST", 192, 210], ["genetic recombination", "TREATMENT", 267, 288], ["The isolates of viruses", "PROBLEM", 399, 422], ["the species Alphamesonivirus", "TREATMENT", 435, 463], ["some mesoniviruses", "TREATMENT", 537, 555], ["viruses", "OBSERVATION", 415, 422], ["wide", "OBSERVATION_MODIFIER", 481, 485], ["geographic", "OBSERVATION_MODIFIER", 486, 496]]], ["The original four isolates of NDiV were made in northern and central Vietnam from Culex vishnui and Cx. tritaeniorhynchus mosquitoes collected indoors during a surveillance program for Japanese encephalitis virus (JEV) [3] .", [["NDiV", "CHEMICAL", 30, 34], ["Japanese encephalitis", "DISEASE", 185, 206], ["JEV", "DISEASE", 214, 217], ["NDiV", "SIMPLE_CHEMICAL", 30, 34], ["Culex vishnui", "ORGANISM", 82, 95], ["Cx. tritaeniorhynchus mosquitoes", "ORGANISM", 100, 132], ["Japanese encephalitis virus", "ORGANISM", 185, 212], ["JEV", "ORGANISM", 214, 217], ["Culex vishnui", "SPECIES", 82, 95], ["Cx. tritaeniorhynchus", "SPECIES", 100, 121], ["Japanese encephalitis virus", "SPECIES", 185, 212], ["NDiV", "SPECIES", 30, 34], ["Culex vishnui", "SPECIES", 82, 95], ["Cx. tritaeniorhynchus", "SPECIES", 100, 121], ["Japanese encephalitis virus", "SPECIES", 185, 212], ["JEV", "SPECIES", 214, 217], ["NDiV", "TREATMENT", 30, 34], ["a surveillance program", "TREATMENT", 158, 180], ["Japanese encephalitis virus", "PROBLEM", 185, 212]]], ["Our NDiV isolate from Java, Indonesia (Ngewontan strain) was also obtained from a pool of Cx. vishnui mosquitoes in 1981.", [["Ngewontan strain", "ORGANISM", 39, 55], ["Cx. vishnui mosquitoes", "ORGANISM", 90, 112], ["Cx. vishnui", "SPECIES", 90, 101], ["Indonesia (Ngewontan strain", "TREATMENT", 28, 55]]], ["The four NDiV isolates from Houston, Texas (Houston strain) were made from Cx. quinquefasciatus and Aedes albopictus collected outdoors within the Houston metropolitan area during West Nile virus (WNV) surveillance in 2004 and 2010, respectively.", [["Cx. quinquefasciatus", "ORGANISM", 75, 95], ["Aedes albopictus", "ORGANISM", 100, 116], ["West Nile virus", "ORGANISM", 180, 195], ["Cx. quinquefasciatus", "SPECIES", 75, 95], ["Aedes albopictus", "SPECIES", 100, 116], ["Nile virus", "SPECIES", 185, 195], ["Cx. quinquefasciatus", "SPECIES", 75, 95], ["Aedes albopictus", "SPECIES", 100, 116], ["West Nile virus", "SPECIES", 180, 195], ["WNV", "SPECIES", 197, 200]]], ["Interestingly, all of these isolates were from mosquitoes captured in or near human dwellings and from species that feed on humans.", [["human", "ORGANISM", 78, 83], ["humans", "ORGANISM", 124, 130], ["human", "SPECIES", 78, 83], ["humans", "SPECIES", 124, 130], ["human", "SPECIES", 78, 83], ["humans", "SPECIES", 124, 130], ["these isolates", "PROBLEM", 22, 36], ["mosquitoes", "PROBLEM", 47, 57]]], ["The close similarity of isolates from Houston and Vietnam may suggest a recent translocation, possibly during the Vietnam conflict when Houston hosted a major air base for embarkation/disembarkation.", [["a recent translocation", "PROBLEM", 70, 92], ["embarkation/disembarkation", "TREATMENT", 172, 198]]], ["Isolates of Kampaeng Phet, Botang Baru and Karang Sari viruses, which may be considered three new mesonivirus species, have a geographic distribution extending at least from central Thailand to Kalimantan and Java in Indonesia, and have been isolated from at least two species of Culex mosquitoes.Discussion and conclusionsAnother consideration is the potential effect of mesonivirus infection on the susceptibility and vector competence of mosquitoes for viral pathogens of vertebrates.", [["infection", "DISEASE", 384, 393], ["Botang Baru", "ORGANISM", 27, 38], ["Karang Sari viruses", "ORGANISM", 43, 62], ["Culex mosquitoes", "ORGANISM", 280, 296], ["mesonivirus", "ORGANISM", 372, 383], ["Culex mosquitoes", "SPECIES", 280, 296], ["Karang Sari viruses", "PROBLEM", 43, 62], ["new mesonivirus species", "PROBLEM", 94, 117], ["mesonivirus infection", "PROBLEM", 372, 393], ["viral pathogens of vertebrates", "PROBLEM", 456, 486], ["Sari viruses", "OBSERVATION", 50, 62], ["infection", "OBSERVATION", 384, 393]]], ["For example, both Cx. vishnui and Cx. tritaeniorhynchus are important vectors of JEV in Asia, and Cx. quinquefasciatus is the major vector of WNV in Houston.", [["JEV", "DISEASE", 81, 84], ["Cx. quinquefasciatus", "DISEASE", 98, 118], ["WNV", "DISEASE", 142, 145], ["Cx. vishnui", "ORGANISM", 18, 29], ["Cx. tritaeniorhynchus", "ORGANISM", 34, 55], ["JEV", "ORGANISM", 81, 84], ["Cx. quinquefasciatus", "ORGANISM", 98, 118], ["WNV", "ORGANISM", 142, 145], ["Cx. tritaeniorhynchus", "SPECIES", 34, 55], ["Cx. quinquefasciatus", "SPECIES", 98, 118], ["Cx. vishnui", "SPECIES", 18, 29], ["Cx. tritaeniorhynchus", "SPECIES", 34, 55], ["JEV", "SPECIES", 81, 84], ["Cx. quinquefasciatus", "SPECIES", 98, 118], ["WNV", "SPECIES", 142, 145], ["WNV", "OBSERVATION", 142, 145]]], ["Recent experimental studies with Ae. aegypti mosquitoes infected with certain strains of the Wolbachia indicate that the presence of the symbiont bacterium interferes with dengue virus replication and decreases .", [["dengue", "DISEASE", 172, 178], ["Ae. aegypti mosquitoes", "ORGANISM", 33, 55], ["dengue virus", "ORGANISM", 172, 184], ["Ae. aegypti", "SPECIES", 33, 44], ["Ae. aegypti", "SPECIES", 33, 44], ["dengue virus", "SPECIES", 172, 184], ["Recent experimental studies", "TEST", 0, 27], ["Ae. aegypti mosquitoes infected", "PROBLEM", 33, 64], ["the Wolbachia", "PROBLEM", 89, 102], ["the symbiont bacterium", "PROBLEM", 133, 155], ["dengue virus replication", "TREATMENT", 172, 196], ["decreases", "OBSERVATION_MODIFIER", 201, 210]]], ["Stem-loop structure predicted previously for NDiV [3] using pseudoknotsRG software, illustrating nucleotides that are substituted in various viruses (red circles).", [["nucleotides", "CHEMICAL", 97, 108], ["pseudoknotsRG", "SIMPLE_CHEMICAL", 60, 73], ["pseudoknotsRG software", "TEST", 60, 82], ["illustrating nucleotides", "PROBLEM", 84, 108]]], ["Nucleotide substitutions (which are primarily non-compensatory) are shown in the boxes.", [["Nucleotide", "CHEMICAL", 0, 10], ["Nucleotide substitutions", "PROBLEM", 0, 24], ["substitutions", "OBSERVATION_MODIFIER", 11, 24]]], ["The corresponding sequence alignment is shown in Additional file 4: Figure S4 .", [["The corresponding sequence alignment", "TEST", 0, 36]]], ["An alternative conserved pseudoknot structure predicted from the multiple sequence alignment using ipknot software.", [["An alternative conserved pseudoknot structure", "PROBLEM", 0, 45], ["pseudoknot structure", "OBSERVATION", 25, 45]]], ["The putative 'slippery' sequence (GGAUUUU) at the ribosomal frame-shift site is shaded in grey. vector competence, possibly by upregulating or priming the mosquito's innate immune system [11, 12] .", [["ribosomal", "ANATOMY", 50, 59], ["ribosomal", "CELLULAR_COMPONENT", 50, 59], ["putative 'slippery' sequence", "DNA", 4, 32], ["GGAUUUU", "DNA", 34, 41], ["ribosomal frame-shift site", "DNA", 50, 76], ["The putative 'slippery' sequence", "TREATMENT", 0, 32], ["ribosomal frame", "OBSERVATION", 50, 65], ["shaded", "OBSERVATION_MODIFIER", 80, 86], ["grey", "OBSERVATION_MODIFIER", 90, 94]]], ["Similar results have been reported for Wolbachia-infected Ae. aegypti and chikungunya virus [11] and with Wolbachia-infected Cx. quinquefaciatus and WNV [13] .", [["chikungunya", "DISEASE", 74, 85], ["Wolbachia-infected", "ORGANISM", 39, 57], ["Ae. aegypti", "ORGANISM", 58, 69], ["chikungunya virus", "ORGANISM", 74, 91], ["Cx. quinquefaciatus", "ORGANISM", 125, 144], ["WNV", "ORGANISM", 149, 152], ["Ae. aegypti", "SPECIES", 58, 69], ["chikungunya virus", "SPECIES", 74, 91], ["Cx. quinquefaciatus", "SPECIES", 125, 144], ["Ae. aegypti", "SPECIES", 58, 69], ["chikungunya virus", "SPECIES", 74, 91], ["Cx. quinquefaciatus", "SPECIES", 125, 144], ["WNV", "SPECIES", 149, 152], ["Wolbachia", "PROBLEM", 39, 48], ["chikungunya virus", "PROBLEM", 74, 91], ["Wolbachia", "PROBLEM", 106, 115]]], ["If a bacterial endosymboint can alter a mosquito's vector competence for arboviruses, it seems plausible that a viral symbiont could have a similar effect [14] .", [["arboviruses", "DISEASE", 73, 84], ["a bacterial endosymboint", "PROBLEM", 3, 27], ["arboviruses", "PROBLEM", 73, 84], ["a viral symbiont", "PROBLEM", 110, 126]]], ["This is an important area for future investigation.Discussion and conclusionsDue to the continuous efforts of the virus discovery program of World Reference Center for Emerging Viruses and Arboviruses (WRCEVA), we have continued to isolate mesoniviruses from various insect vectors collected from widespread geographic locations (e.g., Nepal, Colombia and South Florida) suggesting that these viruses are more common than previously thought.", [["Emerging Viruses", "DISEASE", 168, 184], ["future investigation", "TEST", 30, 50], ["Emerging Viruses", "PROBLEM", 168, 184], ["Arboviruses (WRCEVA)", "TREATMENT", 189, 209], ["various insect vectors", "TREATMENT", 259, 281], ["these viruses", "PROBLEM", 387, 400], ["widespread", "OBSERVATION_MODIFIER", 297, 307], ["geographic", "OBSERVATION_MODIFIER", 308, 318], ["viruses", "OBSERVATION", 393, 400]]], ["Zirkel et al. [4] suggested that these viruses may have their origins in pristine rainforests and emergence may have been facilitated through anthropogenic-induced modifications (e.g., altered land use, deforestation).Discussion and conclusionsThe detailed analysis and comparison of mesonivirus genome architecture conducted here has revealed some unexpected characteristics.", [["mesonivirus genome", "DNA", 284, 302], ["these viruses", "PROBLEM", 33, 46], ["The detailed analysis", "TEST", 244, 265], ["comparison of mesonivirus genome architecture", "TEST", 270, 315], ["viruses", "OBSERVATION", 39, 46], ["pristine rainforests", "OBSERVATION", 73, 93]]], ["Firstly, the presence of block insertions of up to 588 nt in the 5' terminal quadrant of ORF1a of several mesoniviruses has not been reported previously.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 89, 94], ["mesoniviruses", "CANCER", 106, 119], ["ORF1a", "DNA", 89, 94], ["mesoniviruses", "DNA", 106, 119], ["block insertions", "PROBLEM", 25, 41], ["block", "OBSERVATION", 25, 30], ["insertions", "OBSERVATION_MODIFIER", 31, 41], ["terminal", "ANATOMY_MODIFIER", 68, 76], ["quadrant", "ANATOMY_MODIFIER", 77, 85]]], ["The function of this region is presently unknown in mesoniviruses and other nidoviruses and so the structural and functional consequences of these insertions, which contain various imperfect repeats is unclear.", [["mesoniviruses", "CANCER", 52, 65], ["nidoviruses", "CANCER", 76, 87], ["these insertions", "TREATMENT", 141, 157], ["various imperfect repeats", "PROBLEM", 173, 198]]], ["Although sharing similar genome architecture, nidoviruses vary greatly in genome size.", [["nidoviruses", "CANCER", 46, 57], ["genome architecture", "OBSERVATION", 25, 44], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["A previous analysis of the evolution of nidovirus genomes concluded that genome expansion has occurred in a wave-like fashion in which the three major coding regions (ORF1b, ORF1a and the 3'ORFs) expanded consecutively in a hierarchy that reflects the roles of their encoded proteins in the virus replication cycle [15] .", [["nidovirus", "ORGANISM", 40, 49], ["ORF1b", "GENE_OR_GENE_PRODUCT", 167, 172], ["ORF1a", "GENE_OR_GENE_PRODUCT", 174, 179], ["nidovirus genomes", "DNA", 40, 57], ["major coding regions", "DNA", 145, 165], ["ORF1b", "DNA", 167, 172], ["ORF1a", "DNA", 174, 179], ["3'ORFs", "DNA", 188, 194], ["A previous analysis", "TEST", 0, 19], ["nidovirus genomes", "PROBLEM", 40, 57], ["genome expansion", "PROBLEM", 73, 89], ["expansion", "OBSERVATION_MODIFIER", 80, 89]]], ["This implies that nidoviruses have an inherent capacity for genome expansion, most likely associated with the transitional retention of sequences that serve as a resource for the evolution of new functions.", [["nidoviruses", "GENE_OR_GENE_PRODUCT", 18, 29], ["an inherent capacity", "PROBLEM", 35, 55], ["genome expansion", "PROBLEM", 60, 76], ["the transitional retention of sequences", "PROBLEM", 106, 145], ["most likely", "UNCERTAINTY", 78, 89]]], ["The block insertions detected in ORF1a appear to be functionally redundant and their potential role in such evolutionary processes is presently unclear.Discussion and conclusionsThe comparative analysis also revealed that the stemloop structure which had previously been identified at the RFS site of NDiV is not conserved in the other mesoniviruses and so may not be responsible for activating the \u22121 ribosomal frame shift.", [["ribosomal", "ANATOMY", 402, 411], ["ORF1a", "GENE_OR_GENE_PRODUCT", 33, 38], ["NDiV", "GENE_OR_GENE_PRODUCT", 301, 305], ["ORF1a", "DNA", 33, 38], ["RFS site", "DNA", 289, 297], ["NDiV", "PROTEIN", 301, 305], ["\u22121 ribosomal frame", "DNA", 399, 417], ["The block insertions", "TREATMENT", 0, 20], ["The comparative analysis", "TEST", 178, 202], ["the stemloop structure", "PROBLEM", 222, 244], ["block insertions", "OBSERVATION", 4, 20], ["redundant", "OBSERVATION", 65, 74], ["may not be responsible", "UNCERTAINTY", 357, 379], ["ribosomal frame", "OBSERVATION", 402, 417]]], ["Secondary structure predictions using IPknot on the aligned sequences downstream of the conserved 'slippery' sequence site revealed a conserved pseudoknot structure that conformed to all nucleotide substitutions.", [["nucleotide", "CHEMICAL", 187, 197], ["nucleotide", "CHEMICAL", 187, 197], ["IPknot", "DNA", 38, 44], ["conserved 'slippery' sequence site", "DNA", 88, 122], ["Secondary structure predictions", "PROBLEM", 0, 31], ["the conserved 'slippery' sequence site", "TREATMENT", 84, 122], ["a conserved pseudoknot structure", "PROBLEM", 132, 164], ["all nucleotide substitutions", "PROBLEM", 183, 211], ["pseudoknot structure", "OBSERVATION", 144, 164], ["nucleotide substitutions", "OBSERVATION", 187, 211]]], ["However, the predicted structure featured only four relatively short regions of complementarity and no estimations of minimum free energy for the represented structures are available through this algorithm.", [["this algorithm", "TEST", 191, 205], ["four", "OBSERVATION_MODIFIER", 47, 51], ["relatively", "OBSERVATION_MODIFIER", 52, 62], ["short", "OBSERVATION_MODIFIER", 63, 68], ["complementarity", "OBSERVATION", 80, 95], ["no", "UNCERTAINTY", 100, 102]]], ["A possible 'slippery' sequence (CACUUUU) was also detected in the ORF3a/ ORF3b overlap region but no conserved stem-loop or pseudoknot structure was predicted by IPknot in the downstream sequence.", [["ORF3a", "GENE_OR_GENE_PRODUCT", 66, 71], ["ORF3b", "GENE_OR_GENE_PRODUCT", 73, 78], ["slippery' sequence", "DNA", 12, 30], ["ORF3a/ ORF3b overlap region", "DNA", 66, 93], ["IPknot", "PROTEIN", 162, 168], ["downstream sequence", "DNA", 176, 195], ["'slippery' sequence", "TEST", 11, 30], ["conserved stem-loop or pseudoknot structure", "PROBLEM", 101, 144], ["no", "UNCERTAINTY", 98, 100], ["loop", "OBSERVATION", 116, 120], ["pseudoknot structure", "OBSERVATION", 124, 144]]], ["It is, therefore, unclear whether ORF3b is expressed by internal initiation or as a read-through extension of ORF3a, which would generate a double-membrane spanning protein.", [["membrane", "ANATOMY", 147, 155], ["ORF3b", "GENE_OR_GENE_PRODUCT", 34, 39], ["ORF3a", "GENE_OR_GENE_PRODUCT", 110, 115], ["ORF3b", "PROTEIN", 34, 39], ["ORF3a", "PROTEIN", 110, 115], ["double-membrane spanning protein", "PROTEIN", 140, 172], ["a double-membrane spanning protein", "TREATMENT", 138, 172]]], ["Functional analysis of each of the regions corresponding to the RFS in ORF1a/ORF1b and the putative RFS in ORF3a/ORF3b would help resolve the mechanisms of mesonivirus gene expression.Discussion and conclusionsIn conclusion, we have identified and characterized several new mesoniviruses from mosquitoes of human medical importance sampled over time from widespread geographic regions.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 71, 76], ["ORF1b", "GENE_OR_GENE_PRODUCT", 77, 82], ["ORF3a", "GENE_OR_GENE_PRODUCT", 107, 112], ["ORF3b", "GENE_OR_GENE_PRODUCT", 113, 118], ["mesonivirus", "GENE_OR_GENE_PRODUCT", 156, 167], ["human", "ORGANISM", 307, 312], ["RFS", "DNA", 64, 67], ["ORF1a", "DNA", 71, 76], ["ORF1b", "DNA", 77, 82], ["RFS", "DNA", 100, 103], ["ORF3a", "DNA", 107, 112], ["ORF3b", "DNA", 113, 118], ["mesonivirus gene", "DNA", 156, 172], ["human", "SPECIES", 307, 312], ["human", "SPECIES", 307, 312], ["Functional analysis", "TEST", 0, 19], ["the RFS", "TEST", 60, 67], ["ORF1b", "TREATMENT", 77, 82], ["ORF3a/ORF3b", "TREATMENT", 107, 118], ["mesonivirus gene expression", "PROBLEM", 156, 183], ["several", "OBSERVATION_MODIFIER", 262, 269], ["new", "OBSERVATION_MODIFIER", 270, 273], ["mesoniviruses", "OBSERVATION", 274, 287], ["widespread", "OBSERVATION_MODIFIER", 355, 365], ["geographic", "OBSERVATION_MODIFIER", 366, 376]]], ["Several important questions related to their transmission, maintenance in insect hosts in nature, their potential impact of infection on the insect's behavior, fertility, fecundity and survival, their evolution, their mechanisms of gene expression and their potential to be developed as biological control agents, warrant further investigation.Cells and virusesAll viruses used in this study were obtained from the WRCEVA at the University of Texas Medical Branch.", [["Cells", "ANATOMY", 344, 349], ["infection", "DISEASE", 124, 133], ["Cells", "CELL", 344, 349], ["infection", "PROBLEM", 124, 133], ["gene expression", "PROBLEM", 232, 247], ["biological control agents", "TREATMENT", 287, 312], ["further investigation", "TEST", 322, 343], ["viruses", "PROBLEM", 354, 361], ["All viruses", "PROBLEM", 361, 372], ["this study", "TEST", 381, 391], ["infection", "OBSERVATION", 124, 133], ["viruses", "OBSERVATION", 354, 361], ["viruses", "OBSERVATION", 365, 372], ["Branch", "ANATOMY_MODIFIER", 457, 463]]], ["Some were isolated by the authors (RBT and HG), during arbovirus field studies; the remainder were isolated by other investigators and sent to the WRCEVA for identification and further characterization.", [["WRCEVA", "DNA", 147, 153], ["HG", "TEST", 43, 45], ["arbovirus field studies", "TEST", 55, 78], ["further characterization", "TEST", 177, 201]]], ["All isolations were originally made in mosquito cell cultures (C6/36 or AP-61).", [["cell cultures", "ANATOMY", 48, 61], ["mosquito cell cultures", "CELL", 39, 61], ["C6/36", "CELL", 63, 68], ["AP-61", "CELL", 72, 77], ["mosquito cell cultures", "CELL_LINE", 39, 61], ["All isolations", "TREATMENT", 0, 14], ["mosquito cell cultures", "TEST", 39, 61], ["C6", "TEST", 63, 65], ["AP", "TEST", 72, 74]]], ["The proposed names, original sources and geographic origins and GenBank Accession numbers of the sequences obtained for the 13 viruses included in our study are listed below and in Table 1 .Cells and virusesJKT-10701 was isolated from a pool of Culex vishnui mosquitoes collected on 11/26/1981 at Karang Sari, Cilacap (Central Java) Indonesia.", [["Cells", "ANATOMY", 190, 195], ["virusesJKT-10701", "ANATOMY", 200, 216], ["virusesJKT-10701", "CHEMICAL", 200, 216], ["Cells", "CELL", 190, 195], ["virusesJKT-10701", "CELL", 200, 216], ["Culex vishnui mosquitoes", "ORGANISM", 245, 269], ["Culex vishnui", "SPECIES", 245, 258], ["virusesJKT-10701", "SPECIES", 200, 216], ["Culex vishnui", "SPECIES", 245, 258], ["the sequences", "TEST", 93, 106], ["the 13 viruses", "PROBLEM", 120, 134], ["our study", "TEST", 147, 156], ["Cells", "TEST", 190, 195], ["virusesJKT", "TEST", 200, 210]]], ["The initial isolation was made at the Naval Medical Research Unit #2 (NAMRU-2) in Jakarta.Cells and virusesJKT-7774 was isolated at NAMRU-2 from a pool of 50 Culex vishnui collected at Bontag Baru, East Kalimantan, Indonesia in February 1981.", [["Cells", "ANATOMY", 90, 95], ["virusesJKT-7774", "ANATOMY", 100, 115], ["virusesJKT-7774", "CHEMICAL", 100, 115], ["Cells", "CELL", 90, 95], ["virusesJKT-7774", "CELL", 100, 115], ["NAMRU-2", "CELL", 132, 139], ["Culex vishnui", "ORGANISM", 158, 171], ["Culex vishnui", "SPECIES", 158, 171], ["virusesJKT-7774", "SPECIES", 100, 115], ["Culex vishnui", "SPECIES", 158, 171], ["Cells", "TEST", 90, 95], ["virusesJKT", "TEST", 100, 110], ["NAMRU", "TEST", 132, 137]]], ["Strains JKT-9876, JKT-9891 and JKT-9853 were also isolated at NAMRU-2 appear to be almost identical to isolate JKT-7774 in the phylogenetic tree.", [["JKT-9876", "CHEMICAL", 8, 16], ["JKT-9891", "CHEMICAL", 18, 26], ["JKT-9853", "CHEMICAL", 31, 39], ["JKT-7774", "CHEMICAL", 111, 119], ["JKT-9876", "CELL", 8, 16], ["JKT-9891", "CELL", 18, 26], ["JKT-9853", "CELL", 31, 39], ["NAMRU-2", "CELL", 62, 69], ["JKT-7774", "CELL", 111, 119], ["JKT-9876", "SPECIES", 8, 16], ["JKT-9891", "SPECIES", 18, 26], ["JKT-9853", "SPECIES", 31, 39], ["JKT-7774", "SPECIES", 111, 119], ["Strains JKT", "TEST", 0, 11], ["JKT", "TEST", 18, 21], ["JKT", "TEST", 31, 34], ["JKT", "TEST", 111, 114], ["phylogenetic", "ANATOMY_MODIFIER", 127, 139], ["tree", "ANATOMY_MODIFIER", 140, 144]]], ["Since JKT-7774 was the first virus in this group to be isolated, it should be the prototype.Cells and virusesJKT-9876 was isolated at NAMRU-2 from a pool of TVP16740 and TVP16757 -These two viruses were also isolated at UTMB from pools of Aedes albopictus mosquitoes collected in June 2010 as part of the Harris County arbovirus surveillance program in Houston, Texas.Cells and virusesBefore sequencing, all virus stocks were grown in cultures of the C6/36 clone of Ae. albopictus cells [16] , obtained from the American Type Culture Collection (ATCC), Manassas, VA.", [["Cells", "ANATOMY", 92, 97], ["Cells", "ANATOMY", 368, 373], ["cells", "ANATOMY", 481, 486], ["JKT-7774", "CHEMICAL", 6, 14], ["virusesJKT-9876", "CHEMICAL", 102, 117], ["JKT-7774", "CHEMICAL", 6, 14], ["JKT-7774", "GENE_OR_GENE_PRODUCT", 6, 14], ["Cells", "CELL", 92, 97], ["virusesJKT-9876", "CELL", 102, 117], ["NAMRU-2", "CELL", 134, 141], ["TVP16740", "SIMPLE_CHEMICAL", 157, 165], ["TVP16757", "SIMPLE_CHEMICAL", 170, 178], ["Aedes albopictus mosquitoes", "ORGANISM", 239, 266], ["Cells", "CELL", 368, 373], ["Ae.", "ORGANISM", 466, 469], ["albopictus cells", "CELL", 470, 486], ["C6/36 clone", "CELL_LINE", 451, 462], ["Aedes albopictus", "SPECIES", 239, 255], ["JKT-7774", "SPECIES", 6, 14], ["Aedes albopictus", "SPECIES", 239, 255], ["Ae.", "SPECIES", 466, 469], ["albopictus", "SPECIES", 470, 480], ["Manassas", "SPECIES", 553, 561], ["JKT", "TEST", 6, 9], ["the first virus", "PROBLEM", 19, 34], ["Cells", "TEST", 92, 97], ["virusesJKT", "TEST", 102, 112], ["NAMRU", "TEST", 134, 139], ["TVP16740", "TEST", 157, 165], ["TVP16757", "TEST", 170, 178], ["These two viruses", "PROBLEM", 180, 197], ["viruses", "PROBLEM", 378, 385], ["sequencing", "TEST", 392, 402], ["all virus stocks", "PROBLEM", 404, 420], ["cultures", "TEST", 435, 443], ["albopictus cells", "PROBLEM", 470, 486], ["viruses", "OBSERVATION", 378, 385], ["C6", "ANATOMY", 451, 453], ["VA", "ANATOMY", 563, 565]]], ["Infection was characterized by detachment of cells and cell lysis.Transmission electron microscopyFor ultrastructural analysis in ultrathin sections infected cells were fixed for at least 1 hr in a mixture of 2.5% formaldehyde prepared from paraformaldehyde powder, and 0.1% glutaraldehyde in 0.05 M cacodylate buffer pH 7.3 to which 0.03% picric acid and 0.03% CaCl 2 were added.", [["cells", "ANATOMY", 45, 50], ["cell", "ANATOMY", 55, 59], ["sections", "ANATOMY", 140, 148], ["cells", "ANATOMY", 158, 163], ["formaldehyde", "CHEMICAL", 214, 226], ["glutaraldehyde", "CHEMICAL", 275, 289], ["picric acid", "CHEMICAL", 340, 351], ["CaCl 2", "CHEMICAL", 362, 368], ["formaldehyde", "CHEMICAL", 214, 226], ["paraformaldehyde", "CHEMICAL", 241, 257], ["glutaraldehyde", "CHEMICAL", 275, 289], ["cacodylate", "CHEMICAL", 300, 310], ["picric acid", "CHEMICAL", 340, 351], ["CaCl 2", "CHEMICAL", 362, 368], ["cells", "CELL", 45, 50], ["cell", "CELL", 55, 59], ["cells", "CELL", 158, 163], ["formaldehyde", "SIMPLE_CHEMICAL", 214, 226], ["paraformaldehyde", "SIMPLE_CHEMICAL", 241, 257], ["glutaraldehyde", "SIMPLE_CHEMICAL", 275, 289], ["picric acid", "SIMPLE_CHEMICAL", 340, 351], ["CaCl 2", "SIMPLE_CHEMICAL", 362, 368], ["Infection", "PROBLEM", 0, 9], ["detachment of cells", "PROBLEM", 31, 50], ["cell lysis", "TREATMENT", 55, 65], ["Transmission electron microscopy", "TEST", 66, 98], ["ultrastructural analysis", "TEST", 102, 126], ["ultrathin sections infected cells", "TREATMENT", 130, 163], ["paraformaldehyde powder", "TREATMENT", 241, 264], ["cacodylate buffer pH", "TREATMENT", 300, 320], ["picric acid", "TREATMENT", 340, 351], ["detachment", "OBSERVATION", 31, 41], ["cells", "OBSERVATION", 45, 50], ["cell lysis", "OBSERVATION", 55, 65]]], ["The monolayers were washed in 0.1 M cacodylate buffer, cells were scraped off and processed further as a pellet.", [["monolayers", "ANATOMY", 4, 14], ["cells", "ANATOMY", 55, 60], ["cacodylate", "CHEMICAL", 36, 46], ["monolayers", "CELL", 4, 14], ["cells", "CELL", 55, 60], ["cells", "TREATMENT", 55, 60], ["monolayers", "OBSERVATION_MODIFIER", 4, 14]]], ["The pellets were post-fixed in 1% OsO 4 in 0.1 M cacodylate buffer pH 7.3 for 1 h, washed with distilled water and en bloc stained with 2% aqueous uranyl acetate for 20 min at 60\u00b0C. The pellets were dehydrated in ethanol, processed through propylene oxide and embedded in Poly/Bed 812 (Polysciences, Warrington, PA).", [["OsO 4", "CHEMICAL", 34, 39], ["uranyl acetate", "CHEMICAL", 147, 161], ["ethanol", "CHEMICAL", 213, 220], ["propylene oxide", "CHEMICAL", 240, 255], ["Poly/Bed 812", "CHEMICAL", 272, 284], ["OsO 4", "CHEMICAL", 34, 39], ["cacodylate", "CHEMICAL", 49, 59], ["uranyl acetate", "CHEMICAL", 147, 161], ["ethanol", "CHEMICAL", 213, 220], ["propylene oxide", "CHEMICAL", 240, 255], ["Poly/Bed 812", "CHEMICAL", 272, 284], ["aqueous uranyl acetate", "SIMPLE_CHEMICAL", 139, 161], ["ethanol", "SIMPLE_CHEMICAL", 213, 220], ["propylene oxide", "SIMPLE_CHEMICAL", 240, 255], ["Poly/Bed 812", "SIMPLE_CHEMICAL", 272, 284], ["The pellets", "TREATMENT", 0, 11], ["distilled water", "TREATMENT", 95, 110], ["en bloc", "TREATMENT", 115, 122], ["2% aqueous uranyl acetate", "TREATMENT", 136, 161], ["propylene oxide", "TREATMENT", 240, 255], ["embedded in Poly/Bed", "TREATMENT", 260, 280], ["pellets", "OBSERVATION_MODIFIER", 4, 11]]], ["Ultrathin sections were cut on Leica EM UC7 ultramicrotome (Leica Microsystems, Buffalo Grove, IL), stained with lead citrate and examined in a Philips 201 transmission electron microscope at 60 kV.Next generation sequencing Library constructionViral RNA (0.05-1.7 \u03bcg) was fragmented by incubation at 94\u00b0C for 8 min in 19.5 ul of fragmentation buffer (Illumina 15016648).", [["sections", "ANATOMY", 10, 18], ["lead citrate", "CHEMICAL", 113, 125], ["citrate", "CHEMICAL", 118, 125], ["citrate", "SIMPLE_CHEMICAL", 118, 125], ["constructionViral RNA", "RNA", 233, 254], ["Ultrathin sections", "TEST", 0, 18], ["lead citrate", "TREATMENT", 113, 125], ["Next generation sequencing Library constructionViral RNA", "TREATMENT", 198, 254], ["fragmentation", "OBSERVATION", 330, 343]]], ["First and second strand synthesis, adapter ligation and amplification of the library were performed using the Illumina TruSeq RNA Samplec Preparation kit under conditions prescribed by the manufacturer (Illumina).", [["second strand synthesis", "TREATMENT", 10, 33], ["adapter ligation", "TREATMENT", 35, 51], ["the library", "TREATMENT", 73, 84], ["the Illumina TruSeq RNA", "TREATMENT", 106, 129]]], ["Samples were tracked using the \"index tags\" incorporated into the adapters as defined by the manufacturer.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["the \"index tags", "TREATMENT", 27, 42]]]], "cfb03431670da70ab0a1cac08df0d45d8f420ad2": [["BackgroundInterleukin (IL)-35 cytokine is a relatively newly discovered member of IL-12 family which are unique in structure as they are dimer formed by two subunits.", [["Interleukin (IL)-35", "GENE_OR_GENE_PRODUCT", 10, 29], ["IL-12", "GENE_OR_GENE_PRODUCT", 82, 87], ["Interleukin (IL)-35 cytokine", "PROTEIN", 10, 38], ["IL-12 family", "PROTEIN", 82, 94], ["BackgroundInterleukin (IL)", "TREATMENT", 0, 26]]], ["Existing family members (IL-12, \u221223, \u221227) are similar in structure, receptor binding, and downstream signaling pathways that positively or negatively regulate the immune system.", [["immune system", "ANATOMY", 163, 176], ["IL-12", "GENE_OR_GENE_PRODUCT", 25, 30], ["\u2212", "GENE_OR_GENE_PRODUCT", 32, 33], ["\u221227", "GENE_OR_GENE_PRODUCT", 37, 40], ["IL", "PROTEIN", 25, 27], ["receptor binding", "PROBLEM", 68, 84]]], ["IL-35 also strongly inhibits immune function and this review will state the structure and secretion of IL-35, its effect and regulation in B cells and T cells as well as the therapeutic prospects of recombinant IL-35 (rIL-35) and IL-35 regulation role in various diseases.BackgroundInterleukin-35 (IL-35) structure and secretion IL-35 was found by Niedbala [1] and Collison [2] almost simultaneously and it is reported to contain IL-12\u03b1 chain p35 and IL-27\u03b2 chain Epstein-Barr virus-induced gene 3 (Ebi3) connected by disulfide bond.", [["B cells", "ANATOMY", 139, 146], ["T cells", "ANATOMY", 151, 158], ["disulfide", "CHEMICAL", 518, 527], ["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-35", "GENE_OR_GENE_PRODUCT", 103, 108], ["B cells", "CELL", 139, 146], ["T cells", "CELL", 151, 158], ["IL-35", "GENE_OR_GENE_PRODUCT", 211, 216], ["rIL-35", "GENE_OR_GENE_PRODUCT", 218, 224], ["IL-35", "GENE_OR_GENE_PRODUCT", 230, 235], ["Interleukin-35", "GENE_OR_GENE_PRODUCT", 282, 296], ["IL-35", "GENE_OR_GENE_PRODUCT", 298, 303], ["IL-35", "GENE_OR_GENE_PRODUCT", 329, 334], ["Collison [2]", "SIMPLE_CHEMICAL", 365, 377], ["IL-12", "GENE_OR_GENE_PRODUCT", 430, 435], ["p35", "GENE_OR_GENE_PRODUCT", 443, 446], ["IL-27", "GENE_OR_GENE_PRODUCT", 451, 456], ["Epstein-Barr virus", "ORGANISM", 464, 482], ["-induced gene 3", "GENE_OR_GENE_PRODUCT", 482, 497], ["Ebi3", "GENE_OR_GENE_PRODUCT", 499, 503], ["IL-35", "PROTEIN", 0, 5], ["IL-35", "PROTEIN", 103, 108], ["B cells", "CELL_TYPE", 139, 146], ["T cells", "CELL_TYPE", 151, 158], ["Interleukin-35 (IL-35", "PROTEIN", 282, 303], ["IL", "PROTEIN", 329, 331], ["IL", "PROTEIN", 430, 432], ["p35", "PROTEIN", 443, 446], ["induced gene 3", "DNA", 483, 497], ["Ebi3", "DNA", 499, 503], ["IL", "TEST", 0, 2], ["secretion of IL", "TEST", 90, 105], ["regulation in B cells and T cells", "TREATMENT", 125, 158], ["recombinant IL", "TREATMENT", 199, 213], ["IL", "TREATMENT", 230, 232], ["various diseases", "PROBLEM", 255, 271], ["BackgroundInterleukin", "TEST", 272, 293], ["secretion IL", "TEST", 319, 331], ["IL", "TEST", 430, 432], ["IL", "TEST", 451, 453], ["Barr virus", "TREATMENT", 472, 482], ["various diseases", "OBSERVATION", 255, 271]]], ["IL-35, initially named at the 13th International Congress of Immunology, is the new focus of cytokines research.", [["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL", "PROTEIN", 0, 2], ["cytokines", "PROTEIN", 93, 102], ["cytokines research", "TREATMENT", 93, 111], ["new", "OBSERVATION_MODIFIER", 80, 83], ["cytokines", "OBSERVATION", 93, 102]]], ["IL-35 is similar to other IL-12 family members which are heterodimeric glycoproteins formed with disulfide-linked \u03b1 (p19, p28, or p35) and \u03b2 (p40 or EBi3) chains.", [["disulfide", "CHEMICAL", 97, 106], ["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-12", "GENE_OR_GENE_PRODUCT", 26, 31], ["p19", "GENE_OR_GENE_PRODUCT", 117, 120], ["p28", "GENE_OR_GENE_PRODUCT", 122, 125], ["p35", "GENE_OR_GENE_PRODUCT", 130, 133], ["\u03b2", "GENE_OR_GENE_PRODUCT", 139, 140], ["p40", "GENE_OR_GENE_PRODUCT", 142, 145], ["EBi3", "GENE_OR_GENE_PRODUCT", 149, 153], ["IL-35", "PROTEIN", 0, 5], ["IL-12 family members", "PROTEIN", 26, 46], ["heterodimeric glycoproteins", "PROTEIN", 57, 84], ["disulfide-linked \u03b1", "PROTEIN", 97, 115], ["p19", "PROTEIN", 117, 120], ["p28", "PROTEIN", 122, 125], ["p35", "PROTEIN", 130, 133], ["\u03b2 (p40 or EBi3) chains", "PROTEIN", 139, 161]]], ["The \u03b1-chain has 4-\u03b1-helical bundles, a typical cytokine structure, and the \u03b2-chain is homologous to the soluble cytokine receptor. p35 and p40 combine to form IL-12; p19 and p40 combine to form IL-23; p28 and Ebi3 combine to form IL-27 [3] .", [["\u03b1-chain", "SIMPLE_CHEMICAL", 4, 11], ["\u03b2-chain", "GENE_OR_GENE_PRODUCT", 75, 82], ["p35", "GENE_OR_GENE_PRODUCT", 131, 134], ["p40", "GENE_OR_GENE_PRODUCT", 139, 142], ["IL-12", "GENE_OR_GENE_PRODUCT", 159, 164], ["p19", "GENE_OR_GENE_PRODUCT", 166, 169], ["p40", "GENE_OR_GENE_PRODUCT", 174, 177], ["IL-23", "GENE_OR_GENE_PRODUCT", 194, 199], ["p28", "GENE_OR_GENE_PRODUCT", 201, 204], ["Ebi3", "GENE_OR_GENE_PRODUCT", 209, 213], ["IL-27", "GENE_OR_GENE_PRODUCT", 230, 235], ["\u03b1-chain", "PROTEIN", 4, 11], ["cytokine structure", "PROTEIN", 47, 65], ["\u03b2-chain", "PROTEIN", 75, 82], ["soluble cytokine receptor", "PROTEIN", 104, 129], ["p35", "PROTEIN", 131, 134], ["p40", "PROTEIN", 139, 142], ["IL-12", "PROTEIN", 159, 164], ["p19", "PROTEIN", 166, 169], ["p40", "PROTEIN", 174, 177], ["IL-23", "PROTEIN", 194, 199], ["p28", "PROTEIN", 201, 204], ["Ebi3", "PROTEIN", 209, 213], ["IL", "PROTEIN", 230, 232], ["a typical cytokine structure", "PROBLEM", 37, 65], ["the soluble cytokine receptor", "TREATMENT", 100, 129], ["IL", "TEST", 159, 161], ["p19", "TREATMENT", 166, 169], ["IL", "TEST", 194, 196], ["cytokine structure", "OBSERVATION", 47, 65]]], ["IL-35 is composed of p35 and Ebi3, and it differs from the expression and secretion way of other IL-12 members.", [["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["p35", "GENE_OR_GENE_PRODUCT", 21, 24], ["Ebi3", "GENE_OR_GENE_PRODUCT", 29, 33], ["IL-12", "GENE_OR_GENE_PRODUCT", 97, 102], ["IL-35", "PROTEIN", 0, 5], ["p35", "PROTEIN", 21, 24], ["Ebi3", "PROTEIN", 29, 33], ["IL-12 members", "PROTEIN", 97, 110]]], ["In response to bacteria, bacterial products, or intracellular parasites, IL-12, IL-23, and IL-27 are secreted by activated antigenpresenting cells, including B cells, monocyte, macrophages and dendritic cells [4] [5] [6] .", [["intracellular", "ANATOMY", 48, 61], ["antigenpresenting cells", "ANATOMY", 123, 146], ["B cells", "ANATOMY", 158, 165], ["monocyte", "ANATOMY", 167, 175], ["macrophages", "ANATOMY", 177, 188], ["dendritic cells", "ANATOMY", 193, 208], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 61], ["IL-12", "GENE_OR_GENE_PRODUCT", 73, 78], ["IL-23", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-27", "GENE_OR_GENE_PRODUCT", 91, 96], ["antigenpresenting cells", "CELL", 123, 146], ["B cells", "CELL", 158, 165], ["monocyte", "CELL", 167, 175], ["macrophages", "CELL", 177, 188], ["dendritic cells", "CELL", 193, 208], ["IL-27", "PROTEIN", 91, 96], ["antigenpresenting cells", "CELL_TYPE", 123, 146], ["B cells", "CELL_TYPE", 158, 165], ["monocyte", "CELL_TYPE", 167, 175], ["macrophages", "CELL_TYPE", 177, 188], ["dendritic cells", "CELL_TYPE", 193, 208], ["bacteria", "PROBLEM", 15, 23], ["bacterial products", "TEST", 25, 43], ["intracellular parasites", "TEST", 48, 71], ["IL", "TEST", 73, 75], ["IL", "TEST", 80, 82], ["IL", "TEST", 91, 93], ["activated antigenpresenting cells", "TEST", 113, 146], ["B cells", "TEST", 158, 165], ["monocyte", "TEST", 167, 175], ["dendritic cells", "TEST", 193, 208], ["bacterial products", "OBSERVATION", 25, 43], ["dendritic cells", "OBSERVATION", 193, 208]]], ["IL-35 was initially reported to be produced by Treg cells and was essential for maximizing the inhibitory role of Treg cells [2] .", [["Treg cells", "ANATOMY", 47, 57], ["Treg cells", "ANATOMY", 114, 124], ["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["Treg cells", "CELL", 47, 57], ["Treg cells", "CELL", 114, 124], ["IL-35", "PROTEIN", 0, 5], ["Treg cells", "CELL_TYPE", 47, 57], ["Treg cells", "CELL_TYPE", 114, 124], ["IL", "TEST", 0, 2], ["Treg cells", "OBSERVATION", 114, 124]]], ["Recently studies suggest that regulatory B cells (Breg) also produce IL-35 and rIL-35 fusion proteins can induce Breg cells to secret IL-10 and IL-35 [7, 8] .IL-35 receptors and signal transductionPeptide chain sharing is common to the IL-12 family as they bind to receptors to activate signal transducer and activator of transcription (STAT) proteins [9] .", [["regulatory B cells", "ANATOMY", 30, 48], ["Breg", "ANATOMY", 50, 54], ["Breg cells", "ANATOMY", 113, 123], ["B cells", "CELL", 41, 48], ["Breg", "CELL", 50, 54], ["IL-35", "GENE_OR_GENE_PRODUCT", 69, 74], ["rIL-35", "GENE_OR_GENE_PRODUCT", 79, 85], ["Breg cells", "CELL", 113, 123], ["IL-10", "GENE_OR_GENE_PRODUCT", 134, 139], ["IL-35", "GENE_OR_GENE_PRODUCT", 144, 149], [".IL-35 receptors", "GENE_OR_GENE_PRODUCT", 157, 173], ["IL-12", "GENE_OR_GENE_PRODUCT", 236, 241], ["signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 287, 335], ["STAT", "GENE_OR_GENE_PRODUCT", 337, 341], ["regulatory B cells", "CELL_TYPE", 30, 48], ["Breg", "CELL_TYPE", 50, 54], ["IL", "PROTEIN", 69, 71], ["rIL-35 fusion proteins", "PROTEIN", 79, 101], ["Breg cells", "CELL_TYPE", 113, 123], ["IL-10 and IL-35 [7, 8] .IL-35 receptors", "PROTEIN", 134, 173], ["IL-12 family", "PROTEIN", 236, 248], ["signal transducer and activator of transcription (STAT) proteins", "PROTEIN", 287, 351], ["Recently studies", "TEST", 0, 16], ["regulatory B cells", "PROBLEM", 30, 48], ["IL", "TEST", 69, 71], ["rIL-35 fusion proteins", "TREATMENT", 79, 101], ["secret IL", "TEST", 127, 136], ["IL", "TEST", 144, 146], ["signal transduction", "TEST", 178, 197], ["regulatory B cells", "OBSERVATION", 30, 48]]], ["IL-35 is uniquely anti-inflammatory cytokine in contrast to other IL-12 pro-inflammatory cytokines [9] .", [["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-12", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-35", "PROTEIN", 0, 5], ["anti-inflammatory cytokine", "PROTEIN", 18, 44], ["IL", "PROTEIN", 66, 68], ["inflammatory cytokines", "PROTEIN", 76, 98], ["IL", "TREATMENT", 0, 2], ["uniquely anti-inflammatory cytokine in contrast", "TREATMENT", 9, 56], ["other IL", "TEST", 60, 68], ["inflammatory cytokines", "PROBLEM", 76, 98]]], ["This difference is thought to be associated with the receptors and signaling pathways specific to IL-35 and future studies should confirm these assertions.", [["IL-35", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL", "PROTEIN", 98, 100], ["IL", "TEST", 98, 100], ["future studies", "TEST", 108, 122], ["thought to be", "UNCERTAINTY", 19, 32]]], ["An obstacle to understanding the molecular mechanism underlying IL-35 is the lack of clarity about the IL-35 receptor (IL-35R) and its signal transduction pathway [9] .", [["IL-35", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-35 receptor", "GENE_OR_GENE_PRODUCT", 103, 117], ["IL-35R", "GENE_OR_GENE_PRODUCT", 119, 125], ["IL-35", "PROTEIN", 64, 69], ["IL-35 receptor", "PROTEIN", 103, 117], ["IL-35R", "PROTEIN", 119, 125], ["the IL-35 receptor (IL", "TREATMENT", 99, 121]]], ["Collison's group reported that mouse IL-35R differed from traditional cytokine receptors.", [["mouse", "ORGANISM", 31, 36], ["IL-35R", "GENE_OR_GENE_PRODUCT", 37, 43], ["mouse IL-35R", "PROTEIN", 31, 43], ["cytokine receptors", "PROTEIN", 70, 88], ["mouse", "SPECIES", 31, 36], ["mouse", "SPECIES", 31, 36], ["traditional cytokine receptors", "TREATMENT", 58, 88]]], ["IL-35R is composed of dimers which are IL-12R\u03b22 homodimers, gp130 homodimers or IL-IL-12R\u03b22/gp130 heterodimer [6] .", [["IL-35R", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-12R\u03b22", "GENE_OR_GENE_PRODUCT", 39, 47], ["gp130", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL-IL-12R\u03b22", "GENE_OR_GENE_PRODUCT", 80, 91], ["gp130", "GENE_OR_GENE_PRODUCT", 92, 97], ["IL-35R", "PROTEIN", 0, 6], ["IL-12R\u03b22 homodimers", "PROTEIN", 39, 58], ["gp130 homodimers", "PROTEIN", 60, 76], ["IL", "PROTEIN", 80, 82], ["IL", "PROTEIN", 83, 85], ["12R\u03b22", "PROTEIN", 86, 91], ["gp130 heterodimer", "PROTEIN", 92, 109], ["IL", "TREATMENT", 0, 2], ["IL", "TEST", 39, 41], ["IL", "TEST", 80, 82], ["IL", "TEST", 83, 85]]], ["IL-35 binds to IL-35R and initiates signal transduction and exert biological function.", [["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-35R", "GENE_OR_GENE_PRODUCT", 15, 21], ["IL-35", "PROTEIN", 0, 5], ["IL-35R", "PROTEIN", 15, 21], ["IL", "TREATMENT", 0, 2], ["signal transduction", "TEST", 36, 55]]], ["IL-12R\u03b22 or gpl30 homodimer activates STAT4 or STAT1, but only IL-35R in the IL-12R\u03b22/gp130 heterodimer form can induce STAT1-and STAT4-activated signaling pathways to mediate Treg cell function and positively or negatively feedback regulate IL-35 gene expression [2] .", [["Treg cell", "ANATOMY", 176, 185], ["IL-12R\u03b22", "GENE_OR_GENE_PRODUCT", 0, 8], ["gpl30", "GENE_OR_GENE_PRODUCT", 12, 17], ["STAT4", "GENE_OR_GENE_PRODUCT", 38, 43], ["STAT1", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-35R", "GENE_OR_GENE_PRODUCT", 63, 69], ["IL-12R\u03b22", "GENE_OR_GENE_PRODUCT", 77, 85], ["gp130", "GENE_OR_GENE_PRODUCT", 86, 91], ["STAT1", "GENE_OR_GENE_PRODUCT", 120, 125], ["STAT4", "GENE_OR_GENE_PRODUCT", 130, 135], ["Treg cell", "CELL", 176, 185], ["IL-35", "GENE_OR_GENE_PRODUCT", 242, 247], ["IL-12R\u03b22", "PROTEIN", 0, 8], ["gpl30 homodimer", "PROTEIN", 12, 27], ["STAT4", "PROTEIN", 38, 43], ["STAT1", "PROTEIN", 47, 52], ["IL-35R", "PROTEIN", 63, 69], ["IL", "PROTEIN", 77, 79], ["12R\u03b22", "PROTEIN", 80, 85], ["gp130 heterodimer", "PROTEIN", 86, 103], ["STAT1", "PROTEIN", 120, 125], ["STAT4", "PROTEIN", 130, 135], ["IL", "PROTEIN", 242, 244], ["IL", "TREATMENT", 0, 2], ["IL", "TEST", 63, 65], ["STAT1", "TEST", 120, 125], ["IL", "TEST", 242, 244]]], ["IL-35 is reported to activate STAT1 and STAT4 in T cells [7] where IL-35 binds to gp130 and IL-12R\u03b22 receptors [2] , both of which depend on JAK-STAT signaling to introduce intracellular responses.", [["T cells", "ANATOMY", 49, 56], ["intracellular", "ANATOMY", 173, 186], ["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["STAT1", "GENE_OR_GENE_PRODUCT", 30, 35], ["STAT4", "GENE_OR_GENE_PRODUCT", 40, 45], ["T cells", "CELL", 49, 56], ["IL-35", "GENE_OR_GENE_PRODUCT", 67, 72], ["gp130", "GENE_OR_GENE_PRODUCT", 82, 87], ["IL-12R\u03b22 receptors", "GENE_OR_GENE_PRODUCT", 92, 110], ["JAK", "GENE_OR_GENE_PRODUCT", 141, 144], ["STAT", "GENE_OR_GENE_PRODUCT", 145, 149], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 173, 186], ["IL-35", "PROTEIN", 0, 5], ["STAT1", "PROTEIN", 30, 35], ["STAT4", "PROTEIN", 40, 45], ["T cells", "CELL_TYPE", 49, 56], ["IL-35", "PROTEIN", 67, 72], ["gp130 and IL-12R\u03b22 receptors", "PROTEIN", 82, 110], ["JAK", "PROTEIN", 141, 144], ["STAT", "PROTEIN", 145, 149], ["IL", "TEST", 0, 2], ["STAT4 in T cells", "TEST", 40, 56], ["IL", "TEST", 67, 69], ["gp130", "TEST", 82, 87], ["IL", "TEST", 92, 94], ["JAK", "TEST", 141, 144]]], ["However in B cells, IL-35 signaling mediates STAT1 and STAT3 activation through IL-12R\u03b22: IL-27Ra heterodimers [8] (Fig. 1 ).IL-35 regulation and signal transduction in Breg cellsB cells have been traditionally thought to contribute to immune defense by secreting antibodies and antigen presentation but they also have function in immune regulation as Breg cells [10] .", [["B cells", "ANATOMY", 11, 18], ["Breg cellsB cells", "ANATOMY", 169, 186], ["Breg cells", "ANATOMY", 352, 362], ["B cells", "CELL", 11, 18], ["IL-35", "GENE_OR_GENE_PRODUCT", 20, 25], ["STAT1", "GENE_OR_GENE_PRODUCT", 45, 50], ["STAT3", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-12R\u03b22", "GENE_OR_GENE_PRODUCT", 80, 88], ["IL-27Ra", "GENE_OR_GENE_PRODUCT", 90, 97], ["IL-35", "GENE_OR_GENE_PRODUCT", 125, 130], ["Breg cellsB cells", "CELL", 169, 186], ["Breg cells", "CELL", 352, 362], ["B cells", "CELL_TYPE", 11, 18], ["STAT1", "PROTEIN", 45, 50], ["STAT3", "PROTEIN", 55, 60], ["IL", "PROTEIN", 125, 127], ["Breg cellsB cells", "CELL_LINE", 169, 186], ["Breg cells", "CELL_TYPE", 352, 362], ["IL", "TEST", 20, 22], ["STAT3 activation", "TEST", 55, 71], ["IL", "TEST", 80, 82], ["IL", "TEST", 90, 92], ["heterodimers", "TEST", 98, 110], ["IL", "TEST", 125, 127], ["signal transduction in Breg cellsB cells", "PROBLEM", 146, 186], ["immune defense", "PROBLEM", 236, 250], ["secreting antibodies", "TEST", 254, 274], ["antigen presentation", "PROBLEM", 279, 299]]], ["There are multiple B cell subsets which have immune regulation function, such as CD138+ plasma cells [11] , B10 cells (CD1d hi CD5 hi ) [10] , CD21 hi CD23 hi CD24 hi transitional 2-marginal zone precursor cells [12] , and Tim-1 + B cells [13] , but Breg cells do not have a unified determined phenotype.", [["B cell", "ANATOMY", 19, 25], ["CD138+ plasma cells", "ANATOMY", 81, 100], ["B10 cells", "ANATOMY", 108, 117], ["transitional 2-marginal zone precursor cells", "ANATOMY", 167, 211], ["Tim-1 + B cells", "ANATOMY", 223, 238], ["Breg cells", "ANATOMY", 250, 260], ["B cell subsets", "CELL", 19, 33], ["CD138", "GENE_OR_GENE_PRODUCT", 81, 86], ["B10 cells", "CELL", 108, 117], ["CD5", "GENE_OR_GENE_PRODUCT", 127, 130], ["CD21", "GENE_OR_GENE_PRODUCT", 143, 147], ["CD23", "GENE_OR_GENE_PRODUCT", 151, 155], ["CD24", "GENE_OR_GENE_PRODUCT", 159, 163], ["Tim-1", "GENE_OR_GENE_PRODUCT", 223, 228], ["Breg cells", "CELL", 250, 260], ["B cell subsets", "CELL_TYPE", 19, 33], ["CD138", "PROTEIN", 81, 86], ["plasma cells", "CELL_TYPE", 88, 100], ["B10 cells", "CELL_TYPE", 108, 117], ["CD1d", "PROTEIN", 119, 123], ["CD21", "PROTEIN", 143, 147], ["CD23", "PROTEIN", 151, 155], ["CD24", "PROTEIN", 159, 163], ["marginal zone precursor cells", "CELL_TYPE", 182, 211], ["Tim-1 + B cells", "CELL_LINE", 223, 238], ["Breg cells", "CELL_LINE", 250, 260], ["multiple B cell subsets", "PROBLEM", 10, 33], ["immune regulation function", "PROBLEM", 45, 71], ["CD138", "TEST", 81, 86], ["plasma cells", "TEST", 88, 100], ["B10 cells", "TEST", 108, 117], ["CD1d", "TEST", 119, 123], ["hi", "TEST", 131, 133], ["CD21", "TEST", 143, 147], ["CD23", "TEST", 151, 155], ["hi", "TEST", 156, 158], ["CD24", "TEST", 159, 163], ["hi", "TEST", 164, 166], ["transitional", "TEST", 167, 179], ["marginal zone precursor cells", "TEST", 182, 211], ["Tim", "TEST", 223, 226], ["B cells", "TEST", 231, 238], ["Breg cells", "TEST", 250, 260], ["multiple", "OBSERVATION_MODIFIER", 10, 18], ["B cell subsets", "OBSERVATION", 19, 33], ["precursor cells", "OBSERVATION", 196, 211]]], ["It is generally recognized that Breg cells play a role in immunosuppressive function by secreting IL-10 under the stimulation of toll-like receptor (TLR) agonists, CD40L, and IL-21 [14] .IL-35 regulation and signal transduction in Breg cellsFurthermore immunosuppressive pathways of Breg cells may not solely depend on IL-10 [15] as research suggests that Breg cells can produce IL-35 and that rIL-35 can induce Breg cells to secrete IL-10 and IL-35 [7, 8] .", [["Breg cells", "ANATOMY", 32, 42], ["Breg cells", "ANATOMY", 231, 241], ["Breg cells", "ANATOMY", 283, 293], ["Breg cells", "ANATOMY", 356, 366], ["Breg cells", "ANATOMY", 412, 422], ["rIL-35", "CHEMICAL", 394, 400], ["Breg cells", "CELL", 32, 42], ["IL-10", "GENE_OR_GENE_PRODUCT", 98, 103], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 129, 147], ["TLR", "GENE_OR_GENE_PRODUCT", 149, 152], ["CD40L", "GENE_OR_GENE_PRODUCT", 164, 169], ["IL-21", "GENE_OR_GENE_PRODUCT", 175, 180], [".IL-35", "GENE_OR_GENE_PRODUCT", 186, 192], ["Breg cells", "CELL", 231, 241], ["Breg cells", "CELL", 283, 293], ["IL-10", "GENE_OR_GENE_PRODUCT", 319, 324], ["Breg cells", "CELL", 356, 366], ["IL-35", "GENE_OR_GENE_PRODUCT", 379, 384], ["rIL-35", "GENE_OR_GENE_PRODUCT", 394, 400], ["Breg cells", "CELL", 412, 422], ["IL-10", "GENE_OR_GENE_PRODUCT", 434, 439], ["IL-35", "GENE_OR_GENE_PRODUCT", 444, 449], ["Breg cells", "CELL_LINE", 32, 42], ["IL-10", "PROTEIN", 98, 103], ["CD40L", "PROTEIN", 164, 169], ["Breg cells", "CELL_LINE", 231, 241], ["Breg cells", "CELL_TYPE", 283, 293], ["IL", "PROTEIN", 319, 321], ["Breg cells", "CELL_TYPE", 356, 366], ["IL", "PROTEIN", 379, 381], ["rIL-35", "PROTEIN", 394, 400], ["Breg cells", "CELL_TYPE", 412, 422], ["IL", "PROTEIN", 434, 436], ["IL", "PROTEIN", 444, 446], ["immunosuppressive function", "TREATMENT", 58, 84], ["secreting IL", "TREATMENT", 88, 100], ["receptor (TLR) agonists", "TREATMENT", 139, 162], ["CD40L", "TEST", 164, 169], ["IL", "TEST", 175, 177], ["signal transduction in Breg cells", "TREATMENT", 208, 241], ["immunosuppressive pathways of Breg cells", "TREATMENT", 253, 293], ["IL", "TEST", 319, 321], ["Breg cells", "PROBLEM", 356, 366], ["IL", "TEST", 379, 381], ["secrete IL", "TEST", 426, 436], ["IL", "TEST", 444, 446], ["Breg cells", "OBSERVATION", 32, 42]]], ["B-cell-derived IL-35 also acts on T cell-induced Foxp3 + Treg cells [7, 15] (Fig. 2) .", [["B-cell", "ANATOMY", 0, 6], ["T cell", "ANATOMY", 34, 40], ["Foxp3 + Treg cells", "ANATOMY", 49, 67], ["B-cell", "CELL", 0, 6], ["IL-35", "GENE_OR_GENE_PRODUCT", 15, 20], ["T cell", "CELL", 34, 40], ["Foxp3", "GENE_OR_GENE_PRODUCT", 49, 54], ["T cell", "CELL_TYPE", 34, 40], ["Foxp3", "PROTEIN", 49, 54], ["Treg cells", "CELL_TYPE", 57, 67], ["derived IL", "TEST", 7, 17], ["T cell", "TEST", 34, 40], ["Treg cells", "OBSERVATION", 57, 67]]], ["Although rIL-35 inhibits B220 hi B cell proliferation, it selectively induces CD19 + CD5 + B220 lo Breg cell proliferation in vivo [7] .IL-35 regulation and signal transduction in Breg cellsUnlike T cells, inhibition of gp130 (with small interfering RNA [siRNA] or neutralizing antibodies) does not affect IL-35-mediated of B cell proliferation or IL-10 secretion.", [["B220 hi B cell", "ANATOMY", 25, 39], ["CD19 + CD5 + B220 lo Breg cell", "ANATOMY", 78, 108], ["Breg cells", "ANATOMY", 180, 190], ["T cells", "ANATOMY", 197, 204], ["B cell", "ANATOMY", 324, 330], ["rIL-35", "CHEMICAL", 9, 15], ["rIL-35", "CHEMICAL", 9, 15], ["rIL-35", "GENE_OR_GENE_PRODUCT", 9, 15], ["B220", "GENE_OR_GENE_PRODUCT", 25, 29], ["B cell", "CELL", 33, 39], ["CD19", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD5", "GENE_OR_GENE_PRODUCT", 85, 88], ["B220", "GENE_OR_GENE_PRODUCT", 91, 95], [".IL-35", "GENE_OR_GENE_PRODUCT", 135, 141], ["Breg cells", "CELL", 180, 190], ["T cells", "CELL", 197, 204], ["gp130", "GENE_OR_GENE_PRODUCT", 220, 225], ["small interfering RNA", "GENE_OR_GENE_PRODUCT", 232, 253], ["IL-35", "GENE_OR_GENE_PRODUCT", 306, 311], ["B cell", "CELL", 324, 330], ["IL-10", "GENE_OR_GENE_PRODUCT", 348, 353], ["rIL", "PROTEIN", 9, 12], ["B220", "PROTEIN", 25, 29], ["CD19", "PROTEIN", 78, 82], ["CD5", "PROTEIN", 85, 88], ["B220", "PROTEIN", 91, 95], ["Breg cells", "CELL_LINE", 180, 190], ["T cells", "CELL_TYPE", 197, 204], ["gp130", "PROTEIN", 220, 225], ["small interfering RNA", "RNA", 232, 253], ["neutralizing antibodies", "PROTEIN", 265, 288], ["IL-35", "PROTEIN", 306, 311], ["rIL", "TEST", 9, 12], ["CD19", "TEST", 78, 82], ["CD5", "TEST", 85, 88], ["vivo", "TEST", 126, 130], [".IL", "TEST", 135, 138], ["signal transduction in Breg cells", "TREATMENT", 157, 190], ["inhibition of gp130", "PROBLEM", 206, 225], ["small interfering RNA", "PROBLEM", 232, 253], ["neutralizing antibodies", "TEST", 265, 288], ["IL", "TEST", 306, 308], ["B cell proliferation", "PROBLEM", 324, 344], ["cell proliferation", "OBSERVATION", 35, 53], ["Breg cell proliferation", "OBSERVATION", 99, 122], ["Breg cells", "OBSERVATION", 180, 190], ["cell proliferation", "OBSERVATION", 326, 344]]], ["In contrast, silence of IL-12R\u00df2 and IL-27Ra in B cells completely blocks inhibition function of IL-35.", [["B cells", "ANATOMY", 48, 55], ["IL-12R\u00df2", "GENE_OR_GENE_PRODUCT", 24, 32], ["IL-27Ra", "GENE_OR_GENE_PRODUCT", 37, 44], ["B cells", "CELL", 48, 55], ["IL-35", "GENE_OR_GENE_PRODUCT", 97, 102], ["IL-12R\u00df2", "PROTEIN", 24, 32], ["IL-27Ra", "PROTEIN", 37, 44], ["B cells", "CELL_TYPE", 48, 55], ["IL-35", "PROTEIN", 97, 102], ["IL", "TEST", 24, 26], ["IL", "TREATMENT", 37, 39], ["IL", "TEST", 97, 99]]], ["Thus IL-35 may mediate biological activity in different cell types via different receptors and STAT signaling pathways and future studies are required to confirm those [14] .IL-35 regulation and signal transduction in T cellsIL-35 is a novel inhibitory cytokine that may be specifically produced by Treg cells.", [["cell", "ANATOMY", 56, 60], ["Treg cells", "ANATOMY", 299, 309], ["IL-35", "GENE_OR_GENE_PRODUCT", 5, 10], ["cell", "CELL", 56, 60], ["STAT", "GENE_OR_GENE_PRODUCT", 95, 99], [".IL-35", "GENE_OR_GENE_PRODUCT", 173, 179], ["T cellsIL-35", "GENE_OR_GENE_PRODUCT", 218, 230], ["Treg cells", "CELL", 299, 309], ["IL-35", "PROTEIN", 5, 10], ["STAT", "PROTEIN", 95, 99], ["inhibitory cytokine", "PROTEIN", 242, 261], ["Treg cells", "CELL_TYPE", 299, 309], ["T cellsIL-35", "SPECIES", 218, 230], ["IL", "TREATMENT", 5, 7], ["future studies", "TEST", 123, 137], [".IL", "TEST", 173, 176], ["signal transduction in T cellsIL", "TEST", 195, 227], ["a novel inhibitory cytokine", "TREATMENT", 234, 261], ["Treg cells", "OBSERVATION", 299, 309]]], ["It is required for maximal suppressive activity of Treg.", [["Treg", "ANATOMY", 51, 55], ["Treg", "CELL", 51, 55], ["Treg", "CELL_TYPE", 51, 55], ["maximal suppressive activity of Treg", "TREATMENT", 19, 55]]], ["In addition, IL-35 can block the proliferation of Th1 and Th17 cells by limiting early T cell rest on the G1 phase of cell division [16] .", [["Th17 cells", "ANATOMY", 58, 68], ["T cell", "ANATOMY", 87, 93], ["cell", "ANATOMY", 118, 122], ["IL-35", "GENE_OR_GENE_PRODUCT", 13, 18], ["Th1", "CELL", 50, 53], ["Th17 cells", "CELL", 58, 68], ["T cell", "CELL", 87, 93], ["cell", "CELL", 118, 122], ["IL-35", "PROTEIN", 13, 18], ["Th1 and Th17 cells", "CELL_TYPE", 50, 68], ["the proliferation of Th1 and Th17 cells", "PROBLEM", 29, 68], ["Th1", "ANATOMY", 50, 53], ["Th17 cells", "OBSERVATION", 58, 68]]], ["Although IL-35 can inhibit Th1 proliferation, it is resistant to Treg conversion due to the potent inhibition of Ebi3 and p35 transcription by IFN\u03b3 from Th1.", [["Treg", "ANATOMY", 65, 69], ["IL-35", "GENE_OR_GENE_PRODUCT", 9, 14], ["Th1", "CELL", 27, 30], ["Treg", "CELL", 65, 69], ["Ebi3", "GENE_OR_GENE_PRODUCT", 113, 117], ["p35", "GENE_OR_GENE_PRODUCT", 122, 125], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 143, 147], ["Th1", "GENE_OR_GENE_PRODUCT", 153, 156], ["IL-35", "PROTEIN", 9, 14], ["Ebi3", "PROTEIN", 113, 117], ["p35", "PROTEIN", 122, 125], ["IFN\u03b3", "PROTEIN", 143, 147], ["Th1", "CELL_TYPE", 153, 156], ["IL", "TEST", 9, 11], ["Th1 proliferation", "PROBLEM", 27, 44], ["Treg conversion", "TREATMENT", 65, 80], ["Ebi3 and p35 transcription", "TREATMENT", 113, 139], ["Th1 proliferation", "OBSERVATION", 27, 44]]], ["Moreover, IL-35 blocks Th2 development by repressing GATA3 and IL-4 expression and limiting Th2 proliferation.", [["IL-35", "GENE_OR_GENE_PRODUCT", 10, 15], ["Th2", "GENE_OR_GENE_PRODUCT", 23, 26], ["GATA3", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-4", "GENE_OR_GENE_PRODUCT", 63, 67], ["Th2", "GENE_OR_GENE_PRODUCT", 92, 95], ["IL", "PROTEIN", 10, 12], ["GATA3", "PROTEIN", 53, 58], ["IL-35 blocks", "TREATMENT", 10, 22], ["repressing GATA3 and IL", "TREATMENT", 42, 65], ["limiting Th2 proliferation", "PROBLEM", 83, 109], ["Th2 proliferation", "OBSERVATION", 92, 109]]], ["IL-35 can also mediate conversion of Th2 cells to Treg, although this can be blocked by IFN-\u03b3 [17] .IL-35 regulation and signal transduction in T cellsLike TGF-\u03b2 and IL-10, IL-35 can induce the development of an induced regulatory T cell (iTreg) population, iTr35, which suppressed T-cell proliferation via IL-35 [2] . iTreg do not express Foxp3, IL-10, and TGF\u03b2 (Fig. 3) . iTr35 were as effective as nTregs at restoring immune homeostasis and preventing autoimmunity disease in Foxp3 \u2212/\u2212 mice by limiting the proliferation of T cells and so prevented the modeling of EAE and IBD and promoted the proliferation of B16 tumor cells.", [["Th2 cells", "ANATOMY", 37, 46], ["Treg", "ANATOMY", 50, 54], ["regulatory T cell", "ANATOMY", 220, 237], ["T-cell", "ANATOMY", 282, 288], ["Treg", "ANATOMY", 320, 324], ["T cells", "ANATOMY", 527, 534], ["B16 tumor cells", "ANATOMY", 614, 629], ["iTr35", "CHEMICAL", 374, 379], ["autoimmunity", "DISEASE", 455, 467], ["EAE", "DISEASE", 568, 571], ["IBD", "DISEASE", 576, 579], ["tumor", "DISEASE", 618, 623], ["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["Th2 cells", "CELL", 37, 46], ["Treg", "CELL", 50, 54], [".IL-35", "SIMPLE_CHEMICAL", 99, 105], ["T", "CELL", 144, 145], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 156, 161], ["IL-10", "GENE_OR_GENE_PRODUCT", 166, 171], ["IL-35", "GENE_OR_GENE_PRODUCT", 173, 178], ["T cell", "CELL", 231, 237], ["iTreg", "CELL", 239, 244], ["iTr35", "GENE_OR_GENE_PRODUCT", 258, 263], ["T-cell", "CELL", 282, 288], ["IL-35", "GENE_OR_GENE_PRODUCT", 307, 312], ["Treg", "CELL", 320, 324], ["Foxp3", "GENE_OR_GENE_PRODUCT", 340, 345], ["IL-10", "GENE_OR_GENE_PRODUCT", 347, 352], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 358, 362], ["iTr35", "GENE_OR_GENE_PRODUCT", 374, 379], ["Foxp3", "GENE_OR_GENE_PRODUCT", 479, 484], ["T cells", "CELL", 527, 534], ["B16 tumor cells", "CELL", 614, 629], ["IL-35", "PROTEIN", 0, 5], ["Th2 cells", "CELL_TYPE", 37, 46], ["Treg", "CELL_TYPE", 50, 54], ["IFN", "PROTEIN", 88, 91], ["TGF", "PROTEIN", 156, 159], ["IL-35", "PROTEIN", 173, 178], ["regulatory T cell (iTreg) population", "CELL_TYPE", 220, 256], ["iTr35", "PROTEIN", 258, 263], ["IL", "PROTEIN", 307, 309], ["Treg", "CELL_TYPE", 320, 324], ["Foxp3", "PROTEIN", 340, 345], ["IL-10", "PROTEIN", 347, 352], ["TGF\u03b2", "PROTEIN", 358, 362], ["iTr35", "PROTEIN", 374, 379], ["Foxp3", "PROTEIN", 479, 484], ["T cells", "CELL_TYPE", 527, 534], ["B16 tumor cells", "CELL_LINE", 614, 629], ["mice", "SPECIES", 489, 493], ["mice", "SPECIES", 489, 493], ["IL", "TREATMENT", 0, 2], ["Th2 cells", "TREATMENT", 37, 46], ["IFN", "TEST", 88, 91], [".IL", "TEST", 99, 102], ["signal transduction", "TEST", 121, 140], ["TGF", "TEST", 156, 159], ["IL", "TEST", 166, 168], ["IL", "TEST", 307, 309], ["Foxp3", "TEST", 340, 345], ["IL", "TEST", 347, 349], ["autoimmunity disease", "PROBLEM", 455, 475], ["the proliferation of T cells", "PROBLEM", 506, 534], ["EAE", "PROBLEM", 568, 571], ["IBD", "PROBLEM", 576, 579], ["the proliferation of B16 tumor cells", "PROBLEM", 593, 629], ["Th2 cells", "OBSERVATION", 37, 46], ["preventing", "UNCERTAINTY", 444, 454], ["autoimmunity disease", "OBSERVATION", 455, 475], ["IBD", "OBSERVATION", 576, 579], ["proliferation", "OBSERVATION_MODIFIER", 597, 610], ["B16 tumor cells", "OBSERVATION", 614, 629]]], ["Adoptive transfer IL-35 treatment increased the proliferation of Foxp3 + CD39 + CD4 + T cells which secreted IL-10 for autoimmune protection in a collagen-induced arthritis model [18] .", [["Foxp3 + CD39 + CD4 + T cells", "ANATOMY", 65, 93], ["arthritis", "DISEASE", 163, 172], ["IL-35", "GENE_OR_GENE_PRODUCT", 18, 23], ["Foxp3", "GENE_OR_GENE_PRODUCT", 65, 70], ["CD39", "GENE_OR_GENE_PRODUCT", 73, 77], ["IL-10", "GENE_OR_GENE_PRODUCT", 109, 114], ["collagen", "GENE_OR_GENE_PRODUCT", 146, 154], ["Foxp3", "PROTEIN", 65, 70], ["CD39", "PROTEIN", 73, 77], ["CD4", "PROTEIN", 80, 83], ["T cells", "CELL_TYPE", 86, 93], ["IL-10", "PROTEIN", 109, 114], ["collagen", "PROTEIN", 146, 154], ["Adoptive transfer IL", "TREATMENT", 0, 20], ["treatment", "TREATMENT", 24, 33], ["Foxp3", "TEST", 65, 70], ["CD39", "TEST", 73, 77], ["CD4", "TEST", 80, 83], ["T cells", "PROBLEM", 86, 93], ["IL", "TEST", 109, 111], ["autoimmune protection", "TREATMENT", 119, 140], ["a collagen-induced arthritis model", "TREATMENT", 144, 178], ["arthritis", "OBSERVATION", 163, 172]]], ["However, whether the presence of IL-35 can mediate Treg amplification under physiological conditions is still uncertain.IL-35 regulation and signal transduction in T cellsWhile gp130 is fairly ubiquitously expressed, IL-12R\u03b22 is expressed mainly on the surfaces of activated T cells, natural killer cells, B cells, and dendritic cells [19] .", [["T cells", "ANATOMY", 164, 171], ["T cells", "ANATOMY", 275, 282], ["natural killer cells", "ANATOMY", 284, 304], ["B cells", "ANATOMY", 306, 313], ["dendritic cells", "ANATOMY", 319, 334], ["IL-35", "GENE_OR_GENE_PRODUCT", 33, 38], ["Treg", "CELL", 51, 55], ["IL-35", "GENE_OR_GENE_PRODUCT", 120, 125], ["T cells", "CELL", 164, 171], ["gp130", "GENE_OR_GENE_PRODUCT", 177, 182], ["IL-12R\u03b22", "GENE_OR_GENE_PRODUCT", 217, 225], ["T cells", "CELL", 275, 282], ["natural killer cells", "CELL", 284, 304], ["B cells", "CELL", 306, 313], ["dendritic cells", "CELL", 319, 334], ["IL", "PROTEIN", 33, 35], ["IL", "PROTEIN", 120, 122], ["T cells", "CELL_TYPE", 164, 171], ["gp130", "PROTEIN", 177, 182], ["IL-12R\u03b22", "PROTEIN", 217, 225], ["activated T cells", "CELL_TYPE", 265, 282], ["natural killer cells", "CELL_TYPE", 284, 304], ["B cells", "CELL_TYPE", 306, 313], ["dendritic cells", "CELL_TYPE", 319, 334], ["Treg amplification", "TREATMENT", 51, 69], ["IL", "TEST", 120, 122], ["signal transduction in T cells", "TREATMENT", 141, 171], ["IL", "TEST", 217, 219], ["activated T cells", "PROBLEM", 265, 282], ["dendritic cells", "PROBLEM", 319, 334], ["killer cells", "OBSERVATION", 292, 304], ["dendritic cells", "OBSERVATION", 319, 334]]], ["IL-12R\u03b22 is undetectable on most resting T cells, but can be rapidly upregulated by exposure to IL-2, IFN-\u03b3, IL-12, IL-27, and TNF-\u03b1.", [["T cells", "ANATOMY", 41, 48], ["IL-12R\u03b22", "GENE_OR_GENE_PRODUCT", 0, 8], ["T cells", "CELL", 41, 48], ["IL-2", "GENE_OR_GENE_PRODUCT", 96, 100], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 102, 107], ["IL-12", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-27", "GENE_OR_GENE_PRODUCT", 116, 121], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 127, 133], ["IL-12R\u03b22", "PROTEIN", 0, 8], ["resting T cells", "CELL_TYPE", 33, 48], ["IFN", "PROTEIN", 102, 105], ["TNF", "PROTEIN", 127, 130], ["IL", "TEST", 0, 2], ["IL", "TEST", 96, 98], ["IFN", "TEST", 102, 105], ["IL", "TEST", 109, 111], ["IL", "TEST", 116, 118], ["TNF", "TEST", 127, 130]]], ["Indeed, IL-2 or IL-27 pretreatment increases T cell sensitivity to IL-35 mediated suppression [9] .IL-35 regulation and signal transduction in T cellsIL-35 mediates the inhibitory effect on T cells through the signal pathway of STAT1 and STAT4, but also lead to the pro-inflammatory effects by activating the STAT molecule of IFN-\u03b3 and IL-12, in which the key difference is that IL-35 induced STAT1-STAT4 heterodimer formation [20, 21] .Recombinant IL-35Highly purified heterodimeric cytokine IL-35 is difficult to obtain and this is a limitation to immunology research, especially for elucidating the role of this cytokine in autoimmune, infectious diseases and tumor immunity.", [["T cell", "ANATOMY", 45, 51], ["T cellsIL-35", "ANATOMY", 143, 155], ["T cells", "ANATOMY", 190, 197], ["tumor", "ANATOMY", 663, 668], ["autoimmune, infectious diseases", "DISEASE", 627, 658], ["tumor", "DISEASE", 663, 668], ["IL-2", "GENE_OR_GENE_PRODUCT", 8, 12], ["IL-27", "GENE_OR_GENE_PRODUCT", 16, 21], ["T cell", "CELL", 45, 51], ["IL-35", "GENE_OR_GENE_PRODUCT", 67, 72], [".IL-35", "SIMPLE_CHEMICAL", 98, 104], ["T cellsIL-35", "GENE_OR_GENE_PRODUCT", 143, 155], ["T cells", "CELL", 190, 197], ["STAT1", "GENE_OR_GENE_PRODUCT", 228, 233], ["STAT4", "GENE_OR_GENE_PRODUCT", 238, 243], ["STAT", "GENE_OR_GENE_PRODUCT", 309, 313], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 326, 331], ["IL-12", "GENE_OR_GENE_PRODUCT", 336, 341], ["IL-35", "GENE_OR_GENE_PRODUCT", 379, 384], ["STAT1", "GENE_OR_GENE_PRODUCT", 393, 398], ["STAT4", "GENE_OR_GENE_PRODUCT", 399, 404], ["IL-35Highly", "GENE_OR_GENE_PRODUCT", 449, 460], ["IL-35", "GENE_OR_GENE_PRODUCT", 493, 498], ["tumor", "CANCER", 663, 668], ["T cells", "CELL_TYPE", 190, 197], ["STAT1", "PROTEIN", 228, 233], ["STAT4", "PROTEIN", 238, 243], ["STAT molecule", "PROTEIN", 309, 322], ["IFN", "PROTEIN", 326, 329], ["IL-12", "PROTEIN", 336, 341], ["IL-35", "PROTEIN", 379, 384], ["STAT1", "PROTEIN", 393, 398], ["STAT4", "PROTEIN", 399, 404], ["Recombinant IL-35Highly purified heterodimeric cytokine IL-35", "PROTEIN", 437, 498], ["cytokine", "PROTEIN", 615, 623], ["T cellsIL-35", "SPECIES", 143, 155], ["IL", "TREATMENT", 16, 18], ["T cell sensitivity", "TEST", 45, 63], ["IL", "TEST", 67, 69], ["signal transduction in T cellsIL", "TEST", 120, 152], ["T cells", "TREATMENT", 190, 197], ["the pro-inflammatory effects", "PROBLEM", 262, 290], ["IFN", "TEST", 326, 329], ["IL", "TEST", 336, 338], ["IL", "TEST", 379, 381], ["STAT1-STAT4 heterodimer formation", "TREATMENT", 393, 426], ["Recombinant IL", "TEST", 437, 451], ["purified heterodimeric cytokine IL", "TEST", 461, 495], ["infectious diseases", "PROBLEM", 639, 658], ["tumor immunity", "PROBLEM", 663, 677], ["tumor", "OBSERVATION", 663, 668]]], ["Transgenic technology has been applied to infect cells to establish a rIL-35 mouse model in which rIL-35 is a heterodimer of p35 and Ebi3 [7] .", [["cells", "ANATOMY", 49, 54], ["cells", "CELL", 49, 54], ["rIL", "GENE_OR_GENE_PRODUCT", 70, 73], ["mouse", "ORGANISM", 77, 82], ["rIL-35", "GENE_OR_GENE_PRODUCT", 98, 104], ["p35", "GENE_OR_GENE_PRODUCT", 125, 128], ["Ebi3", "GENE_OR_GENE_PRODUCT", 133, 137], ["rIL-35", "PROTEIN", 98, 104], ["p35", "PROTEIN", 125, 128], ["Ebi3", "PROTEIN", 133, 137], ["mouse", "SPECIES", 77, 82], ["Transgenic technology", "TREATMENT", 0, 21], ["a rIL", "TREATMENT", 68, 73]]], ["Similar to IL-27, IL-35 is not secreted as a disulfide-linked heterodimer as Ebi3 associates non-covalently with the IL-12p35 [22] .", [["disulfide", "CHEMICAL", 45, 54], ["IL-27", "GENE_OR_GENE_PRODUCT", 11, 16], ["IL-35", "GENE_OR_GENE_PRODUCT", 18, 23], ["Ebi3", "GENE_OR_GENE_PRODUCT", 77, 81], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 117, 125], ["IL", "PROTEIN", 11, 13], ["IL-35", "PROTEIN", 18, 23], ["disulfide-linked heterodimer", "PROTEIN", 45, 73], ["Ebi3", "PROTEIN", 77, 81], ["IL", "PROTEIN", 117, 119], ["IL", "TEST", 11, 13], ["IL", "TEST", 18, 20], ["the IL", "TREATMENT", 113, 119]]], ["The native Ebi3/p35 heterodimer would be difficultly to isolate in vivo because only about 4% of the secreted Ebi3 co-precipitated with the IL-12p35 in vitro over expression studies in COS7 cells [22] .", [["COS7 cells", "ANATOMY", 185, 195], ["Ebi3", "GENE_OR_GENE_PRODUCT", 11, 15], ["p35", "GENE_OR_GENE_PRODUCT", 16, 19], ["Ebi3", "GENE_OR_GENE_PRODUCT", 110, 114], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 140, 148], ["COS7 cells", "CELL", 185, 195], ["Ebi3", "PROTEIN", 11, 15], ["p35 heterodimer", "PROTEIN", 16, 31], ["Ebi3", "PROTEIN", 110, 114], ["IL-12p35", "PROTEIN", 140, 148], ["COS7 cells", "CELL_LINE", 185, 195], ["The native Ebi3/p35 heterodimer", "TREATMENT", 0, 31], ["the IL", "TREATMENT", 136, 142]]], ["Meanwhile, as the absence of IL-12p35 substantial amount of the Ebi3 degraded in the ER (endoplasmic reticulum), thereby reducing the bioavailability of ebi3.", [["ER", "ANATOMY", 85, 87], ["endoplasmic reticulum", "ANATOMY", 89, 110], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 29, 37], ["Ebi3", "GENE_OR_GENE_PRODUCT", 64, 68], ["ER", "GENE_OR_GENE_PRODUCT", 85, 87], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 89, 110], ["ebi3", "GENE_OR_GENE_PRODUCT", 153, 157], ["IL-12p35", "PROTEIN", 29, 37], ["Ebi3", "PROTEIN", 64, 68], ["ER", "PROTEIN", 85, 87], ["ebi3", "PROTEIN", 153, 157], ["IL", "TEST", 29, 31]]], ["These contribute to the low levels of IL-35 in vivo [23] .", [["IL-35", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL", "PROTEIN", 38, 40], ["the low levels of IL", "PROBLEM", 20, 40], ["low", "OBSERVATION_MODIFIER", 24, 27]]], ["Others generated recombinant mouse IL-35 (rIL-35) using a bicistronic vector containing IRES (internal ribosomal entry site) that allowed stoichio etric expression of the Ebi3 and IL-12p35 [2] .", [["ribosomal", "ANATOMY", 103, 112], ["mouse", "ORGANISM", 29, 34], ["IL-35", "GENE_OR_GENE_PRODUCT", 35, 40], ["rIL-35", "GENE_OR_GENE_PRODUCT", 42, 48], ["ribosomal", "CELLULAR_COMPONENT", 103, 112], ["Ebi3", "GENE_OR_GENE_PRODUCT", 171, 175], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 180, 188], ["recombinant mouse IL-35", "PROTEIN", 17, 40], ["rIL", "PROTEIN", 42, 45], ["bicistronic vector", "DNA", 58, 76], ["IRES", "DNA", 88, 92], ["internal ribosomal entry site", "DNA", 94, 123], ["Ebi3", "PROTEIN", 171, 175], ["IL", "PROTEIN", 180, 182], ["mouse", "SPECIES", 29, 34], ["mouse", "SPECIES", 29, 34], ["recombinant mouse IL", "TREATMENT", 17, 37], ["a bicistronic vector", "TREATMENT", 56, 76], ["IRES (internal ribosomal entry site", "TREATMENT", 88, 123]]], ["Another approach that has been used is to construct a heterodimeric protein covalently linking Ebi3 and IL-12p35 [24] .IL-35regulation in various diseases(1) IL-35 and autoimmune diseases.IL-35regulation in various diseasesEarly studies mainly used a model of p35 or ebi3 deficient mice.", [["autoimmune diseases", "DISEASE", 168, 187], ["Ebi3", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 104, 112], ["IL-35regulation", "GENE_OR_GENE_PRODUCT", 119, 134], ["IL-35", "GENE_OR_GENE_PRODUCT", 158, 163], ["IL-35regulation", "GENE_OR_GENE_PRODUCT", 188, 203], ["p35", "GENE_OR_GENE_PRODUCT", 260, 263], ["ebi3", "GENE_OR_GENE_PRODUCT", 267, 271], ["mice", "ORGANISM", 282, 286], ["heterodimeric protein", "PROTEIN", 54, 75], ["Ebi3", "PROTEIN", 95, 99], ["IL", "PROTEIN", 104, 106], ["IL", "PROTEIN", 119, 121], ["IL", "PROTEIN", 188, 190], ["p35", "PROTEIN", 260, 263], ["ebi3", "PROTEIN", 267, 271], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 282, 286], ["IL", "TREATMENT", 119, 121], ["various diseases", "PROBLEM", 138, 154], ["IL", "TEST", 158, 160], ["autoimmune diseases", "PROBLEM", 168, 187], ["IL", "TREATMENT", 188, 190], ["various diseases", "PROBLEM", 207, 223], ["Early studies", "TEST", 223, 236], ["a model of p35", "TREATMENT", 249, 263], ["various", "OBSERVATION_MODIFIER", 138, 145], ["diseases", "OBSERVATION", 146, 154], ["autoimmune diseases", "OBSERVATION", 168, 187], ["various diseases", "OBSERVATION", 207, 223]]], ["However, the absence of IL-12\u03b1 affects the function of IL-12 as well as that of IL-27 and IL-35.", [["IL-12\u03b1", "GENE_OR_GENE_PRODUCT", 24, 30], ["IL-12", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-27", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-35", "GENE_OR_GENE_PRODUCT", 90, 95], ["IL-12\u03b1", "PROTEIN", 24, 30], ["IL-12", "PROTEIN", 55, 60], ["IL-27", "PROTEIN", 80, 85], ["IL", "PROTEIN", 90, 92], ["IL", "TREATMENT", 24, 26], ["IL", "TEST", 80, 82], ["IL", "TEST", 90, 92]]], ["Despite these complexities, Ebi3\u2212/\u2212 and Il-12a\u2212/\u2212 mice model also provide the proof that IL-35 have immune suppressive function in some autoimmune diseases such as experimental autoimmune uveitis (EAU) [7] , experimental allergic encephalomyelitis (EAE) [2] , collagen-induced arthritis (CIA) [25] , encephalitis [26] , and other conditions.", [["autoimmune diseases", "DISEASE", 136, 155], ["autoimmune uveitis", "DISEASE", 177, 195], ["EAU", "DISEASE", 197, 200], ["allergic encephalomyelitis", "DISEASE", 221, 247], ["EAE", "DISEASE", 249, 252], ["arthritis", "DISEASE", 277, 286], ["CIA", "DISEASE", 288, 291], ["encephalitis", "DISEASE", 300, 312], ["Ebi3", "GENE_OR_GENE_PRODUCT", 28, 32], ["\u2212", "GENE_OR_GENE_PRODUCT", 34, 35], ["Il-12a\u2212", "GENE_OR_GENE_PRODUCT", 40, 47], ["IL-35", "GENE_OR_GENE_PRODUCT", 89, 94], ["collagen", "GENE_OR_GENE_PRODUCT", 260, 268], ["Ebi3", "PROTEIN", 28, 32], ["IL-35", "PROTEIN", 89, 94], ["collagen", "PROTEIN", 260, 268], ["mice", "SPECIES", 50, 54], ["Ebi3", "TEST", 28, 32], ["Il", "TREATMENT", 40, 42], ["immune suppressive function", "PROBLEM", 100, 127], ["some autoimmune diseases", "PROBLEM", 131, 155], ["experimental autoimmune uveitis", "PROBLEM", 164, 195], ["experimental allergic encephalomyelitis", "PROBLEM", 208, 247], ["collagen-induced arthritis (CIA)", "PROBLEM", 260, 292], ["encephalitis", "PROBLEM", 300, 312], ["autoimmune diseases", "OBSERVATION", 136, 155], ["autoimmune uveitis", "OBSERVATION", 177, 195], ["allergic encephalomyelitis", "OBSERVATION", 221, 247], ["arthritis", "OBSERVATION", 277, 286]]], ["That IL-35 fusion protein obtained from genetic engineering produced data consistent with the knockout model results and studies indicates that injection of rIL-35 can be used to protect against allergic airway model [27] as well as colitis [20] and autoimmune diabetes [28] .", [["airway", "ANATOMY", 204, 210], ["rIL-35", "CHEMICAL", 157, 163], ["allergic airway", "DISEASE", 195, 210], ["colitis", "DISEASE", 233, 240], ["autoimmune diabetes", "DISEASE", 250, 269], ["rIL-35", "CHEMICAL", 157, 163], ["IL-35", "GENE_OR_GENE_PRODUCT", 5, 10], ["rIL-35", "GENE_OR_GENE_PRODUCT", 157, 163], ["airway", "MULTI-TISSUE_STRUCTURE", 204, 210], ["IL-35 fusion protein", "PROTEIN", 5, 25], ["rIL", "PROTEIN", 157, 160], ["That IL", "TREATMENT", 0, 7], ["fusion protein", "TEST", 11, 25], ["studies", "TEST", 121, 128], ["injection of rIL", "TREATMENT", 144, 160], ["allergic airway model", "PROBLEM", 195, 216], ["colitis", "PROBLEM", 233, 240], ["autoimmune diabetes", "PROBLEM", 250, 269], ["colitis", "OBSERVATION", 233, 240]]], ["Studies show that IL-35 regulates immune function via T cells in many diseases.", [["T cells", "ANATOMY", 54, 61], ["IL-35", "GENE_OR_GENE_PRODUCT", 18, 23], ["T cells", "CELL", 54, 61], ["IL-35", "PROTEIN", 18, 23], ["T cells", "CELL_TYPE", 54, 61], ["Studies", "TEST", 0, 7], ["IL", "TEST", 18, 20], ["many diseases", "PROBLEM", 65, 78], ["many", "OBSERVATION_MODIFIER", 65, 69], ["diseases", "OBSERVATION", 70, 78]]], ["In NOD transgenic mice, infusion of IL-35 over expressing islet cells significantly alleviated symptoms of diabetes and local inflammatory responses, reduced the number of effector CD4 + and CD8 + T cells in pancreatic islet tissue, inhibited infiltration of T cells from transitioning from G1 to S phases, and decreased effector T cells proliferation [28] .", [["islet cells", "ANATOMY", 58, 69], ["effector CD4 + and CD8 + T cells", "ANATOMY", 172, 204], ["pancreatic islet tissue", "ANATOMY", 208, 231], ["T cells", "ANATOMY", 259, 266], ["effector T cells", "ANATOMY", 321, 337], ["diabetes", "DISEASE", 107, 115], ["NOD transgenic mice", "ORGANISM", 3, 22], ["IL-35", "GENE_OR_GENE_PRODUCT", 36, 41], ["islet cells", "CELL", 58, 69], ["CD4", "GENE_OR_GENE_PRODUCT", 181, 184], ["CD8", "GENE_OR_GENE_PRODUCT", 191, 194], ["pancreatic islet tissue", "TISSUE", 208, 231], ["T cells", "CELL", 259, 266], ["effector T cells", "CELL", 321, 337], ["IL-35", "PROTEIN", 36, 41], ["expressing islet cells", "CELL_TYPE", 47, 69], ["effector CD4 + and CD8 + T cells", "CELL_TYPE", 172, 204], ["T cells", "CELL_TYPE", 259, 266], ["effector T cells", "CELL_TYPE", 321, 337], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["infusion of IL", "TREATMENT", 24, 38], ["significantly alleviated symptoms", "PROBLEM", 70, 103], ["diabetes", "PROBLEM", 107, 115], ["local inflammatory responses", "PROBLEM", 120, 148], ["effector CD4", "TEST", 172, 184], ["CD8 + T cells in pancreatic islet tissue", "PROBLEM", 191, 231], ["infiltration of T cells", "PROBLEM", 243, 266], ["decreased effector T cells proliferation", "PROBLEM", 311, 351], ["diabetes", "OBSERVATION", 107, 115], ["inflammatory", "OBSERVATION_MODIFIER", 126, 138], ["pancreatic", "ANATOMY", 208, 218], ["islet tissue", "OBSERVATION", 219, 231], ["infiltration", "OBSERVATION_MODIFIER", 243, 255], ["T cells", "OBSERVATION", 259, 266], ["decreased", "OBSERVATION_MODIFIER", 311, 320], ["effector T cells proliferation", "OBSERVATION", 321, 351]]], ["In a type II CIA model, infusion of rIL-35 reduced local inflammatory responses by inhibiting Th17 cell differentiation.", [["Th17 cell", "ANATOMY", 94, 103], ["rIL-35", "CHEMICAL", 36, 42], ["rIL-35", "CHEMICAL", 36, 42], ["rIL-35", "SIMPLE_CHEMICAL", 36, 42], ["Th17 cell", "CELL", 94, 103], ["rIL", "PROTEIN", 36, 39], ["a type II CIA model", "TREATMENT", 3, 22], ["infusion of rIL", "TREATMENT", 24, 39], ["inflammatory", "OBSERVATION", 57, 69], ["Th17 cell differentiation", "OBSERVATION", 94, 119]]], ["In an Ebi3 subunit knockout mouse model, enhanced Th17 cell infiltration and aggravated inflammatory response was noted [1] .IL-35regulation in various diseasesTo study a potential regulatory role of IL-35+ Breg, a model of EAU was established and rIL-35 or IL-35+ Breg could control the incidence and development of EAU.", [["Th17 cell", "ANATOMY", 50, 59], ["EAU", "DISEASE", 224, 227], ["EAU", "DISEASE", 317, 320], ["Ebi3", "GENE_OR_GENE_PRODUCT", 6, 10], ["mouse", "ORGANISM", 28, 33], ["Th17 cell", "CELL", 50, 59], ["IL-35regulation", "GENE_OR_GENE_PRODUCT", 125, 140], ["IL-35", "GENE_OR_GENE_PRODUCT", 200, 205], ["EAU", "CANCER", 224, 227], ["rIL-35", "GENE_OR_GENE_PRODUCT", 248, 254], ["IL-35", "GENE_OR_GENE_PRODUCT", 258, 263], ["Ebi3 subunit", "PROTEIN", 6, 18], ["IL", "PROTEIN", 125, 127], ["IL", "PROTEIN", 200, 202], ["rIL", "PROTEIN", 248, 251], ["IL", "PROTEIN", 258, 260], ["mouse", "SPECIES", 28, 33], ["mouse", "SPECIES", 28, 33], ["enhanced Th17 cell infiltration", "PROBLEM", 41, 72], ["aggravated inflammatory response", "PROBLEM", 77, 109], ["IL", "TREATMENT", 125, 127], ["various diseases", "PROBLEM", 144, 160], ["IL", "TEST", 200, 202], ["rIL", "TEST", 248, 251], ["IL", "TEST", 258, 260], ["enhanced", "OBSERVATION_MODIFIER", 41, 49], ["Th17 cell infiltration", "OBSERVATION", 50, 72], ["inflammatory", "OBSERVATION_MODIFIER", 88, 100], ["various diseases", "OBSERVATION", 144, 160], ["EAU", "OBSERVATION", 317, 320]]], ["IL-35+ Breg cell-mediated protection depended on induction and proliferation of endogenous Breg cells and Foxp3+ Treg cells and inhibition of pathogenic Th1 and Th17 effector cells [7] .", [["IL-35+ Breg cell", "ANATOMY", 0, 16], ["Breg cells", "ANATOMY", 91, 101], ["Treg cells", "ANATOMY", 113, 123], ["Th17 effector cells", "ANATOMY", 161, 180], ["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["Breg cell", "CELL", 7, 16], ["Breg cells", "CELL", 91, 101], ["Foxp3", "GENE_OR_GENE_PRODUCT", 106, 111], ["Treg cells", "CELL", 113, 123], ["Th1", "CELL", 153, 156], ["Th17 effector cells", "CELL", 161, 180], ["endogenous Breg cells", "CELL_LINE", 80, 101], ["Foxp3", "PROTEIN", 106, 111], ["Treg cells", "CELL_TYPE", 113, 123], ["pathogenic Th1 and Th17 effector cells", "CELL_TYPE", 142, 180], ["IL", "TEST", 0, 2], ["Breg cell-mediated protection", "TREATMENT", 7, 36], ["endogenous Breg cells", "PROBLEM", 80, 101], ["Treg cells", "TREATMENT", 113, 123], ["pathogenic Th1 and Th17 effector cells", "TREATMENT", 142, 180], ["Breg cell", "OBSERVATION", 7, 16], ["endogenous Breg cells", "OBSERVATION", 80, 101], ["pathogenic Th1", "OBSERVATION", 142, 156]]], ["Adoptive infusion of rIL-35mediated Breg cells improved the animal health after EAU eradication as well.", [["rIL-35mediated Breg cells", "ANATOMY", 21, 46], ["EAU", "DISEASE", 80, 83], ["rIL-35mediated Breg cells", "CELL", 21, 46], ["rIL-35mediated Breg cells", "CELL_LINE", 21, 46], ["Adoptive infusion", "TREATMENT", 0, 17], ["rIL-35mediated Breg cells", "TREATMENT", 21, 46], ["EAU eradication", "TREATMENT", 80, 95]]], ["This suggested that in vitro study of functional rIL-35+ Breg cells may give insight into potential roles for Breg and IL-35 Breg cells in autoimmune disease and cancer.", [["Breg cells", "ANATOMY", 57, 67], ["Breg", "ANATOMY", 110, 114], ["IL-35 Breg cells", "ANATOMY", 119, 135], ["cancer", "ANATOMY", 162, 168], ["autoimmune disease", "DISEASE", 139, 157], ["cancer", "DISEASE", 162, 168], ["rIL-35", "CHEMICAL", 49, 55], ["rIL-35", "GENE_OR_GENE_PRODUCT", 49, 55], ["Breg cells", "CELL", 57, 67], ["Breg", "CELL", 110, 114], ["IL-35", "GENE_OR_GENE_PRODUCT", 119, 124], ["cancer", "CANCER", 162, 168], ["rIL", "PROTEIN", 49, 52], ["Breg cells", "CELL_TYPE", 57, 67], ["Breg and IL-35 Breg cells", "CELL_LINE", 110, 135], ["vitro study", "TEST", 23, 34], ["functional rIL", "TEST", 38, 52], ["Breg cells", "PROBLEM", 57, 67], ["Breg and IL-35 Breg cells", "TREATMENT", 110, 135], ["autoimmune disease", "PROBLEM", 139, 157], ["cancer", "PROBLEM", 162, 168], ["Breg cells", "OBSERVATION", 125, 135], ["autoimmune disease", "OBSERVATION", 139, 157], ["cancer", "OBSERVATION", 162, 168]]], ["IL-35-derived Treg cells (i.e., iTR35) can maintain Breg cells, but IL-35+ Breg cells can also induce Treg cells.", [["IL-35-derived Treg cells", "ANATOMY", 0, 24], ["Breg cells", "ANATOMY", 52, 62], ["Breg cells", "ANATOMY", 75, 85], ["Treg cells", "ANATOMY", 102, 112], ["IL-35", "GENE_OR_GENE_PRODUCT", 0, 5], ["Treg cells", "CELL", 14, 24], ["iTR35", "GENE_OR_GENE_PRODUCT", 32, 37], ["Breg cells", "CELL", 52, 62], ["IL-35", "GENE_OR_GENE_PRODUCT", 68, 73], ["Breg cells", "CELL", 75, 85], ["Treg cells", "CELL", 102, 112], ["Treg cells", "CELL_TYPE", 14, 24], ["Breg cells", "CELL_TYPE", 52, 62], ["IL", "PROTEIN", 68, 70], ["Breg cells", "CELL_TYPE", 75, 85], ["Treg cells", "CELL_TYPE", 102, 112], ["IL", "TEST", 0, 2], ["IL", "TEST", 68, 70], ["Breg cells", "PROBLEM", 75, 85], ["Treg cells", "OBSERVATION", 14, 24], ["Breg cells", "OBSERVATION", 52, 62], ["Treg cells", "OBSERVATION", 102, 112]]], ["Therefore, in an inflammation-derived IL-35-dependent regulatory environment, different cell populations generated by IL-35 may interact via positive feed forward mechanisms and induce iTR35 and IL-35 + Breg cells through infectious tolerance [7] (Fig. 4) .IL-35 and tumor immunityPrevious work suggests that IL-35 plays a role in tumor immune escape.", [["cell", "ANATOMY", 88, 92], ["IL-35 + Breg cells", "ANATOMY", 195, 213], ["tumor", "ANATOMY", 267, 272], ["tumor", "ANATOMY", 331, 336], ["tumor", "DISEASE", 267, 272], ["tumor", "DISEASE", 331, 336], ["IL-35", "GENE_OR_GENE_PRODUCT", 38, 43], ["cell populations", "CELL", 88, 104], ["IL-35", "GENE_OR_GENE_PRODUCT", 118, 123], ["iTR35", "GENE_OR_GENE_PRODUCT", 185, 190], ["IL-35", "GENE_OR_GENE_PRODUCT", 195, 200], ["IL-35", "GENE_OR_GENE_PRODUCT", 257, 262], ["tumor", "CANCER", 267, 272], ["IL-35", "GENE_OR_GENE_PRODUCT", 309, 314], ["tumor", "CANCER", 331, 336], ["IL", "PROTEIN", 118, 120], ["iTR35 and IL-35 + Breg cells", "CELL_LINE", 185, 213], ["IL-35", "PROTEIN", 257, 262], ["IL-35", "PROTEIN", 309, 314], ["an inflammation", "PROBLEM", 14, 29], ["different cell populations", "TREATMENT", 78, 104], ["iTR35", "TEST", 185, 190], ["IL", "TEST", 195, 197], ["IL", "TREATMENT", 257, 259], ["tumor immunity", "TREATMENT", 267, 281], ["tumor immune escape", "PROBLEM", 331, 350], ["inflammation", "OBSERVATION", 17, 29], ["tumor", "OBSERVATION", 267, 272], ["tumor", "OBSERVATION", 331, 336], ["immune escape", "OBSERVATION", 337, 350]]], ["Ebi3 expression was increased in Hodgkin's lymphoma [29] and more Treg cells and inhibitory cytokines were noted in peripheral blood and tumor microenvironments of patients with pancreatic or breast carcinomas [30] .", [["Hodgkin's lymphoma", "ANATOMY", 33, 51], ["Treg cells", "ANATOMY", 66, 76], ["peripheral blood", "ANATOMY", 116, 132], ["tumor", "ANATOMY", 137, 142], ["pancreatic", "ANATOMY", 178, 188], ["breast carcinomas", "ANATOMY", 192, 209], ["Hodgkin's lymphoma", "DISEASE", 33, 51], ["tumor", "DISEASE", 137, 142], ["pancreatic or breast carcinomas", "DISEASE", 178, 209], ["Ebi3", "GENE_OR_GENE_PRODUCT", 0, 4], ["Hodgkin's lymphoma", "CANCER", 33, 51], ["Treg cells", "CELL", 66, 76], ["peripheral blood", "ORGANISM_SUBSTANCE", 116, 132], ["tumor", "CANCER", 137, 142], ["patients", "ORGANISM", 164, 172], ["pancreatic", "CANCER", 178, 188], ["breast carcinomas", "CANCER", 192, 209], ["Ebi3", "PROTEIN", 0, 4], ["Treg cells", "CELL_TYPE", 66, 76], ["inhibitory cytokines", "PROTEIN", 81, 101], ["patients", "SPECIES", 164, 172], ["Ebi3 expression", "TEST", 0, 15], ["Hodgkin's lymphoma", "PROBLEM", 33, 51], ["more Treg cells", "PROBLEM", 61, 76], ["inhibitory cytokines", "TEST", 81, 101], ["peripheral blood", "PROBLEM", 116, 132], ["pancreatic or breast carcinomas", "PROBLEM", 178, 209], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["Hodgkin's lymphoma", "OBSERVATION", 33, 51], ["Treg cells", "OBSERVATION", 66, 76], ["peripheral", "ANATOMY_MODIFIER", 116, 126], ["blood", "ANATOMY", 127, 132], ["tumor", "OBSERVATION", 137, 142], ["pancreatic", "ANATOMY", 178, 188], ["breast", "ANATOMY", 192, 198], ["carcinomas", "OBSERVATION", 199, 209]]], ["Ebi3 expression in lung cancer cells has also been found to be associated with tumor progression and siRNA-mediated down-regulation of the Eib3 gene inhibited proliferation of lung cancer cells [31] .", [["lung cancer cells", "ANATOMY", 19, 36], ["tumor", "ANATOMY", 79, 84], ["lung cancer cells", "ANATOMY", 176, 193], ["lung cancer", "DISEASE", 19, 30], ["tumor", "DISEASE", 79, 84], ["lung cancer", "DISEASE", 176, 187], ["Ebi3", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung cancer cells", "CELL", 19, 36], ["tumor", "CANCER", 79, 84], ["Eib3", "GENE_OR_GENE_PRODUCT", 139, 143], ["lung cancer cells", "CELL", 176, 193], ["Ebi3", "PROTEIN", 0, 4], ["lung cancer cells", "CELL_TYPE", 19, 36], ["Eib3 gene", "DNA", 139, 148], ["lung cancer cells", "CELL_TYPE", 176, 193], ["Ebi3 expression in lung cancer cells", "PROBLEM", 0, 36], ["tumor progression", "PROBLEM", 79, 96], ["siRNA", "TEST", 101, 106], ["lung cancer cells", "PROBLEM", 176, 193], ["lung", "ANATOMY", 19, 23], ["cancer", "OBSERVATION", 24, 30], ["tumor", "OBSERVATION", 79, 84], ["proliferation", "OBSERVATION_MODIFIER", 159, 172], ["lung", "ANATOMY", 176, 180], ["cancer", "OBSERVATION", 181, 187]]], ["Similarly, inoculation of b16 tumor cells in Ebi3knockout mice showed enhanced anti-tumor immunity Fig. 4 a B cell-derived IL-35 can suppress T-cell and monocytic responses.", [["b16 tumor cells", "ANATOMY", 26, 41], ["B cell", "ANATOMY", 108, 114], ["T-cell", "ANATOMY", 142, 148], ["monocytic", "ANATOMY", 153, 162], ["tumor", "DISEASE", 30, 35], ["b16 tumor cells", "CELL", 26, 41], ["Ebi3knockout mice", "ORGANISM", 45, 62], ["anti-tumor", "CANCER", 79, 89], ["B cell", "CELL", 108, 114], ["IL-35", "GENE_OR_GENE_PRODUCT", 123, 128], ["T-cell", "CELL", 142, 148], ["monocytic", "CELL", 153, 162], ["b16 tumor cells", "CELL_LINE", 26, 41], ["B cell", "CELL_TYPE", 108, 114], ["IL-35", "PROTEIN", 123, 128], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["inoculation of b16 tumor cells", "TEST", 11, 41], ["a B cell", "TEST", 106, 114], ["derived IL", "TEST", 115, 125], ["b16 tumor cells", "OBSERVATION", 26, 41], ["anti-tumor immunity Fig.", "OBSERVATION", 79, 103], ["monocytic responses", "OBSERVATION", 153, 172]]], ["IL-10, IL-35, and TGF-\u03b2 induce the Treg cell population. b Breg cells activate Treg cells through IL-10 production and B7 costimulatory molecules.", [["Treg cell", "ANATOMY", 35, 44], ["Breg cells", "ANATOMY", 59, 69], ["Treg cells", "ANATOMY", 79, 89], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-35", "GENE_OR_GENE_PRODUCT", 7, 12], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 18, 23], ["Treg cell", "CELL", 35, 44], ["Breg cells", "CELL", 59, 69], ["Treg cells", "CELL", 79, 89], ["IL-10", "GENE_OR_GENE_PRODUCT", 98, 103], ["B7 costimulatory molecules", "GENE_OR_GENE_PRODUCT", 119, 145], ["TGF-\u03b2", "PROTEIN", 18, 23], ["Treg cell population", "CELL_TYPE", 35, 55], ["Breg cells", "CELL_TYPE", 59, 69], ["Treg cells", "CELL_TYPE", 79, 89], ["IL-10", "PROTEIN", 98, 103], ["B7 costimulatory molecules", "PROTEIN", 119, 145], ["IL", "TEST", 0, 2], ["IL", "TEST", 7, 9], ["TGF", "TEST", 18, 21], ["the Treg cell population", "TREATMENT", 31, 55], ["Breg cells", "TEST", 59, 69], ["IL", "TEST", 98, 100], ["Treg cell population", "OBSERVATION", 35, 55], ["Treg cells", "OBSERVATION", 79, 89]]], ["Activated Treg cells release IL-10, suppresses the autoreactive Th1response in patients with EAE.", [["Treg cells", "ANATOMY", 10, 20], ["EAE", "DISEASE", 93, 96], ["Treg cells", "CELL", 10, 20], ["IL-10", "GENE_OR_GENE_PRODUCT", 29, 34], ["patients", "ORGANISM", 79, 87], ["Activated Treg cells", "CELL_TYPE", 0, 20], ["IL-10", "PROTEIN", 29, 34], ["patients", "SPECIES", 79, 87], ["Activated Treg cells release IL", "TREATMENT", 0, 31], ["Treg cells", "OBSERVATION", 10, 20], ["autoreactive Th1response", "OBSERVATION", 51, 75]]], ["IL-10-and TGF-\u03b2-producing Breg cells can suppress T-cell responses. c A subset of Breg cells also acquires the ability to produce IL-10.", [["Breg cells", "ANATOMY", 26, 36], ["T-cell", "ANATOMY", 50, 56], ["Breg cells", "ANATOMY", 82, 92], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["TGF-\u03b2-", "GENE_OR_GENE_PRODUCT", 10, 16], ["Breg cells", "CELL", 26, 36], ["T-cell", "CELL", 50, 56], ["Breg cells", "CELL", 82, 92], ["IL-10", "GENE_OR_GENE_PRODUCT", 130, 135], ["TGF-\u03b2-producing Breg cells", "CELL_LINE", 10, 36], ["Breg cells", "CELL_LINE", 82, 92], ["IL", "PROTEIN", 130, 132], ["IL", "TEST", 0, 2], ["TGF", "TEST", 10, 13], ["Breg cells", "PROBLEM", 82, 92], ["IL", "TEST", 130, 132], ["Breg cells", "OBSERVATION", 82, 92]]], ["Breg cells from the tumor bed support Treg expansion in vitro and in vivo, suppress T cell proliferation in vitro, suppress IFN-\u03b3 production and inhibit CD8+ cytolytic T cell activity.", [["Breg cells", "ANATOMY", 0, 10], ["tumor bed", "ANATOMY", 20, 29], ["Treg", "ANATOMY", 38, 42], ["T cell", "ANATOMY", 84, 90], ["CD8+ cytolytic T cell", "ANATOMY", 153, 174], ["tumor", "DISEASE", 20, 25], ["Breg cells", "CELL", 0, 10], ["tumor bed", "MULTI-TISSUE_STRUCTURE", 20, 29], ["Treg", "CELL", 38, 42], ["T cell", "CELL", 84, 90], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 124, 129], ["CD8", "GENE_OR_GENE_PRODUCT", 153, 156], ["T cell", "CELL", 168, 174], ["Breg cells", "CELL_TYPE", 0, 10], ["IFN", "PROTEIN", 124, 127], ["CD8", "PROTEIN", 153, 156], ["Breg cells", "PROBLEM", 0, 10], ["the tumor", "PROBLEM", 16, 25], ["Treg expansion in vitro", "TREATMENT", 38, 61], ["T cell proliferation", "PROBLEM", 84, 104], ["IFN", "TEST", 124, 127], ["CD8", "TEST", 153, 156], ["tumor", "OBSERVATION", 20, 25], ["cell proliferation", "OBSERVATION", 86, 104], ["cytolytic T cell activity", "OBSERVATION", 158, 183]]], ["These B regulatory properties inhibit the anti-tumor response and lead to enhanced tumor growth relative to wild-type mice and the metastatic potential of tumor cells were suppressed.", [["tumor", "ANATOMY", 83, 88], ["tumor cells", "ANATOMY", 155, 166], ["tumor", "DISEASE", 83, 88], ["tumor", "DISEASE", 155, 160], ["B", "GENE_OR_GENE_PRODUCT", 6, 7], ["anti-tumor", "CANCER", 42, 52], ["tumor", "CANCER", 83, 88], ["mice", "ORGANISM", 118, 122], ["tumor cells", "CELL", 155, 166], ["tumor cells", "CELL_TYPE", 155, 166], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 118, 122], ["enhanced tumor growth", "PROBLEM", 74, 95], ["tumor cells", "PROBLEM", 155, 166], ["tumor", "OBSERVATION", 83, 88], ["metastatic", "OBSERVATION_MODIFIER", 131, 141], ["tumor cells", "OBSERVATION", 155, 166]]], ["In an IL-35-positive tumor cell microenvironment, studies showed that there were significant increase in CD11b + Gr1+ myeloid-derived suppressor cells (MDSC) and vascular endothelial growth factors promoted tumor angiogenesis [32] .", [["IL-35-positive tumor cell", "ANATOMY", 6, 31], ["CD11b + Gr1+ myeloid-derived suppressor cells", "ANATOMY", 105, 150], ["MDSC", "ANATOMY", 152, 156], ["tumor", "ANATOMY", 207, 212], ["tumor", "DISEASE", 21, 26], ["tumor", "DISEASE", 207, 212], ["IL-35", "GENE_OR_GENE_PRODUCT", 6, 11], ["tumor cell", "CELL", 21, 31], ["CD11b", "GENE_OR_GENE_PRODUCT", 105, 110], ["Gr1", "GENE_OR_GENE_PRODUCT", 113, 116], ["MDSC", "CELL", 152, 156], ["vascular endothelial growth factors", "GENE_OR_GENE_PRODUCT", 162, 197], ["tumor", "CANCER", 207, 212], ["CD11b", "PROTEIN", 105, 110], ["Gr1", "PROTEIN", 113, 116], ["myeloid-derived suppressor cells", "CELL_TYPE", 118, 150], ["MDSC", "CELL_TYPE", 152, 156], ["vascular endothelial growth factors", "PROTEIN", 162, 197], ["an IL", "TEST", 3, 8], ["significant increase", "PROBLEM", 81, 101], ["CD11", "TEST", 105, 109], ["Gr1", "TEST", 113, 116], ["myeloid", "PROBLEM", 118, 125], ["suppressor cells", "PROBLEM", 134, 150], ["vascular endothelial growth factors", "PROBLEM", 162, 197], ["tumor angiogenesis", "PROBLEM", 207, 225], ["tumor cell microenvironment", "OBSERVATION", 21, 48], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["myeloid", "ANATOMY", 118, 125], ["suppressor cells", "OBSERVATION", 134, 150], ["vascular endothelial", "ANATOMY", 162, 182], ["tumor", "OBSERVATION", 207, 212]]], ["These MDSCs were immunosuppressive and inhibited cytotoxic T cells.", [["MDSCs", "ANATOMY", 6, 11], ["cytotoxic T cells", "ANATOMY", 49, 66], ["MDSCs", "CELL", 6, 11], ["cytotoxic T cells", "CELL", 49, 66], ["MDSCs", "CELL_TYPE", 6, 11], ["cytotoxic T cells", "CELL_TYPE", 49, 66], ["immunosuppressive", "TREATMENT", 17, 34], ["cytotoxic T cells", "PROBLEM", 49, 66], ["MDSCs", "OBSERVATION", 6, 11], ["cytotoxic T cells", "OBSERVATION", 49, 66]]], ["In this way, tumor cell-generated IL-35 may protect against cytotoxic T-cell-mediated damage.", [["tumor cell", "ANATOMY", 13, 23], ["T-cell", "ANATOMY", 70, 76], ["tumor", "DISEASE", 13, 18], ["tumor cell", "CELL", 13, 23], ["IL-35", "GENE_OR_GENE_PRODUCT", 34, 39], ["T-cell", "CELL", 70, 76], ["IL-35", "PROTEIN", 34, 39], ["tumor cell", "TEST", 13, 23], ["IL", "TEST", 34, 36], ["mediated damage", "PROBLEM", 77, 92], ["tumor cell", "OBSERVATION", 13, 23], ["damage", "OBSERVATION", 86, 92]]], ["In contrast, applications of neutralizing antibody to IL-35 significantly inhibited tumor cell proliferation [32] .IL-35 and tumor immunityAlthough many studies have shown that IL-35 contributes to immunosuppressive function in the mouse model, but this effect is limited in humans [33] .", [["tumor cell", "ANATOMY", 84, 94], ["tumor", "ANATOMY", 125, 130], ["tumor", "DISEASE", 84, 89], ["tumor", "DISEASE", 125, 130], ["IL-35", "GENE_OR_GENE_PRODUCT", 54, 59], ["tumor cell", "CELL", 84, 94], [".IL-35", "SIMPLE_CHEMICAL", 114, 120], ["tumor", "CANCER", 125, 130], ["IL-35", "GENE_OR_GENE_PRODUCT", 177, 182], ["mouse", "ORGANISM", 232, 237], ["humans", "ORGANISM", 275, 281], ["IL", "PROTEIN", 54, 56], ["IL-35", "PROTEIN", 177, 182], ["mouse", "SPECIES", 232, 237], ["humans", "SPECIES", 275, 281], ["mouse", "SPECIES", 232, 237], ["humans", "SPECIES", 275, 281], ["neutralizing antibody", "TEST", 29, 50], ["IL", "TEST", 54, 56], ["tumor cell proliferation", "TEST", 84, 108], [".IL", "TEST", 114, 117], ["tumor immunity", "TREATMENT", 125, 139], ["many studies", "TEST", 148, 160], ["IL", "TEST", 177, 179], ["immunosuppressive function", "PROBLEM", 198, 224], ["tumor cell proliferation", "OBSERVATION", 84, 108], ["immunosuppressive function", "OBSERVATION", 198, 224]]], ["No expression of IL-35-derived Treg cells had been observed in early investigations in humans.", [["Treg cells", "ANATOMY", 31, 41], ["IL-35", "GENE_OR_GENE_PRODUCT", 17, 22], ["Treg cells", "CELL", 31, 41], ["humans", "ORGANISM", 87, 93], ["IL-35", "PROTEIN", 17, 22], ["Treg cells", "CELL_TYPE", 31, 41], ["humans", "SPECIES", 87, 93], ["humans", "SPECIES", 87, 93], ["Treg cells", "TREATMENT", 31, 41]]], ["This suggests that IL-35 may not be constitutively expressed in humans.", [["IL-35", "GENE_OR_GENE_PRODUCT", 19, 24], ["humans", "ORGANISM", 64, 70], ["IL", "PROTEIN", 19, 21], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 64, 70], ["may not be", "UNCERTAINTY", 25, 35]]], ["However, it can be produced in specific tissues and cell types after a certain inflammatory stimulus.", [["tissues", "ANATOMY", 40, 47], ["cell", "ANATOMY", 52, 56], ["tissues", "TISSUE", 40, 47], ["cell", "CELL", 52, 56], ["a certain inflammatory stimulus", "PROBLEM", 69, 100], ["cell types", "OBSERVATION", 52, 62], ["inflammatory", "OBSERVATION_MODIFIER", 79, 91]]], ["Recent studies have shown that, under strong stimulation, Treg can produce IL-35, and CD4 + T cells under the stimulation of IL-35 can express IL-35similar to iTr35 in mice [34] .", [["Treg", "ANATOMY", 58, 62], ["CD4 + T cells", "ANATOMY", 86, 99], ["Treg", "CELL", 58, 62], ["IL-35", "GENE_OR_GENE_PRODUCT", 75, 80], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["IL-35", "GENE_OR_GENE_PRODUCT", 125, 130], ["IL-35similar", "GENE_OR_GENE_PRODUCT", 143, 155], ["iTr35", "GENE_OR_GENE_PRODUCT", 159, 164], ["mice", "ORGANISM", 168, 172], ["Treg", "CELL_TYPE", 58, 62], ["IL", "PROTEIN", 75, 77], ["CD4", "PROTEIN", 86, 89], ["T cells", "CELL_TYPE", 92, 99], ["IL", "PROTEIN", 125, 127], ["IL", "PROTEIN", 143, 145], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 168, 172], ["Recent studies", "TEST", 0, 14], ["IL", "TEST", 75, 77], ["CD4 + T cells", "TREATMENT", 86, 99], ["the stimulation of IL", "TREATMENT", 106, 127]]], ["Similarly, in humans, CD8 + Treg can suppress the immune response against prostate cancer by expressing CTLA-4 and IL-35 [35] .", [["CD8 + Treg", "ANATOMY", 22, 32], ["prostate cancer", "ANATOMY", 74, 89], ["prostate cancer", "DISEASE", 74, 89], ["humans", "ORGANISM", 14, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 22, 25], ["prostate cancer", "CANCER", 74, 89], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 104, 110], ["IL-35", "GENE_OR_GENE_PRODUCT", 115, 120], ["CD8", "PROTEIN", 22, 25], ["Treg", "CELL_TYPE", 28, 32], ["CTLA", "PROTEIN", 104, 108], ["IL", "PROTEIN", 115, 117], ["humans", "SPECIES", 14, 20], ["humans", "SPECIES", 14, 20], ["prostate cancer", "PROBLEM", 74, 89], ["CTLA", "TEST", 104, 108], ["IL", "TEST", 115, 117], ["prostate", "ANATOMY", 74, 82], ["cancer", "OBSERVATION", 83, 89]]], ["Although more research is required to draw any conclusions, preliminary information suggests that elevated serum IL-35 is associated with tumor malignancy [36] [37] [38] and clinical stage and decreased IL-35 is associated with autoimmune disease and chronic infection [39] [40] [41] .", [["serum", "ANATOMY", 107, 112], ["tumor", "ANATOMY", 138, 143], ["tumor", "DISEASE", 138, 143], ["malignancy", "DISEASE", 144, 154], ["autoimmune disease", "DISEASE", 228, 246], ["chronic infection", "DISEASE", 251, 268], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["IL-35", "GENE_OR_GENE_PRODUCT", 113, 118], ["tumor", "CANCER", 138, 143], ["IL-35", "GENE_OR_GENE_PRODUCT", 203, 208], ["serum IL-35", "PROTEIN", 107, 118], ["IL-35", "PROTEIN", 203, 208], ["elevated serum IL", "PROBLEM", 98, 115], ["tumor malignancy", "PROBLEM", 138, 154], ["clinical stage", "TEST", 174, 188], ["decreased IL", "PROBLEM", 193, 205], ["autoimmune disease", "PROBLEM", 228, 246], ["chronic infection", "PROBLEM", 251, 268], ["associated with", "UNCERTAINTY", 122, 137], ["tumor malignancy", "OBSERVATION", 138, 154], ["associated with", "UNCERTAINTY", 212, 227], ["autoimmune disease", "OBSERVATION", 228, 246], ["chronic", "OBSERVATION_MODIFIER", 251, 258], ["infection", "OBSERVATION", 259, 268]]], ["(Fig. 4) .IL-35 and infectious diseasesIL-35, as an inhibitory cytokine, plays an important role in infectious diseases.", [["infectious diseases", "DISEASE", 100, 119], ["IL-35", "GENE_OR_GENE_PRODUCT", 10, 15], ["diseasesIL-35", "GENE_OR_GENE_PRODUCT", 31, 44], ["IL-35", "PROTEIN", 10, 15], ["infectious diseasesIL-35", "PROTEIN", 20, 44], ["inhibitory cytokine", "PROTEIN", 52, 71], ["IL", "TEST", 10, 12], ["infectious", "OBSERVATION", 20, 30], ["infectious", "OBSERVATION", 100, 110]]], ["The study suggested that Mycobacterium tuberculosis (M. tuberculosis) could induce T cell proliferation and foster IFN-\u03b3 production in p35deficient mice, P40 deficient mice, and wild-type mice, thus eliminating the pathogen.", [["T cell", "ANATOMY", 83, 89], ["Mycobacterium tuberculosis", "DISEASE", 25, 51], ["Mycobacterium tuberculosis", "ORGANISM", 25, 51], ["M. tuberculosis", "ORGANISM", 53, 68], ["T cell", "CELL", 83, 89], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 115, 120], ["p35deficient", "ORGANISM", 135, 147], ["mice", "ORGANISM", 148, 152], ["P40 deficient mice", "ORGANISM", 154, 172], ["wild-type", "ORGANISM", 178, 187], ["mice", "ORGANISM", 188, 192], ["IFN", "PROTEIN", 115, 118], ["\u03b3", "PROTEIN", 119, 120], ["Mycobacterium tuberculosis", "SPECIES", 25, 51], ["M. tuberculosis", "SPECIES", 53, 68], ["mice", "SPECIES", 148, 152], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 188, 192], ["Mycobacterium tuberculosis", "SPECIES", 25, 51], ["M. tuberculosis", "SPECIES", 53, 68], ["mice", "SPECIES", 148, 152], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 188, 192], ["The study", "TEST", 0, 9], ["Mycobacterium tuberculosis (M. tuberculosis)", "PROBLEM", 25, 69], ["T cell proliferation", "PROBLEM", 83, 103], ["IFN", "TEST", 115, 118], ["the pathogen", "PROBLEM", 211, 223], ["Mycobacterium tuberculosis", "OBSERVATION", 25, 51], ["cell proliferation", "OBSERVATION", 85, 103]]], ["Mice lacking p40 have been found to be less able to show antigen-specific responses than those lacking the p35 subunit.", [["Mice", "ORGANISM", 0, 4], ["p40", "GENE_OR_GENE_PRODUCT", 13, 16], ["p35", "GENE_OR_GENE_PRODUCT", 107, 110], ["p40", "PROTEIN", 13, 16], ["p35 subunit", "PROTEIN", 107, 118], ["Mice", "SPECIES", 0, 4]]], ["However, their ability to counteract infection is less pronounced than that of wild-type mice [42] .", [["infection", "DISEASE", 37, 46], ["mice", "ORGANISM", 89, 93], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["infection", "PROBLEM", 37, 46], ["infection", "OBSERVATION", 37, 46], ["less pronounced", "OBSERVATION_MODIFIER", 50, 65]]], ["In addition, the protective responses can be induced in wild-type and p35deficient mice by inoculating with vaccines, and increased the secretion of IFN-\u03b3 and IL-17.", [["p35deficient", "ORGANISM", 70, 82], ["mice", "ORGANISM", 83, 87], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 149, 154], ["IL-17", "GENE_OR_GENE_PRODUCT", 159, 164], ["IFN-\u03b3 and IL-17", "PROTEIN", 149, 164], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["vaccines", "TREATMENT", 108, 116], ["IFN", "TEST", 149, 152], ["IL", "TEST", 159, 161]]], ["However, P40-deficient mice did not produce antigen-specific IFN-\u03b3 or IL-17, and increased the infection load of bacteria.", [["infection", "DISEASE", 95, 104], ["P40", "GENE_OR_GENE_PRODUCT", 9, 12], ["mice", "ORGANISM", 23, 27], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 61, 66], ["IL-17", "GENE_OR_GENE_PRODUCT", 70, 75], ["P40", "PROTEIN", 9, 12], ["IFN", "PROTEIN", 61, 64], ["IL-17", "PROTEIN", 70, 75], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["P40", "TEST", 9, 12], ["antigen", "TEST", 44, 51], ["IFN", "TEST", 61, 64], ["IL", "TEST", 70, 72], ["the infection load of bacteria", "PROBLEM", 91, 121], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["infection", "OBSERVATION", 95, 104]]], ["In addition, treatment of p35-deficient mice with Candida albicans (C. albicans) reduced the rate of fungal infection and was associated with little to no obvious symptoms of infection relative to P19-deficient mice.", [["fungal infection", "DISEASE", 101, 117], ["infection", "DISEASE", 175, 184], ["p35", "GENE_OR_GENE_PRODUCT", 26, 29], ["mice", "ORGANISM", 40, 44], ["Candida albicans", "ORGANISM", 50, 66], ["C. albicans", "ORGANISM", 68, 79], ["P19", "GENE_OR_GENE_PRODUCT", 197, 200], ["mice", "ORGANISM", 211, 215], ["p35", "PROTEIN", 26, 29], ["P19", "PROTEIN", 197, 200], ["mice", "SPECIES", 40, 44], ["Candida albicans", "SPECIES", 50, 66], ["C. albicans", "SPECIES", 68, 79], ["mice", "SPECIES", 211, 215], ["mice", "SPECIES", 40, 44], ["Candida albicans", "SPECIES", 50, 66], ["C. albicans", "SPECIES", 68, 79], ["mice", "SPECIES", 211, 215], ["p35-deficient mice", "TREATMENT", 26, 44], ["Candida albicans", "PROBLEM", 50, 66], ["C. albicans", "PROBLEM", 68, 79], ["fungal infection", "PROBLEM", 101, 117], ["obvious symptoms of infection", "PROBLEM", 155, 184], ["P19-deficient mice", "TREATMENT", 197, 215], ["fungal", "OBSERVATION_MODIFIER", 101, 107], ["infection", "OBSERVATION", 108, 117], ["infection", "OBSERVATION", 175, 184]]], ["In p35-deficient mice and those in which p35 gene was disrupted, the immunosuppressive function of IL-35 was inhibited, which impaired anti-fungal immunity [43] .", [["p35", "GENE_OR_GENE_PRODUCT", 3, 6], ["p35", "GENE_OR_GENE_PRODUCT", 41, 44], ["IL-35", "GENE_OR_GENE_PRODUCT", 99, 104], ["p35", "PROTEIN", 3, 6], ["p35 gene", "DNA", 41, 49], ["IL-35", "PROTEIN", 99, 104], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["IL", "TEST", 99, 101]]], ["The CD4 + T cells in the peripheral blood of patients with chronic hepatitis B also showed high levels of expression of p35 and EB13 protein, indicating that IL-35 was related to the immune response of chronic hepatitis B patients [44] .", [["CD4 + T cells", "ANATOMY", 4, 17], ["peripheral blood", "ANATOMY", 25, 41], ["chronic hepatitis B", "DISEASE", 59, 78], ["chronic hepatitis B", "DISEASE", 202, 221], ["CD4", "GENE_OR_GENE_PRODUCT", 4, 7], ["peripheral blood", "ORGANISM_SUBSTANCE", 25, 41], ["patients", "ORGANISM", 45, 53], ["p35", "GENE_OR_GENE_PRODUCT", 120, 123], ["EB13", "GENE_OR_GENE_PRODUCT", 128, 132], ["IL-35", "GENE_OR_GENE_PRODUCT", 158, 163], ["patients", "ORGANISM", 222, 230], ["CD4", "PROTEIN", 4, 7], ["T cells", "CELL_TYPE", 10, 17], ["p35", "PROTEIN", 120, 123], ["EB13 protein", "PROTEIN", 128, 140], ["IL-35", "PROTEIN", 158, 163], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 222, 230], ["The CD4", "TEST", 0, 7], ["T cells", "PROBLEM", 10, 17], ["chronic hepatitis B", "PROBLEM", 59, 78], ["high levels of expression of p35", "PROBLEM", 91, 123], ["EB13 protein", "TEST", 128, 140], ["IL", "TEST", 158, 160], ["chronic hepatitis B patients", "PROBLEM", 202, 230], ["CD4 + T cells", "OBSERVATION", 4, 17], ["peripheral", "ANATOMY_MODIFIER", 25, 35], ["blood", "ANATOMY", 36, 41], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["hepatitis", "OBSERVATION", 67, 76], ["high levels", "OBSERVATION_MODIFIER", 91, 102], ["chronic", "OBSERVATION_MODIFIER", 202, 209], ["hepatitis", "OBSERVATION", 210, 219]]], ["These results showed that, during the acute infection process, IL-35 preferentially activated Th1 cells, stimulated proliferation of Treg cells, and inhibited the differentiation of Th17 cells, thereby preventing excessive tissue damage caused by the clearing of pathogens.", [["Th1 cells", "ANATOMY", 94, 103], ["Treg cells", "ANATOMY", 133, 143], ["Th17 cells", "ANATOMY", 182, 192], ["tissue", "ANATOMY", 223, 229], ["infection", "DISEASE", 44, 53], ["tissue damage", "DISEASE", 223, 236], ["IL-35", "GENE_OR_GENE_PRODUCT", 63, 68], ["Th1 cells", "CELL", 94, 103], ["Treg cells", "CELL", 133, 143], ["Th17 cells", "CELL", 182, 192], ["tissue", "TISSUE", 223, 229], ["IL-35", "PROTEIN", 63, 68], ["Th1 cells", "CELL_TYPE", 94, 103], ["Treg cells", "CELL_TYPE", 133, 143], ["Th17 cells", "CELL_TYPE", 182, 192], ["the acute infection process", "PROBLEM", 34, 61], ["IL", "TEST", 63, 65], ["stimulated proliferation of Treg cells", "PROBLEM", 105, 143], ["Th17 cells", "PROBLEM", 182, 192], ["excessive tissue damage", "PROBLEM", 213, 236], ["pathogens", "PROBLEM", 263, 272], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 44, 53], ["Th1 cells", "OBSERVATION", 94, 103], ["Treg cells", "OBSERVATION", 133, 143], ["Th17 cells", "OBSERVATION", 182, 192], ["excessive tissue", "OBSERVATION_MODIFIER", 213, 229], ["damage", "OBSERVATION", 230, 236], ["clearing", "OBSERVATION_MODIFIER", 251, 259], ["pathogens", "OBSERVATION", 263, 272]]], ["In the chronic infection and inflammation, IL-35 selectively inhibited effector cells, including Th17 cells, which slowed down the development of autoimmune diseases [1] .", [["effector cells", "ANATOMY", 71, 85], ["Th17 cells", "ANATOMY", 97, 107], ["chronic infection", "DISEASE", 7, 24], ["inflammation", "DISEASE", 29, 41], ["autoimmune diseases", "DISEASE", 146, 165], ["IL-35", "GENE_OR_GENE_PRODUCT", 43, 48], ["effector cells", "CELL", 71, 85], ["Th17 cells", "CELL", 97, 107], ["IL-35", "PROTEIN", 43, 48], ["effector cells", "CELL_TYPE", 71, 85], ["Th17 cells", "CELL_TYPE", 97, 107], ["the chronic infection", "PROBLEM", 3, 24], ["inflammation", "PROBLEM", 29, 41], ["IL", "TREATMENT", 43, 45], ["Th17 cells", "TREATMENT", 97, 107], ["autoimmune diseases", "PROBLEM", 146, 165], ["chronic", "OBSERVATION_MODIFIER", 7, 14], ["infection", "OBSERVATION", 15, 24], ["inflammation", "OBSERVATION", 29, 41], ["effector cells", "OBSERVATION", 71, 85], ["Th17 cells", "OBSERVATION", 97, 107], ["autoimmune diseases", "OBSERVATION", 146, 165]]], ["Future studies may address whether IL-35 shares its receptors with other IL-12 members and rIL-35 may help clarify these biological effects and identify other cell types or subtypes involved in immune regulation by producing IL-35.", [["cell", "ANATOMY", 159, 163], ["IL-35", "GENE_OR_GENE_PRODUCT", 35, 40], ["IL-12", "GENE_OR_GENE_PRODUCT", 73, 78], ["rIL-35", "GENE_OR_GENE_PRODUCT", 91, 97], ["cell", "CELL", 159, 163], ["IL-35", "GENE_OR_GENE_PRODUCT", 225, 230], ["IL-35", "PROTEIN", 35, 40], ["IL-12 members", "PROTEIN", 73, 86], ["rIL", "PROTEIN", 91, 94], ["IL", "PROTEIN", 225, 227], ["Future studies", "TEST", 0, 14]]], ["How IL-35 inhibits cell proliferation, why different cells mediate different signaling pathways, and potential prospects of clinical use of IL-35 (rIL-35 and IL-35 Breg cells) as a chemotherapeutic or to treat autoimmune diseases or organ transplantation also await further study.", [["cell", "ANATOMY", 19, 23], ["cells", "ANATOMY", 53, 58], ["IL-35 Breg cells", "ANATOMY", 158, 174], ["organ", "ANATOMY", 233, 238], ["autoimmune diseases", "DISEASE", 210, 229], ["IL-35", "GENE_OR_GENE_PRODUCT", 4, 9], ["cell", "CELL", 19, 23], ["cells", "CELL", 53, 58], ["IL-35", "GENE_OR_GENE_PRODUCT", 140, 145], ["rIL-35", "GENE_OR_GENE_PRODUCT", 147, 153], ["IL-35 Breg cells", "CELL", 158, 174], ["organ", "ORGAN", 233, 238], ["IL-35", "PROTEIN", 4, 9], ["IL-35 Breg cells", "CELL_LINE", 158, 174], ["cell proliferation", "PROBLEM", 19, 37], ["IL", "TEST", 140, 142], ["rIL", "TEST", 147, 150], ["IL-35 Breg cells", "TREATMENT", 158, 174], ["a chemotherapeutic", "TREATMENT", 179, 197], ["autoimmune diseases", "PROBLEM", 210, 229], ["organ transplantation", "TREATMENT", 233, 254], ["further study", "TEST", 266, 279], ["cell proliferation", "OBSERVATION", 19, 37]]]]}